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 Abstract 
Malaria is a life-threatening disease which is responsible for roughly one million 
deaths annually.  Previous successes in attempting to eradicate the disease have only 
been short lived, owing to the increased development of resistance in the parasite.  
There is a continued need for novel compounds which act at novel therapeutic 
targets, with the Plasmodium falciparum cytochrome bc1 complex (Pfbc1) 
representing one such target.  Its inhibition halts the biochemical generation of ATP, 
thus resulting in parasite cell death.  Work described in this thesis was concerned 
with utilising molecular modelling, synthesis and biological testing to develop novel 
antimalarial compounds, which selectively inhibit this target. 
The structural details of a number of compounds known to be active or inactive 
against Pfbc1 were used in combination with six different ligand based virtual 
screening techniques, and applied to the ZINC lead like library of compounds to 
identify potential chemotypes active against malaria.  These methods included 
fingerprint similarity searching, principal component analysis, and naïve Bayesian 
classification.  The hits from each of these methods were merged and formed part of 
a consensus analysis in which compounds identified across several methods were 
deemed of more interest than those which appeared less frequently.  Each molecule 
was given a score based on its number of occurrences in the virtual screening 
methods and also its physicochemical properties.  Compounds were filtered to 
remove those with unfavourable chemical properties, or which contained known 
toxicophores.  19 compounds were ultimately purchased and tested in vitro against 
the 3D7 strain of the malaria parasite.  5 of the compounds reported single digit µM 
IC50 values, with each containing novel structural chemotypes.  The lead candidate 
contained a benzothiazole core, and reported an IC50 value against 3D7 of 4.53 ± 
1.86 µM.  Additional testing showed the compounds to be inactive against bovine 
bc1, which is promising as strong bovine bc1 inhibition has been shown to be 
indicative of cardiotoxicity in humans. 
Molecular docking was extensively employed to rationalise the activity of Pfbc1 
inhibitors such as atovaquone and HDQ.  A number of quinolone containing 
compounds were also subject to docking, with key observations made with regard to 
interactions thought to be crucial to their antimalarial activity.  The hits from LBVS 
were also the focus of docking, further supporting their potential as Pfbc1 inhibitors. 
QSARs were developed for a series of 4-aminoquinoline compounds which had been 
tested against both the NF54 and K1 strains of malaria.  MLR, PLS and kNN 
machine learning methods were investigated, with molecular descriptors contained 
within valid models interpreted.  Significant models were identified and shown to 
have strong predictive abilities for both strains.  QSAR models were similarly 
developed for a series of thiazolide compounds with activity against hepatitis C.  
SVM was found to give a significant model which was able to predict the cell safety 
of the thiazolide derivatives. 
The rational design of the novel pyrroloquinolone chemotype led to the synthesis of 
7 synthetic analogues to investigate its SAR, via alkylation and Winterfeldt 
oxidation reactions.  The compounds reported 3D7 activity values between 75 nM 
and 1.02 µM, with molecular docking supporting their potential for Qo binding and 
thus Pfbc1 inhibition. 
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1. Introduction 
1.1 Malaria 
Malaria is a life-threatening disease which is responsible for roughly one million 
deaths and some half a billion clinical episodes each year.
1-3
  In Africa, a child dies 
every 45 seconds of the disease.  It is transmitted through the bite of the female 
anopheles mosquito which acts as a vector for the malaria parasite.  Approximately 
40% of the world’s population are exposed to the risk of malaria, mainly those in 
tropical and sub-tropical countries.
4, 5
  This is due to the significant amount of 
rainfall and consistently high temperatures in these regions.  These features 
combined with areas of stagnant waters in which the larvae can mature provides 
optimum conditions for continuous breeding of the mosquitoes, and thus persistent 
transmission of the disease.
6
  The mosquitoes only feed during the night (dusk till 
dawn) when bite prevention is imperative.
7
  Previous successes in attempting to 
eradicate the disease were only short lived due to increasing resistance of the 
mosquito to insecticides,
8
 and of the parasite to established drugs.
9
 
Malaria is caused by a parasite called Plasmodium, of which there are four main 
human species: Plasmodium falciparum (P. falciparum), Plasmodium vivax (P. 
vivax), Plasmodium ovale (P. ovale), and Plasmodium malariae (P. malariae).
10
  
Recently there have been reported cases of human infection with a fifth species, 
Plasmodium knowlesi (P. knowlesi), which is usually found in monkeys.
11, 12
  P. 
vivax and P. falciparum are the most common of the Plasmodium species, but P. 
falciparum is by far the deadliest, with higher mortality rates than the other 
species.
13, 14
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Malaria is an acute febrile illness, with symptoms of the disease only becoming 
apparent around ten to fifteen days after the infective mosquito bite.  Initial 
symptoms include fever, chills, headache and vomiting, and thus may be mild and 
unrecognisable as malaria.  However, if not treated, P. falciparum quickly progresses 
to severe illness and may lead to death.  Children with severe disease often develop 
other conditions such as severe anaemia, respiratory distress, or cerebral malaria, and 
in adults multi-organ involvement is frequent, with the blood supply to vital organs 
becoming disrupted.
1
 
Those living in endemic areas progressively acquire a semi-immune status following 
repeated bites, reducing acute infection symptoms and disease severity.
15
  However, 
immunity may be partially lost after years in non-endemic countries, as occurs 
frequently in migrants from endemic countries that move to Europe or North 
America.
16
  Therefore, those individuals have an elevated risk of illness when they 
return to their country of original to visit friends and family.
17
 
Malaria is geographically specific due to the ecological conditions required for the 
mosquito vector, yet countries that have eliminated its presence generally 
experienced economic growth in the subsequent years compared to those of 
neighbouring countries.  The disease poses a huge burden where it is endemic, and 
can cut gross domestic product (GDP) by as much as 1.3%.
1, 18
  These aggregated 
annual losses have resulted in substantial differences in GDP between countries with 
and without malaria, and in some heavily burdened countries, the disease accounts 
for up to 40% of all public health expenditures. 
The disease also poses worldwide implications due to increases in air travel, with 
those from malaria free areas of the world especially vulnerable when they become 
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infected.
1
  About 30,000 international travellers develop malaria each year, resulting 
in around 150 deaths.
19
  It is vital that travellers to high risk areas be educated about 
personal preventative measures that can be used to reduce the possibility of 
infection, such as wearing long sleeve shirts, sleeping in air conditioned rooms, 
using mosquito repellents and insecticides, as well as using bed nets and window 
screens.
20
 
1.2 Plasmodium Life Cycle 
The life cycle of the malaria parasite consists of a sexual cycle which takes place 
within the mosquito, and an asexual cycle which occurs in man, as depicted by figure 
1.1.
10, 21-23
 
 
Fig. 1.1  Plasmodium life cycle.  Retrieved from the Centre for Disease Control and Prevention 
(CDC).  (Available at http://www.cdc.gov/malaria/about/biology/) 
Within the asexual cycle there is an exo-erythrocytic and an erythrocytic phase.  The 
exo-erythrocytic stage involves infection of the liver, whereas the erythrocytic phase 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(http://www.cdc.gov/malaria/about/biology/). 
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is concerned with infection of the red blood cells (RBCs).  Following the blood meal 
of an infected female mosquito, Plasmodium sporozoites from the mosquitoes saliva 
enter the bloodstream, where within thirty minutes they move to and infect the 
hepatocytes (liver cells).  Over the next ten to fourteen days they undergo an exo-
erythrocytic stage of development and multiplication into liver schizonts.  These 
schizonts then rupture releasing merozoites into the bloodstream, which can then go 
on to invade the RBCs. 
When the merozoites enter the RBCs the erythrocytic phase of the life cycle begins.  
This is again an asexual stage of multiplication, where the merozoites develop into 
motile intracellular ring forms of the parasite termed trophozoites.  During 
maturation within the RBC, the parasite remodels the host cell by inserting parasite 
proteins and phospholipids into the red blood cell membrane.  The host’s 
haemoglobin is digested and transported to the parasite’s food vacuole where it 
provides a source of amino acids.  Free haem is a by-product of this reaction and is 
ordinarily toxic to the Plasmodium; however, it is rendered harmless by 
polymerisation to haemozoin,
24
 a non-toxic molecule which collects as an insoluble 
crystal in the parasite food vacuole. 
Following mitotic replication of its nucleus, the trophozoites mature into schizonts, 
whose rapid growth and division releases additional merozoites into the bloodstream 
when the schizont ruptures.  It is this rupturing of the schizont and release of further 
merozoites into the blood which gives rise to the classic symptom of malaria, which 
is the cyclical occurrence of sudden coldness followed by rigor and then spiking 
fever and sweating, lasting anywhere between four to six hours.  These merozoites 
are released into the bloodstream and can bind to and enter further RBCs, repeating 
the erythrocytic cycle. 
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This cycle occurs in simultaneous waves (from invading merozoites to rupturing 
schizont) every two days in P. vivax, P. ovale and P. falciparum, and every three 
days for P. malariae.  For P. knowlesi this process repeats roughly every day.  
However, in non-immune patients, particularly those infected with P. falciparum, 
parasites tend to mature asynchronously resulting in irregular fever patterns.
25
 
On entering the liver cells, some sporozoites in P. vivax and P. ovale infections may 
not develop into exo-erythrocytic phase merozoites, but instead become dormant 
liver parasites termed hypnozoites. 
26, 27
  Hypnozoites are responsible for long 
incubation periods and late relapses in the disease.  After a period of dormancy, the 
hypnozoites reactivate and release merozoites weeks to months after the initial 
prophylaxis and treatment of the primary infection, reactivating the exo-erythrocytic 
cycle.  Hypnozoites pose a threat when it comes to eradicating the disease due to the 
potential relapses in malaria.
28
 
During the erythrocytic phase, some merozoites can differentiate into gametocytes 
which are a sexual form of the Plasmodium.  These male and female forms of the 
parasite can only complete the sex cycle if they are taken from the blood of an 
infected person when the mosquito takes its blood meal.  Since the gametocytes are 
formed in the blood of the vertebrate host, this host is in fact the definitive host of 
the disease.  The parasites multiplication in the mosquito is known as the sporogonic 
phase.  Over a period of two weeks the sexual cycle is completed through 
fertilisation of the female gametocyte by the male gametocyte, forming a zygote.  
These zygotes become motile and elongated and are termed ookinetes, at which 
point they can invade the mid-gut wall of the mosquito and develop into oocysts.  
The oocysts can then grow, rupture, and release sporozoites which migrate to the 
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mosquitoes salivary glands, ready to infect human hosts and continue the malaria life 
cycle through subsequent bites. 
1.3 Antimalarial Chemotherapy 
An early diagnosis of malaria and onset of treatment reduces the disease and 
prevents death, whilst also contributing to a reduction in transmission rates.  Malaria 
is typically diagnosed through the microscopic examination of blood,
29
 but both 
saliva and urine have been investigate as less invasive alternative.
30
  However, many 
areas cannot afford laboratory diagnostic testing so quite often a diagnosis is made at 
home based on a history of recurrent fevers.
31
  This can lead to misdiagnosis and 
therefore improper treatment for potential underlying conditions such as pneumonia 
and meningitis.  Significant developments in commercial antigen detection methods 
for malaria diagnosis have been made and field tested in areas where microscopy is 
unavailable.
32
  These tests require only a single drop of blood and are completed 
within twenty minutes, the results of which are easily interpretable through the 
presence or absence of a coloured stripe on the testing dipstick.  Concerns with this 
method though are that the results are qualitative not quantitative, and are unable to 
determine the number of parasites present in the blood, and thus disease progression. 
Once a malaria diagnosis has been made, drug chemotherapy has proven to be an 
effective strategy to treat and cure the disease.  Different drugs act on different 
stages of the Plasmodium life cycle, with many being used not only to treat infected 
individuals, but also in a chemoprophylaxis approach to prevent the disease in 
travellers.
15, 33
  With regard to both treatment and prophylaxis there are a number of 
options available. 
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Traditionally, antimalarial drugs were classified based on which stage of the 
Plasmodium life cycle they targeted.
34
  Blood schizonticides act on the asexual 
intraerythrocytic stages of the parasite, and are sufficient to cure P. falciparum 
infections as this Plasmodium has no dormant liver phase.  Tissue schizonticides kill 
hepatic schizonts, thus preventing the invasion of erythrocytes.  Hypnozoiticides are 
required though to fully cure P. vivax and P. ovale infections, as they kill the 
persistent intrahepatic stage parasites which cause relapses in malaria, and as such 
should be combined with blood and tissue schizonticides.
35
  Finally, 
gametocytocides destroy intraerythrocytic sexual forms of the parasite, preventing 
transmission from human to mosquito, thereby halting the Plasmodium life cycle. 
The first medicine used in the treatment of malaria was found in the powdered bark 
of the chinchona tree, the active ingredients of which were the quinoline alkaloids 
quinine and quinidine (fig. 1.2).
34
 
  
Quinine Quinidine 
Fig. 1.2  Quinine and quinidine, the first antimalarial agents. 
Attempts at synthesising quinine led to the surreptitious discovery of a number of 
quinoline analogues active against malaria, which in turn drove a number of 
structure activity relationship (SAR) studies to design more activity antimalarial 
agents.  The end result of these studies was the discovery of chloroquine (CQ), 
which went on to become the foundation of malaria chemotherapy for at least two 
decades.
36-39
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1.3.1 Chloroquine (4-Aminoquinolines) 
Chloroquine (fig. 1.3) is a 4-aminoquinoline compound and was previously one of 
the most important synthetic chemotherapeutic agents in history.  The World Health 
Organisation (WHO) once considered it its drug of choice for the Global Eradication 
Program, and until recently CQ was the cornerstone of antimalarial treatment and 
prophylaxis.
7, 21
 
 
Fig. 1.3  Chloroquine, a 4-aminoquinoline compound. 
CQ is a relatively affordable drug that has been widely tested, and which despite 
having a narrow therapeutic index with a therapeutic dose of only 10 mg kg
-1
, is 
reasonably well tolerated owing to its efficacy, tolerability, and safety in pregnancy 
and childhood.
15, 34
  However, long term prophylaxis may lead to irreversible 
neuromyopathy, retinopathy and other conditions, but these incidences are rare.
40
 
The mechanism of action of CQ is still a matter of much debate, but it is commonly 
agreed that it is a potent blood schizonticidal drug which acts against the erythrocytic 
forms of all Plasmodium.
41, 42
  As previously discussed, the parasite consumes large 
amounts of haemoglobin within the host cell which is shuttled by vesicles to the food 
vacuole, also called the digestive vacuole (DV).  During the digestion of 
haemoglobin it is broken down into its component peptides which are thought to be 
exported from the DV, leaving behind ferriprotoporphyrin IX (FPIX), also known as 
haem.
43-45
  Ordinarily this free haem is toxic to the parasite at high concentrations, 
but the parasite disposes of this hazardous waste through the formation of an 
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insoluble polymer called haemozoin.  CQ acts similar to other 4-aminoquinlines by 
forming a complex with this free haem, preventing its polymerisation to 
haemozoin.
46,47
 
CQ is a dibasic compound with pKa values of 10.2 and 8.1 for the diethylamine and 
quinoline ring nitrogen’s respectively.48  Unprotonated CQ is membrane permeable 
and thought to distribute equally across all cell compartments.  However, CQ 
becomes trapped in the acidic DV (estimated pH of 5.2-5.8)
49
 as a dication, where it 
can accumulate by some orders of magnitude in its membrane impermeable form.
50
  
Most NMR and molecular modelling studies
51
 seem to suggest that the quinoline 
part of CQ binds to the porphyrin ring system of haem with face-to-face π 
staggering, and that this binding allows for the build-up of non-crystalline haem, 
ultimately leading to parasite cell death.
52
  The clinical use of CQ has diminished of 
late however, due to the continued development of resistance in the malaria 
parasites.
34
 
1.3.1.1  Chloroquine Resistance 
CQ was the most widely used antimalarial drug in the 1940’s,53 but by the late 50’s 
(only twelve years after its initial introduction) the first cases of P. falciparum CQ 
resistance began to emerge in Thailand and Cambodia.
15
  Due to its massive use, 
chloroquine resistant (CQR) Plasmodium strains developed in many regions, and 
have successively spread over almost all the malaria endangered parts of the 
world.
54, 55
  Presently, more than 80% of wild isolates are resistant to CQ.
56
 
The mechanism of action of CQ resistance has been the subject of much research.  It 
is believed to be removed from its site of action in the DV due to an enhanced efflux 
of the compound from the parasite vesicles, as a result of increased expression of the 
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multidrug resistance transporter P-glycoprotein.  This influences the sensitivity of 
the malaria parasites to a diverse range of drugs.
57-59
  The primary cause of CQ 
resistance is a mutation in the Pfcrt gene that codes for a protein called the P. 
falciparum chloroquine resistance transporter (Pfcrt).  This 10-transmembrane 
domain transport protein belongs to the drug metabolite transporter (DMT) 
superfamily located in the membrane of the DV.  It is proposed that the role of this 
protein is to transport amino acids or small peptides from haemoglobin degradation, 
into the cytoplasm.
60
 
CQR strains of the parasite all have a threonine residue in place of a lysine at 
position 76 of the protein.
61, 62
  Ordinarily, the positively charge lysine side chain is 
thought to prevent access of the dicationic form of CQ to the substrate binding site of 
the transporter, but the K76T mutation replaces this positively charged side chain 
with a neutral moiety.  This alteration in the membrane protein affects the ion 
trapping effect which CQ activity is reliant upon, by allowing the CQ dication to 
access the transporter, which in turn decreases the concentration of CQ in the DV 
down a steep concentration gradient.
48
  This leads to a reduction in the overall 
concentration of CQ at its site of action, and thus a decrease in the sensitivity of the 
parasite. 
Research into the 4-aminoquinoline class of compounds continues to be an active 
area, with a number of modifications to the CQ structure able to circumvent the 
aforementioned resistance mechanism.
42, 63, 64
  Three main observations to combat 
resistance have been made: elongation or shortening of the diaminoalkyl side chain; 
introduction of lipophilic or aromatic moieties into the side chain; dimerization of 
two 4-aminoquinolines by a linker of variable nature and length.  Amodiaquine (fig. 
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1.4) is an example of one such enhancement of CQ, in which the lipophilicity of the 
side chain was increased through introduction of an aromatic structure. 
 
Fig. 1.4  Amodiaquine, a synthetic derivative of CQ. 
Though there is a certain degree of cross resistance between amodiaquine and CQ, 
amodiaquine is effective against low level CQ resistant P. falciparum.
40
  However, 
adverse reactions such as hepatotoxicity and agranulocytosis from prolonged 
prophylaxis have lead to amodiaquine being removed from the market in western 
countries,
65-68
 but the drug may continue to find use in the developing world,
69
 and is 
still an antimalarial recommended by the WHO.
70
 
1.3.2 Artemisinins and Endoperoxides 
Artemisinins and synthetic peroxides are another class of antimalarial drug whose 
origins are based in natural product chemistry.  Extracts of the herb Artemisia annua, 
also known as sweet wormwood have been used in traditional Chinese medicine for 
two thousand years for the treatment of fever.  The active ingredient is artemisinin 
(ART, fig. 1.5), a sesquiterpene lactone which was isolated in 1971, and has been 
used in China for the treatment of malaria since 1972.
71
  It is a highly active 
antimalarial agent with studies reporting IC50 values in the nanomolar (nM) 
concentration activity range.
72, 73
  An IC50 measurement is simply the concentration 
of drug required to inhibit 50% of a biological process, giving a quantitative value of 
a compounds inhibitory activity. 
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Fig. 1.5  Artemisinin, a sesquiterpene lactone antimalarial. 
ART has a 1,2,4-trioxane substructure, the endoperoxide of which is believed to be 
essential for antimalarial activity.
34
  The exact mechanism of action of such 
compounds is still a topic of much debate, but they are believed to act within the 
parasite DV, where it is proposed that iron(II)-mediated cleavage of the 
endoperoxide bridge leads to the formation of an oxyl radical, which rapidly 
rearranges to different C-centred radicals that may be primary or secondary in 
nature.  One or both of these radicals may be the active species, whose formation is 
believed to be activated by free haem in the DV.  The C-centred radicals are thought 
to react with free haem preventing its detoxification, as well as alkylating to vital 
parasite proteins, inhibiting a multitude of enzymes and leading to parasite cell 
death.
45, 74-78
 
Artemisinins predominately act against the late ring stages of the Plasmodium life 
cycle in which metabolic activity is highest.  However, in contrast to other 
antimalarials, they also act against the small ring stages present in the erythrocytes a 
few hours after infection.  Additionally, artemisinins are also active against the 
sexual blood stages of the parasite, reducing rates of parasite transmission in the 
process.
79
  This combined with artemisinins high activity can reduce parasite 
biomass 10,000 fold in a single asexual cycle, making them the most active and 
rapidly acting antimalarials known today.
80, 81
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1.3.2.1  Artemisinin Resistance 
As was seen with the 4-aminoquinoline class of compounds, there are growing 
concerns with regard to parasites developing resistance in many parts of the world, 
and it was thought that the plant derived compound ART remained the only globally 
effective treatment.
82
  However, scientists claim to have found the first evidence of 
resistance towards ART in parts of Southeast Asia.
4, 83, 84
  Emerging resistance is 
responsible for a recent increase in malaria mortality, particularly in countries which 
had previously eliminated its presence.  In China and Southeast Asia, ART is often 
used without taking precautions against conditions which may lead to resistance of 
Plasmodium to the drug, so there are concerns that the effectiveness of ART 
treatment may be reduced in the near future, as seen with the 4-aminoquinolines.
84
  
Artemisinin combination therapy (ACT) is now the most significant and effective 
treatment protocol for malaria.  However, the combination therapies have shelf lives 
of as little as three years, which is a major limitation when distributing these drugs.
85
 
Despite the emergence of resistance to artemisinins it is still very much an active 
area of research.  ART itself is poorly soluble in water and oil so semi-synthetic 
derivatives have been developed to improve its lipophilicity.  Reducing the lactone 
substructure of ART into a hemiacetal creates dihydroartemisinin (fig. 1.6), which 
can undergo alkylation to yield artemether and arteether, both characterised by an 
acetal moiety. 
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Dihydroartemisinin Artemether Arteether 
Fig. 1.6  Dihydroartemisinin, artemether and arteether, synthetic peroxides and derivatives of ART. 
Artemether and arteether both have antimalarial activity (dihydroartemisinin also 
exhibits some antimalarial activity).  However, artemether is the more prevalent of 
the two, displaying IC50 values in the nM range.
86-88
  Artemisinins are often used in 
combination therapies to improve their half lives and reduce their rate of clearance.
89
  
An alternative modification of dihydroartemisinin is artesunate (fig. 1.7), in which 
the hemiacetal OH group can be acylated with succinic acid.  Despite the instability 
of artesunate, the succinic ester group is rapidly cleaved to release the active agent, 
dihydroartemisinin. 
 
Fig. 1.7  Artesunate, a synthetic peroxide and derivative of ART. 
A major limitation with semi-synthetic ART derivatives is that their production 
relies on a sufficient supply of ART isolated from plants,
34
 the extraction of which 
commonly has a yield of only 0.6%.
90
  This, along with the increased use of ACT 
across the world means that raw material is in short supply.
91
 
Once it was clear that the antimalarial activity of ART and its derivates was 
attributed to the endoperoxide substructure, research began to develop fully synthetic 
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endoperoxide antimalarials.
78, 92
  A complicated synthetic procedure for such 
endoperoxides often leaves them unsuitable for upscale production, with many often 
occurring as racemic products with poor pharmacokinetic profiles.  However, much 
work lead to the discovery of OZ-277 (fig. 1.8), also known as arterolane.  At first 
glance its molecular structure may look like an unlikely pharmacological candidate, 
owing to the presence of an ozonide group and adamantane substituent, but it was 
the first endoperoxide compound to enter into clinical trials.
93, 94
 
 
Fig. 1.8  OZ-277/Arterolane, a synthetic endoperoxide antimalarial. 
Whilst 4-aminoquinolines and ART derivates and endoperoxides represent some of 
the most important antimalarial treatment options to date, there are in fact many 
other options which have been considered. 
1.3.3 Chimeric Compounds 
With the assumption that 4-aminoquinoline and trioxane compounds act on haem 
within the Plasmodium life cycle, chimeric compounds attempt to incorporate both 
of these structural moieties into their design.
95, 96
  The most promising compound in 
this trioxaquine series is shown in figure 1.9, and was found to be active in the nM 
range, alkylating to haem in vitro.
97
 
 
Fig. 1.9  A trioxaquine compound active against Plasmodium in the nM range. 
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Another compound shown to have high nM activity against chloroquine sensitive 
(CQS) and resistant Plasmodium strains
86, 98, 99
 was mefloquine (fig. 1.10), a 
synthetic analogue of quinine (fig. 1.2).  However, despite initial clinical successes, 
resistance has since developed against mefloquine,
88, 100
 and though combination 
therapy is recommended with artesunate (fig. 1.7),
101
 pharmacokinetic concerns may 
lead to the selection of resistant strains.
102, 103
  Yet despite concerns with mefloquine, 
its incorporation into chimeric molecules has lead to some favourable results for this 
class of compound. 
 
Fig. 1.10  Mefloquine, a synthetic analogue of quinine. 
A biologically cleavable chimera of mefloquine and 10-trifluoromethylartemisinin 
has been prepared (fig. 1.11), showing IC50 values in the nM range against a number 
of parasite strains.
104
 
 
Fig. 1.11  Biologically cleavable chimera of mefloquine and 10-trifluoromethylartemisinin. 
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1.3.4 Antifolates 
Antifolates are another example of antimalarial compounds, with drugs such as 
proguanil (fig. 1.12) being introduced in the late 1940’s for the treatment and 
prophylaxis of malaria.
34
  Tetrahydrofolic acid plays a key role in the biosynthesis of 
thymine, purine nucleotides, and several amino acids, but humans depend entirely on 
a dietary intake of dihydrofolic acid, which then undergoes reduction via 
dihydrofolate reductase (DHFR) to tetrahydrofolic acid.  Pathogenic microorganisms 
however, including Plasmodia, synthesise dihydrofolic acid directly from simple 
precursors, utilising dihydropteroate synthase (DHPS).  DHPS is completely absent 
in humans making it an attractive drug target.  Additionally, DHFR is also 
sufficiently different in Plasmodia to that of humans, allowing for the development 
of selective inhibitors against both enzymes.  DHFR and DHPS inhibitors have long 
been used in the treatment of bacteria and protozoal infections, with their use as 
antimalarials also well documented.
105, 106
 
Proguanil acts as a prodrug, yielding the active metabolite cycloguanil (fig. 1.12) 
through oxidative ring closure.  Cycloguanil is effective against sporozoites acting as 
a DHFR inhibitor to halt the folate biosynthetic pathway.  However, due to 
widespread use of these compounds resistant strains have begun to emerge.
107, 108
  
Resistance is thought to have developed through an accumulation of mutations in the 
dhfr gene, which leads to steric clashes when compounds such cycloguanil try to 
bind with PfDHFR.  The folate biosynthetic pathway can therefore continue as 
normal. 
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Proguanil Cycloguanil 
Fig. 1.12  Prodrug proguanil and its active metabolite cycloguanil. 
With emerging resistance across many of the antimalarial classes, and mortality and 
morbidity rates on the rise, there is a necessary need for continued research into 
antimalarial drug development.  This should include the search for novel drugs 
which act at novel targets, the results of which may overcome the clinical resistance 
observed in many marketed antimalarials.
54, 109, 110
 
1.3.5 Mitochondrial Electron Transport Chain Inhibitors 
In recent years the mitochondrial electron transport chain (mtETC) has been 
explored for the development of new antimalarials treatments.  In higher organisms 
the electron transport chain (ETC) occurs within the inner mitochondrial membrane, 
where electron transfer is coupled with the transfer of protons across a membrane.  
The resulting electrochemical proton gradient is used to generate chemical energy in 
the form of adenosine triphosphate (ATP), which plays a critical role in 
respiration.
111, 112
 
The ETC has long been recognised as a potential target for antimalarial 
chemotherapy.
113, 114
  It is comprised of four enzyme complexes:  NADH:ubiquinone 
oxidoreductase (complex I), succinate:ubiquinone oxidoreductase (complex II or 
SDH), ubiquinol:cytochrome c oxidoreductase (complex III or cytochrome bc1 
complex), cytochrome c oxidase (complex IV).
115
  Complexes II and IV are 
conserved in Plasmodia compared to other eukaryotes, but a type II NADH 
dehydrogenase (PfNDH2) replaces complex I.  Also within the Plasmodia are other 
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oxidoreductases, such as dihydroorotate dehydrogenase (PfDHODH) that is present 
within the mitochondria, and has an important role in de novo pyrimidine 
biosynthesis.
116
  Pyrimidine biosynthesis is essential for the formation of nucleic 
acids, glycoproteins and phospholipids in the Plasmodia, as unlike many other 
eukaryote cells, malaria parasites obtain most of their ATP from glycolysis, rather 
than oxidative phosphorylation within the mitochondria.
117, 118
  Glycolysis is a 
metabolic pathway which converts glucose into pyruvate, with the free energy 
released en route used to form ATP and reduced nicotinamide adenine dinucleotide 
(NADH).  As such, the malaria parasites rely completely on pyrimidine biosynthesis 
for ATP generation, with the mtETC responsible for maintaining an electrochemical 
gradient across the mitochondrial membrane, as well as providing a constant pool of 
ubiquinone required for pyrimidine synthesis.
119
  Thus, shutting down the mtETC 
completely, halts critical metabolic pathways within the microorganism, making the 
four enzymes within the ETC, valid and attractive targets.
120
  These four drug targets 
have all been exploited as discovery leads for selective inhibition: PfNDH2; SDH; 
cytochrome bc1 complex; PfDHODH. 
Figure 1.13 illustrates the mtETC.  PfNDH2, which is the alternative complex I in 
Plasmodia, catalyses the electron transfer from NADH to ubiquinone, also known as 
coenzyme Q10 (CoQ).  This maintains a constant pool of nicotinamide adenine 
dinucleotide (NAD
+
) required for reductive metabolic pathways such as glycolysis 
and the tricarboxylic acid cycle,
121
 also known as Krebs cycle.  Krebs cycle is of 
central importance in all living cells, occurring in the matrix of the mitochondria and 
converting carbohydrates, fats and proteins into carbon dioxide and water, which are 
necessary to generate energy.  Succinate dehydrogenase (SDH) feeds electrons along 
the mtETC to the cytochrome bc1 complex, by oxidising the reduced form of flavin 
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adenine dinucleotide (FADH2) back to flavin adenine dinucleotide (FAD), thus 
continuing the cycle.
122
  PfDHODH is the final enzyme in the biosynthesis of 
pyrimidine, and catalyses the oxidation of dihydroorotate to orotate at the outer side 
of the membrane.  The pair of electrons taken from dihydroorotate in this oxidation 
are then transferred through the flavin mononucleotide (FMN) co-factor to 
ubiquinone, which has been generated at the cytochrome bc1 complex.
123-125
 
 
Fig. 1.13  Mitochondrial electron transport chain.  (T. Rodrigues, F. Lopes and R. Moreira, Curr. 
Med. Chem., 2010, 17, 929-956.) 
Inhibition of any of these steps interferes with the main objective of the mtETC, 
which is to regenerate the ubiquinone necessary for the final step of pyrimidine 
biosynthesis, and thus the generation of energy.
126
  These enzymatic complexes are 
structurally different from those homologous to human enzymes, so compounds 
specifically designed to be potent and selective inhibitors of these Plasmodium 
enzymes promise to be exciting antimalarial agents. 
PfNDH2 is a relatively new drug target for which there are few known inhibitors 
available.  What is known though it that whilst the ETC is generally well conserved 
across species, the first component (Complex I) differs in P. falciparum, and it is this 
difference which can be exploited for antimalarial study.
127
  In eukaryotes, Complex 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Fig. 1 - T. Rodrigues, F. Lopes and R. Moreira, Curr. Med. Chem., 2010, 
17, 929-956.). 
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I is composed of NADH:quinone oxidoreductase, also known as rotenone-sensitive 
NADH dehydrogenase.
128
  This oxidises NADH, helping to generate the 
electrochemical potential necessary to produce ATP.  However, P.falciparum codes 
for an alternative non-proton pumping enzyme called PfNDH2, also known as 
rotenone-insensitive NADH dehydrogenase.  Inhibition of this complex stops the 
electron transport chain, and thus the synthesis of ATP.  It is this protein which is 
absent in the host and specific to the parasite, making it an attractive drug target. 
A known inhibitor of PfNDH2 is 1-hydroxy-2-dodecyl-4(1H)-quinolone (HDQ, fig. 
1.14), a highly potent compound with an IC50 value in the nM range.  Its side effects 
are also limited at effective antimalarial concentrations,
129, 130
 but it has been found 
that HDQ’s specificity and effectiveness at PfNDH2 are lacking, and has been found 
to be a more potent inhibitor of PfDHODH.  Thus, specific and selective inhibitors 
for PfNDH2 have still yet to be developed.  Whilst SDH is also well considered as 
an antimalarial drug target, many compounds which inhibit SDH, such as 5-
substituted 2,3-dimethoxy-6-phytyl-1,4-benzoquinone derivatives (fig. 1.15), also 
have a duel inhibitory effect at PfNDH2, so whilst selectivity is a concern, this is 
hopefully something which can be optimised in the future.
120
 
 
Fig. 1.14  HDQ, potent inhibitor of PfNDH2. 
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Fig. 1.15  5-substituted 2,3-dimethoxy-6-phytyl-1,4-benzoquinone derivatives with duel inhibition 
against SDH and PfNDH2. 
Whilst research is ongoing amongst the four drug targets, the most prolific and 
relevant to this thesis is that of complex III.  This target forms the basis of much of 
the work described within this thesis, and will now be fully introduced. 
1.3.5.1  Complex III - Cytochrome bc1 Complex 
The cytochrome bc1 complex represents the only enzyme complex common to 
almost every respiratory ETC whose structures have been studied.
131, 132
  In short, the 
cytochrome bc1 complex is a key enzyme of the mtETC in all metazoa, as well as 
many fungi and protozoa.  It catalyses the transfer of electrons from ubiquinol (a 
reduced form of CoQ) to cytochrome c, a small heme protein which transfers 
electrons between complex III and IV.
111, 133
  This electron transfer is coupled with 
the translocation of protons across the inner mitochondrial membrane, with the 
resulting electrochemical gradient utilised for ATP generation. 
The cytochrome bc1 complex in P. falciparum (Pfbc1) exists as a dimer of two 
monomeric units, each consisting of ten different polypeptides.
134
  Three of these 
polypeptide subunits make up the catalytic core as illustrated in figure 1.16: 
cytochrome b; cytochrome c1; Rieske iron-sulphur protein (ISP).
135
  These three 
subunits participate directly in the electron transfer pathway, with evidence 
suggesting that the highly mobile ISP is crucial for the activity of the complex.
136-138
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The remaining subunits are likely to contribute to complex stability and the assembly 
process.
139
 
 
Fig. 1.16  (a) Homodimeric structure of the yeast cytochrome bc1 complex (PDB accession code 
3CX5).  (b) The structure and Q-cycle mechanism of the catalytic core of the bc1 complex.  (V. 
Barton, N. Fisher, G. A. Biagini, S. A. Ward and P. M. O'Neill, Curr. Opin. Chem. Biol., 2010, 14, 
440-446.) 
The protomotive Q-cycle mechanism provides the most satisfactory model which 
accounts for the electron transfer and proton translocating activity through 
cytochrome bc1, and has been extensively reviewed.
111, 133, 140-146
  The Q-cycle (fig. 
1.16) requires two distinct quinone binding sites; the quinol oxidation (Qo) site and 
the quinone reduction (Qi) site.  These are located on the opposite sides of the 
membrane, linked by a transmembrane electron transfer pathway provided by the 
membrane spanning cytochrome b subunit.  Cytochrome b provides the Qo and Qi 
sites via two B-type heme moieties bound to the subunit, termed bL and bH 
respectively.  Ubiquinol that is produced by dehydrogenases, binds to the Qo site 
where it is oxidised to release two protons and two electrons into the intermembrane 
space.  In a bifurcated reaction where each electron follows down a separate path, 
one electron reduces the iron-sulphur cluster in the head domain of the Rieske 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Fig. 1 - V. Barton, N. Fisher, G. A. Biagini, S. A. Ward and P. M. O'Neill, 
Curr. Opin. Chem. Biol., 2010, 14, 440-446.) 
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protein, whilst the other reduces bL on cytochrome b.  Subsequently, heme bL is 
oxidised by neighbouring heme bH, which further recycles the electron through 
reduction of ubiquinone to ubiquinol at the Qi site.  The reduced ISP undergoes a 
conformational shift in which the histidine acceptor residue at the head group rotates, 
allowing for close contact of ISP with the heme of cytochrome c1, and thus the 
transfer of an electron.  The reduced cytochrome c1 is then oxidised by cytochrome 
c, which acts as an electron donor to cytochrome c oxidase (complex IV), allowing 
the ETC to continue. 
Pfbc1 is a major drug target in the mtETC, with several species of the complex 
having been cocrystallised with a number of ligands bound in the Qo and Qi sites, 
providing further insight into the complex function.
135, 147-149
  Pfbc1 inhibitors have a 
number of potential binding pockets.
120
  Some compounds bind within the Qo site, 
blocking the electron transfer from ubiquinol to the ISP, and electron transfer onto 
the bL centre.  Whilst others prevent electron transfer from ISP to cytochrome c1, as 
well as electron transfer onto the bL centre.  Compounds can also inhibit the Qi site, 
thereby blocking electron transfer from the bH centre to ubiquinone. 
Inhibitors specific to the Qo or Qi targets are well known.  Myxothiazol and 
stigmatellin are potent Qo inhibitors (fig. 5.2), whilst the natural antibiotic antimycin 
A selectively binds at Qi (fig. 5.3).  The mode of action of these compounds is well 
documented from a variety of crystallographic, spectroscopic and kinetic studies.
148, 
150
  However, the use of these compounds is limited in terms of therapeutics, as they 
are often highly toxic in mammals and other non-pathogenic organisms.  The overall 
structure of the cytochrome bc1 complex, particularly at its catalytic core, is highly 
conserved between species, but the Qo site in Pfbc1 does have some unusual 
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structural features, which may help drive efforts towards target selectivity.  Selective 
quinol antagonists are therefore potent and attractive inhibitors. 
1.3.5.2  Atovaquone 
Atovaquone (ATOV, fig. 1.17) is currently the only drug in clinical use which 
targets Pfbc1.
151-153
  It inhibits the cytochrome bc1 complex, thus collapsing the 
mitochondrial membrane potential leading to parasite cell death.  It also displays 
broad antiprotozoal activity in the low nM range for several development stages of 
Plasmodia.  Unfortunately, high levels of resistance to ATOV have been observed 
which correlate to a number of point mutations in cytochrome b.  As a result of this, 
ATOV is now used in combination with proguanil in an attempt to improve the 
efficiency of the compound, and to decrease the enzymes mutation rate.  In 
combination the drug is marketed as malarone.
154
 
 
Fig. 1.17  Atovaquone, currently the only licensed drug to inhibit Pfbc1. 
ATOV has yet to be cocrystallised with Pfbc1, so a direct study regarding its mode of 
action has yet to be performed.  However, ATOV is a potent inhibitor of Baker’s 
yeast (Saccharomyces cerevisiae), the bc1 complex for which shows high sequence 
homology with that of the parasite.
155
  Through electron paramagnetic resonance 
(EPR) spectroscopy of the Rieske ISP cluster, site-directed mutagenesis of model 
organism cytochrome b, and gene sequencing of ATOV resistant Plasmodium 
species, it has been shown that ATOV is a competitive inhibitor of ubiquinol at the 
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Qo site.
156
  This results in the collapse of the parasitic mitochondrial membrane 
potential, whilst having no effect on its mammalian counterpart.
119
 
The Qo site is a large domain within cytochrome b, formed from components of the 
C-terminal region of transmembrane helix C, the surface helix cd1 (residues 138-
155), and the stretch encompassing the PEWY loop/ef helix to transmembrane helix 
F1 (residues 269-295).
150
  ATOV binds in the Qo site when the soluble domain of the 
Rieske protein is proximal to cytochrome b, and interacts directly with the ISP.  This 
prevents mobilisation to cytochrome c1, and consequently impairs the mitochondrial 
transmembrane potential.
117, 152, 157, 158
. 
 
Fig. 1.18  H-bond interactions of atovaquone (X) within the Qo site.  (J. J. Kessl, B. B. Lange, T. 
Merbitz-Zahradnik, K. Zwicker, P. Hill, B. Meunier, H. Palsdottir, C. Hunte, S. Meshnick and B. L. 
Trumpower, J. Biol. Chem., 2003, 278, 31312-31318.) 
Figure 1.18 illustrates two hydrogen bond interactions which are observed between 
ATOV and amino acids in the Qo site.  The hydroxyl group of the naphthoquinone 
ring bonds to the imidazole nitrogen of His181 (histidine) of the Rieske protein.
159
  
An additional water mediated hydrogen bond interaction exists on the opposite side 
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of the ring system, between the carbonyl group at position 4 of the quinone ring and 
the carboxyl group of Glu272 (glutamic acid) of cytochrome b.
156, 157
  Additional 
hydrophobic contacts are thought to occur between the lipophilic trans substituted p-
chlorophenyl ring system with the side chain residues Ile147 (isoleucine) and 
Leu275 (leucine).
159
  ATOV locks the conformation of ISP to the binding conformer, 
immobilising the cluster and preventing electron transfer.  This collapses the 
membrane potential, but also impacts on the metabolic enzymes which depend on 
the ETC, such as PfDHODH.
126
 
1.3.5.2.1  Atovaquone Resistance 
There has been evidence to suggest the existence of ATOV resistance in P. 
falciparum as early as the first few months of this century,
160
 with clinical trials 
demonstrating that when used as a monotherapy, there is a high rate of recrudescence 
of infection.
161, 162
  Resistance mutations associated with ATOV are predominantly 
restricted to the highly conserved PEWY region, which helps recognition and 
electron transfer within the Qo site.
115
  The most common point mutations observed 
in ATOV resistant isolates of P. falciparum are at codon 268 in cytochrome b.
163-166
  
Y268 is highly conserved across phyla and located within the ef helix of the Qo site.  
The exchange of a tyrosine group in wild-type parasites to either a serine (Y268S) or 
asparagine (Y268N) has been found to increase the IC50 values of ATOV 800 to 
10,000 fold.
167-169
  The side chain of the residue is likely to participate in stabilising 
the hydrophobic interaction with bound ubiquinol,
134
 with molecular modelling 
suggesting a similar stabilising interaction for ATOV when bound in yeast 
cytochrome b.
156
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However, the Y268X mutation seems not to be the only requirement for treatment 
failure.
167
  Mutations at residue 133 from methionine to isoleucine (M133I), and at 
271 from leucine to phenylalanine (L271F) have been generated in vitro, and have 
been identified in other Plasmodium species to bring about resistance.
166, 170, 171
  
Other mutations in positions 258, 267, 272 and 280 have also resulted in a 1,000 fold 
increase in the drugs effective IC50 value.
109, 172
  Aside from the obvious drawbacks 
of emerging resistance towards ATOV, there are also other factors at play which 
limit its potential.  Whilst the drug may have excellent antimalarial activity, it has 
poor pharmaceutical properties, such as low bioavailability and high plasma protein 
binding.
119
  Despite this Pfbc1 still remains a strong target for antimalarial drug 
development, in particular the well studied ubiquinol oxidation (Qo) site. 
Yet although there have been continued advances in the field, malaria is still one of 
the most prevalent and devastating diseases of our time.
173
  There are relatively few 
effective therapies remaining, and an urgent need for novel classes of antimalarial 
targets and drug classes.  Collaborative efforts such as the Bill & Melinda Gates 
foundation
174
 and the Medicines for Malaria Venture (MMV)
175
 now lead the way 
with regard to improving existing methods and developing new tools to prevent and 
treat malaria, with the common goal being the eradication of the disease. 
1.4 Drug Design and Discovery 
The drug discovery process is highly complex and requires an interdisciplinary and 
concerted approach to design effective and commercially viable drugs.  It is a time 
consuming effort taking on average ten to fifteen years from preclinical discovery to 
regulatory approval, and whilst the total cost is subject to much contention and 
debate, it is now thought to cost around one billion US dollars to get a new drug to 
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market.
176-179
  There are continued pressures to produce new and more effective 
therapies for a whole host of diseases, whilst simultaneously cutting down both the 
cost and timeframe for discovery.  Experience has shown that drug discovery and 
development is a difficult and risky business, with only one in ten of the drugs which 
enter clinical development overcoming the relevant hurdles required for regulatory 
approval, and ultimately reaching the market.
180, 181
 
The drug development process begins with the scientific study of a disease, the 
results of which may afford a potential target for which chemical intervention is 
possible.  Following target identification the search can begin to find compounds 
which interact with this site of interest, which may be a receptor, enzyme, ion 
channel or even DNA or RNA.
182
  Once an initial active structure has been found, a 
cycle of iterative steps can begin which involve optimisation and refinement of the 
structure, to improve its activity and pharmacological profile, ready for clinical 
development.  If the clinical phase is successful and regulatory approval is granted, 
marketing can begin. 
Despite a long period of success, the drug discovery pipelines have been relatively 
thin in the last decade, with drug launches steadily falling over recent years.
183
  This 
may be attributed to several factors which affect the drug discovery process.
184
  The 
more precise the medicinal target of interest is, then the less likely it is that a new 
drug will be developed.  That is, finding a drug to treat a disease would be easier 
than finding a drug to target a specific part of a disease pathway.  Medicinal chemists 
also influence the outcome of drug discovery based on their knowledge of structure 
optimisation, and their understanding of the disease target, as well as the facilities 
which are available both for synthesis and biological screening.  The total cost of 
developing a new drug is also a hugely limiting factor during the drug discovery 
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process.  Of about 5,000 to 10,000 compounds initially studied, only one reaches the 
market.  Not only that but expensive synthetic routes can hamper production, as well 
as the high regulatory standards which must be met for new drugs. 
There are a number of important features that an ideal drug should possess.  It should 
be safe and effective at its desired target, preferably being orally absorbed and 
bioavailable.  Metabolic stability is also important, with an attractive half-life in the 
body with minimal side effects and toxicity.  It should also have selective 
distribution within the target tissues, with all of these requirements combined 
increasing the demands on drug discovery. 
Decreasing success rates for drug discovery may be due in part to changes in 
conventional discovery methods.  There is evidence of the use of medicines and 
drugs as far back as 3100 BC,
184
 and for many diseases, not least that of malaria, 
little emphasis needs to be placed on the continued need for new drugs.  However, 
the majority of the time, drug discovery is a process of trial and error.  Commonly, 
drug development has revolved around the use of high throughput screening (HTS), 
which involves the use of robotics to quickly screen multiple compounds against a 
particular biochemical target.  At the lead generation stage, HTS requires a library of 
compounds and an assay for which to measure activity of these compounds 
against.
185
  Successful hits are generally considered to be those with IC50 values of 
about 10 micromolar (µM) or less,
186
 with extensive lead optimisation typically 
employed to lower this value to the 1 to 10 nM range.  Lead hits can also be used in 
the understanding of the interaction or role of a particular biochemical process.  
Sometimes though, HTS yields no hits,
187
 and the combination of high costs and low 
hit rates has put the large scale approaches of the early 1990s currently out of 
favour.
188
 
Chapter I 
34 
 
These disadvantages as well as the attraction of more deterministic approaches to 
combat disease led to the concept of ‘rational’ drug design.  New understandings of 
the relationship between structure and biological activity have ushered in the 
beginning of modern drug development, with the new era cutting costs by almost a 
third, and development time from between 10 to 15, to 6 to 8 years.
184
 
Computer aided drug design (CADD) has emerged as a powerful technique in drug 
discovery, and is threatening to turn more traditional approaches upside-down.
189
  
CADD approaches are now widely used in the pharmaceutical industry to accelerate 
the drug discovery process,
190, 191
 and allow for more focus to be placed on the most 
promising compounds in a series, minimising the overall synthetic and biological 
testing load. 
1.5 Molecular Design Loop 
The molecular design loop can be considered as the ‘rational’ approach to most 
modern drug discovery endeavours, and consists of a three phase cycle of design, 
synthesis and testing (fig. 1.19).
192
  In essence the molecular design loop involves 
marrying together computational efforts with chemical synthesis and biological 
testing in an iterative manner.  Analysis of the results from one iteration provides 
useful information and knowledge that enables the next cycle of the loop to be 
initiated, with improvements made along the way.  With the three specialist fields 
combined, chances of achieving success are greatly improved. 
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Fig. 1.19  Molecular design loop. 
Whilst the focus of this thesis is very much centred on the use and application of 
computational chemistry techniques, it does touch on elements of chemical synthesis 
and biological testing.  The following sections will introduce each of these topics in 
a context relevant to how they have been utilised. 
1.6 Computational Chemistry 
Computational chemistry uses the principles of computer science to assist in solving 
chemical problems.  It is an ever expanding field which seeks to predict 
quantitatively, molecular structures, properties and reactivities by computational 
means.  Modelling helps to increase predictions over conventional methods, with 
calculations often based on existing and readily available knowledge.
193
  Its role in 
drug discovery is becoming more important, as it is believed to offer a means of 
improving efficiency to greatly reduce resource requirements, ultimately increasing 
the overall efficiency of drug development.
194-197
  The reality is that the use of 
computational methods permeates all aspects of drug discovery, and those who are 
most proficient in its use have the advantage over their competitors. 
1 
Computational 
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2 
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Biological 
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Computational chemistry can be used in the prediction of properties related to drug-
likeness, as taking onboard ADME (absorption, distribution, metabolism and 
excretion) consideration early in pre-clinical development, may help to avoid costly 
late-stage pre-clinical and clinical failures.
198
  There are several protocols which 
already exist to try and remove compounds which appear non-drug-like before they 
undergo, often expensive, synthetic investigation.  Possibly the most widely 
recognised of these is Lipinski’s rule of five.199, 200  These guidelines state that in 
general, orally active compounds tend to fail less than 2 of the following criteria:  
 No more than five hydrogen-bond donors 
 No more than ten hydrogen-bond acceptors 
 Molecular weight (MW) no greater than 500 Daltons (Da) 
 Partition coefficient log P less than five 
In addition to this though, most chemical software companies now offer modules for 
the computation of ADME related properties,
201
 the predictions of which come from 
relationships trained on experimental data.
202
  The amount of data and reliability of 
the corresponding predictions does however vary, from excellent for 
physicochemical properties such as log P, to more limited for properties such as log 
BB (an index of blood-brain barrier permeability).
203
  Chemical software packages 
such as ADMET Predictor
204
 can calculate this additional information, from which 
informed decisions can be made as to candidates drug like potential. 
1.7 Chemoinformatics 
Chemoinformatics (a branch of computational chemistry) is concerned with the 
application of computational methods to tackle chemical problems, with particular 
emphasis being on the manipulation of chemical information.
192
  It involves the use 
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of computational and informational techniques, which can be applied to a range of 
problems within chemistry.  These in silico techniques are often extensively used 
within pharmaceutical design, with the term chemoinformatics coined in the late 
1990s.
205, 206
 
“Chemoinformatics is the mixing of those information resources to transform data 
into information and information into knowledge for the intended purpose of making 
better decisions faster in the area of drug lead identification and optimisation.”205, 
207
 
1.8 Virtual Screening 
The use of chemoinformatics within the molecular design loop exist in many forms, 
but its widespread use to improve the efficiency of drug discovery, both in industry 
and academia is well documented and cannot be overstated.
186, 208-211
  Most of the 
techniques used within chemoinformatics can be summed up under the guise of 
virtual screening.  Virtual screening is the in silico analogue of biological screening, 
with its aim being to score, rank and/or filter a set of structures from a chemical 
library using one or more computational procedures, to help decide which 
compounds to screen, synthesise or purchase.
192
  Virtual screening has been shown 
to be more efficient than commonly used empirical screening, with some reporting 
that ligand discovery hit rates (the number of compounds binding to a target, divided 
by the total number tested) are greater in virtual screening by two or three orders of 
magnitude when compared with traditional HTS.
212-215
 
There are many different criteria by which structures may be scored, filtered, or 
otherwise assessed in a virtual screening experiment, and it has been proposed that 
virtual screening may be most effective when a succession of methods of increasing 
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complexity are used.
216
  There are several main classes of virtual screening, as 
shown by figure 1.20.  The exact method employed is dependent on the amount of 
structural and biological data available.
217
  Methods fall within one of two 
categories; either they are ligand based or structure based.  Structure based methods 
require the 3D structure of the protein drug target,
218
 whilst ligand based methods 
can be used with only the chemical structures of known active and inactive 
compounds at a particular target. 
 
Fig. 1.20  Virtual screening techniques. 
1.8.1 Ligand Based Virtual Screening 
Ligand based virtual screening (LBVS) is used in the absence of a 3D protein 
structure, with lead identification and optimisation being dependant on the 
availability of pharmacologically relevant agents and their bioactivities.
219-222
  
Approaches include similarity searching, pharmacophore mapping, and a host of 
machine learning methods including quantitative structure activity relationships 
(QSAR).
222-224
  LBVS is useful when there is little to no experimental or structural 
data available for a biological target of interest, with methods involving the use of 
biological data and the chemical structures of active/inactive compounds.
225
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1.8.1.1  Similarity Searching 
Similarity searching is useful in novel hit identification when there are very few, or 
perhaps even only one active compound known against a particular target.  If there is 
more than one compound available this simply acts to enrich further exploration of 
the chemical space which is being sampled.  Similarity searching in chemical 
databases was first introduced in the mid 1980s,
226, 227
 and offers a complementary 
alternative to substructure searching.  Substructure searching involves the 
specification of a precise query structure, which is then used to search a database of 
compounds to identify those of interest which contain that particular substructure.  
This approach has its limitations though, as certainty around the chosen substructure 
may be ambiguous at best if only one active compound is known, and the library 
would simply be partitioned into those which contain the query and those which 
didn’t.  A simple query may also yield a large number of hits which are not ranked, 
making selection of the most promising candidates difficult. 
Similarity searching on the other hand does as the name suggests.  Here the query 
compound is used to search a database to find those compounds which are most 
similar to it, comparing each molecule in turn and ranking the compounds in order of 
decreasing similarity to the query.  Similarity searching offers several advantages.  
For one there is no need to define a precise substructure with which to search.  The 
user also has control over the number of compounds output, with every compound 
given a numerical score as a similarity measure, so a threshold can be placed only 
considering compounds which exceed a particular level of similarity to the query or 
queries. 
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Like many virtual screening methods, similarity searching utilises the similarity 
principle, which states that structurally similar compounds are more likely to exhibit 
similar properties.
228-231
  Given a molecule of known biological activity, you would 
expect, according to the similarity principle, structurally similar compounds to 
exhibit similar activity.  This characteristic has been referred to as neighbourhood 
behaviour.
229
  Similarity searching is widely used to identify compounds for 
screening from a library, based on an initial molecule which is known to possess 
some desirable activity. 
1.8.1.1.1  Tanimoto Coefficient 
The main consideration with similarity searching is how best to assess the degree of 
similarity between compounds.  There are many ways of quantifying similarity, but 
perhaps the most commonly used in virtual screening is that of the Tanimoto 
coefficient.
192
  It is a similarity method based on two-dimensional (2D) fingerprints, 
which are simply binary vectors that indicate either the presence (“1”) or absence 
(“0”) of a particular substructural fragments within a molecule.  It offers a method of 
quantifying the fragments in common between two molecules.
227
  The Tanimoto 
coefficient between two molecules, A and B (   ), can be calculated using equation 
1.1, where   represents the number of bits (“1”) or fragments which are present in 
molecule A,   the number of bits in molecule B, and   the number of bits common to 
both molecules. 
     
 
     
 
Eq. 1.1  Tanimoto coefficient. 
Figure 1.21 illustrates a hypothetical example of how the Tanimoto similarity 
coefficient is calculated.  In this example, the similarity between molecules A and B 
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can be quantified with a Tanimoto coefficient value of 0.56.  The Tanimoto 
coefficient can range between 0 and 1, with a value of 1 indicating that the molecules 
have identical fingerprint representations, and a value of 0 indicating that there is no 
similarity or common fragments between the two.  Recent studies have suggested 
that 2D fingerprints generally perform better than 3D structure based methods in 
virtual screening.
232
 
 
    
 
     
 
Fig. 1.21  Calculating similarity between molecules A and B using binary vectors and the Tanimoto 
coefficient.  (A. R. Leach and V. J. Gillet, An Introduction to Chemoinformatics, Springer, 2007.) 
1.8.1.2  Pharmacophore Mapping 
Another LBVS approach which can be used in the absence of receptor details is 
pharmacophore mapping.
224
  Unlike similarity searching which can be performed 
when only one active compound is known, pharmacophore mapping requires a 
number of molecules in order to build up a consensus pharmacophore model.  A 
pharmacophore can be defined as the ensemble of steric and electronic features that 
are necessary to ensure the optimal supramolecular interaction with a specific 
biological target, to either trigger or block its response.
233, 234
  Pharmacophore 
models are often employed and found computationally by extracting common 
features from the superimposed structures of known actives.
235
  It does not represent 
a real molecule or a real association of functional groups, but instead is a purely 
abstract concept that accounts for the common molecular interaction capacities of a 
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group of compounds towards their target structure, and can be considered as the 
largest common denominator shared by a set of active molecules. 
The pharmacophore model may represent the key positioning of pharmacophoric 
descriptors within a hypothetical binding site, including H-bond donors, H-bond 
acceptors, hydrophobic and aromatic groups, as well as positive and negative 
ionisable sites.  These groups represent chemical features complementary to the 
receptor in 3D space, and will most likely be involved in binding and contribute to 
the activity at the target site.  The use of these features is an extension of the concept 
of bioisosterism, which recognises that certain functional groups have similar 
biological, chemical and physical properties.
236, 237
 
A common binding mode of all reference ligands is a prerequisite for building a 
meaningful model, meaning that all molecules within a dataset should be active at 
the same target within a biomolecular disease pathway.
225, 235, 238
  There are however 
concerns with pharmacophore mapping, chiefly how the conformational flexibility of 
the molecules is taken into account, and also the potentially large number of 
pharmacophoric group combinations. 
Pharmacophore mapping is of particular use when trying to identify structures with 
desirable bioactivity profiles from a large and previously unexplored area of 
chemical space.
239
  This is due to the abstract nature of pharmacophore mapping, in 
that it depends on atomic properties rather than element types, and not on any 
specific chemical connectivity.  Even a simple pharmacophore model can afford a 
set of considerations which can greatly reduce the search space, and provide a more 
focussed approach to selecting molecules from a chemical library. 
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1.8.1.3  Quantitative Structure Activity Relationship 
Quantitative structure activity relationships (QSAR) or quantitative structure 
property relationships (QSPR) represents a branch of statistical machine learning 
used to correlate the structural or physicochemical properties of a molecule with a 
measured property, such as biological or chemical reactivity.
192
  The idea of SAR 
dates back to 1868 when reports were made of the correlation between paralysing 
activity and the nature of quarternary groups in a collection of strychnine like 
compounds.
240
  More recently however, studies in the 1960’s by Hansch 
demonstrated QSARs applicability and usefulness, leading to its growing use.
241, 242
  
QSAR is commonly used in predictive toxicology to avoid drug attrition,
233
 as 
toxicity has been one of the main causes of drug failure.
180
  QSAR methods have 
therefore gone some way to answer the call for in silico methods for the predictive 
evaluation of drug toxicity, in order to minimise animal testing. 
QSAR can be used to build mathematical relationships between the structural 
attributes and target properties of compounds in a chemical dataset.
223, 243, 244
  These 
structural attributes or molecular descriptors as they are commonly referred to, 
describe the various chemical properties of the compounds, and when numerically 
expressed, may predict the biological activity of the compounds in the dataset.  
When a successful relationship has been found, it may be used to predict the 
biological activity of external structures not used during model generation.  Such 
QSAR models have the general form shown in equation 1.2. 
                                    
Eq. 1.2  General QSAR equation. 
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When QSAR was first derived by Hansch for a series of structurally related 
compounds,
241, 245, 246
 the molecular descriptors which were quantified related to the 
electronic and hydrophobic characteristics of the compounds.  Using these, a 
relationship was proposed between molecular structure and the property of interest.  
This led to equation 1.3, where   represents the concentration of compound required 
to produce a standard response in a given time,       the logarithm of the molecules 
partition coefficient between 1-octanol and water, and   the appropriate Hammett 
substitution parameter.  The values of   represent coefficients of the equation. 
    
 
 
                
Eq. 1.3  Hansch QSAR equation. 
A set of known ligands can provide the basis for a target specific QSAR model, with 
the models built used to predict the potential activity of other molecules based on 
their own molecular structures.
247
  For example, drug activity may be predicted 
without knowing the nature of the binding site for that compound, through a 
correlation of molecular properties of the ligands and their measured activities, 
useful when there is no 3D protein structure available. 
1.8.1.3.1  Molecular Descriptors 
Molecular descriptors are a set of properties/values associated with molecular 
structures, that encode molecular/chemical information in numerical form.
248, 249
  
The concept of molecular descriptors was developed with the advent of QSAR, when 
very early on it was discovered that the steric, electronic and hydrophobic properties 
of molecules were largely responsible for drug behaviour.
250
  QSAR has since 
evolved to encompass more than 3,000 descriptors as a means of encapsulating 
molecular properties.
251,246
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Molecular descriptors are generated from chemical structures using programs that 
can perform various feature recognition calculations to produce a series of values for 
each compound.
252, 253
  These values are compressed representations of the chemical 
structure, and may consist of 0, 1, 2 and 3D molecular properties.  Zero-dimensional 
(0D) descriptors represent dimensionless properties which are independent of 
molecular connectivity and conformations.  These may include features such as 
molecular weight and atom counts,
252, 254
 and are essentially features which are based 
solely on a compounds molecular formula.
255
  One-dimensional (1D) descriptors 
capture chemical functionality and the fragments of a molecule, and represent 
molecular properties such as hydrophilic factors and bond counts.
251, 254
  2D 
descriptors can correspond to physicochemical and topological properties,
256
 
encoding for charges and topological bond distances between atoms.  Finally, 3D 
descriptors encode for structural geometry, chirality, and the respective charges and 
electrostatic surfaces of molecules.
257
  However, assigning 3D descriptors can be 
problematic, as it is necessary to predict the conformation and/or alignment of the 
different compounds in their active conformations, which can be difficult for highly 
flexible molecules.
258
 
It is hoped that by combining 0, 1, 2 and 3D molecular descriptors, the majority of a 
compounds molecular properties can be represented numerically.  However, even 
when 3D descriptors are omitted, QSAR analysis using just 0, 1 and 2D descriptors 
can still provide powerful and reliable results, together with readily interpretable 
models.
259
  Both 2D and 3D QSAR approaches have been developed successfully,
260, 
261
 but their use is dependent on the molecular descriptors available, and the 
mathematical approaches used to establish correlation between the target property 
and the descriptors. 
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1.8.1.3.2  Multiple Linear Regression 
Perhaps the most popular and widely used machine learning technique for QSAR 
development, from which many other approaches are based upon, is linear 
regression.  In its simplest form it has a linear equation as shown by equation 1.4,
192, 
262
 where   represents the dependent variable,   the independent variable, and   
some sort of constant term.  The dependent variable is the property one is trying to 
develop a QSAR model for such as the biological activity, and the independent 
variable would be a molecular descriptor of some sort.  The aim of linear regression 
is to give the smallest possible sum of squared differences between the actual 
dependent observations, and those predicted from the regression equation. 
       
Eq. 1.4  Simple linear equation. 
Multiple linear regression (MLR) is an expansion of simple linear regression, and 
involves more than one independent variable.  It is the traditional statistical approach 
for deriving QSAR models for a dataset, relating the dependent variable ( ), to a 
number of independent variables ( ) using linear equations, similar to that of 
equation 1.5. 
                    
Eq. 1.5  Multiple linear regression equation. 
The gradient ( ) and constant ( ) can be calculated using equations 1.6 and 1.7 
respectively. 
  
                 
 
   
          
 
   
 
Eq. 1.6  Calculating the gradient. 
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Eq. 1.7  Calculating the constant. 
  represents the number of data points, and     and     are the means of the 
independent and dependent variables represented by equations 1.8 and 1.9 
respectively. 
    
 
 
   
 
   
 
Eq. 1.8  Independent variable. 
    
 
 
   
 
   
 
Eq. 1.9  Dependent variable. 
Before developing a QSAR it is necessary to standardise the independent variables, 
so that each descriptor has an equal contribution to the overall analysis.  The 
descriptors often have substantially different numerical ranges, so it is important that 
they be scaled appropriately, giving each an equal chance of contributing to the 
overall analysis.  Otherwise, a descriptor which has a large range of values will 
overwhelm any variation seen in a descriptor which has a smaller range of values, 
and thus bias the results.  One such method is unit variance scaling, also known as 
autoscaling.
192
  The variables are standardised to have a mean of zero and a standard 
deviation (SD) of one.  This is performed by dividing each descriptor value by the 
standard deviation for that descriptor across all observations (molecules), leaving 
each scaled descriptor with a variance of one. 
The quality of a regression can be assessed in a number of ways, the most common 
of which is to calculate the squared correlation coefficient (  ), which looks at the 
goodness-of-fit for the data.     estimates the proportion of the variation in the 
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dependent variable which is explained by the regression equation.
263
  It has a value 
between zero and one representing the extent of the relationship between the 
dependent and independent variables.  If there is no linear relationship then     , 
indicating that none of the variation in the dependent variable is explained by the 
independent variables.  Conversely, an    value of 1 corresponds to a perfect fit.  
The value of    is found by first calculating the total sum of squares (TSS), the 
explained sum of squares (ESS), and the residual sum of squares (RSS), as shown by 
equations 1.10, 1.11 and 1.12 respectively.  In these equations    represents the 
observed dependent variable, and         the values calculated by feeding the relevant 
independent variables into the regression equation.   
             
 
 
   
 
Eq. 1.10  Calculation of total sum of squares (TSS). 
                  
 
 
   
 
Eq. 1.11  Calculation of explained sum of squares (ESS). 
                 
 
 
   
 
Eq. 1.12  Calculation of residual sum of squares (RSS). 
TSS, ESS and RSS are then all used together in the manner described in equation 
1.13 to calculate   . 
   
   
   
 
       
   
   
   
   
 
Eq. 1.13  Calculation of the    relationship. 
Several recommendations have been made about the optimum value of    in order 
for a model to be considered to have a good fit, yet without over training the data 
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(perfect relationship).
264
  As its value is subjective it is therefore essential to use 
additional statistical methods in order to truly validate a model.  A general rule of 
thumb though is that a QSAR model shows promise if it has an    value greater than 
about 0.7.
265
 
The adjusted    value (    
 ) is interpreted similar to   , except that it takes into 
consideration the number of degrees of freedom.
262
  It is adjusted by dividing the 
residual sum of squares and total sum of squares by their respective degrees of 
freedom, as shown by equation 1.14, where   represents the number of observations 
and   the number of variables.  The value of     
  decreases if an added variable does 
not reduce the unexplained variance in the data. 
    
            
   
     
  
Eq. 1.14  Calculation of the adjusted    (    
 ). 
There are many other criteria which need to be satisfied in order to be confident in a 
models performance.  There are also many other machine learning methods which 
can be employed to develop QSAR models.  Further discussion and review of these 
approaches and validation criteria can be found in Chapter VI. 
1.8.1.4  Machine Learning Methods 
Machine learning encompasses a whole set of techniques which can be used in 
LBVS, and have become increasingly popular in drug discovery because of their 
emphasis on obtaining accurate predictions.
266
  Machine learning could fall under the 
heading of data mining, and can identify relationships in large, multidimensional 
datasets, between the molecular structures and properties of interest.  In initial virtual 
screening it is often better to simply consider molecules as either “active” or 
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“inactive”, or to use activity bins of moderate sizes, such as “high”, “medium” or 
“low”, rather than actual numerical values.  Using these parameters, machine 
learning techniques can be considered as classification methods, with the aim being 
to derive computational models which enable the activity class of new structures to 
be predicted.  In essence, these models can rank chemical structures according to 
their chances of clinical success, greatly aiding the prioritisation of compounds for 
synthesis or selection from a chemical library, saving time, expense and focusing 
biological testing.
267
 
Even with only a few reference compounds, machine learning can significantly aid 
LBVS.
268-270
  Numerous approaches have been developed for building classification 
models for various responses, with these models used to predict labels for a given 
compound based on its structure.  An important method which utilises machine 
learning theory is support vector machines (SVM), which can also be used for the 
generation of QSAR models.
271, 272
  SVM has become very popular as it can produce 
robust SAR models, by attempting to find a boundary or hyperplane that separates 
two classes of compounds (active and inactive).
192
  The hyperplane is positioned 
using examples in the training set (molecules for which biological data exists) which 
are known as the support vectors.  Molecules in the test set (those still to be 
classified) are mapped onto the same feature space and their activity predicted 
according to which side of the hyperplane they fall on.  The distance of a compound 
from the boundary line can be used to assign a confidence level to the prediction, 
such that the greater the distance from the boundary line, the higher the confidence 
in the prediction and vice versa.  One example of its use is in the prediction of active 
compounds against a series of G-protein coupled receptors (GPCRs).
273
  Robust and 
extensively validated models were generated which were able to classify compounds 
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as active or inactive against a number of GPCR assays.  SVM is explored further in 
Chapter VI, with alternative machine learning methods discussed in Chapter II. 
1.8.1.5  Ligand Based Virtual Screening Successes 
There are several examples of LBVS being used successfully within antimalarial 
drug design.
274-278
  One involves the analysis of two diverse sets of compounds 
active against the D6 and NF54 parasite strains of malaria,
279
 both of which are 
mefloquine resistant but CQ sensitive.  The molecules were collected from a number 
of literature sources, and statistically significant QSAR models developed and used 
to predict the activity of compounds structurally similar to those used in the study.  
The ultimate validation for these models was their ability to predict activities for 
these new compounds, which were in good agreement with experimental data.  The 
mechanism of action for these two series was also discussed by analyzing the 
physicochemical meaning behind the molecular descriptors incorporated into the 
QSAR equations.
279
  The results provided the first step towards the prediction of 
novel active compounds, with modelling leading synthetic efforts. 
Other work includes the analysis of inhibitory activities for a series of analogues 
against P. falciparum and the rat protein farnesyltransferase (PFT).
275
  QSARs were 
developed for the two enzymes in order to explore the similarities and differences 
between the two.  The results suggested that molecules with a minimum energy 
arrangement and a low positively/negatively charged surface area are optimum for P. 
falciparum activity, as are those which are less hydrophobic.  Conversely, a more 
positively/negatively charged surface area seemed to be preferred for molecules 
active against the rat-PFT enzyme, with results from this study used to develop 
analogues which were selective for the malaria parasite enzyme. 
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Many more instances of LBVS successes exist outside of antimalarials,
280
 with one 
example being the identification of new lead candidates which show potent dual 
inhibition against phosphodiesterase (PDE) -1 and -5, for development as potential 
cardiovascular therapeutics.
281
  The virtual screening methods, which included 
classification and regression tree analysis using pharmacophore descriptors, 
demonstrated a high predictive ability for bioactivity of new chemical compounds.  
Of the 19 compounds which were tested in the study, 11 had greater than 50% 
inhibition at 10mM, with 7 of them of interest as dual PDE1 and PDE5 inhibitors.  
The uses of LBVS methods is continually being investigated and compared to those 
of SBVS.
282
 
1.8.2 Structure Based Virtual Screening 
Structure based virtual screening (SBVS) has played an important role in drug 
discovery and development.
283-286
  Its use depends on the availability of a 3D protein 
structure, be it through x-ray crystallography, nuclear magnetic resonance (NMR), or 
predicted by homology modelling (the construction of a 3D model for a protein 
based on its amino acid sequence).
186, 218
  From these structures new ligands active 
against a particular target may be designed.
287
  Often it involves the extensive use of 
molecular docking to predict the binding poses and the strength of binding for 
potential ligands within a protein active site.
218
 
Most drugs now arise through discovery programs that begin with the identification 
of a biomolecular target of therapeutic value.
186
  To this end, the molecular docking 
of chemical libraries can be used to identify lead compounds which can be optimized 
in the molecular design loop, through the synthesis and assaying of numerous 
analogues around a SAR.  Crystal structure determinations for complexes of some 
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analogues with the biomolecular target are often possible, and can greatly inform the 
optimisation of lead compounds by studying drug interactions within the binding 
site.
288 
The possible analogues of even a simple hit can define an enormous and largely 
inaccessible chemical space.  Chemical space is a concept which represents the space 
spanned by all possible molecules,
289, 290
 with estimates commonly citing the size of 
drug like chemical space (i.e. compounds with a MW < 500 Da) to contain around 
10
63
 small molecules.
291, 292
  A 3D structure of a compound bound to its target can 
serve to restrict that chemical space to only that which will be most profitable to 
explore.  The ability to see how an active site is configured (the nature and 
conformations of the amino acid side chains), particularly in the presence of an 
inhibitor gives us a detailed insight into the requirements of a system.
288
 
1.8.2.1  Molecular Docking 
The most common structure based virtual screening approach is molecular 
docking.
285, 293
  Molecular docking techniques have been developed over many years, 
with its initial use geared towards methods for the detailed analysis of small numbers 
of molecules.  However, several factors have now played a part in its move towards 
higher throughput structure based methods.  The continued development and 
improvement of high performance computer hardware has provided unparalleled 
amounts of dedicated computing power at relatively low costs to researchers.  There 
has also been a significant effort in expanding the development of new algorithms 
for molecular docking, with tools for analysing the output of such calculations 
enabling scientists to navigate more effectively through large quantities of generated 
data. 
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The aim of molecular docking experiments is to predict the preferred orientation of 
one molecule to a second, when bound to form a stable complex.
294
  Protein-ligand 
docking is of massive importance in rational drug design to predict the binding 
orientation of small molecules within a protein, as knowledge of the preferred 
orientation of a ligand may be used to predict its strength of association or binding 
affinity.
295
  Molecular docking attempts to find the best match/fit between a receptor 
and a ligand, and involves the prediction of a ligand conformation/orientation within 
a binding site. 
A large number of methods have been proposed for molecular docking,
285, 296-298
 but 
it essentially consists of two problems.  The first is the necessity of a mechanism for 
exploring the space of possible protein-ligand geometries, often referred to as the 
poses.  The second is the need to be able to score or rank these poses in order to 
identify the most likely binding modes for each compound in the series, and to 
assign a priority order to the molecules. 
The difficulty with molecular docking is that it involves many degrees of freedom 
around possible binding orientations.  The translation and rotation of one molecule 
relative to another involves six degrees of freedom, and there are in addition the 
conformational degrees of freedom of both the ligand and the protein.  The solvent 
may also play a significant role in determining the protein-ligand geometry, and the 
free energy of binding, even though it is often ignored.  Predictions may be possible 
using interactive molecular graphics programs if the binding mode is well 
understood, or if the ligand is an analogue of a currently available x-ray structure, 
but generally, manual docking is difficult when dealing with large numbers of 
structures and novel ligands. 
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Docking algorithms can be classified according to the degrees of freedom that they 
consider.
192
  Earlier algorithms only considered the translational and rotational 
degrees of freedom of the protein and ligand, treating each as a rigid body.  The most 
widely used algorithms at present allow for the ligand to fully explore its 
conformational degrees of freedom, but some programs also allow for very limited 
conformational flexibility within certain protein side chains.
293, 299
 
An example of a docking algorithm is DOCK.
287, 300-302
  DOCK is generally 
considered to have been one of the major advances in molecular docking, though its 
earliest version only considered rigid body docking and was designed to identify 
molecules with a high degree of shape complementarity to the protein binding site.  
Overlapping spheres of varying radii, derived from the molecular surface of the 
protein are used to create a negative image of the active site.  Ligand atoms are then 
matched to the sphere centres so that the distances between the atoms equal the 
distances between corresponding sphere centres.  This enables the ligand 
conformation to be orientated within the active site, which once checked to ensure 
there are no unacceptable steric interactions, is ready for scoring. 
More recent algorithms take the ligand conformational degrees of freedom into 
account, and can be classified according to the way they explore conformational 
space.  The simplest way is to initially generate a range of ligand conformations 
using a conformational search algorithm in the absence of the receptor, and to then 
dock these conformations using a rigid body algorithm.
303
  Conformations may also 
be generated on the fly in the presence of the receptor binding site.
304
  Force field 
energy evaluation is often used to select energetically favourable conformations, as it 
has been found that ligands generally prefer to adopt local minimum conformation 
when binding to proteins.
305
  This supports the use of local minimum conformations 
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for docking, but also suggests caution is still necessary to prevent excessive energy 
minimisation when generating ligand conformations for virtual screening.  There are 
however, other methods which explore the orientational and conformational degrees 
of freedom at the same time.  These fall under the categories of Monte Carlo 
algorithms, genetic algorithms and incremental construction approaches. 
Monte Carlo docking algorithms are closely related to those employed for 
conformational search analysis.
306
  At each iteration of the procedure either an 
internal conformation of the ligand is changed, or the entire molecule is subjected to 
a translation or a rotation within the binding site.  If the energy of the new 
conformation is lower than that of its predecessor, then the new configuration is 
accepted.  The first docking program to implement a Monte Carlo simulated 
annealing algorithm was that of AutoDock.
306, 307
 
Genetic algorithms (GA) belong to the larger class of evolutionary algorithms 
(EA).
308
  They are based on various computational models of Darwinian evolution, 
and have been widely used in computational chemistry.
309-311
  GA can be used to 
perform molecular docking,
312-315
 in which each chromosome encodes one 
conformation of the ligand together with its orientation within the binding site.  A 
scoring function is then used to calculate the fitness of each member of the 
population, and to select individuals for further iteration.  DOCK
314
 and GOLD
316
 
are both examples of programs which have implemented GA in docking.
307
  Owing 
to the random nature of both GA and Monte Carlo methods, it is usual to perform a 
number of runs to optimise the solutions, and select the structures with the highest 
scores. 
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Incremental construction approaches construct conformations of the ligand within 
the binding site in a series of stages.
316-318
  Typically the algorithm will identify one 
or more base fragments which are docked into the binding site.  These fragments are 
often large and rigid parts of the ligand such as ring systems, and the orientation of 
the base fragments in the active site forms the basis of a systematic conformational 
analysis for the remainder of the ligand, with the protein binding site providing an 
additional set of constraints that can be used to fine tune the search.  The docking 
programs DOCK 4.0
319
 and FlexX
316
 both utilise incremental construction 
algorithms.
307
 
1.8.2.1.1  Scoring Functions 
It is important to make the distinctions between a docking study and a SBVS 
experiment.  Docking involves the prediction of the binding mode of individual 
molecules, to identify the orientation that is closest in geometry to the observed x-ray 
structure.  Studies to evaluate the performance of docking programs using datasets 
derived from the Protein Data Bank (PDB), showed that when the native ligand was 
docked backed into the active site, they were able to correctly predict the binding 
geometries in more than 70% of cases.
320-322
  It is not however always clear which 
docking program will give the best result for a particular case,
323, 324
 it is therefore 
important to carefully consider the results from individual studies. 
For a SBVS experiment, once a pose has been generated in the binding site it is 
necessary to score or rank that ligand, using some function related to the free energy 
of association between the protein and ligand in forming that intermolecular 
complex.  There are a wide range of scoring functions available,
325
 and the ability to 
accurately predict the potency of ligand binding within a protein is of significant 
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value, providing useful starting points for drug discovery.
326, 327
  Once the ligands are 
docked the resulting interactions can be scored, giving a quantitative measure of fit 
quality.  Scoring functions are approximate mathematical methods used to predict 
the strength of the non-covalent interactions between two molecules after they have 
been docked, also referred to as binding affinity.  It is common practice to use 
scoring functions in protein-ligand docking,
328
 but they can also be used to predict 
the strength of intermolecular interactions between two proteins,
329
 or even between 
a protein and DNA.
330
  Scoring functions can be grouped into three categories: force 
field based, empirical, and knowledge based.
331
 
Force field based scoring functions may make a smooth transition to empirical 
scoring functions, and include methods such as GOLDScore
313, 320
 (see Chapter V).  
The scores are estimated by summing the strength of intermolecular van der Waals 
and electrostatic interactions between all atoms of the two molecules in the complex.  
Intramolecular energies of the two binding partners are also frequently included, and 
since binding normally takes place in the presence of water, the desolation energies 
of the ligand and the protein are sometimes taken into account using implicit 
solvation, which is a method of representing a solvent as a continuous medium, 
rather than as explicit solvent molecules.  Force field based scoring functions are 
primarily derived from force fields such as AMBER,
332
 which are frequently used in 
molecular dynamics simulations. 
Empirical scoring functions include ChemScore,
333, 334
 (see Chapter V) and are 
derived to reproduce data of experimentally determined complex structures based on 
physicochemical properties.  They are based on counting the number of various 
types of interactions between the two binding partners.
335
  Counting may be based on 
the number of ligand and receptor atoms in contact with each other, or by calculating 
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the change in solvent accessible surface area in the complex compared to the 
uncomplexed ligand and protein.  The coefficients of the scoring function are usually 
fitted using MLR methods, and may include contributions from hydrogen bonding, 
ionic interactions, lipophilic interactions and the loss of internal conformational 
freedom of the ligand. 
Knowledge based methods rely on the idea that a sufficiently large data sample can 
serve to derive rules and general principles inherently stored in this knowledge 
database.
331, 336-339
  One such scoring function is DrugScore,
338
 which is used to 
describe the binding geometry of ligands in proteins.  It is based on statistical 
observations of intermolecular close contacts in large 3D datasets, such that the 
interaction potential between each ligand-protein atom pair is calculated as a 
potential of mean force.  The method is founded on the assumption that close 
intermolecular interactions between certain types of atoms or functional groups that 
occur more frequently than one would expect by a random distribution, are likely to 
be energetically favourable and therefore contribute favourably to binding affinity.
340
 
With the docking of a large compound library comes the generation of a vast amount 
of data, comprising the predicted binding pose for each compound, along with the 
predicted binding affinity of that ligand at the target.  It is therefore conceivable that 
you could choose a list of compounds to be tested based upon the rank ordering of 
these compounds.
341
  It is well known, however, that current scoring functions used 
in virtual screening are often inadequate at predicting the true binding affinity of a 
ligand for a receptor,
342
 and there is currently no universally applicable scoring 
function.
343
  One popular strategy to attempt to overcome this is the concept of 
consensus scoring.
344-346
  In this approach, when a given docking function is used to 
generate the top ranked poses for the compounds in a target receptor, other scoring 
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functions are used to rescore the top ranked pose for each ligand.  Only those top 
ranked compounds common to each scoring function (consensus) are then chosen for 
biological testing, with this approach showing improvements in the true hit outputs 
from virtual screening.
347
 
As there are a multitude of possible parameters which govern the operation of 
docking programs, it is well recommended to spend time investigating the various 
options available for each docking run which is performed.
192
  Molecular docking 
and particular scoring functions are discussed further in Chapter V. 
1.8.2.2  Structure Based Virtual Screening Successes 
The successes of SBVS are well documented,
293, 348-350
 with the computational 
approaches used varying widely in their methodology, performance and speed.  
Some are capable of providing accurate binding models, whilst others are more 
suitable for the fast searching of large databases.
285, 351-358
  SBVS has contributed 
significantly to the introduction of many compounds into clinical trials, as well as 
led to numerous drug approvals.  One such drug is dorzolamide,
359
 which was 
introduced into the market in 1995.  It is a carbonic anhydrase inhibitor which acts as 
a topical anti-glaucoma agent, and was the first drug which resulted directly from 
SBVS.
360
 
Another example was the discovery of compounds that inhibit DNA gyrase.
187
  DNA 
gyrase is a well established antibacterial target, and the study initially involved the 
random screening of compounds using HTS.  This led to no lead structures, so an 
alternative approach using molecular docking was considered.  350,000 compounds 
were docked, indicating 3,000 molecules of interest.  When these 3,000 molecules 
were tested 150 hits were reported.  7 of these were later validated as true, novel 
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DNA gyrase inhibitors that bound at the ATP binding site.  One compound was ten 
times more potent as a DNA gyrase inhibitor than novobiocin, a well known 
inhibitor. 
A further example is work performed in developing antimicrobial agents against 
Chlamydia pneumoniae.
361
  C. pneumoniae is an intracellular parasite that can cause 
pneumonia, bronchitis, sinusitis, pharyngitis, and atherosclerosis.  The therapeutic 
target of interest was dimethyladenosine transferase, but given that no crystal 
structure was available for this, Bacillus subtilis RNA methyltransferase (PDB 
accession code 1QAO)
362
 was used as a surrogate.  A database of 300,000 
compounds which had been filtered for undesirable chemical groups was docked into 
the protein binding site using FlexX,
316
 after which the top 2,000 molecules were 
inspected and of these, 33 were purchased.  Eight molecules demonstrated greater 
than 50% inhibition at 50 µM in a cell assay, demonstrating that the use of surrogate 
proteins is a viable option if no exact crystal structure of the target exists.
280
 
SBVS can greatly reduce the drug discovery timeframe, due to an enhanced 
understanding of the optimal non-covalent contacts to be made.
363
  However, both 
LBVS and SBVS techniques have the potential to enhance our knowledge and 
understanding as to how certain agents elicit a biological response.  They can also be 
used to optimise existing compounds and allow for the design of novel scaffolds 
with greater selectivity and potency, not least in the field of antimalarial 
chemotherapy.  Insight garnered from computational studies can be fed directly back 
into synthetic work, thus continuing the molecular design loop (fig. 1.19). 
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1.9 Chemical Synthesis 
The next phase of the molecular design loop (fig 1.19), following on from 
computational chemistry is chemical synthesis.  The importance of chemical 
synthesis in drug discovery needs very little emphasis, as nearly all clinical agents 
will have at some point undergone synthetic optimisation or design.
364
 
1.9.1 Synthetic Discovery of Chloroquine 
Within antimalarial chemotherapy there exists no better example of a synthetically 
derived drug than CQ.  As previously discussed, until resistance began to emerge 
towards CQ it was considered the safe and affordable drug of choice in the treatment 
of malaria.
34
  It was the serendipitous end point of efforts which began with the 
attempted synthesis of quinine (fig. 1.2) in 1856.
365
  The total synthesis of quinine 
wasn’t reported till much later in 1944,366 but initial efforts lead to the synthesis of 
mauveine, the first synthetic chemical dye, eventually leading to the birth of the 
chemical industry.
367
  These dyes were used to stain microorganisms to enhance their 
visibility under the microscope, but it was noticed that methylene blue was 
particularly effective in staining the malaria parasites (fig. 1.22). 
Chapter I 
63 
 
 
Fig. 1.22  History of synthetic efforts affording the discovery of chloroquine.  (M. Schlitzer, 
ChemMedChem, 2007, 2, 944-986.) 
In 1891, two malaria patients were cured using methylene blue, and it became the 
first synthetic agent to be used in antimalarial therapy.
368
  However, due to 
prominent but reversible side effects, included turning the urine green and the sclera 
blue, therapeutically it was not used further, but instead formed the basis of 
antimalarial development through chemical modifications of its structure.  A key 
modification was the replacement of one methyl group with a dialkylaminoalkyl side 
chain to give an intermediate compound, the side chain of which was then connected 
to different heterocyclic systems such as quinoline.  This gave rise to pamaquine 
(fig. 1.22), the first synthetic antimalarial drug, which unfortunately failed during 
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clinic evaluation due to multiple side effects including haemolytic anaemia.
369
  The 
congeneric molecule primaquine was better tolerated, and became the main 
representative for the 8-aminoquinoline class of compounds.
370
  Connection of the 
diethylaminoisopentylamino side chain to an acridine heterocycle yielded mepacrine, 
which though popular at one point when the US was cut off from its supply of 
quinine, had substantial side effects that included staining the eyes and skin 
yellow.
371
  The major success in the drug design came with the introduction of the 
diethylaminoisopentylamino side chain into position 4 of a 7-aminoquinoline by 
German inventors, yielding a compound called resochin, later changed to CQ.
372
  
Further study also yielded sontoquin,
373
 a structurally similar compound to that of 
CQ, but whose use was overshadowed by that of CQ, which became the foundation 
of antimalarial chemotherapy.
36-39
 
1.9.1.1  Chloroquine Analogues 
Despite its increasingly limited use, the 4-aminoquinoline chemotype of CQ is still 
the subject of much synthetic investigation.  It is widely accepted that the 4-
aminoquinoline pharmacophore plays a critical role in the complexation of CQ to 
FPIX to prevent the formation of haemozoin and thus parasite growth.
374
  Whilst the 
amino groups in the side chain are considered essential for trapping high 
concentrations of the drug in the acidic DV of the parasite.
375
 
Various studies have revealed that structural changes at the 7-position of the CQ core 
reduces its antimalarial activity,
375, 376
 but modifications of the side chain at the 4-
position pose a more promising site for optimisation.  One study which detailed 
modifications of the side chain with N,N-diethylaminoalkyl side chains with spacers 
consisting of two to twelve methylene units were found to be as effective as CQ 
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against CQS parasite strains (fig. 1.23).
377
  More importantly, the homologs with 
either short or long linkers between the two amino functions showed very good 
activity against CQR parasite strains as well. 
 
Fig. 1.23  Areas for CQ modifications. 
Analogues of CQ with branched and linear side chains containing two and three 
methylenes between the amino groups were also found to have both in vitro and in 
vivo antiparasitic activity, comparable to CQ, against both CQS and CQR strains.
378, 
379
  More recently, work has continued to modify not only the length of the CQ side 
chain, but also its basicity.
380-382
  In particular, success has been had with 4-amino-7-
chloroquinolines which have a short linear side chain bearing two aliphatic tertiary 
amino functions, proving to be highly potent antimalarials of equal effectiveness 
against both CQS and CQR strains (fig. 1.24).
383
 
 
Fig. 1.24  4-amino-7-chloroquiolines with short linear side chains bearing two aliphatic tertiary amino 
functions for improved activity. 
The modifications and studies described here clearly highlight the possibility for 
fresh opportunities using an old chemotype, and work will most likely continue with 
the aminoquinolines indefinitely.  However, with many potential antimalarial targets 
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to hit, and an almost endless amount of chemical space to explore, it is important to 
consider other synthetic approaches and options available. 
1.9.2 Synthesis of Novel Antimalarial Compounds 
Many potential antimalarial targets have been discussed during the introduction, but 
perhaps the most relevant to explore with regard to the work described in this thesis 
(see Chapter VII), is the synthetic efforts towards Pfbc1 inhibitors. 
1.9.2.1  Hydroxynaphthoquinones 
ATOV (fig. 1.17) is currently the only approved treatment against Pfbc1, acting as a 
competitive inhibitor of CoQ.  However, despite its excellent antimalarial activity,
119
 
attempts to improve its low bioavailability are ongoing, and have resulted in the 
design of several alternatives that substitute the 3-hydroxyl functionality for more 
lipophilic ester and ether groups.
384
  Whilst these molecules all had potent 
antimalarial activity, the modifications did not improve their predicted oral 
bioavailabilities.  In a further study, a series of ATOV alternatives were developed 
based on a potent hydroxynaphthoquinone inhibitor, incorporating trifluoromethyl 
derivatives as well as straight and branched alkyl chains onto the quinoid carbon-
carbon double bond.
385
  The molecule in figure 1.25 observed good activity and 
selectivity for the Qo site of the parasite bc1 complex, and these fluorinated 
hydroxynaphthoquinones may potentially have significant advantages over ATOV 
for future development. 
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Fig. 1.25  Fluorinated hydroxynaphthoquinone derivative. 
1.9.2.2  Pyridones 
The antimalarial properties of pyridones such as clopidol (fig. 1.26) are well known 
against CQR strains of P. falciparum, with GlaxoSmithKline (GSK) reporting the 
preclinical evaluation of a new class of antimalarial 4(1H)-pyridones targeting the 
bc1 complex in 2006.
386
  The study found that halogenations at the C-3 position gave 
a ten-fold increase in activity in vitro, with the introduction of the ATOV trans-(4-
chlorophenyl)cyclohexyl side chain at the C-5 position not only reducing 
metabolism, but also increasing in vivo efficacy.  Substitution at C-5 with a 
phenoxyaryl side chain also gave increased activity,
387
 with the most promising 
candidate being a non-chiral 4(1H)-pyridone derivative, GW844520 (fig. 1.26), 
which showed activity against ATOV resistant parasite strains and high selectivity 
for Pfbc1 over mammalian bc1.
150
  GW844520 showed much promise as a drug 
candidate with a good half life for short term therapy, a relatively easy chemical 
synthetic route, and no observed cross resistance before entering preclinical 
development.
386
  However, development of GW844520 has since been terminated 
owing to unexpected cardiotoxicity, which may be related to off target inhibition of 
human bc1 function.
388
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Clopidol GW844520 
Fig. 1.26  Pyridone derivatives clopidol and GW844520. 
Whilst GW844520 development has halted, there is still much synthetic work being 
performed to optimise the SAR around pyridone,
387, 389, 390
 as not only do they show 
promising in vivo activity against ATOV and CQ resistant malaria strains, but they 
also show in vitro and in vivo activity against liver stages of the parasite, for 
potential use in casual antimalarial prophylaxis. 
1.9.2.3  Quinolones 
Quinolones are another class of antimalarial compound which act through inhibition 
of complex III of the ETC.  They have been shown to bind at the Qo site of the 
cytochrome bc1 complex,
155
 through investigation of several alkyl and alkoxy 4(1H)-
quinolone derivatives of the basic core structure.
391
  Simple quinolones without long 
side chains were found to have higher IC50 values than their alkyl substituted 
counterparts (fig. 1.27). 
  
Fig. 1.27  Simple and alkyl substituted quinolones. 
A trifluoromethyl head group on the terminal end of the alkyl chain resulted in a 70-
fold increase in activity and was also expected to block cytochrome P450 mediated 
oxidation of the compound.  However, there are concerns with these compounds 
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over their selectivity for Pfbc1, as the flexibility of the side chains may result in off 
target mammalian bc1 inhibition. 
By using knowledge gained from computational study, the process of chemical 
synthesis may become more streamlined due to the prior selection of favourable 
compounds, affording a number of time and cost saving benefits.  The molecular 
design loop (fig, 1.19) can then be completed using biological testing techniques. 
1.10 Biological Testing 
Testing techniques permeate all aspects of the drug discovery process,
176
 and can 
quite often form the starting point for a drug discovery project, such as by providing 
the initial information required for a LBVS study.
192
  Therefore, biological testing is 
as vital to drug discovery as any other part of the molecular design loop.  Similar to 
chemical synthesis, the scope of biological testing greatly extends beyond that 
described in this thesis, and will therefore be discussed only in the context with 
which it has been used. 
1.10.1  Bioassays 
Bioassays allow for the effect of a substance against a living organism to be 
measured, something which is essential for the development of new drugs.  They can 
determine either qualitatively or quantitatively, the in vitro effect of a substance at a 
particular concentration against the organism/tissue/enzyme/receptor of interest, 
when compared to that of a standard preparation.  Bioassays have been used 
extensively throughout antimalarial drug design, with new assays and techniques 
continually being developed and optimised to yield more reliable and consistent 
results.
388, 392-394
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Choosing the right bioassay is crucial, as it should be quick, simple and reliable, as 
usually many compounds require testing.
364
  During the early stages of drug 
discovery, in vivo mammalian testing is generally not possible, so testing needs to be 
carried out in vitro on isolated enzymes or membranes.  Generally though, in vitro 
testing is cheaper and much easier to carry out than in vivo testing, with the process 
often being automated.  Later however, if promising candidates emerge, despite the 
controversies surrounding human testing, in vivo analysis is essential to check that a 
drug is interacting with a specific target and having the desired pharmacological 
effect, as well as to monitor its pharmacokinetic properties.  These properties 
determine the fate of a substance once it has been administered, and how it affects 
the body by considering its ADME properties.
21
 
Target specificity and selectivity is crucial in drug discovery, as the more selective a 
compound is, then the less likely it is to interact with different targets and have 
undesirable effects.  Earlier a number of biomolecular targets for malaria were 
discussed (i.e. Pfbc1, PfNDH2), and whilst the word antimalarial encompasses many 
different compounds which are active against different pathways of malaria, the 
problem is a lot more complex than whether they simply kill the parasite or not.  An 
ideal target would be one which is unique to the parasite and not present in humans, 
to reduce the likelihood of off-target toxicity. 
With increased development of resistance against many existing drug classes, 
antimalarial research has now moved towards more novel targets.  One such example 
involves the study of the fourth enzyme within the pyrimidine biosynthetic pathway, 
PfDHODH.
116, 395
  HTS identified a number of chemical scaffolds which were active 
against malaria parasites in a whole cell growth inhibition assay, but which also 
observed good correlation with the PfDHODH assay.  That is, molecules were found 
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to be active against malaria, yet selective for the parasite PfDHODH enzyme.  This 
kind of approach is common within antimalarial drug design; to first identify active 
compounds against the malaria parasite using whole cell screening, and to then 
screen active hits using bioassays which determine specific sites of action.
173
  
Further discussion of biological testing and its various methods takes place in 
Chapter IV. 
1.11 Aims of this Thesis 
This concludes the introduction.  The following chapters detail the research 
performed throughout this PhD.  Chapter II discusses the use of LBVS methods to 
screen a large chemical library in order to identify novel structural chemotypes 
which could potentially act against malaria by inhibiting Pfbc1.  Chapter III outlines 
the complex filtering and scoring functions which were applied to enable the rational 
selection of the most promising candidates which resulted from LBVS, together with 
diversity analysis and the final selection of compounds.  Chapter IV concludes the 
LBVS work with the testing of the selected compounds against a number of 
bioassays, with the resulting hits reported together with in depth interpretation of 
their chemical significance and possible modes of action.  Chapter V details the 
structure based work which was performed, discussing a number of molecular 
docking studies which were performed to rationalise and investigate the possible 
mode of action of compounds which inhibit complex III of the ETC.  From this work 
considerations were put forward with regard to optimising the activity of compounds 
active against Pfbc1.  Additionally, further support for the hits from LBVS was 
gathered through docking at bc1.  Chapter VI outlines a number of QSAR models 
which were developed for a series of 4-aminoquinoline compounds against both a 
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CQS and CQR strain of malaria.  Additionally, a predictive model was developed to 
assess the drug safety of a series of thiazolide compounds active against the hepatitis 
C virus.  Finally, Chapter VII reports a short chemical series of novel 
pyrroloquinolone containing compounds, which were designed, synthesised and 
tested for their antimalarial potential.  The results from these chapters will ultimately 
be summarised, and the future direction of the research discussed. 
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2. Ligand Based Virtual Screening Methods 
With the continued development of resistance to existing drug classes, there is an 
ever increasing need for new antimalarial compounds which act against novel 
targets.  Pfbc1 is one such target, confirmed through the study of acridinediones and 
other such compounds, which inhibit parasite mitochondrial function in the nM 
range.
1, 2
  ATOV (fig. 1.17) is currently the only licensed Pfbc1 inhibitor, used in 
combination with proguanil (fig. 1.12) under the branding Malarone.
3-6
  Compounds 
which inhibit Pfbc1 disrupt the ETC by inhibiting the intrinsic membrane protein 
within the mitochondria, preventing the Q-cycle and thus the generation of ATP, 
which plays a critical role in respiration.  Inhibition of ATP generation therefore 
results in parasite cell death.
7-9
  Of critical importance however is that bc1 inhibitors 
remain selective for the parasite and not human bc1, as this can lead to issues with 
regard to toxicity.  To this end a wide range of LBVS techniques were employed and 
will be discussed in this chapter.  The objective was to identify novel antimalarial 
chemotypes active against Pfbc1.  These methods were then combined as part of a 
consensus study, as detailed in Chapter III. 
2.1 Identification of Initial Data 
The virtual screening of chemical libraries has become an essential tool for 
identifying lead compounds.
10-14
  As stated in Chapter I, virtual screening utilises the 
similarity principle, which states that structurally similar compounds are more likely 
to exhibit similar properties.
15-18
  Through many successful applications, virtual 
screening has proven to be a rapid and cost effective strategy for evaluating large 
virtual databases of chemical compounds.
19, 20
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Antimalarial drug discovery efforts within the Chemistry Department at The 
University of Liverpool have predominantly been concerned with the synthesis and 
testing of compounds around a particular chemotype, to enable a SAR study and 
subsequent optimisation around the chemotype.  Through collaboration with the 
Liverpool School of Tropical Medicine (LSTM), compounds can be screened against 
a required assay, the results from which then drive forward further investigation.  
There therefore exists vast quantities of biological and chemical data waiting to be 
utilised, and it is this information which can form the ideal starting point of a LBVS 
study. 
With the biochemical target of interest known (Pfbc1), it was necessary to identify 
suitable compounds for use in virtual screening.  At LSTM, compounds are routinely 
screened for their whole cell growth inhibition, that is, their reported inhibition of the 
3D7 CQS parasite.  Given that the objective was to find compounds which 
selectively inhibit Pfbc1, the data for virtual screening needed to have been tested 
against this assay.  Unfortunately however, owing to the difficulties, expense, and 
time required to obtain sufficient amounts of purified Pfbc1, compounds are not 
routinely screened against this particular bioassay, and therefore accurate 
quantitative IC50 values against Pfbc1 were only available for a limited number of 
compounds. 
The compounds which had been tested against Pfbc1, and therefore used during 
virtual screening are reported in table 2.1, together with their quantitative Pfbc1 
activity values and qualitative classifications.
21
  These compounds varied 
significantly in structure and activity, with some active in the single nM range (i.e. 
Freddie-2-aryl), with others up to several µM (i.e. BC029).  Whilst compounds such 
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as ATOV and GW844520 are known inhibitors of Pfbc1, most of the others were 
novel structures synthesised at Liverpool.  Given that the compounds varied in their 
activity values so widely, it was necessary to place qualitative cut offs with which to 
define compounds as either active or inactive.  Whilst it is true that all of the 
compounds exhibited some Pfbc1 inhibition, in order to maximise the enrichment of 
virtual screening, only the most potent compounds were defined as active.  Several 
of the virtual screening methods employed also required qualitative results, rather 
than quantitative.  Ultimately, compounds were considered active if they had Pfbc1 
IC50 values of less than 100 nM, or if they exhibited complete parasite bc1 inhibition 
in the nM range.  Those with IC50 values greater than 100 nM, or which exhibited 
µM inhibition were considered inactive.  Using these constraints, of the nineteen 
compounds tested against Pfbc1, twelve were active and the other seven inactive. 
Table. 2.1  Compounds with known activity against Pfbc1. 
Name Compound 
Pfbc1 IC50 
Activity 
Classification 
Freddie-2-aryl 
 
40.9 nM Active 
Freddie-3-aryl 
 
52.6 nM Active 
Atovaquone 
 
2.7 nM Active 
Myxothiazol 
 
3.5 ± 0.5 nM Active 
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Stigmatellin 
 
12 ± 1 nM Active 
GW844520 
 
32 ± 13 nM Active 
WR249685 
(S 
enantiomer) 
 
3 ± 2 nM Active 
Floxacrine 
(racemic) 
 
802 ± 183 nM Inactive 
Ruan 1 
 
60% 
inhibition at 
1.4 µM 
Inactive 
Ruan 2 
 
3.5 nM Active 
Ruan 4 
 
32% 
inhibition at 
1.4 µM 
Inactive 
Ruan 10 
 
62% 
inhibition at 
1.4 µM 
Inactive 
Ruan 11 
 
60% 
inhibition at 
1.4 µM 
Inactive 
HDQ 
 
25 nM Active 
DRUG 1 
 
Complete 
inhibition at 
2.8 µM 
Inactive 
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DRUG 2 
 
Complete 
inhibition at 
281 nM 
Active 
DRUG 3 
 
Complete 
inhibition at 
281 nM 
Active 
DRUG 6 
 
Complete 
inhibition at 
281 nM 
Active 
BC029 
 
9.28 µM Inactive 
 
2.2 Chemical Library 
A chemical library is a collection of compounds readily available for use in HTS and 
virtual screening,
22
 and can be widely used for the exploration of chemical space.
23, 
24
  As stated in Chapter I, chemical space is the space spanned by all possible 
molecules, with the total number of possible small drug like molecules that populate 
chemical space estimated to exceed 10
60
.
25
  With such a vast amount of space it is 
understandable that its exploration has been limited, with only around 60 million 
small molecules registered with the Chemical Abstracts Service (CAS) as of 
September 2011.
26
  Though the systematic exploration of chemical space is possible 
through in silico databases of virtual compounds,
27, 28
 it is expected that much of 
chemical space contains nothing of biological interest, with searches around specific 
and focussed areas potentially yielding better results.
29
 
Chemical libraries are available from agencies such as the National Cancer Institute 
(NCI),
30
 who have structures for hundreds of thousands of compounds.  However, 
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many other commercial companies also have libraries of varying sizes available.  
Perhaps one of the most complete, or at least largest chemical library resources is 
that of ZINC.
31
  ZINC is a free database of commercially available compounds ready 
for virtual screening, compiled from purchasable compounds across numerous 
sources.  In its entirety, it currently consists of over thirteen million compounds 
whose structures and vendor details, as well as other physicochemical properties are 
readily available for download and use. 
Subsets of the full thirteen million compounds exist that are amenable to particular 
virtual screening needs.  For the LBVS work described here the ZINC lead like 
library
32
 of compounds was chosen, which at the time this work commenced 
consisted of 2,710,002 unique compounds (version 7).  Given that this was the lead 
like library, a number of filters had previously been applied in order to identify the 
most lead like compounds from ZINC.  Lead structures represent important 
chemotypes for drug development, ones that are generally pharmacologically active, 
and consist of simple chemical features amenable to chemical optimisation.
33
  By 
utilising considerations put forward to evaluate drug likeness,
32
 filters were applied 
to the entirety of ZINC to establish this subset of lead like compounds.  Molecules 
passed if their log P value was greater than or equal to 2.5, but no more than 3.5, 
whilst their MW was greater than or equal to 250, but not more than 350 Da.  These 
filters were used as the optimisation of low potency leads is often accompanied by an 
increase in MW and lipophilicity as a consequence of affinity enhancement, thus 
making µM hits suitable for optimisation.
32
  Additionally, there are no fewer than 5 
and no more than 7 rotatable bonds (RBs) in any of the molecules contained in the 
lead like library, which is in line with Veber’s guidelines for oral bioavailability.34, 35  
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Veber found that reduced molecular flexibility, as measured by the number of RBs, 
was an important consideration for good oral bioavailability, as was a low polar 
surface area (PSA).  The observations were that compounds which have ten or fewer 
RBs and a PSA of equal to or less than 140 Å
2
, have a higher probability of good 
oral bioavailability.  Reduced PSA was also found to correlate better with an 
increased permeation rate than log P, with an increase in the RB count having a 
negative effect on the permeation rate.  It has also been found that in vitro ligand 
affinity decreases 0.5 kcal/mol on average for every two RBs.
34, 36
 
2.3 Ligand Based Virtual Screening Techniques 
With a suitable chemical library selected and a number of seed molecules identified, 
various LBVS approaches could now be applied, and given that there is currently no 
crystal structure of Pfbc1 available, this was the most appropriate direction with 
which to conduct research to find novel antimalarial chemotypes.  With the structural 
information for a number of compounds tested against Pfbc1 known, a whole host of 
ligand based and classification techniques were available for use.  In combination, 
these techniques were used in a consensus approach, allowing emphasis to be placed 
onto particular molecules which were selected from multiple screening methods.  It 
involved combining highly disparate properties in order to improve performance by 
enriching the data.
37
  In total, six methods were used and performed in parallel 
against the ZINC lead like library, based on the active and inactive query compounds 
(table 2.1).  These methods together with the results will now be discussed. 
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2.3.1 Fingerprint Similarity Searching 
Fingerprint similarity searching relies heavily on the similarity principle, which 
states that structurally similar compounds are more likely to exhibit similar 
properties.
15-18
  However, it is this principle which has been exploited throughout 
most of the LBVS work.  Fingerprint similarity searching is perhaps the simplest of 
the LBVS methods used, requiring only the identity of the active compounds (table 
2.1) to use as queries, and the ZINC lead like library to screen.  Fingerprint similarity 
searching was performed using 2D fingerprints,
14
 with similarity between the queries 
and those in the library quantitatively assessed using the Tanimoto coefficient.
38, 39
 
Pipeline Pilot Student Edition v6.1
40
 was used to develop a protocol with which to 
perform fingerprint similarity searching, as it allows for the creation of workflows 
for the processing of data, including chemical data.  The chemical structures of the 
twelve active compounds were first drawn with ChemBioDraw,
41
 and then exported 
as SMILES (Simplified Molecular Input Line Entry System).
42, 43
  SMILES is a form 
of linear notation used for describing chemical structures of molecules.  The ZINC 
lead like library was similarly manipulated in its SMILES format (readily 
downloadable), which was particularly useful given its size, as SMILES can encode 
for many structures yet requiring little storage space.  Within the workflow the active 
molecules were tagged as reference structures, and it was these reference structures 
which were then used to screen the ZINC lead like library for similar compounds.  
Molecular similarity between the reference structures and those in ZINC was 
assessed using molecular fingerprint. 
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2.3.1.1  Molecular Fingerprints 
Molecular fingerprints
44
 are representations of chemical structures, originally 
designed to assist in chemical database substructure searching.
38, 45  Molecular 
fingerprints have since found use in similarity searching,
46
 clustering,
47
 and 
classification.
48
  Several methods are available, including Extended Connectivity 
Fingerprints (ECFP), Functional Class Fingerprints (FCFP),
49
 and MDL Public 
Keys, which have been shown to be effective in similarity searching applications.
50, 
51
 
2.3.1.1.1  ECFP 
ECFPs are a recently developed fingerprint methodology, explicitly designed to 
capture molecular features relevant to molecular activity.
49
  They were first 
introduced in 2000 with the introduction of Pipeline Pilot,
52, 53
  and have since been 
applied to a broad range of scientifically relevant problems using a variety of 
analysis methods.  Whilst not designed for substructure searching, they are well 
suited to tasks related to predicting and gaining insight into drug activity,
54
 and can 
be used much like other fingerprint methods for similarity searching, clustering and 
virtual screening. 
ECFPs are derived using a variant of the Morgan algorithm,
55
 which was proposed 
as a method for solving the molecular isomorphism problem.  In the Morgan 
algorithm, an iterative process assigns numeric identifiers to each atom, at first using 
a rule that encodes the numbering invariant atom information into an initial atom 
identifier, and later using the identifiers from the previous iterations.  Thus, 
identifiers generated are independent of the original numbering of the atoms, with 
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the iterative process continued until every atom identifier is unique, or at least as 
close to unique as symmetry allows.  The intermediate results are discarded and the 
final identifiers provide a canonical numbering scheme for the atoms.  Initially, each 
atom is assigned a connectivity value equal to the number of connected atoms.
14
  In 
the second and subsequent iterations, a new connectivity value is calculated as the 
sum of the connectivity values of the neighbours. The procedure is repeated until the 
number of different connectivity values reaches a maximum.  In the case of aspirin 
(fig. 2.1), there are initially three different connectivity values (1, 2, 3).  This 
increases in the subsequent iterations to six, eight and finally eleven.  The atom with 
the highest connectivity value is then chosen as the first atom in the connection table, 
with its neighbours then listed in order of their connectivity values, and then their 
neighbours listed and so on.  If a tie occurs then additional properties such as atomic 
number and bond order are considered.  For example, the two oxygen’s of the 
carboxylic acid in aspirin have the same connectivity value, as do the terminal 
methyl and the carbonyl oxygen of the acetyl group.  These conflicts can be resolved 
by consideration of the bond order and atomic number respectively. 
 
Fig. 2.1  Illustration of how the Morgan algorithm iteratively constructs atomic connectivity values 
for aspirin.  (A. R. Leach and V. J. Gillet, An Introduction to Chemoinformatics, Springer, 2007.) 
Chapter II 
 
96 
 
The ECFP algorithm makes several changes to the standard Morgan algorithm.  
Firstly, ECFP generation terminates after a predetermined number of iterations, as 
oppose to continuing until identifier uniqueness is achieved.  The initial atom 
identifiers, and all identifiers after each iteration, are collected into a set, and it is this 
set which defines the extended connectivity fingerprint.  Rather than discarding the 
intermediate atom identifiers, the ECFP algorithm retains them, with finding these 
partially disambiguated atom identifiers being the goal of the process.  This means 
that the iteration process does not have to proceed to completion, but is performed 
for a predetermined number of iterations.  Secondly, since perfectly accurate 
disambiguation is not required, algorithmic optimisations are possible.  For example, 
in the standard Morgan process, the identifiers must be carefully recorded after each 
iteration to avoid mathematical overflow and possible collision of atom 
environments given the same identifier.  However, this recoding has the side effect 
of creating identifiers that are not comparable between different molecules, whereas 
in the ECFP algorithm, this computationally expensive step is replaced with a fast 
hashing scheme.  The result of this is saving computational effort for fingerprint 
generation, and more importantly, allowing for the generation of identifiers which 
are comparable across molecules. 
There are three sequential stages in ECFP generation:
49
 
1. An initial assignment stage in which each atom has an integer identifier 
assigned to it. 
2. An iterative updating stage in which each atom identifier is updated to reflect 
the identifiers of each atoms neighbours, including identification of whether 
it is a structural duplicate of other features. 
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3. A duplicate identifier removal stage in which multiple occurrences of the 
same feature are reduced to a single representative in the final feature list.  
(The occurrence count may be retained if one requires a set of counts rather 
than a standard binary fingerprint.) 
Atoms are first assigned an integer identifier such as atomic number, and then 
collected together into an initial fingerprint set.  Next, each atom collects its own 
identifier and the identifiers of its neighbouring atoms into an array, with a hash 
function applied to reduce this array back into a new, single integer identifier.  These 
new identifiers replace the old and are added into the fingerprint set.  This iteration is 
repeated a predetermined number of times, and once complete, duplicate identifiers 
in the set are removed and the remaining integer identifiers in the fingerprint set 
define the ECFP fingerprint. 
ECFPs are intended to capture precise atom environment substructural features, with 
the initial atom identifier for the standard ECFP fingerprint using atom information 
from the Daylight atomic invariants rule.
43
  The Daylight atomic invariants are six 
properties of an atom in a molecule that do not depend on initial atom numbering.
56
  
These properties are: the number of immediate neighbours that are heavy (non-
hydrogen) atoms; the valence minus the number of hydrogen’s; the atomic number; 
the atomic mass; the atomic charge; and the number of attached hydrogen’s.  One 
additional property is also included, and that is whether the atom is contained in at 
least one ring.  To create an integer identifier from this information, these values are 
hashed into a single 32-bit integer value, and this value is the initial atom identifier. 
ECFPs have adopted the convention of being described as ECFP, but in practicality 
this is followed by an underscore and a number.  The appended number is the 
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effective diameter of the largest feature, and is equal to twice the number of 
iterations performed.  For example, if three iterations are performed, the largest 
possible fragment will have a width of six bonds, therefore the fingerprint name will 
end in six (ECFP_6).  Increasing iterations extends the environment of the atom to 
include higher order neighbours, such that ECFP_2 considers the first order 
neighbours, with ECFP_4 extending this to the third order neighbours.
14
 
2.3.1.1.2  FCFP 
There exists a variant to the standard ECFP algorithm, termed FCFP.  FCFP intends 
to capture more abstract role based substructural features, derived from the 
functional class, or pharmacophore role of the atoms in a molecule.  The highly 
specific atom information contained in the initial atom identifiers for ECFPs, allows 
the generation process to rapidly discover identifiers that represent a broad set of 
precisely defined structural features.  However, for some purposes, this specificity 
may be undesirable, and some level of abstraction useful.  For example, a chlorine or 
a bromine substituent on a ring may be functionally equivalent but would be 
distinguished by the ECFP process.  It may therefore be preferable to have all 
halogens appear as equivalent atom types in the fingerprint process, and similarly for 
all hydrogen bond acceptors or donors to appear equivalent. 
FCFPs are generated using a more abstract, pharmacophoric set of initial atom 
identifiers.
57
  Each atom is identified by a six-bit code, where a given bit is 
considered “on” if the atom plays the associated role.  These atom roles are: 
hydrogen bond donor or acceptor; negatively or positively ionisable; aromatic; 
halogen.  An atom could potentially have more than one role, or none at all.  The six-
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bit code for each atom is the initial atom identifier, and once these are calculated the 
process of calculating FCFPs proceeds identical to that of the ECFP process.  
Similarly, FCFPs are also followed by a number indicating the number of iterations 
performed. 
2.3.1.1.3  MACCS 
Developments in molecular database optimisation led to the first explicitly binary 
fingerprint for substructure searching, used by the MACCS system from Molecular 
Design Limited (MDL).
58
  Molecular descriptors can be encoded into binary keybits, 
with either a one-to-one relationship between descriptors and keybits, or using 
hashing to create a many-to-one or many-to-many relationship.  An ordered 
collection of keybits constitutes a keyset, which have been used successfully in 
substructure searching.
45
  For example, a number of topological features in a query 
molecule can be used to set keybits, with a search for molecules matching that query 
being used to screen out all molecules in the database which do not set those same 
keybits.  Other keybits include the assessment of an atom to see whether it is a 
halogen, and they may even comment on the nature of its neighbours.  Two 
particular MDL keysets have been widely explored, one containing 960 keybits, the 
other 166 keybits.
51, 58
  The keyset containing 166 bits is a subset of the full 960 
keys,
59
 and is called the MDL public keys.  It was developed for the rapid 
substructure searching of databases, and are readily calculated in Pipeline Pilot.
40
  
These keysets have found use in a variety of drug discovery techniques including 
QSAR
59
 and virtual screening,
60
 but the design of new keysets continues to be of 
interest, with the examination of in vitro affinity fingerprints,
61, 62
 in silico affinity 
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fingerprints,
63, 64
 and feature trees
65
 as methods of producing keysets optimised for 
similarity searches. 
Within Pipeline Pilot Student Edition v6.1
40
 there are several molecular fingerprint 
methods available.  Even the most intelligently selected set of keys is limited in its 
coverage.
51
  To this end the fingerprint similarity searching of the reference 
compounds in the ZINC lead like library was repeated to incorporate the results from 
multiple fingerprint methods.  In total, seven fingerprints were used: ECFP_2; 
ECFP_4; ECFP_6; FCFP_2; FCFP_4; FCFP_6; MDLPublicKeys.  The molecular 
fingerprints simply compare each of the reference structures to the compounds in the 
chemical library.  To identify those which were most similar a cut-off parameter was 
required.  To assess the level of similarity the Tanimoto coefficient (Chapter I) was 
used, as this has been successfully applied across many virtual screening methods.
66
  
The cut-off parameter was as follows: to only consider a compound from ZINC 
sufficiently similar if it had a minimum Tanimoto coefficient value of 0.7, and a 
maximum value of 0.99, compared to one of the reference structures.  By searching 
for novel chemotypes we are looking for molecules to retain some similarity to one 
of the known actives (utilising the similarity principle), but that they not be identical 
(hence the maximum value of 0.99).  Virtual screening aims to move through 
chemical space in an informed manner, using existing knowledge to make rational 
decisions.  By selecting a minimum Tanimoto coefficient value of 0.7 (that is 70% of 
the binary fingerprints are set to “1”), this would allow for some similarity between 
the molecules, but also incorporating diversity into their structures.  Diversity will 
also arise given the way in which the seven different molecular fingerprint methods 
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are calculated.  This cut-off is also supported across the literature.
67-72
  The number 
of hits from ZINC for the different fingerprint methods is detailed in table 2.2. 
Table. 2.2  Results of fingerprint similarity searching. 
Molecular Fingerprint Method Number of Hits from ZINC 
ECFP_2 21 
ECFP_4 1 
ECFP_6 0 
FCFP_2 1161 
FCFP_4 17 
FCFP_6 3 
MDLPublicKeys 11133 
It was found that increasing the number of iterations for a particular fingerprint 
method did not identify any new molecules (i.e. all of the hits from ECFP_4 had 
already been identified by ECFP_2).  By extending the number of iterations, 
fingerprints became more specific and thus, when screening a chemical library, 
fewer compounds were considered similar due to these extended and precise 
fingerprints.  As the number of iterations increased, the number of newly discovered 
identifiers decreased, until eventually no new molecules were discovered, as 
observed with ECFP_6.  It has previously been suggested that fewer than two 
iterations is sufficient for similarity searching.
49
  Due to this, only the results from 
ECFP_2, FCFP_2 and MDLPublicKeys were considered as these all identified 
unique sets of compounds, with further iterations giving no new chemical 
information.  Recent research has however shown that these fingerprint methods do 
indeed explore different areas of chemical space, with each contributing its own 
unique information.
73
 
The results from these methods were merged in Pipeline Pilot Student Edition v6.1,
40
 
and structural duplicates removed such that only 11,655 unique compounds were 
identified from fingerprint similarity searching.  These unique compounds went on 
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to form part of the consensus analysis to identify those of most interest across the 
LBVS work.  Fingerprint similarity searching was performed according to the 
‘Fingerprint Similarity Searching Protocol’ as detailed in the Experimental Chapter. 
2.3.2 Turbo Similarity Searching 
It is understood that the effectiveness of similarity methods can vary greatly from 
problem to problem, so the use of several different methods is recommended when 
performing similarity searches.
74-76
  Turbo similarity searching can be seen as an 
expansion of fingerprint similarity searching, and may be useful when details of just 
a single active compound are available.
77, 78
  It can be useful in exploring the 
chemical space available, provided that the query compounds are not too tightly 
clustered, and incorporate an element of structural diversity.  Turbo similarity 
searching uses information about the nearest neighbours to an active structure in a 
conventional similarity search, to increase the effectiveness of virtual screening.
79
 
Fingerprint similarity searching is used to initially identify the nearest neighbours of 
a query structure to those in a chemical library.  These nearest neighbours are then 
used as the seeds in a new similarity search, with the resulting hit lists being 
combined.  In its simplest form, turbo similarity searching involves moving through 
chemical space by considering the nearest neighbours, of the nearest neighbours.  
The rationale behind turbo similarity searching is once again based upon the 
similarity principle, as it is assumed that the nearest neighbours of the initial query 
compound are themselves active, and as such may also be used as queries for 
subsequent similarity searching.
14
  Studies have shown that consistent improvement 
in performance can be achieved over more conventional similarity searching 
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methods based on the initial search only, and that multiple queries, such as the 
presumption that nearest neighbours are active, can be combined to increase the 
enrichment.
80
  Figure 2.2 gives a simple representation of how turbo similarity 
searching works, with the active molecule used as the initial query to identify the 
nearest neighbours, and then these themselves used to identify additional nearest 
neighbours. 
 
Fig. 2.2  Illustration of turbo similarity searching. 
Pipeline Pilot Student Edition v6.1
40
 was used to develop a suitable protocol for 
turbo similarity searching, with the twelve active compounds (table 2.1) tagged as 
reference structures, and the ZINC lead like library used for screening.  Molecular 
similarity between the two was assessed using the ECFP_2, FCFP_2 and 
MDLPublicKeys fingerprints.  The Tanimoto coefficient was used to assess the 
similarity between the reference structures and the hits from ZINC; however, a more 
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stringent cut-off parameter was put in place.  Whereas with fingerprint similarity 
searching molecules were required to have a Tanimoto coefficient value greater than 
only 0.7, for turbo similarity searching this was increased to 0.8.  This was done to 
fall in line with the very nature of turbo similarity searching, as the method is 
concerned with moving further out into chemical space, and is heavily based upon 
the assumption that the nearest neighbours of the active query may potentially be 
active.  This is an optimistic assumption, as it would be highly unlikely that every hit 
from fingerprint similarity searching would yield an active result, thus the value was 
raised.  A cut-off of 0.8 will still allow for some level of diversity in the reported 
structures, and indeed expand upon the chemical space being sampled, but without 
straying too far from the initial, active query, thus hopefully retaining some of the 
chemical features which made that structure active. 
Besides the alteration in the lower limit of the Tanimoto coefficient parameter, the 
protocol was initially identical to that of the fingerprint similarity search.  Where it 
differed was that instead of terminating after one search, a further iteration was 
performed, with the nearest neighbours of the initial query (the hits), used to perform 
another similarity search of the chemical library using the same fingerprint method.  
Similarity was assessed using the Tanimoto coefficient.  To control the amount of 
space being searched, a cap was placed on the number of nearest neighbours to be 
used as queries in the second iterations of similarity searching.  Only the top 250 
scoring compounds from the initial search (those closest to an active structure 
according to their Tanimoto coefficient) were used as seeds for an additional search.  
With regard to ECFP_2 and FCFP_2, this did not pose too much of a concern as the 
first search only produced 3 and 76 hits respectively.  However, when using 
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MDLPublicKeys the cap had to be employed as there were 336 hits.  When both 
rounds of similarity searching were complete, the hits were merged and duplicate 
molecules removed.  The results for these searches are shown in table 2.3, with the 
number of hits from ZINC reported for each fingerprint method. 
Table. 2.3  Results of turbo similarity searching. 
Molecular Fingerprint Method Number of Hits from ZINC 
ECFP_2 19 
FCFP_2 1053 
MDLPublicKeys 13261 
The number of hits for each method is comparable to those from fingerprint 
similarity searching (table 2.2).  However, had the minimum Tanimoto value been 
left at 0.7, then the number of hits for ECFP_2, FCFP_2 and MDLPublicKeys would 
have been 204, 44,869 and 150,716 respectively, greater than 10 fold the number of 
hits in all cases.  So, whilst the reasoning behind the higher cut-off was sound, it had 
the additional benefit of reducing the number of hits, thereby reducing the potential 
noise in the data.  As before the compounds from each of the different fingerprint 
methods were merged and duplicate molecules removed, resulting in 13,771 unique 
compounds identified by this method, ready for inclusion in the consensus analysis.  
Turbo similarity searching was performed according to the ‘Turbo Similarity 
Searching Protocol’ as detailed in the Experimental Chapter. 
2.3.3 Bioisostere Substructure Searching 
Isosteres are atoms or groups of atoms that have the same valency, and which have 
similar chemical or physical properties.
81
  Examples include silicon and carbon, and 
carbon dioxide (CO2) and nitrous oxide (NO2).  More specific examples in terms of 
functional groups include the understand that SH, NH2 and CH3 are isosteres of OH, 
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and that S, NH, and CH2 are isosteres of O.
82
  Isosteres can be used to determine 
whether a particular group is an important binding group or not, by altering the 
character of the molecule in as controlled a way as possible.  For example, replacing 
O with CH2 will make little difference to the size of the analogue, but may have a 
marked effect on its polarity, electronic distribution and bonding.  Whilst replacing 
OH with the larger SH may not have such an influence on the electronic character, 
but steric factors become more significant.  Isosteric groups may also be used to 
determine whether a particular group is involved in hydrogen bonding, such that 
replacing an OH with CH3 would completely eliminate hydrogen bonding, yet a NH2 
group would not. 
A biologically active compound containing an isostere is called a bioisostere.  These 
are frequently used in drug design as they may still be recognised and accepted by 
the body, but its function will be altered compared to the parent molecule.  This is 
through varying the character of a molecule in a rational way, with respect to 
features such as size, polarity, electronic distribution and bonding.
83, 84
  They have 
also been employed by chemists for the modification of lead properties.  A 
bioisostere is a group that can be used to replace another group whilst retaining the 
desired biological activity.  They are often used to replace a functional group that is 
important for target binding but is problematic in another way.  A good example of 
successful and simple bioisostere replacement is that of the anti-tumour drug 5-
fluorouracil (fig. 2.3).
85
  The drug is a pyrimidine analogue which acts as an 
irreversible inhibitor of thymidylate synthase, blocking the synthesis of pyrimidine 
thymidine which is a nucleotide essential for deoxyribonucleic acid (DNA) 
replication.  5-flouoruracil therefore causes cancer cell death due to a lack of 
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thymidine required for replication.  Fluorine is often used as an isostere of hydrogen 
since it is similar in size (Van der Waals radii of 1.47 and 1.20 Å respectively).
86
  
However, it is more electronegative and can be used to vary the electronic properties 
of a drug.  The presence of fluorine in place of enzymatically labile hydrogen can 
disrupt the enzymatic reaction, as C-F bonds are not easily broken.
87
  It was this 
understanding which was utilised in the manipulation of uracil, such that 5-
fluorouracil is accepted by the target enzyme as it appears almost identical to the 
natural substrate, but the mechanism of the enzyme-catalysed reaction is totally 
disrupted as the fluorine has replaced the hydrogen, which is normally lost during the 
mechanism. 
 
 
 
Uracil  5-fluorouracil 
Fig. 2.3  Uracil and 5-fluorouracil. 
Bioisosteric replacement and scaffold hopping are well used within drug design to 
improve the synthetic accessibility, potency and drug like properties of compounds, 
as well as to move into and around novel chemical space.
88
  Bioisosteric replacement 
is concerned with the swapping of functional groups that have similar properties, 
whereas scaffold hopping involves the replacement of the core framework in a 
molecule to try and improve the properties of that molecule.  Additional examples of 
the successful use of bioisosteric replacement within drug discovery includes the 
design of novel nucleoside derivatives in the search for new drugs active against the 
human immunodeficiency virus (HIV).
89
  Derivatives were synthesised based on 
bioisosteres of lamivudine (fig. 2.4), which is used for the treatment of the hepatitis 
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B virus (HBV) and HIV.  More recent work includes the design of novel indole-3-
heterocycles, with the one in figure 2.4 found to be a potent CB1 cannabinoid 
receptor agonist, a member of the GPCR superfamily.
90
  CB1 is a potential 
therapeutic target against pain, glaucoma, brain injury, multiple sclerosis and 
obesity,
91
 with the novel indole-3-heterocycle in figure 2.4, synthesised based on a 
bioisosteric replacement of the piperazine amide heterocycle group.  This led to 
improved in vitro and in vivo stability, as well as an increased duration of action. 
 
 
Lamivudine 
Fig. 2.4  Lamivudine and a novel indole-3-heterocycle. 
Owing to its successes within drug discovery, bioisostere substructure searching was 
deemed of potential interest with regard to this research and was performed based on 
the quinolone core substructure detailed in figure 2.5.  Of the twelve active 
compounds, eight of them contained this quinolone core structure, and thus was the 
most common fragment/chemotype amongst the actives, making it the most 
appropriate query.  The groups labelled A in figure 2.5 represent possible attachment 
points which were taken into consideration in the template query. 
 
Fig. 2.5  Quinolone core template, where A represents possible attachment points. 
Chapter II 
 
109 
 
BROOD 1.1.2
92
 was used to identify bioisosteres of the query structure by searching 
fragment databases using a number of different metrics of similarity.  Fragment 
databases may originate from the deconstruction of molecular databases using 
pseudoretrosynthesis,
93
 and can be used in bioisosteric de novo design through 
comparison of parts of the active lead structure, to fragments abstracted from 
pharmacologically active molecules.  By creating fragment libraries from databases 
of biologically active molecules, this allows for the identification of building block 
fragments that are rich in biologically recognised elements and privileged motifs and 
structures.
93
  Fragment based screening inherently incorporates chemical variety, and 
has been found to decrease the drug discovery process timescale, and even improve 
the understanding of the pharmacophore at the active site.
94
 
BROOD
92
 pioneered the technique of fragment replacement from the perspective of 
shape based template comparison.  It was designed to help explore chemical and 
property space around a lead structure, generating analogues of the lead by replacing 
selected fragments in the molecules with fragments that have similar shape and 
electrostatics.  The software allows a user to enter a single query fragment and 
search a large database of known molecular fragments in order to identify fragments 
that are similar.  Each database fragment is compared to the query fragment in 3D 
with regard to its shape, chemistry, electrostatics and geometric presentation of 
attachment groups.  The best fragments in each of the four classes are then saved as 
potential bioisosteres.  Four searching methods were used to search for bioisosteres 
of quinolone, each encompassing different structural criteria as follows: 
1. color – Those with the best overlap of shape, atom-types and attachment 
geometry. 
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2. elect – Those with the best overlap of shape, electrostatics and attachment 
geometry. 
3. struc – Those with the best replication of the attachment geometry (ignoring 
chemical properties). 
4. queryAnalog – Those that are close analogues of the query fragment. 
The results from each search are referred to as hitlists.  The color bioisostere hitlist is 
the most general and practical set of bioisosteres.  These fragments are those deemed 
most similar to the query structure, based on the sum of shape similarity and atom-
type similarity, including attachment points.  By default, the color force field treats 
all color interactions with equal weighting.  These weights can be used to distinguish 
between better bioisosteres.  The elect or electrostatic bioisostere hitlist is analogous 
to the color method in its utility.  There are however, two critical differences in how 
the similarity of fragments is evaluated.  The first difference is that rather than 
comparing atom-types, the electrostatic potential projected into the area around the 
molecules is compared.  This comparison is evaluated by the electrostatic overlap 
between the query structure and the fragments, as determined by the Poisson-
Boltzmann equation which describes electrostatic interactions.
95
  The second 
difference is that there is no consideration of the attachment points in the 
electrostatic term, so an additional term taking the difference in attachment point 
position into account is added.  However, the elect calculation is more 
computationally expensive than that of color.  The struc or structure bioisostere 
hitlist is very specialised, and is concerned with giving the best alignment of 
attachment points as measured by the root mean square deviation (RMSD) between 
the query structure and fragments, regardless of shape, chemistry and electrostatics.  
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The hitlist will report fragments that can present substituents in a similar manner to 
the query structure.  The final bioisostere hitlist is that of queryAnalog.  This hitlist 
contains all fragments that have similar graphs to the query structure.  Similar graphs 
are considered to be all those fragments that have identical uncoloured graphs or 
uncoloured graphs that differ by only one or two atoms from the query.  Each of 
these fragments is orientated and evaluated by the color method to allow appropriate 
visual comparison of the fragment to the query.  While this hitlist often contains 
many fragments that are obvious replacements for a query, such as those which 
would be selected by an experienced medicinal chemist, they may also include 
fragments with dramatically different chemistry from that seen in the query.  
BROOD
92
 also considers bioisosteric fragments that contain ring systems, so that in 
practice, this often produces small, rigid, ring systems that quite nicely overlay with 
linear query fragments. 
BROOD 1.1.2
92
 contains some 170,000 fragments spread across the f5 (around 
140,000 fragments) and f50 (around 30,000 fragments) libraries.  The de novo 
generation of fragments may seem attractive but often yields unrealistic chemical 
fragments.
96
  The fragment libraries in BROOD however, are derived from a 
collection of roughly 12 million commercially available compounds.  These 
contained roughly 1 million unique molecular fragments, each with 15 or fewer 
heavy atoms, and one to three attachment points.  Potentially toxic, reactive or 
chemically complex fragments were removed, with the remaining half a million 
fragments ranked according to their frequency in the original 12 million compounds.  
f50 contains fragments which occurred in 50 or more of the original molecules, with 
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f5 containing all those fragments which occurred in 5 or more of the original 
molecules (hence its large size). 
Each of these libraries was searched four times for bioisosteres of the quinolone core 
(fig. 2.5), based on the four different bioisostere searching methods available.  Table 
2.4 illustrates the results of quinolone bioisostere searching across the two fragment 
libraries for the four methods.  By default, the maximum number of fragments per 
query for each of the search methods was set to 200.  These were ranked by shape 
and chemistry for their similarity based on the quinolone query.  That is, fragments 
that were more similar to the query were reported first, ensuring only the most 
appropriate bioisosteres were used.  Across the four bioisostere searching methods 
applied to the f5 library, there were a total of 670 fragments reported.  However, 
when these were merged using Pipeline Pilot
40
 there were found to be only 546 
unique entries.  This is because several of the fragments appeared multiple times (84 
appeared twice and 20 appeared three times).  Similarly for the f50 library, 619 
fragments were identified, but there were again a number of fragments found 
multiple times, with some 451 unique fragments (96 appeared twice and 36 appear 
three times). 
Table. 2.4  Number of bioisosteres identified from the f5 and f50 fragment libraries for the four 
different search types. 
 Number of Fragments Identified from Library 
Bioisostere Search Method f5 f50 
color 200 200 
elect 200 200 
struc 200 200 
queryAnalog 70 19 
Number of Unique Fragments: 546 451 
When the two unique fragment hitlists were merged the number of unique fragments 
was reduced further to 848.  There therefore appears to be some overlap between the 
Chapter II 
 
113 
 
f5 and f50 fragment libraries.  Within Pipeline Pilot Student Edition v6.1
40
 these 848 
bioisosteres were subjected to analysis to find only those which contained novel 
fragments.  This had two benefits in that it reduced the number of bioisosteres to 
create a more focused approach, but also removed additional duplicate fragments.  
The novel fragment types were found using the ‘Find Novel Fragments’ component 
in Pipeline Pilot to identify the unique molecular fragments in the dataset, such that 
each occurred only once.  Novel fragments were defined based on their ring 
assemblies to find potential drug-like structures amenable to chemical optimisation.  
276 novel fragments were identified, with these filtered further to include only 
fragments with a ring count greater than one.  This was to remove simpler 
heterocyclic structures, and identify unique fragments that looked like potential 
chemotypes, as inspection of the compounds tested against Pfbc1 showed them all to 
contain fairly rigid ring assemblies.  Fragments were also filtered to remove those 
which contained charged groups, to keep the fragments to be used as bioisosteres as 
uncomplicated as possible.  These filters reduced the fragment set to 166 
bioisosteres, several examples of which can be found in figure 2.6 (see appendix for 
all 166 bioisosteres). 
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Fig. 2.6  Examples of quinolone bioisosteres identified from the BROOD
92
 fragments libraries. 
Most of the bioisosteres are simple modifications of the quinolone core structure.  
However, some of them do vary quite significantly in their appearance, such as the 
pyrazole containing tricyclic, suggesting that their similarity to quinolone must lie 
elsewhere, such as in their shape or electrostatic distribution.  What is clear though is 
that the bioisosteres do indeed cover a range of chemical diversity. 
With the 166 bioisosteres in hand a substructure search of the ZINC lead like library 
could be performed.  This was done by developing a protocol within Pipeline Pilot 
Student Edition v6.1,
40
 to identify all those molecules within the chemical library 
that contained one or more of the bioisosteres.  Of the 2.7 million molecules in the 
ZINC lead like library, 466,840 were found to contain a bioisostere, equating to just 
over 17% of the total number of compounds found in the library.  Measures were 
therefore adopted to reduce this number further, to optimise the diversity across the 
hits.  Of the 166 bioisosteres, 15 did not appear in any of the compounds in ZINC, 
and as such are not represented.  However, of the 151 that did appear the number of 
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hits per bioisostere varied greatly.  70 of the fragments had between 1 and 200 hits, 
whilst the other 81 all had greater than 200 hits each.  In one instance, a particular 
bioisostere was found to be present in 46,393 compounds.  These results are shown 
in figure 2.7. 
 
Fig. 2.7  Graph to illustrate the frequency of hits per bioisostere from the ZINC lead like library. 
In order to reduce the number of hits to best sample the chemical space, a 
representative number of molecules was taken when the number of hits exceeded a 
certain threshold.  This threshold was set to 200 hits, so that when the number of hits 
fell below this threshold for a particular bioisostere, all molecules were taken 
forward.  Yet when the number of hits was greater than 200, a diverse sample of 
these molecules was taken to get a good representation of the chemical space 
available.  The merits of using a cut-off of 200 could be argued for and against, but it 
allowed for a relatively similar number of hits to be considered per bioisostere, and 
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as such, prevented overemphasis of any particular bioisostere.  Diversity analysis 
was performed in Pipeline Pilot Student Edition v6.1,
40
 utilising the ‘Diverse 
Molecules’ component by selecting the 200 most diverse molecules from the hits for 
a particular bioisostere, based on FCFP_4 fingerprints.  Following this the hits for 
each bioisostere were merged and resulted in 20,319 unique molecules.  Though 
slightly larger than the number of hits from fingerprint similarity and turbo similarity 
searching (11,655 and 13,771 respectively), the number of hits for consideration 
during consensus analysis is of a similar order of magnitude, and is a much more 
manageable size when compared with the original 466,840 hits.  Also, despite the 
decreased number of hits, we can still be assured of the chemical diversity described 
within the dataset owing to the similarity calculations performed.  The bioisostere 
substructure searching was performed according to the ‘Bioisostere Substructure 
Searching Protocol’ as described in the Experimental Chapter. 
2.3.4 Principle Component Analysis 
The dimensionality of a dataset is the number of variables or molecular descriptors 
used to describe each of the objects or molecules in that dataset.
14
  Principle 
component analysis (PCA) is commonly used to reduce this dimensionality, 
especially when there are significant correlations between some or all of the 
descriptors.
14
  PCA was conceived in 1901,
97
 and acts by calculating a new set of 
variables based on the previously calculated molecular descriptors or properties for 
the dataset.  These new variables, termed principle components (PCs), explain much 
of the variance in the original data, but generally with fewer variables.  It is a 
common statistical technique used for finding patterns in data of high 
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dimensionality, where graphical analysis would not normally be appropriate.  From 
this it would then be possible to highlight similarities and differences in the data. 
The simple 2D example shown in figure 2.8 illustrates the concept of PCs very 
effectively.  As can be seen, the scatter plot shows a high degree of correlation 
between the    and    values, and it would be possible to explain the variation in 
this data by introducing a single variable which is a linear combination of these two, 
such as        .  This new variable   can be referred to as a principal 
component. 
Fig. 2.8  Graph to illustrate principal components in their simplest form. 
In the case of a multidimensional dataset, that is one which consists of more than 
two variables.  Each of the PCs comprises a linear combination of the original 
descriptors as described by equations 2.1. 
 
z = x1- x2 
x2 
x1 
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Eq. 2.1  Equations to illustrate the principal components in a multidimensional example. 
In equations 2.1,     represents the  
th
 principal component, with      the coefficient 
of the descriptor   , and   being the number of descriptors.  The first PC maximises 
the variance in the data and explains the largest proportion of the variance, thus the 
data has the greatest spread across the first PC.  The second PC accounts for the 
maximum variance in the data that is not already explained by the first PC, and so on 
and so forth for any additional PCs.  An interesting property of the PCs is that they 
are all orthogonal to each other, so that the highest possible variance in the data can 
be explained.  With regard to the simple 2D example in figure 2.8, this would mean 
that the second PC would be uncorrelated to the first, and perpendicular to it. 
The total number of PCs which can be calculated for a dataset is equal to the smaller 
of the number of molecules in the set, or the total number of descriptors.  To explain 
all of the variance in the data it would usually be required to include all of the PCs.  
However, for most datasets the greatest proportion of variance is explained by only a 
small number of PCs, due to correlations between the original variables.  As the 
number of PCs increases the additional information explained decreases, until 
eventually new PCs explain no new variance. 
PCs are calculated from the variance-covariance matrix, such that if A is the matrix 
with   rows (corresponding to   molecules) and   columns (for the   descriptors) 
then the variance-covariance matrix is the     matrix AAT, with superscript T 
indicating a transposed matrix in which the rows and columns of the matrix have 
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been interchanged.  The eigenvectors of this matrix are the coefficients      of the 
PCs, with the first PC which explains the largest amount of variance corresponding 
to the largest eigenvalues, and the second PC accounting for the second largest 
eigenvalues and so on.  The eigenvalues indicate the proportion of the variance that 
is explained by each of the PCs, and if the eigenvalues are labelled   , then the first 
  PCs account for the fraction of the total variation in the dataset as shown in 
equation 2.2. 
  
   
 
   
   
 
Eq. 2.2  Equation to calculate the total variance explained by principal components. 
It is usual to autoscale each of the   variables before extracting the PCs (autoscaling 
will be discussed more fully in chapter VI) so that each variable will contribute a 
variance of one to the total dataset, which will thus have a total variance of  .  This 
means that if a PC has an eigenvalue less than one, then it can be considered to 
explain less variance than one of the original descriptors.  It is therefore common to 
only consider PCs with eigenvalues greater than one. 
PCA has found many applications in drug discovery.  One recent example includes 
its use in the assessment of chemical diversity.
98
  P-glycoprotein is one of the best 
characterised transporter proteins responsible for the multidrug resistance phenotype 
exhibited by cancer cells, and as such, represents one of the main barriers to 
chemotherapeutic treatment in cancer.
99
  There is therefore widespread interest in 
elucidating whether existing drugs may be candidates as P-glycoprotein substrates or 
inhibitors.  Work has been performed concerned with creating a pharmacophore 
model based on known P-glycoprotein inhibitors.  This model was then applied to 
the DrugBank
100
 database.  This highlighted a number of molecules of interest, 
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twelve of which were later found to be novel P-glycoprotein inhibitors.  PCA was 
used to assess the diversity of these hits, and to comment on any potential SARs 
which existed.  Descriptors commonly used in drug like profiling (i.e. log P; PSA; 
MW) were employed, and it was found that three PCs best represented the spread of 
variance in the data.  When a graphical projection of these PCs was analysed, it was 
shown that there was segregation in 3D space between P-glycoprotein inhibitors and 
activators, with this observation being utilised to comment on potential areas of 
chemical optimisation (fig. 2.9). 
 
Fig. 2.9  Example of PCA being used to distinguish between P-glycoprotein inhibitors and activators.  
Yellow circle: activators; Blue circle: inhibitors.  (A. Palmeira, F. Rodrigues, E. Sousa, M. Pinto, M. 
H. Vasconcelos and M. X. Fernandes, Chemical Biology & Drug Design, 2011, 78, 57-72.) 
Earlier work has involved using PCA to analyse a small set of 141 anticancer agents 
from the NCI, whose mechanisms of action had been well defined.
101, 102
  PCA score 
plots showed distinct clusters of compounds for some of the mechanisms of action 
examined.  More recently, this work has been extended to analyse a much larger 
database of 25,026 compounds,
103
 with PCA proving to be a useful tool in 
identifying outliers in this dataset, as well as entry errors.
104
  This ultimately led to a 
cleaner and more correct database.  It was also found that compounds which had 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Fig. 6 - A. Palmeira, F. Rodrigues, E. Sousa, M. Pinto, M. H. Vasconcelos 
and M. X. Fernandes, Chemical Biology & Drug Design, 2011, 78, 57-
72.). 
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similar activity profiles against a number of assays were found to group together in 
PCA space, with dissimilar compounds more scattered across the plot (fig. 2.10).  
The grouping clearly reflects the different mechanisms of action of the compounds in 
the dataset. 
 
Fig. 2.10  Example of PCA being used to identify the grouping of anticancer agents with similar 
activity patterns.  (L. M. Shi, Y. Fan, J. K. Lee, M. Waltham, D. T. Andrews, U. Scherf, K. D. Paull 
and J. N. Weinstein, Journal of Chemical Information and Computer Sciences, 1999, 40, 367-379.) 
A more relevant example would be the use of PCA to perform SAR analysis on a 
number of antimalarial compounds.
105
  Eighty structures were found to exhibit 
varying activities against the malaria parasite, belonging to eight different compound 
classes, including primary, secondary and tertiary amines, as well as quaternary 
ammonium and bisammonium salts.  The Broto autocorrelation technique was used 
to calculate a number of molecular descriptors which describe the physicochemical 
properties of the molecules, such as their molecular geometry, lipophilicity, and 
ability to give or receive hydrogen bonds.
106
  The generated PCA model was found 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Fig. 5 Panel A - L. M. Shi, Y. Fan, J. K. Lee, M. Waltham, D. T. 
Andrews, U. Scherf, K. D. Paull and J. N. Weinstein, Journal of Chemical 
Information and Computer Sciences, 1999, 40, 367-379.). 
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to explain 98.55% of the variance in the data with only three PCs, and was also 
found to correctly classify compounds as either poorly active or active with 98% 
accuracy.  Interpretation of the PCA model (fig. 2.11) also illustrated that both the 
size and shape of the molecules was crucial for antimalarial potency, with bulkier 
molecules having improved activity.  In this respect, axis 1 principally discriminates 
active (bulkier) from poorly active (smaller) compounds. 
 
Fig. 2.11  Example of PCA being used to determine antimalarial activity.  Active compounds (IC50 ≤ 
1.5 µM) are underlined, with the most active (IC50 ≤ 0.3 µM) in italics.  (M. Calas, G. Cordina, J. 
Bompart, M. BenBari, T. Jei, M. L. Ancelin and H. Vial, Journal of Medicinal Chemistry, 1997, 40, 
3557-3566.) 
Within this thesis, PCA was used to generate PCs for the active compounds based on 
their physicochemical descriptors.  The resulting PCA model was then applied to the 
ZINC lead like library of compounds to identify potential compounds of interest.  
Pipeline Pilot Student Edition v6.1
40
 was used to generate a protocol with which to 
perform PCA, based on the structures and properties of the twelve molecules 
previously described as active against Pfbc1 (table 2.1).  The following eight 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Fig. 1 - M. Calas, G. Cordina, J. Bompart, M. BenBari, T. Jei, M. L. 
Ancelin and H. Vial, Journal of Medicinal Chemistry, 1997, 40, 3557-
3566.). 
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molecular descriptors were calculated within Pipeline Pilot for each of the twelve 
compounds: AlogP; Molecular_Weight; Num_H_Donors; Num_H_Acceptors; 
Num_RotatableBonds; Num_Atoms; Num_Rings; Num_AromaticRings.  These 
were chosen as they describe many properties classically considered to describe drug 
like properties,
107, 108
 and whilst several of these descriptors are also well 
documented for their application within Lipinski’s rule of five,109 recent work has 
shown that the additional descriptors improve the accuracy of correctly classifying 
drug like compounds, compared with Lipinski’s properties alone.110  A PCA model 
was built using these eight molecular descriptors, with requirements defined such 
that the minimum variance explained by the model be no less than 75%.  A 
successful PCA model was found for the data, the statistics for which are shown in 
table 2.5.  The table shows the variance explained by each PC, as well as the relative 
contributions from the different molecular descriptors.  It was found that only two 
PCs were required to explain over 75% of the variance in the data (variance 
explained by two PCs was 81%), with the first three PCs explaining a total variance 
of 92%.  Successive PCs were shown to only marginally improve the explained 
variance, with the fourth PC explaining only an additional 6%.  Therefore the PCA 
model was comprised of only the first 3 PCs. 
Table. 2.5  Details of the principal components from PCA. 
Property PC1 PC2 PC3 
StandardDeviation 2.008968248 1.276653102 0.880959517 
VarianceExplained 0.576564775 0.232834735 0.110869953 
TotalVarianceExplained 0.576564775 0.809399509 0.920269462 
ALogP -6.98E-02 -0.606789183 0.658393792 
Molecular_Weight -0.4232148 0.263800905 0.380984102 
Num_H_Acceptors -0.404689723 0.412420968 -0.116774579 
Num_RotatableBonds -0.436041043 -0.267068747 -0.10482064 
Num_Atoms -0.435556746 0.295048617 0.334732928 
Num_Rings 0.384249182 0.40889702 0.237622919 
Num_AromaticRings 0.353200539 0.257970423 0.477738711 
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Figure 2.12 represents the twelve active molecules across 3D PC space.  As can be 
seen, the molecules are well distributed across this region of chemical space, 
suggesting that they are diverse in nature.  There is very little clustering which is 
encouraging, so it can be deduced that the twelve active compounds are each 
contributing unique information to the PCA model. 
 
Fig. 2.12  Graph to illustrate the twelve active compounds across 3D principal component space. 
The PCA model could next be applied to the ZINC lead like library of compounds to 
identify any of interest.  The same eight molecular descriptors were calculated for 
each of the molecules in the chemical library, and the PCA model applied to the 
compounds.  With the PC values calculated for the molecules in ZINC they could be 
plotted as before, to represent the spread of the molecules in 3D PC space.  This is 
illustrated in figure 2.13, and shows the molecules covering a much larger area of PC 
space, quite closely clustered with a few outliers.  However, this is to be expected as 
we must remember that the structures within the lead like library have already 
undergone filtering to ensure that only the most promising lead like structures form 
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part of the chemical library, and therefore already fall under certain physicochemical 
parameters.  Additionally, the distances across the axes in figure 2.13 are much 
larger than those in figure 1.12, again supporting the conclusion that the compounds 
in ZINC include a wide array of diverse structures. 
 
Fig. 2.13  Graph to illustrate the PCA model applied to the 2.7 million molecules of the ZINC lead 
like library. 
With the PCA model applied to the ZINC lead like library of compounds, it was 
necessary to consider the best way to select compounds of potential interest.  To do 
this the known active compounds were used as reference structures within the 3D PC 
space.  The closest molecules from the ZINC lead like library to these known actives 
were then selected, with closeness assessed using Euclidean distance.  Where the 
Tanimoto coefficient measures the similarity between two compounds, Euclidean 
distance essentially measures the distance between two molecules in variable 
space.
14, 111
  In this instance variable space is described by the PCs, and therefore 
Euclidean distance looks at the distance between molecules in this PC space.  Similar 
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to the Tanimoto coefficient, binary variables can be used to give distance values 
which range upwards of 0.  A Euclidean distance of 0 would indicate that the pair of 
molecules occupy an identical region of space according to the variables used, but as 
the value increases they move further away from each other, becoming less close.  
The Euclidean distance between a pair of molecules using continuous variables can 
be calculated using equation 2.3, where     represents the distance between 
molecules A and B, and    the value of the continuous variables. 
              
 
 
   
 
   
 
Eq. 2.3  Euclidean distance. 
Euclidean distances were assigned to each of the molecules in ZINC, based on which 
known active molecule it was closest to.  In order to try to achieve the correct 
balance of similarity and diversity, only the 5,000 compounds from ZINC closest to 
a known active were selected.  This was to keep the exploration of chemical space as 
concentrated and focused as possible.  When the PCs of these 5,000 closest 
compounds was plotted in 3D space (fig. 2.14), the molecules were found to 
encompass much physicochemical diversity, thus they made for an interesting 
contribution towards the LBVS consensus study.  Principal component analysis was 
performed according to the ‘Principal Component Analysis Protocol’ as detailed in 
the Experimental Chapter. 
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Fig. 2.14  Graph to illustrate the 5,000 closest molecules from ZINC to known active based on their 
Euclidean distances in principal component space. 
2.3.5 Naïve Bayesian Classification 
The four LBVS methods described thus far were all concerned with only the 
structures of the active compounds.  The next two methods (Bayesian and decision 
tree classification) however, utilise the structures and chemical properties of both the 
active, and the inactive compounds (table 2.1).  Whilst individual data points can be 
of enormous importance with regard to identifying hits (i.e. substructure searching), 
trends can only be observed if there is sufficient amounts of data available.
112
  By 
using the structural information contained within the active and inactive molecules, 
trends in the data can be spotted, modelled and exploited, so that each compound in a 
chemical library can be assessed for its relative merits with regard to the information 
available.  Data mining algorithms such as the application of naïve Bayesian 
classification have two major aims depending on their particular setting.  One is to 
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help interpret the data, whilst the other is to predict experimental quantities of novel 
molecules. 
Naïve Bayesian classification is a probabilistic classifier method based on the Bayes’ 
theorem,
113
 originally published in the eighteenth century by statistician Thomas 
Bayes.  In its simplest form, a naïve Bayes classifier assumes that the presence or 
absence of one particular feature is unrelated to the presence or absence of another.  
That is, that the variables are independent of one another.  The Bayes’ theorem can 
be used to model the probability distribution of an output variable, if conditional 
probabilities of the input variables for a set of classes are known. 
The Bayes’ theorem can be derived relatively easily through several assumptions.  
That the conditional probability of an event  , given event  , can be written as: 
       
      
    
 
Similarly the probability of event  , given event  , can be written as: 
       
      
    
 
The joint probability,       , is common to both equations, hence after 
rearranging and equating the remainder we arrive at: 
                      
This can then be rearranged further to give the most commonly known form of the 
Bayes’ theorem: 
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In chemoinformatics, event   typically represents the presence or absences of a 
particular molecular feature in a molecule, with the predicted likelihood of event   
being the activity of said molecule.  Hence, using Bayes’ theorem to assess the 
distribution of features in a dataset with different classes (i.e. active and inactive), 
allows for the prediction of class membership given certain features in a molecule. 
    , termed the prior in Bayes’ nomenclature, makes an assumption about the 
likelihood of   in the absence of any additional information.  In many cases, 
information from a given dataset can be used to make an estimate of the prior, so that 
in situations such as virtual screening, in which compounds are ranked relative to 
one another, the prior will be identical for every compound, with a uniform prior 
(      ) often used for simplicity. 
As the probability      may be zero for a particular property not encountered in the 
training set, this exception needs to be treated differently, as do cases where the 
sample size is very small.  In cases where a feature is only present once in an active 
molecule, but never in an inactive molecule, the likelihood according to the naïve 
Bayes’ classifier that a new molecule will show that feature is 100%.  To overcome 
such situations the Laplacian or Laplace correction is used, which adds k virtual 
samples to the dataset with the assumption that in each of them a particular feature 
will be present.
114
 
Bayes’ theorem is often employed in classification tasks and is termed naïve 
Bayesian classification.  It gets its name (naïve) from the fact that it only considers 
the frequency of individual features in the classification, and not their mutual 
dependence.  This assumes that every input variable increases or decreases the 
confidence in a particular category assignment for a molecule.  Classification 
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analysis can even be performed when the variables are numerical in nature.  Whilst 
nominal attributes are more easily dealt with, there are a number of ways in which 
these numerical attributes can be processed.  One option is the use of binning to 
assign specific values to a particular bin that spans across the range of values.  Bin 
borders can be at either fixed intervals or set such that bins are equally populated.  
An alternative option is to assume the molecules follow Gaussian distribution, and to 
then use particular variable thresholds to classify molecules accordingly. 
Whilst other machine learning methods have been shown to occasionally perform 
better than naïve Bayesian classification,
115
 its ability to accommodate knowledge 
from multiple active compounds has shown it to outperform other commonly used 
methods which are based on both 2D and 3D features.
116, 117
  It’s true strength lies in 
its combination of very good performance, together with its time efficient learning 
and ability to handle multiple categories of variables efficiently. 
The main thrust of naïve Bayesian classification and its use to distinguish between 
active and inactive compounds is based upon two core assumptions:
118
 (i) that the 
descriptors in the training set are equally important as each other, and (ii) that the 
descriptors are independent of one another.  From this the combined probability of a 
particular activity classification is obtained by multiplying the individual 
probabilities.  Though, these assumptions are often violated, naïve Bayesian 
classification is robust to such violations, and tolerant towards noise in the 
experimental data.
119
 
Machine learning approaches such as Bayesian classification have been extensively 
applied to the field of molecular similarity,
116, 117, 120
 as well as other virtual 
screening and scaffold hopping problems.
18, 50, 78, 121
  Even though naïve Bayesian 
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classification is a relatively recent addition to the arsenal of tools available for 
chemoinformaticians, it has shown to be of great use when implemented in 
conjunction with classical modelling techniques, to assist in the rapid virtual 
screening of large compound libraries in a systematic manner.
122
  As mentioned 
previously the Bayesian classifiers have the added benefit of being able to handle a 
variety of numerical or binary data, making the addition of new parameters to 
existing models a relatively straight forward process.  As a result, during a drug 
discovery project these classifiers can evolve with the needs of the projects, going 
from general models in the lead finding stage, to increasingly precise models during 
optimisation. 
One example involves the use of Bayesian statistics to model both general 
(multifamily) and specific (single target) kinase inhibitors, to be used in the 
therapeutic intervention of cancer, inflammatory diseases and diabetes.
54
  A 
generalised model generated using inhibitor data for multiple kinase classes showed 
meaningful enrichment for several specific kinase targets.  The results were used to 
prioritise compounds for screening, and to optimally select compounds from third 
party data collections.  The observed benefits of this approach was to find 
compounds that were not structurally related to known actives, and to find novel 
targets for which there was not enough information available to build a specific 
kinase model. 
Given that classification methods utilise the structures of both the active and inactive 
compounds, the structural information of the twelve active and seven inactive 
molecules tested against Pfbc1 (table 21.1) were used to generate naïve Bayesian 
models.  It has been found that when only a small number of active data points are 
available, the performance of a model may suffer as a result,
112
 with small being 
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defined as a dozen or so active compounds.
123
  Above this and it has been found that 
Bayes classifier should give good performance in typical virtual screening situations, 
as shown in large scale retrospective virtual screening studies.
117
  Though there are 
only twelve compounds active against Pfbc1 (and seven inactive), generated models 
were statistically analysed to ensure definitive model significance.  Additionally, as 
there is coverage of the inactive class this has been found to be beneficial,
124
 as 
otherwise the Bayes classifier may not be able to draw conclusions from a specific 
feature set, and thus remain undecided about the classification of a new molecule. 
The nineteen molecules were each assigned a qualitative label of either ‘yes’ or ‘no’, 
depending on whether they were active of inactive respectively.  For each of these 
nineteen compounds a number of molecular descriptors were calculated using 
Pipeline Pilot Student Edition v6.1.
40
  As we had successfully used a number of 
physicochemical descriptors for PCA model generation, the same eight molecular 
descriptors were decided upon for use with naïve Bayesian classification.  To refresh 
these descriptors were: AlogP; Molecular_Weight; Num_H_Donors; 
Num_H_Acceptors; Num_RotatableBonds; Num_Atoms; Num_Rings; 
Num_AromaticRings.  The Num_Fragments descriptor was also included.  It should 
be noted that additional descriptor sets were considered (i.e. the twenty molecular 
properties available within KNIME
125
).  However, Bayesian models generated using 
these descriptors were statistically insignificant, thus additional discussion with 
regard to such descriptor sets will not occur. 
With the nineteen compounds in the dataset correctly labelled and their descriptors 
calculated, it was now time to build a protocol with which to perform Bayesian 
classification.  This was done using KNIME,
125
 a dataflow/workflow program 
similar to Pipeline Pilot.  It contains specific components making it perfectly suited 
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to data mining problems.  An initial set of filters were applied to remove any 
redundant or uninformative descriptors.  A low variance filter with the variance 
upper bound set to zero resulted in all descriptors being removed that contained only 
a constant value.  Num_Fragments was one such descriptor, showing no variance 
across the molecules.  Next a linear correlation component was applied to calculate 
the measure of correlation between each of the eight remaining descriptors with 
respect to one another.  As all of the variables were numerical in nature, the 
Pearson’s product moment coefficient was used to assess the correlations.126  The 
Pearson’s product moment coefficient offers a measure of linear correlation between 
two variables, with values ranging between +1 to indicate a strongly positive 
correlation, and -1 to indicate a strongly negative one.  The correlations between the 
descriptors can be observed using the correlation matrix shown in table 2.6.  
Analysis showed which descriptors were redundant, contributing little or no unique 
information to the overall model.  Most of the descriptors appeared to have very little 
correlation to each other; however, there was a strong correlation between 
Num_Atoms and Molecular_Weight.  Num_Atoms was also fairly highly correlated 
to Num_H_Acceptors.  Such strong correlations were resolved using a correlation 
filter, with descriptors removed which had a correlation threshold of greater than 0.9.  
This cut-off did indeed remove the Num_Atoms descriptor, resulting in only seven 
physicochemical descriptors for use in Bayesian model development. 
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Table. 2.6  Correlation matrix between the physicochemical descriptors in the Bayesian model. 
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0.52 -0.02 -0.57 0.50 0.38 0.12 0.53 
Molecular_Weight 
  
0.72 -0.34 0.98 0.61 -0.03 0.28 
Num_H_Acceptors 
   
-0.19 0.79 0.60 -0.22 -0.11 
Num_H_Donors 
    
-0.35 -0.25 -0.15 -0.52 
Num_Atoms 
     
0.67 -0.04 0.29 
Num_RotatableBonds 
      
-0.68 -0.12 
Num_Rings 
       
0.66 
Num_AromaticRings 
        
Prior to model generation the molecular descriptors had to be normalised.  Min-Max 
normalisation was performed to create a linear transformation of the values across all 
the molecules for each of the descriptors.  This linear transformation involved 
scaling the range of values for each descriptor, with a maximum and minimum value 
for each descriptor across the molecules of 1 and 0 respectively. 
The naïve Bayesian learner component in KNIME
125
 was used to create a Bayesian 
model to classify compound activity, based on the Gaussian distribution of the 
normalised descriptors for the nineteen compounds in the training set.  The model 
could then be tested using the naïve Bayes predictor component in KNIME,
125
 to 
predict the class membership of external compounds.  To begin with the naïve 
Bayesian model was applied to the same nineteen compounds used in the training.  
This was to give a clear idea as to how well the model was performing internally, 
and to illustrate whether or not it was valid.  The results of classification prediction 
when the actual class membership is known can be represented in a confusion of 
contingency matrix.
127
  In such a matrix, the rows represent the actual classes, with 
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the columns representing the predicted classes which have been assigned based on 
the model.  The matrix shows the number of classifications which have been made 
correctly, and also where discrepancies in predictions occur.  Table 2.7 gives the 
confusion matrix for the generated naïve Bayesian model when it was applied to the 
initial nineteen active and inactive molecules used in model development. 
Table. 2.7  Confusion matrix of the naïve Bayesian model.  Letters correspond to which variables are 
used when calculating the Cooper statistics (table 2.8). 
Actual \ Predicted Yes No Marginal totals 
Yes 
9 
  
3 
  
12 
    
No 
2 
  
5 
  
7 
    
Marginal totals 
11 
    
8 
    
19 
        
From the confusion matrix it is possible to calculate a number of statistics which are 
useful for model validation, termed the Cooper statistics.
128
  These were originally 
described in the seventies for the validation of carcinogen screening tests,
129
 but have 
been extensively applied to assess the results of classification and Bayesian 
approaches.
128, 130
  The Cooper statistics associated with the confusion matrix in table 
2.7 are shown in table 2.8, as is the description and formula required for their 
calculation. 
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Table. 2.8  Cooper statistics for the naïve Bayesian model.  Letters correspond to which variables 
from the confusion matrix (table 2.7) are used when calculating the Cooper statistics. 
Statistic Formula Value Definition 
Sensitivity (True 
positive rate) 
 
     
 0.75 
Fraction of active chemicals correctly 
assigned 
Specificity (True 
negative rate) 
 
     
 0.71 
Fraction of non-active chemicals correctly 
assigned 
Concordance or 
accuracy 
     
         
 0.74 Fraction of chemicals correctly assigned 
Positive prediction 
 
     
 0.82 
Fraction of chemicals correctly assigned as 
active out of the active assigned chemicals 
Negative prediction 
 
     
 0.63 
Fraction of chemicals correctly assigned as 
non-active out of the non-active assigned 
chemicals 
False positive (over-
classification) rate 
 
     
 
              
0.29 
Fraction of non-active chemicals that are 
falsely assigned to be active 
False negative (under-
classification) rate 
 
     
 
              
0.25 
Fraction of active chemicals that are 
falsely assigned to be non-active 
Perhaps the most important and relevant statistic from table 2.8 is the accuracy or 
concordance.  For the naïve Bayesian model this was shown to be 0.74, that is that 
74% of the time, the Bayesian model correctly predicted the activity class for the 
compounds used to build the model, with fourteen of the nineteen compounds 
classified correctly.  It has previously been put forward that for standalone 
classification models, the Cooper statistics should be significantly greater than 
50%.
128
  This is clearly obeyed for this model, and there are also a number of other 
encouraging statistics, i.e. that 82% of the active compounds were correctly assigned 
as active.  What is also encouraging is that the percentage of false negatives (25%) is 
reasonably small given the size of the dataset. 
Whilst these statistics are all encouraging with regard to the naïve Bayesian model, it 
is still necessary to perform external validation.  External validation refers to the 
application of the model to chemical structures which were not used in the training 
set to generate the model, yet whose actual activity classes are known (test set).  
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External validation has proven to be one of the most stringent forms of validation, 
yet the test set compounds must all lie within a sufficient domain of applicability in 
order to be useful.  To test the model for its external validation, the dataset was 
partitioned using stratified sampling, such that 70% of the molecules (13 
compounds) were in the training set, and 30% (6 compounds) in the test set, a 
splitting pattern which has been supported by the literature.
128
  A new model was 
built using the training set, and then applied to the training set molecules to give the 
confusion matrix and Cooper statistics observed in tables 2.9 and 2.10 respectively.  
As can be seen, the model performs strong internally, with an accuracy of 77%. 
Table. 2.9  Confusion matrix of the naïve Bayesian model built using 70% of the molecules, and 
applied to the training set. 
Actual \ Predicted Yes No Marginal totals 
Yes 6 2 8 
No 1 4 5 
Marginal totals 7 6 13 
 
Table. 2.10  Cooper statistics for the naïve Bayesian model built using 70% of the molecules, and 
applied to the training set. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.75 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.80 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.77 Fraction of chemicals correctly assigned 
Positive prediction 0.86 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.67 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.20 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.25 
Fraction of active chemicals that are falsely assigned to be 
non-active 
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The true test of its predictive ability lies in its potential to correctly predict the 
activity class of compounds not used during model development (i.e. those in the 
training set).  Thus the model was applied to the test set of compounds (the other 
30% of the dataset) and the same analysis performed.  The confusion matrix and 
Cooper statistics for the external set of compounds is shown in tables 2.11 and 2.12 
respectively. 
Table. 2.11  Confusion matrix of the naïve Bayesian model built using 70% of the molecules, and 
applied to the test set. 
Actual \ Predicted Yes No Marginal totals 
Yes 3 1 4 
No 1 1 2 
Marginal totals 4 2 6 
 
Table. 2.12  Cooper statistics for the naïve Bayesian model built using 70% of the molecules and 
applied to the test set. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.75 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.50 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.67 Fraction of chemicals correctly assigned 
Positive prediction 0.75 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.50 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.50 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.25 
Fraction of active chemicals that are falsely assigned to be 
non-active 
Whilst the externally accuracy of the model fell to 67%, this is still significantly 
higher than the aforementioned 50% significance level, and as such can be 
considered as significant and potentially useful.  From this it was possible to deduce 
that a sound model had indeed been developed, and whilst the statistics could be 
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considered a little low, this may be attributed to the fact that the test set consisted of 
only six molecules.  Additional confidence and support for the model was attained 
by using the leave-one-out (LOO) cross validation procedure.
128
  This involved 
employing   training sets in which one molecule had been excluded from the 
original dataset.  A total of   models were then developed by using each of the 
training sets containing     objects, with the developed model used to predict the 
activity class of the excluded compound.  For classification models such as this, the 
cross validated Cooper statistics can be calculated to test the overall accuracy of the 
models developed.  Tables 2.13 and 2.14 show the confusion matrix and Cooper 
statistics respectively for the LOO cross validation of the naïve Bayesian model.  
Cross validation was performed one hundred times and an average across all the 
results taken. 
Table. 2.13  Confusion matrix of one hundred iterations of the LOO cross validation calculation for 
the naïve Bayesian model. 
Actual \ Predicted Yes No Marginal totals 
Yes 11 1 12 
No 6 1 7 
Marginal totals 17 2 19 
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Table. 2.14  Cooper statistics of one hundred iterations of the LOO cross validation calculation for 
the naïve Bayesian model. 
Statistic Value Definition 
Sensitivity (True positive rate) 0.92 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.14 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.63 Fraction of chemicals correctly assigned 
Positive prediction 0.65 
Fraction of chemicals correctly assigned as active 
out of the active assigned chemicals 
Negative prediction 0.50 
Fraction of chemicals correctly assigned as non-
active out of the non-active assigned chemicals 
False positive (over-
classification) rate 
0.86 
Fraction of non-active chemicals that are falsely 
assigned to be active 
False negative (under-
classification) rate 
0.083 
Fraction of active chemicals that are falsely 
assigned to be non-active 
The overall accuracy across one hundred iterations of the LOO cross validation was 
63%, which was in good agreement with the Cooper statistics of external validation.  
All things considered it appeared that a fairly significant and robust model has 
indeed been developed.  However, before the model was applied to the ZINC lead 
like library of compounds, an additional approach was considered to try and better 
represent the initial data, and thus develop a more significant and accurate model. 
The synthetic minority oversampling technique (SMOTE) can be used to oversample 
the input data, by adding artificial rows to enrich the data.
131
  When using learning 
algorithms it can sometimes be useful to have an equal class distribution of 
molecules in order to achieve a good classification performance.  In cases where 
there is an unbalance in the input data, for instance if there are only a few objects in 
the active class but many in the inactive, this would leave the active class of 
compounds underrepresented, and thus the dataset skewed in favour of the inactive 
compounds.  SMOTE can therefore be used to counteract such discrepancies, and 
adjust the class distribution by adding artificial rows for the active compounds.  The 
SMOTE algorithm works by creating a synthetic object which is an extrapolation 
between a real object, and one of its nearest neighbours in a particular class.  It picks 
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a point along the line between these two objects and determines the attributes of the 
new object, based on this randomly chosen point.  This oversampling of the data is 
used to enrich the data and hopefully develop more meaningful and useful models. 
The SMOTE component in KNIME
125
 was used to correct the underrepresentation of 
the inactive class in the initial dataset (twelve active; seven inactive).  The SMOTE 
algorithm picked an object from the inactive class, and then randomly selected one 
of its nearest neighbours, drawing the new synthetic object along the line between 
the sample and the nearest neighbour.  The data was oversampled by the minority 
class, so synthetic objects were only added to the inactive class.  Five synthetic 
objects were created, resulting in twelve compounds in each activity class. 
A new naïve Bayesian model was developed using the twenty four molecules 
(twelve active; twelve inactive) in the training set.  This model was built as described 
previously, and then tested on the entire training set to see how well it performed 
internally.  The confusion matrix and Cooper statistics for this model are shown in 
tables 2.15 and 2.16 respectively. 
Table. 2.15  Confusion matrix of naïve Bayesian model built after using SMOTE. 
Actual \ Predicted Yes No Marginal totals 
Yes 9 3 12 
No 3 4 7 
Marginal totals 12 7 19 
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Table. 2.16  Cooper statistics of naïve Bayesian model built after using SMOTE. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.75 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.57 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.68 Fraction of chemicals correctly assigned 
Positive prediction 0.75 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.57 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.43 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.25 
Fraction of active chemicals that are falsely assigned to be 
non-active 
It can be seen that when using SMOTE, the accuracy of the naïve Bayesian model 
fell from 74%, to 68%.  Though not a huge drop, it was still interesting to note that 
oversampling the inactive class led to a less significant model.  To validate this 
conclusion further, the dataset was partitioned as before so that 70% of the molecules 
were in the training set, and the other 30% in a test set.  A new model was developed 
for the training set and then tested internally against the same set of compounds, with 
the confusion matrix and Cooper statistics shown in tables 2.17 and 2.18 
respectively. 
Table. 2.17  Confusion matrix for the naïve Bayesian model built after using SMOTE on 70% of the 
molecules and applied to the training set. 
Actual \ Predicted Yes No Marginal totals 
Yes 5 3 8 
No 1 4 5 
Marginal totals 6 7 13 
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Table. 2.18  Cooper statistics for the naïve Bayesian model built after using SMOTE on 70% of the 
molecules and applied to the training set. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.63 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.80 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.69 Fraction of chemicals correctly assigned 
Positive prediction 0.83 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.57 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.20 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.38 
Fraction of active chemicals that are falsely assigned to be 
non-active 
Initially these results looked encouraging, reporting an accuracy of 69%.  However, 
when the model was applied to the test set the Cooper statistics demonstrated the 
unsuitability of the model, with an accuracy on only 33%, demonstrated by the 
confusion matrix and Cooper statistics in tables 2.19 and 2.20 respectively.  This 
value is much lower than the minimum 50% accuracy which was discussed earlier. 
Table. 2.19  Confusion matrix for the naïve Bayesian model built after using SMOTE on 70% of the 
molecules and applied to the test set. 
Actual \ Predicted Yes No Marginal totals 
Yes 1 3 4 
No 1 1 2 
Marginal totals 2 4 6 
 
 
 
 
Chapter II 
 
144 
 
Table. 2.20  Cooper statistics for the naïve Bayesian model built after using SMOTE on 70% of the 
molecules and applied to the test set. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.25 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.50 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.33 Fraction of chemicals correctly assigned 
Positive prediction 0.50 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.25 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.50 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.75 
Fraction of active chemicals that are falsely assigned to be 
non-active 
Final support for the unsuitability of SMOTE in this example was provided via LOO 
cross validation of the model.  One hundred iterations of the loop were performed, 
with an average accuracy of only 50%, as represented by the confusion matrix and 
Cooper statistics in tables 2.21 and 2.22 respectively. 
Table. 2.21  Confusion matrix of one hundred iterations of the LOO cross validation calculation for 
the naïve Bayesian model built after using SMOTE on 70% of the molecules. 
Actual \ Predicted Yes No Marginal totals 
Yes 11 1 12 
No 11 1 12 
Marginal totals 22 2 24 
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Table. 2.22  Cooper statistics of one hundred iterations of the LOO cross validation calculation for 
the naïve Bayesian model built after using SMOTE on 70% of the molecules. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.92 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.083 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.50 Fraction of chemicals correctly assigned 
Positive prediction 0.50 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.50 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.92 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.083 
Fraction of active chemicals that are falsely assigned to be 
non-active 
The results supported the decision not to use SMOTE, as the raw data alone 
produced a more accurate and significant model.  The consensus of this investigation 
reinforced the decision to simply move forward using the original naïve Bayesian 
model which was developed from only the original compounds, and the seven 
physicochemical descriptors described (tables 2.7 and 2.8). 
The significant Bayesian classification model was applied to the ZINC lead like 
library of compounds.  The physicochemical descriptors for the 2.7 million 
compounds were calculated in Pipeline Pilot Student Edition v6.1,
40
 and then 
normalised in KNIME
125
 according to the normalisation procedure used during 
model development.  The Bayesian model was applied to ZINC, and for each 
molecule a Bayesian probability calculated.  This probability was based upon the 
relationship observed between the molecular descriptors and the associated activity 
classes.  The resulting probabilities allowed for each molecule to be considered as 
either active or inactive, depending upon which side of the probability threshold it 
fell into.  It is useful to keep in mind that when using the Bayesian classification 
technique, the output variable (the probability) is trained in a binary manner, so that 
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the classification which is made only represents the likelihood of a molecule 
showing that particular character.
112
  Compounds with a probability value less than 
0.5 were classified as inactive, whilst those with a probability value greater than 0.5 
were classified as active. 
In Pipeline Pilot Student Edition v6.1
40
 the compounds were filtered to remove any 
which were defined as inactive.  From this it was found that 725,190 compounds 
from ZINC had been classified as active.  The number of hits from this method was 
considerably higher than from previous methods, suggesting that almost a third of 
the compounds in the ZINC lead like library were active.  This is clearly very 
unlikely.  However, despite there being such a large number of hits, the results 
would still enrich the selection of compounds via the consensus study.  Additionally, 
the probability of an active classification may also influence the results and will be 
discussed further in Chapter III.  Naïve Bayesian classification was performed 
according to the ‘Naïve Bayesian Classification Protocol’ as described in the 
Experimental Chapter. 
2.3.6 Decision Tree Analysis 
Decision tree analysis is similar to Bayesian classification, in that it considers the 
chemical structures and properties of both the active and inactive compounds.  
Though some interpretable information can be garnered from Bayesian 
classification, its uses fall mainly in its predictive ability, rather than what it tells us 
about a particular dataset in terms of its chemical properties.  Decision tree analysis 
is very much in contrast to this, as it consists of developing a set of rules that provide 
a means of associating a molecules features or descriptor values, with a particular 
property of interest, such as biological activity.
14
  A decision tree is commonly 
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depicted as a tree like structure, with each node corresponding to a specific rule.  
These rules may correspond to the presence or absence of a particular chemical 
feature, or to a specific threshold value for a descriptor. 
An example of decision tree analysis is shown in figure 2.15.  This decision tree was 
developed for a series of fifty active and twelve inactive sumazole and isomazole 
analogues.  The active molecules were shown to have inotropic properties that can 
increase the force of heart muscle contraction without increasing its rate, and thus 
have found use in cardiac failure to increase heart muscle efficiency.
132
  The decision 
tree could be used to classify unknown molecules by moving down the decision tree, 
answering each of the rules until a terminal node was reached.  The terminal node 
was then used to assign the molecule into an appropriate class.  This particular 
dataset is of interest because the active compounds are surrounded in the descriptor 
space by the inactive molecules, which may ordinarily cause problems when using 
regression methods, but here were found to be beneficial.  The decision tree can be 
used more simply to determine which features appear to give rise to activity, and 
which lead to inactivity. 
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Fig. 2.15  Example of decision tree analysis for a series of sumazole and isomazole analogues for 
their inotropic properties.  (M. A-Razzak and R. C. Glen, Journal of Computer-Aided Molecular 
Design, 1992, 6, 349-383.) 
Another example shows the development of models in order to predict the likelihood 
of diabetes mellitus in patients.
133
  Diabetes mellitus, or diabetes, is a major global 
health problem which affects millions of people worldwide.  Classification 
algorithms have been applied in the past to use patient profiles to predict those at 
greater risk of having diabetes.
134, 135
  Owing to the greatly increased amount of data 
gathered in medical databases, traditional manual analysis has become inadequate, 
and methods for efficient computer based analysis are now indispensible.  In this 
research, classification methods were used to predict whether patients were likely to 
suffer from diabetes, based upon symptoms mined from their medical records.  A 
decision tree was built and tested using data from 768 patients.  This data contained 
information such as the individuals’ age, blood pressure and body mass index (BMI), 
with 268 of the patients in the dataset having been diagnosed with diabetes (i.e. the 
active class).  The subsequent decision tree had an accuracy of 89.3%, and when this 
data was pruned to remove anomalies in the training set such as noise and outliers in 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Diagram 4 - M. A-Razzak and R. C. Glen, Journal of Computer-Aided 
Molecular Design, 1992, 6, 349-383.). 
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order to avoid over fitting during development, the accuracy improved further to 
89.7%. 
There are many methods available for the construction of decision trees, but most of 
them follow the same basic approach, which is to start with the entire dataset and 
identify the descriptor which gives the best initial split.  This enables the dataset to 
be divided into two or more subsets, with the same procedure then applied to each of 
these subsets and so on.  This is repeated until all of the molecules have been 
appropriately divided into their distinct classes, or until no more splits of 
significance can be found.  One group of algorithms, such as ID3 (iterative 
dichotomiser 3) and C4.5, use the results from the field of information theory or 
entropy, to provide a measure of the uncertainty associated with a random variable  
to decide which criteria to choose at each step of the decision tree generation.
136
  If 
there are   molecules divided into           classes, with each class    containing 
   molecules, then the information corresponding to this distribution (also called the 
entropy of the system) is given by equation 2.4, where        .  This equation is 
used to decide which descriptor to use in order to construct the next rule, that is the 
one which gives rise to the largest increase in entropy, also termed the gain. 
          
Eq. 2.4  Equation to calculate the entropy of a system. 
Within this thesis the J48 algorithm was used for the construction of decision trees 
based on the twelve active and seven inactive compounds.  The J48 algorithm is an 
open source Java implementation of the C4.5 algorithm, available from within the 
WEKA (Waikato Environment for Knowledge Analysis) data mining tool.
137
  C4.5 
is itself an improved version of ID3, with ID3 having been developed as an 
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algorithm for use in decision tree generation.
138
  However, a disadvantage of ID3 is 
that it often over fits the training data, which can give rise to decisions trees that are 
too specific, and which may not be resistant to noise when tested on novel 
compounds.  Another disadvantage of ID3 is that it cannot deal with missing 
attributes, requiring that all variables have nominal values.  It also does not have the 
means to manage continuous attributes.  C4.5 was therefore developed as an 
extension of ID3, and has been found to prevent this over fitting of the training data 
by pruning the decision tree when required, thus making it more resistant to noise.
139, 
140
  The decision trees generated by C4.5 can therefore be used for classification 
purposes. 
The J48 algorithm employs an automatic procedure capable of selecting relevant 
features from the training data.
133
  It is able to cut the poor or non-meaningful 
branches through an efficient pruning process, as well as being able to handle both 
continuous and discrete attributes.  In handling continuous attributes, J48 creates a 
threshold, splitting the list into those whose attribute value is above the threshold, 
and those that are below or equal to it, thus creating rules through an iterative 
process. 
The same nine physicochemical descriptors (AlogP; Molecular_Weight; 
Num_H_Donors; Num_H_Acceptors; Num_RotatableBonds; Num_Atoms; 
Num_Rings; Num_AromaticRings; Num_Fragments) which were used for Bayesian 
classification were again employed for decision tree analysis, and calculated in 
Pipeline Pilot Student Edition v6.1.
40
  As with Bayesian classification the twelve 
active compounds were labelled ‘yes’ and the seven inactive ‘no’.  Decision tree 
models were developed using the KNIME
125
 workflow program.  Low variance and 
correlation filters were first applied to remove the Num_Fragments (no variance) and 
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Num_Atoms (strong correlation with Molecular_Weight) descriptors respectively, 
with the descriptor values then normalised using min-max normalisation.  For 
decision tree development it was necessary to convert the activity labels from string 
variables to nominal variables, thus allowing for classification models to be built.  
An initial model was built using all the molecules in the training set.  The ‘J48 
(Weka)’ node was used to develop the model, with the resultant model applied to the 
same training set of compounds using the ‘Decision Tree Predictor’ component.  
This was to review how well the model performed at predicting the correct activity 
class for the structures used during model development.  Success was assessed 
through the use of a confusion matrix and Cooper statistics, which for this model are 
shown by tables 2.23 and 2.24 respectively. 
Table. 2.23  Confusion matrix of the Decision Tree model with all molecules in the training set. 
Actual \ Predicted Yes No Marginal totals 
Yes 10 2 12 
No 0 7 7 
Marginal totals 10 9 19 
 
Table. 2.24  Cooper statistics of the Decision Tree model with all molecules in the training set. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.83 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
1.00 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.90 Fraction of chemicals correctly assigned 
Positive prediction 1.00 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.78 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.00 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.17 
Fraction of active chemicals that are falsely assigned to be 
non-active 
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The Cooper statistics were found to be highly favourable, showing the model to have 
an accuracy of 90%.  However, when the use of SMOTE was investigated with the 
minority class being oversampled (as with the naïve Bayesian classification), the 
accuracy of the model fell to 79%.  SMOTE was therefore not considered further as 
it was proven to worsen the success of decision tree analysis.  To validate this model 
further before it was applied to the ZINC lead like library, the dataset was partitioned 
using stratified sampling, such that 70% of the molecules were now in a training set, 
and the other 30% in a test set.  A new decision tree was developed for this training 
set, and the model applied to the training set.  The confusions matrix and Cooper 
statistics for this model are shown in tables 2.25 and 2.26 respectively. 
Table. 2.25  Confusion matrix of the Decision Tree model built using 70% of the molecules and 
applied to the same training set. 
Actual \ Predicted Yes No Marginal totals 
Yes 6 2 8 
No 0 5 5 
Marginal totals 6 7 13 
 
Table. 2.26  Cooper statistics of the Decision Tree model built using 70% of the molecules and 
applied to the same training set. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.75 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
1.00 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.85 Fraction of chemicals correctly assigned 
Positive prediction 1.00 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.71 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.00 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.25 
Fraction of active chemicals that are falsely assigned to be 
non-active 
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Internally the model looked to perform strongly, with an accuracy of 85%.  
However, to assess its external validity the model was applied to the test set of 
compounds, with the results reported in the confusions matrix and Cooper statistics 
of tables 2.27 and 2.28 respectively. 
Table. 2.27  Confusion matrix of the Decision Tree model built using 70% of the molecules and 
applied to the test set of compounds. 
Actual \ Predicted Yes No Marginal totals 
Yes 2 2 4 
No 0 2 2 
Marginal totals 2 4 6 
 
Table. 2.28  Cooper statistics of the Decision Tree model built using 70% of the molecules and 
applied to the test set of compounds. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.50 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
1.00 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.67 Fraction of chemicals correctly assigned 
Positive prediction 1.00 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.50 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.00 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.50 
Fraction of active chemicals that are falsely assigned to be 
non-active 
Though the accuracy dropped to 67% when tested externally, the minimum criteria 
that the Cooper statistic for accuracy should exceed at least 50% was satisfied.
128
  
Finally, the model built using all nineteen compounds was assessed using the LOO 
cross validation procedure, and measured across one hundred iterations.  The 
confusion matrix and Cooper statistics for the LOO cross validation of the model are 
shown in tables 2.29 and 2.30 respectively. 
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Table. 2.29  Confusion matrix of one hundred iterations of the LOO cross validation calculation for 
the Decision Tree model built using all molecules. 
Actual \ Predicted Yes No Marginal totals 
Yes 11 1 12 
No 6 1 7 
Marginal totals 17 2 19 
 
Table. 2.30  Cooper statistics of one hundred iterations of the LOO cross validation calculation for 
the Decision Tree model built using all molecules. 
Statistic Value Definition 
Sensitivity (True positive 
rate) 
0.92 Fraction of active chemicals correctly assigned 
Specificity (True negative 
rate) 
0.14 Fraction of non-active chemicals correctly assigned 
Concordance or accuracy 0.63 Fraction of chemicals correctly assigned 
Positive prediction 0.65 
Fraction of chemicals correctly assigned as active out of the 
active assigned chemicals 
Negative prediction 0.50 
Fraction of chemicals correctly assigned as non-active out of 
the non-active assigned chemicals 
False positive (over-
classification) rate 
0.86 
Fraction of non-active chemicals that are falsely assigned to 
be active 
False negative (under-
classification) rate 
0.083 
Fraction of active chemicals that are falsely assigned to be 
non-active 
The accuracy was found to be 63% and sufficiently meet the required criteria.  Thus 
it was reasonable to conclude that a validated model had been developed and was 
ready to be applied to the ZINC lead like library.  However, prior to its application, 
the models decision tree as shown by figure 2.16 was inspected, as one of the useful 
features of decision tree analysis is how readily interpretable the results are. 
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Fig. 2.16  Illustration of the decision tree model built using the structures of the twelve active and 
seven inactive compounds, which was subsequently applied to the ZINC lead like library of 
compounds.  ‘Yes’ indicates an active classification and ‘no’ an inactive one. 
Figure 2.16 shows the rules/branches of the decision tree together with their 
associated threshold values.  As can be seen, the decision tree comprises of four 
rules.  The first rule, which according to the J48 algorithm best splits the initial 
dataset, is associated with the Num_Rings descriptor.  It is important to remember 
that the descriptor values, and thus the threshold values, all refer to the normalised 
data, for which the spread of the values across each descriptor have a mean of zero 
and a standard deviation of one.  The first rule states that if the normalised 
Num_Rings descriptor value is less than or equal to zero, then the compound is 
given a ‘yes’ (active) classification.  Three compounds had a Num_Rings value less 
than or equal to zero, and were therefore classified as active.  Next to the 
classification in the decision tree there are usually two numbers in brackets.  The 
first is the number of compounds which terminated at this node based on the prior 
rule, and the second is the number of molecules which were classified incorrectly.  
Thus for this particular rule, all three compounds were classified correctly as active. 
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Moving down the decision tree, those compounds which had a Num_Rings 
descriptor value greater than zero passed to the next branch, which was again 
concerned with the Num_Rings descriptor.  If the normalised descriptor value was 
less than or equal to 0.5 it was classified as ‘no’ (inactive).  Three compounds were 
classified as inactive, however, one was misclassified.  Given that the overall 
accuracy of the model was 90%, the odd misclassification was to be expected.  
Several of the active and inactive compounds have either three or four rings, which 
perhaps makes this rule slightly limiting, as it does not consider enough variance in 
the data to fully distinguishing between all active and inactive compounds. 
Molecules with a normalised Num_Rings value greater than 0.5 passed to the next 
rule, with those having a normalised Molecular_Weight descriptor value equal to or 
less than 0.575473 classified as ‘yes’ (active).  This rule was correct for all of the 
compounds.  The remaining compounds were assessed according to their normalised 
Num_H_Acceptors descriptor values, so that if it was less than or equal to 0.6, they 
were classified as inactive, or active if it was greater than 0.6.  The former parameter 
was correct for five of the six molecules, with the later correct for both molecules 
which terminated here. 
With the model now validated and well understood, it was applied to the 2.7 million 
compounds in the ZINC lead like library.  Unlike Bayesian classification, the 
decision tree analysis did not give a probability for a particular classification, but 
simply either a ‘yes’ or ‘no’ prediction as to whether the compounds may be active 
or inactive.  All the compounds in ZINC were assigned to a particular class, based on 
their molecular descriptor values according to the decision tree shown in figure 2.16.  
The results were filtered in Pipeline Pilot Student Edition v6.1
40
 to remove any 
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compounds assigned as inactive, resulting in 1,838,020 compounds classified as 
active.  This number of hits is considerable larger than even that of Bayesian 
classification, with almost 68% of the chemical library classified as potentially 
active.  Again this would be wildly optimistic if the results were being considered in 
isolation, but would still act to support the consensus study.  Decision tree analysis 
was performed according to the ‘Decision Tree Analysis Protocol’ as described in 
the Experimental Chapter. 
2.4 Merging of the Results 
With hits identified from the ZINC lead like library
31, 32
 using the six different LBVS 
methods that were performed in parallel, the results had to be merged prior to 
consensus analysis.  Table 2.31 illustrates the number of hits for each of the 
methods.  These were merged using Pipeline Pilot Student Edition v6.1,
40
 giving a 
total of 1,910,378 unique ZINC entries.  This meant that around 70% of the 
molecules in ZINC had been selected by one method or another, and as such were 
considered to be worthy of further investigations. 
Table. 2.31  Number of hits from ZINC for each of the LBVS methods which have been performed in 
parallel. 
LBVS Method Number of Hits from ZINC 
Fingerprint Similarity Searching 11,655 
Turbo Similarity Searching 13,771 
Bioisostere Substructure Searching 20,319 
Principal Component Analysis 5,000 
Naïve Bayesian Classification 725,190 
Decision Tree Analysis 1,838,020 
Merge Results: 1,910,378 
The next chapter will now discuss the consensus analysis, together with the scoring 
of the compounds.  A host of filtering methods were employed to identify the most 
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promising lead like candidates, as well as diversity analysis to ultimately select a 
number of compounds for purchase and later biological testing. 
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3. Ligand Based Virtual Screening Scoring & Selection 
Table 3.1 illustrates the number of hits from the ZINC lead like library
1, 2
 for each of 
the LBVS methods which were performed in parallel as described in Chapter II, 
based on the structures of the compounds tested against Pfbc1 (table 2.1).  Merging 
of the hits resulted in 1,910,378 unique entries.  Consensus scoring and analysis was 
used in order to select the most promising candidates from these hits. 
Table. 3.1  Number of hits from ZINC for each of the LBVS methods which have been performed in 
parallel. 
LBVS Method Number of Hits from ZINC 
Fingerprint Similarity Searching 11,655 
Turbo Similarity Searching 13,771 
Bioisostere Substructure Searching 20,319 
Principal Component Analysis 5,000 
Naïve Bayesian Classification 725,190 
Decision Tree Analysis 1,838,020 
Merge Results: 1,910,378 
3.1 Consensus Scoring 
Consensus scoring involves preferentially selecting compounds for purchase and 
biological testing that were identified across multiple virtual screening methods, as 
oppose to those which were just identified by a single technique.  It was hoped that 
through this, compound selection would be as enriched and informed as possible.  
Consensus scoring, or data fusion as it is alternatively known, is widely used within 
protein-ligand docking.
3
  Various scoring functions have demonstrated their ability 
to predict experimental binding affinities,
4-7
 but with the introduction of consensus 
scoring, in which the results from several scoring functions are combined,
8-10
 SBVS 
results have been shown to substantially improve.  This has contributed to better 
enrichments in compound selection over any individual scoring function, allowing 
for precedence in the data to be spotted.  It has been shown that whilst individual 
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scoring functions can on occasion give sufficient results, a consensus of scoring 
methods greatly improves them.
11 
Despite consensus scoring receiving wide acceptance from the virtual screening 
community, there have been relatively few studies dealing with the question as to 
how consensus scoring actually enriches the datasets.  One consideration is that if 
different scoring functions estimate a property independently, and that that property 
relates smoothly to an experimentally determined quantity, then the mean from 
several scoring functions should be a better predictor than each individual score.
12
  
However, because different scoring functions can have different scales, this makes 
combining them problematic.  This is why with SBVS, ranking methods are often 
employed to improve virtual screening performance compared with simply 
combining the raw scores.
3
  To do this each compound is first assigned a rank based 
on its positioning in the primary dataset for each of the different scoring functions.  
These individual ranks are then combined for each molecule across the function 
types to give a final rank,
8, 13
 with the highly ranking compounds across the 
consensus shown to have improved activity over individual scoring functions used in 
isolation. 
Several factors may contribute to this improvement in success rates.
3, 14
  Firstly, 
performing multiple screening methods is similar to repeated sampling, so that the 
mean of the methods will be closer to the true value than any of the individual 
measurements alone.  Secondly, as actives are generally more tightly clustered in 
chemical space than inactives, multiple sampling is more likely to recover more 
actives than inactives.  Finally, the different methods also seem to agree more on the 
ranking of actives than on the inactives.  This concordance arises given that different 
scoring functions focus on different aspects of ligand binding, and thus lead to 
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different false positives.  Additionally, it was found that consensus results tend to be 
more consistent across receptor systems, meaning the user is less dependent on 
picking the correct method for a particular target of interest. 
Whilst consensus scoring has been widely used in SBVS,
9, 12, 15, 16
 in LBVS it has 
mostly been utilised to merge similarity scores and molecular descriptors.
17-21
  These 
consensus decisions are generally based on a combination of the rankings of the 
different methods, but may lead to complications when different and unrelated 
algorithms and procedures are used in parallel.  This is due to the often dissimilar 
formatting of the results (i.e. qualitative; quantitative),
14
 as observed across the six 
LBVS methods described in Chapter II.  Some of the methods provided continuous 
values (i.e. similarity searching), whilst others simply gave binary classifications (i.e. 
Bayesian classification).  Care must therefore be taken when merging highly 
disparate results, in order to obtain the overall improvement in performance which 
consensus scoring can afford. 
The LBVS results (table 3.1) first required normalisation before consensus scoring 
could be performed, with considerations put in place based on the output from each 
particular method.  The consensus score, or virtual screening score (eq. 3.1), was 
made up of the summation of the initial scores assigned to a compounds from each 
of the LBVS methods it was identified by.  Firstly, the initial scores for the hits from 
each LBVS method had to be assigned, and were done so as follows. 
The 11,655 and 13,771 compounds which were identified by fingerprint and turbo 
similarity searching respectively were each assigned a Tanimoto coefficient value, 
corresponding to their closest active neighbour (table 2.1).  Compounds identified 
from fingerprint similarity searching were scored between 0.7 and 1, and those from 
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turbo similarity searching between 0.8 and 1.  Hits more structurally similar to an 
active compound were therefore scored more highly.  It is important to note that 
during normalisation and scoring, a hit from a particular method was not able to 
contribute a score greater than 1.  This was so that the final summation of the results 
would be unbiased, with each method contributing to the overall score. 
The 20,319 diverse hits from the bioisostere substructure searching method were 
each given a score of 1.  As each of these compounds contained at least one of the 
166 bioisosteres that had been calculated based on the quinolone core, it was deemed 
only fair that each be allowed to contribute equally to the overall consensus score.  It 
would have been inaccurate to place emphasis onto any particular bioisostere, given 
that they were all novel fragments, yet to be tested against Pfbc1.  Thus they were all 
considered equally as likely to contribute as potential hits. 
The 5,000 compounds selected from PCA were those which were closest to known 
actives in PC space, according to their Euclidean distances.  The smaller the distance 
then the closer the compound was to a known active.  The distances for the 5,000 
compounds were normalised between 0.5 and 1, such that those with the smallest 
Euclidean distances (closest to known actives) had the highest scores, and those 
furthest away the lowest.  This normalisation and scoring was performed in Pipeline 
Pilot Student Edition v6.1,
22
 with the histogram shown in figure 3.1 illustrating the 
distribution of scores. 
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Fig. 3.1  Histogram of the normalised scores for the compounds identified by PCA. 
Whilst the number of hits for the previous four methods were all fairly similar to one 
another, the number of hits from Bayesian classification and decision tree analysis 
were huge in comparison (table 3.1).  However, the results from Bayesian and 
decision tree could still act to enrich the overall consensus, provided careful 
limitations were placed upon the results of these methods.  The compounds predicted 
as active from Bayesian were also assigned a probability value, which offered a 
quantitative means of assessing the classification (i.e. the higher the probability, the 
greater the support for an active classification).  The probability values for the 
725,190 compounds classified as active were normalised between 0 and 0.5, with the 
highest probability scored at 0.5, and the lowest scored at 0.  These normalised 
values represented the new scores for each compound.  Though the contributions to 
the consensus from this method may be smaller compared to other methods (i.e. 
bioisostere substructure searching), they would still act to strengthen the scores of 
frequently identified compounds, without biasing the data towards those which 
occurred less frequently. 
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Unlike Bayesian classification, decision tree analysis simply classified compounds 
as either active or inactive, with no probability value to support a particular 
classification.  Each compound was therefore scored equally, which owing to the 
massive number of compounds classified as active by this method, was set to only 
0.25.  A score of 0.25 was decided as there were twice as many hits from decision 
tree analysis compared to Bayesian classification, so it seemed only fair to place half 
as much emphasis upon the results of this method.  However, though the overall 
contribution of this method compared to the others is relatively small, it still served 
to strengthen the consensus, offering further support for the more frequently 
occurring compounds, yet not emphasising any compounds identified by only this 
method. 
With the results normalised and individual scores assigned to each hit, the scores 
were combined.  A term referred to as the virtual screening score (VSS; eq. 3.1) was 
calculated using Pipeline Pilot Student Edition v6.1,
22
 and represents the average 
value of the scores for a molecule across all methods it was identified by.  More 
specifically, it is the summation of the scores for each molecule, divided by six to 
account for each of the different LBVS methods.  Therefore, compounds which 
appeared more frequently scored more highly, as appose to those identified by fewer 
methods. 
                        
                                    
 
 
Eq. 3.1  Equation to calculate the virtual screening score (VSS). 
Across the 1,910,378 compounds the VSS values varied considerably, having a 
maximum value of 0.51, and a minimum of 8x10
-9
, with the histogram in figure 3.2 
representing their distribution.  Most compounds scored quite lowly, with only 1,905 
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having a score greater than or equal to 0.2 (proportion not large enough to be visible 
on the histogram due to the overwhelming dominance of the lower scoring bins).  
This observation was not unexpected however, as given the large number of 
compounds identified by Bayesian classification and decision tree analysis, it was 
likely that fewer molecules would score highly (i.e. appear in several LBVS 
methods). 
 
Fig. 3.2  Histogram of the virtual screening scores. 
A final score was ultimately calculated for each of the 1,910,378 compounds.  This 
final score was comprised of several properties, with VSS being the main 
consideration.  However, a number of other properties were also considered, 
including MW, log P and log S.  The importance of MW and log P have already 
been discussed (Chapter I), but log S offers a measure of a compounds aqueous 
solubility, and is often expressed as log units of molar solubility (mol/L).  It is an 
important factor which affects the bioavailability of compounds,
23
 with poorly 
soluble compounds often having bad absorption.  These properties were chosen so 
that compounds were scored, not only according to their frequency from virtual 
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screening, but also based upon their lead like or drug like potential.
24
  It is important 
to be mindful of a compounds physicochemical properties during drug discovery 
endeavours, in order to minimise the potential risks of costly, late stage set backs.
25
 
                                                
Eq. 3.2  Equation to calculate the final score for each compound, based upon the VSS and various 
physicochemical properties. 
In accordance with VSS the physicochemical properties had to be normalised so that 
their contributions ranged between 0 and 1, with more favourable compounds 
scoring more highly.  Throughout the literature there is much debate as to the most 
appropriate physicochemical descriptor values that best assess lead likeness, so a 
number of functions were used instead based on a consensus across the literature.
26-28
  
Additionally, earlier work has shown that the scoring functions illustrated in table 
3.2 have been successfully used to identify novel hits active against PfNDH2.
29
  
These functions were therefore chosen to normalise the physicochemical descriptor 
values.  The functions are also represented graphically in figure 3.3. 
Table. 3.2  Scoring function ranges for the molecular properties. 
Property More desirable range Less desirable range 
log S >-5 <-6 
Log P -1< log P < 4 log P ≤ -2.5; log P ≥ 5.5 
MW <400 >600 
 
 
Fig. 3.3  Graphs illustrating the scoring functions for the calculated molecular properties. 
The scoring functions described in table 3.2 were implemented using the rules shown 
in figure 3.4. 
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log S           if           
           if           
         varies linearly in between 
log P           if           and          
           if           or          
         varies linearly from 0 to 1 between                
         varies linearly from 1 to 0 between              
MW         if       
         if       
       varies linearly between 
Fig. 3.4  Functions applied when calculating the final score for the compounds. 
When calculating the final score the VSS was multiplied by four.  This was to 
emphasise the importance of the virtual screening results over the other 
physicochemical properties that make up the rest of the final score.  Log S and log P 
were both multiplied by one, whereas the function of MW was multiplied by two.  
Given that in general, the MW and complexity of compounds increases down the 
drug discovery pipeline, the MW was allowed to contribute more to the overall score 
compared to log S and log P.  This meant that the final scores were based half on the 
physicochemical properties of the compounds, whilst the other half was on the 
results of virtual screening.  Figure 3.5 shows a histogram of the final scores for the 
1,910,378 compounds.  The maximum score was just over 6 and the minimum less 
than 0.5, though most had a score between 3 and 5.  The results are also tabulated 
across several bins in table 3.3. 
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Fig. 3.5  Histogram of the final scores. 
Table. 3.3  Frequency of hits in particular Final_Score bins.  
Final_Score Ranges Frequency of Hits 
0 to 1 28 
1 to 2 501 
2 to 3 9,457 
3 to 4 239,924 
4 to 5 1,660,168 
5 to 6 298 
6 to 7 2 
With each compound from virtual screening scored, a host of filters were applied in 
order to reduce the number of compounds for consideration, resulting in only those 
of most interest. 
3.2 Compound Filtering 
Filtering was performed through a sequential protocol developed in Pipeline Pilot 
Student Edition v6.1.
22
  Lipinski’s rules30, 31 are widely used in drug design as a 
guideline for compound selection, therefore the dataset was filtered to remove those 
molecules which violated two or more of its recommendations (≤ 5 H-bond donors; 
≤ 10 H-bond acceptors; MW ≤ 500 Da; log P ≤ 5).  Though the ZINC lead like 
library had already undergone some filtering,
2
 the Lipinski filter was used as a 
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precaution to remove potential outliers in the data.  As it turned out there were a total 
of 7,884 compounds which violated two or more of Lipinski’s guidelines (1,902,494 
compounds remained).  Further to this a filter was applied to remove compounds 
which did not follow Veber’s guidelines for oral bioavailability (ten or fewer RBs; 
PSA less than or equal to 140Å
2
).
32
  This however did not remove any additional 
compounds, suggesting that all remaining compounds had acceptable 
physicochemical profiles according to these widely used methods. 
Next chiral molecules were removed.  This was to ensure that potential scaffolds for 
future synthetic optimisation would be as structurally simple and uncomplicated as 
possible.  The enantiomers of chiral compounds can often have different effects as 
drugs.  One example of this is the chiral molecule mefloquine (fig. 3.6), which is a 
potent inhibitor of the malaria parasite, and a synthetic analogue of quinine (fig. 1.2).  
However, mefloquine contains two asymmetric carbon atoms, thus having four 
different stereoisomers.  It is currently sold as a racemate of the (R,S)- and (S,R)-
enantiomers, and is essentially two drugs in one.  Plasma concentrations of the (-)-
enantiomer are significantly higher than those of the (+)-enantiomer, with the 
pharmacokinetics between the two enantiomers also significantly different.
33
  The 
(+)-enantiomer has a shorter half life than the (-)-enantiomer, with some research 
suggesting that it is more effective in treating malaria, as the (-)-enantiomer 
specifically binds to the adenosine receptors in the central nervous system, which 
may explain the drugs psychotropic effects.
34
  Additionally, achiral molecules are 
preferred during screening owing to the cost and difficulty of synthesising chiral 
molecules.
35
  In total 850,246 chiral molecules were removed, leaving just over a 
million (1,052,248) compounds for consideration. 
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Fig. 3.6  (RS, SR)-(±)-Mefloquine structures. 
The next phase of filtering removed the largest proportion of molecules, and was 
concerned with removing those molecules which contained structural motifs which 
may potentially have been considered as “non-drug-like”, based on precedent across 
the literature.  The first set of motifs were those described by the Rishton 
fragments.
36, 37
  When performing screening it is important to be able to distinguish 
between promising drug leads and the many false positives which plague screening 
efforts.  False positives are compounds that have activity in vitro, which is most 
likely due to reasons other than hitting the desired target.  The Rishton fragments 
attempt to provide simple chemical guidelines for the evaluation of positives in 
biochemical screens, with the aim being to select stable, non-covalent ligands, and to 
eliminate those compounds which may react unfavourably.  The early and systematic 
removal of suspected “nasty” compounds is vital to the success of screening efforts, 
which is why in this research these filters were applied before compounds were 
purchased and tested, so as to eliminate any potential difficulties later on.  Such 
fragments may be chemically reactive towards proteins, such as alkylating and 
acylating agents, and may be prone to hydrolysis, or characteristically reactive 
towards biological nucleophiles.  Figure 3.7 illustrates the twenty five structural 
motifs encompassed by the Rishton fragments.
36, 37
  These reactive functional groups 
are generally prone to decomposition under hydrolytic conditions, and are reactive 
towards protein and biological nucleophiles such as glutathione and dithiothreitol.  
They also exhibit poor stability in serum.  It has been stated that compounds which 
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contain these functional groups should not be submitted for assay in a biochemical 
screen, without the understanding that they may produce a false positive readout.  
This generalisation intends to emphasise that reactive compounds that exert their 
effect in a biochemical screen via covalent bonding are false positives.  Regardless 
of potency, the observed biochemical recording will simply be a consequence of 
chemical reactivity, not biological activity.  Potential antimalarials in this research 
were expected to inhibit Pfbc1 through non-covalent interactions, so it was crucial 
that chemically reactive compounds be recognised as such as early as possible. 
 
Fig. 3.7  Rishton fragments.  (G. M. Rishton, Drug Discovery Today, 1997, 2, 382-384.) 
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The Rishton fragments were filtered in combination with an additional 274 structural 
motifs commonly referred to as toxicophores.  Toxicophores represent features or 
groups within a chemical structure that may be responsible for a compounds toxic 
properties, either directly, or through metabolic activation.
38
  A compound often 
exerts its toxicity through covalent bonding, or via oxidation to cellular 
macromolecules such as proteins or DNA, thus causing changes to normal cellular 
biochemistry and physiology, thereby eliciting its toxic effect.  These 274 
toxicophores were taken from several literature sources, and had previous been used 
successfully to identify false positives.
39-45
  By compiling a list of the fragments 
presented within these papers it was hoped that the chemical space across which 
false positives were identified would be expanded.  As with the Rishton fragments, 
these motifs largely remove compounds with specific functional groups that are 
known to interfere with biochemical assays, or cause problems later in drug 
development.  Though most chemical libraries used for screening contain very few, 
if any, of the most troublesome functional groups (i.e. aldehydes, epoxides, α-halo 
ketones), many still contain some problematic motifs.  Table 3.4 contains several 
examples of these toxicophores, with compounds containing these motifs removed 
during filtering (see appendix for all 274 toxicophores). 
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Table. 3.4  Examples of chemical fragments used when filtering compounds, together with reasons 
for their exclusion.  (D. J. Huggins, A. R. Venkitaraman and D. R. Spring, ACS Chem. Biol., 2011, 6, 
208-217.) 
Chemical Fragment Reason for Exclusion 
 
1,2 Dicarbonyl 
Metabolically unstable/potential toxicity due to 
mutagenicity 
 
α,β-Unsaturated Carbonyl 
Prone to reactivity by acting as a Michael 
acceptor 
 
Alkene 
Metabolically unstable due to epoxidation 
 
Aminothiazole 
Potential toxicity 
 
Methylenedioxy 
Metabolically unstable due to acetal 
hydrolysis/prone to oxidation yielding reactive 
quinones 
 
1,2 Dimethoxy 
Prone to oxidation yielding reactive quinones 
 
1,4 Dimethoxy 
Very prone to oxidation yielding reactive 
quinones 
 
Acylhydrazide 
Metabolically unstable due to acyl hydrolysis 
 
Acetal 
Metabolically unstable due to acetal hydrolysis 
 
Thiourea 
Metabolically unstable due to flavin 
oxidation/potential non-specific protein 
binding 
 
Nitro group 
Prone to reduction yielding reactive 
species/potential hepatocarcinogens 
 
Aliphatic ketone 
Metabolically unstable due to nucleophilic 
attack 
 
Unflanked pyridyl 
Potential interference with cytochrome P450s 
due to metal ion coordination 
          
Anthracene/Phenanthrene 
Known DNA intercalation 
The remaining 1,052,248 compounds were filtered to remove those which contained 
any of the Rishton fragments or the literature toxicophores.  Again, this filter 
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removed the largest proportion of molecules (860,056) of all the filtering methods, 
passing only 192,192 compounds to the next stage. 
The last filtering measure was to remove all compounds containing anions and/or 
cations.  Whilst ionic compounds are generally more soluble in water than their 
neutral counterparts, they tend to be less soluble in organic solvents.  Also, 
compounds must pass through cell membranes in order to reach their targets, and 
these lipid bilayers are selectively permeable to ions and organic molecules, and 
control the movements of substances in and out of the cells, generally being 
permeable to only small, uncharged molecules.
46
  As solubility favours charged 
species, and permeability favours neutral ones, there needs to be a balance between 
these opposing properties, allowing for a molecule to dissolve, permeate and be 
absorbed.  This filter reduced the dataset further to 127,725 compounds. 
The remaining compounds still observed a good spread of final scores, with values 
ranging between 5.38 and 2.29.  A cut-off was placed so that only compounds which 
exceeded a particular threshold were considered further.  This cut-off was decided 
through consideration of equation 3.2, and the method by which the final score was 
generated.  According to equation 3.2, it would be possible for a compound to have a 
score of 4 without even taking into account the virtual screening work, provided it 
was sufficiently small, soluble and had favourable lipophilicity.  Though good 
physicochemical properties were highly desirable, the primary aim was to identify 
compounds which had been identified across multiple LBVS methods.  Therefore the 
cut-off was placed just above 4 at 4.5.  Figure 3.8 shows a histogram of the spread of 
scores across the 127,725 filtered compounds, together with a line intersecting the 
point at which the cut-off was placed.  In total there were 2,538 compounds which 
had a final score greater than or equal to 4.5. 
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Fig. 3.8  Histogram representing the distribution of final score values across the 127,725 compounds 
remaining after filtering, with a line intersecting the cut-off value of 4.5. 
3.3 Diversity Analysis & Compound Selection 
With the dataset reduced to 2,538 compounds, several had to be selected for 
purchase and subsequent testing.  Diversity analysis was therefore performed in 
order to best sample the chemical diversity of the molecules available.  This allowed 
for as much chemical space to be covered as possible, given the resources/funds 
available.  Four approaches were used to perform diversity analysis and compound 
selection. 
Firstly the fifty top scoring compounds were selected, as not only had these clearly 
demonstrated good physicochemical properties, but they had also been strongly 
supported across the LBVS research.  These would therefore be the most promising 
candidates if the LBVS results were considered alone.  However, though these fifty 
compounds had the most support, it is unlikely that they fully represented the 
chemical diversity of the entire dataset.   As research was concerned with finding 
novel lead like structures, it was essential that diversity analysis be performed in 
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order to select compounds for purchase and testing which represented the entire 
spread of chemical space sampled. 
Following this the fifty most diverse compounds from the filtered dataset were 
selected based on their FCFP_4 fingerprints.  A sample size of fifty was chosen as 
this allowed for a more focused selection amenable to visual inspection.  Selecting a 
structurally diverse subset of compounds from the dataset allowed for a greater 
exploration of the activity space, and is particularly useful when little is known about 
the range of compounds active against a particular therapeutic target.
47
  Fifty diverse 
structures according to their FCFP_4 fingerprints were selected using the ‘Diverse 
Molecules’ component in Pipeline Pilot Student Edition v6.1.22  Though the final 
scores of these compounds varied (Max=4.822; Min=4.5; Average=4.588), this 
method represented one way of sampling the range of chemical structures available.  
Diverse compound selection was performed according to the ‘Diverse Compound 
Selection Protocol’ as described in the Experimental Chapter. 
3.3.1 Clustering Analysis 
The next two diversity methods involved the use of clustering analysis.  Clustering 
analysis aims to divide a group of objects into clusters so that the objects within each 
cluster are similar, with objects taken from different clusters therefore being 
structurally dissimilar.
45
  When molecules are clustered, a representative subset of 
one of more compounds can be selected from within that cluster, in order to 
represent that class of compounds, as illustrated by figure 3.9.  Clustering analysis 
has found many uses, including in medicine and information sciences, and there are 
a large number of algorithms available for its implementation.  The efficiency of 
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these algorithms various widely, with certain methods better suited to 
pharmaceutical applications and clustering databases of chemical structures.
47-50
 
 
Fig. 3.9  Illustration of clustering analysis and the grouping together of similar compounds.  Red 
circle show the selection of a representative molecule from a particular cluster. 
The overall process of cluster based compound selection is as follows: 
1. Generate descriptors for each compound in the dataset. 
2. Calculate the similarity or distance between all compounds in the dataset. 
3. Use a clustering algorithm to group the compounds within the dataset. 
4. Select a representative subset by selecting one or more compounds from each 
cluster. 
For step 1, the descriptors may include property values such as biological activity, or 
even topological indexes and structural fragments.
51, 52
  For the two clustering 
analysis methods used here, FCFP_4 fingerprints were used to generate the 
descriptor values for each of the compounds in the dataset.  Similarity measures may 
also be used in step 2 to quantify the degree of structural resemblance between pairs 
of molecules,
53
 with Tanimoto once again used to calculate the similarity between 
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the compounds for both of the clustering methods employed.  Where the two 
clustering methods employed vary is in step 3.  Most clustering methods are non-
overlapping, with each object belonging to just one cluster, (in overlapping methods 
compounds can belong to more than one cluster).  The non-overlapping methods are 
divided into two classes, hierarchical and non-hierarchical.  For step 3, one 
hierarchical method was used, and one non-hierarchical method. 
3.3.1.1  Hierarchical Clustering 
Hierarchical clustering methods organise compounds into clusters of increasing size, 
with small clusters of related compounds being grouped together into larger clusters.  
At one extreme each compound is in its own cluster, but after progressive joining of 
these smaller clusters, the compounds ultimately reside within a single cluster at the 
opposite extreme.
54
  The successive levels and relationships between clusters can be 
visualised using a dendrogram, an example of which is in figure 3.10. 
 
Fig. 3.10  A dendrogram representing a hierarchical clustering of seven compounds. 
The dataset is analysed in an iterative manner, such that at each step either a pair of 
clusters are merged, or a single cluster is divided.  Each level of the hierarchy 
represents a partitioning of the dataset.  If a hierarchical method starts with all 
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compounds as singletons, that are then merged iteratively until all compounds are in 
a single cluster, the method is said to be agglomerative, that is from the bottom up in 
terms of the dendrogram. 
Clusters are formed to minimise the total variance of the dataset.
55
  The variance of a 
cluster is measured as the sum of the squared deviation from the mean of the cluster.  
For a cluster,  , of    objects where each object   is represented by a vector      the 
mean (or centroid) of the cluster,     is given by equation 3.3, with the intracluster 
variance,    given by equation 3.4.  The total variance is calculated as the sum of the 
intracluster variances for each cluster.  At each iteration a pair of clusters is chosen 
whose merger leads to the minimum change in total variance.  This is known as 
Ward’s method.55 
    
 
  
     
  
   
 
Eq. 3.3  Definition of the cluster centroid. 
                
 
  
   
 
Eq. 3.4  Definition of intracluster variance. 
The most commonly implemented hierarchical clustering methods are those 
belonging to the family of sequential agglomerative hierarchical non-overlapping 
(SAHN) methods.  One particular example is AGNES,
56
 or agglomerative nesting.  
SAHN methods are traditionally implemented using the stored matrix algorithm.  
Each cluster initially corresponds to an individual item, and as clustering proceeds, 
pairs of clusters are merged together and the number of clusters decreases by one.  
Eventually these evolves into just one cluster containing all items.  The stored matrix 
algorithm is as follows: 
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1. Calculate the initial proximity matrix containing the pairwise proximities 
between all pairs of clusters (singletons) in the dataset. 
2. Scan the matrix to find the most similar pair of clusters, and merge them into 
a new cluster (thus replacing the original pair). 
3. Update the proximity matrix by inactivating one set of entries of the original 
pair and updating the other set (now representing the new cluster). 
4. Repeat steps 2 and 3 until just one cluster remains. 
Contrary to agglomerative methods, there are the divisive hierarchical clustering 
algorithms.  These start with all compounds in a single cluster, and iteratively 
partitions one cluster into two (top to bottom on the dendrogram) until all 
compounds are singletons.  This method is of particular use when only a small 
number of clusters is desired, so that only the first part of the hierarchy needs to be 
produced.  Thus divisive methods can be faster than their agglomerative 
counterparts, though their overall performance is generally inferior.
57
  This has been 
attributed to the fact that the initial criterion for partitioning a cluster is based on 
only a single descriptor, or is monothetic, unlike agglomerative methods which are 
polythetic. 
When using hierarchical clustering methods it is necessary to choose a level from the 
hierarchy in order to define the appropriate number of clusters to represent the 
dataset.  This corresponds to drawing an imaginary line across the dendrogram, with 
the number of vertical lines which intersect this line being equal to the number of 
clusters.  This can be observed in figure 3.11, where the red line dissects the 
dendrogram, thus representing the seven molecules in four clusters.  Visual 
inspections is a useful way to select the appropriate number of clusters, as the 
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dendrogram will accurately report the number of molecules in each cluster, allowing 
for a fair selection of clusters to best represent the dataset. 
 
Fig. 3.11  Choosing the appropriate number of clusters to represent a dataset from a dendrogram.  In 
this case four clusters represent the seven molecules. 
The agglomerative hierarchical method AGNES
56
 was used to perform clustering 
analysis on the 2,538 compounds.  Clustering analysis was performed using the 
programming language R,
58
 which is widely used for statistical software 
development and data analysis.  R was utilised through Pipeline Pilot Student 
Edition v6.1.
22
  AGNES is a hierarchical method which builds clusters from the 
bottom up, starting with all compounds as singletons.  The developed protocol 
merged the molecules into clusters using Ward’s method, with Euclidean distances 
acting as the distance matrix.  In order to decide upon the optimum number of 
clusters the clustering analysis was first allowed to go to completion, so that all 
compounds could be represented by a single cluster.  The resulting dendrogram was 
then inspected to decide upon the most appropriate number of clusters to use.  It was 
required that the number of compounds selected be similar to the other methods, so 
inspection of the dendrogram began at around fifty clusters.  This dendrogram is 
shown in figure 3.12.  It was important that no cluster be more drastically 
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overpopulated than any other.  As can be seen, if 52 clusters were selected, this 
allowed for one cluster to represent over a third of the entire dataset, illustrated by 
the red circle.  To avoid this, a higher number of clusters were chosen.  Investigation 
suggested that sixty four clusters was the minimum number required to give equally 
populated clusters. 
 
Fig. 3.12  Dendrogram representing the clustering of the 2,538 filtered compounds using AGNES.  
Blue lines dissecting the dendrogram represent the stated number of clusters.  Red circle represents 
the potential for one hugely overpopulated cluster. 
With the optimum number of clusters selected the analysis was repeated and each 
molecule assigned to its appropriate cluster.  The most representative compound 
from each of the clusters was selected using FCFP_4 fingerprints, resulting in a 
subset of sixty four compounds which best represented the diversity of the dataset 
according to AGNES hierarchical clustering.  AGNES clustering was performed 
according to the ‘AGNES Clustering Protocol’ described in the Experimental 
Chapter. 
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3.3.1.2  Non-hierarchical Clustering 
Non-hierarchical methods place compounds into clusters without forming a 
hierarchical relationship between them, with several non-hierarchical methods 
finding use in chemical applications such as the single-pass, relocation and nearest 
neighbour methods.
47, 50
  Single-pass methods cluster objects based upon only a 
single pass through the dataset.  The first compound encountered is assigned to the 
first cluster, with the next compound also assigned to that cluster should its 
similarity exceed some specified threshold value.  Otherwise it is assigned to a new 
cluster.  This process is repeated until all compounds have been assigned to clusters.  
Though this method is very fast and simple to implement, its major drawback is that 
it is order dependent.  That is, if the compounds are rearranged and scanned in a 
different order, then the resulting clusters may also be different. 
The best known relocation method is the K-means method, of which there exist 
many variants and different algorithms for its implementation.
59
  The basic algorithm 
acts to minimise the sum of the squared Euclidean distances between each item in a 
cluster and the cluster centroid.  The first step is to choose a set of   seed compounds 
which are usually selected at random.  The remaining compounds are then assigned 
to the nearest seed to give an initial set of   clusters.  The centroids of the clusters 
are then calculated and the objects are reassigned (or relocated) to the nearest cluster 
centroid.  This process of calculating cluster centroids and relocating the compounds 
is repeated until no objects change clusters, or until a user defined number of 
iterations has been performed.  This method is dependent upon the initial set of 
cluster centroids, and different results will usually be found for different initial 
seeds.
60
  Because of this, relocation methods can be adversely affected by outlier 
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compounds which will appear as singletons, as they are not sufficiently similar to 
anything else.  Nevertheless, the computational efficiency and mathematical 
foundation of relocation methods have made them very popular. 
The relocation method CLARA
56
 was employed as an additional means to assess the 
diversity of the 2,538 filtered compounds.  CLARA (clustering large applications) is 
particularly useful for sampling large datasets, similar to the dataset which was in 
question here.  CLARA diversity analysis was performed using the R
58
 programming 
language in Pipeline Pilot Student Edition v6.1.
22
  Ward’s method was used together 
with Euclidean distance as the distance matrix.  Unlike AGNES, it was not necessary 
to inspect a dendrogram in order to select the most appropriate number of clusters, 
but to instead simply define the number of clusters that were required.  Fifty clusters 
were chosen, with the central molecule from each selected based upon its positioning 
in the cluster according to its Euclidean distance.  This identified a further 50 
compounds from diversity analysis.  CLARA clustering was performed according to 
the ‘CLARA Clustering Protocol’ as described in the Experimental Chapter. 
3.4 Visual Inspection 
The four methods of diversity analysis resulted in four subsets of compounds 
(highest scoring; fingerprint analysis; AGNES clustering; CLARA clustering) which 
each sampled the chemical space of the 2,538 filtered compounds differently.  These 
subsets were merged and of the 214 entries recorded, only 205 were unique, as a 
number of the compounds appeared across multiple methods (one compound 
appeared in three diversity methods; seven compounds appeared in two diversity 
methods).  Lists containing the 205 chemical structures were distributed amongst 
members of the antimalarial drug discovery group at Liverpool University.  They 
Chapter III 
 
191 
 
were visually inspected so that potentially undesirable molecules could be spotted 
prior to final selection.  This was to draw upon the extensive experience of senior 
members within the group as to the synthesisability of the chemotypes, and provided 
an ideal opportunity to spot any compounds that had slipped through despite 
rigorous filtering. 
In total 66 additional compounds were removed, resulting in only 139 remaining.  
There were several reasons as to why certain compounds were recommended for 
removal.  Several appeared to be very large, and given that chemical optimisation 
generally increases a lead compounds MW, their removal seemed wise.  Some were 
simply too simple, consisting of very basic, small ring systems, whilst others closely 
resembled chemotypes that had already been investigated within the group, such as 
quinolone and chromone.  Perhaps the most crucial observation was the removal of 
all compounds that contained a furan ring.  This observation alone highlighted the 
importance of visual inspection, as it was initially thought that this toxicophore 
would have been included within the Rishton fragments.  It was proposed that the 
furan moiety may potentially react with nucleophiles in the body under acid 
conditions, a possible mechanism for which is illustrated in figure 3.13. 
 
Fig. 3.13  Mechanism to illustrate potential toxicity concerns with regard to furan. 
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3.5 Final Selection/Purchasing Compounds 
The final subset of 139 compounds were deemed to be the most promising lead like 
candidates to result from the extensive LBVS, filtering and diversity analysis work 
with regard to the Pfbc1 biochemical target (see appendix for all 139 compounds).  It 
was these compounds, or a further subset thereof, which were therefore required for 
biological testing.  Using the ZINC website
61
 it is possible to generate vendor 
information for a set of compounds, by simply inputting the necessary ZINC IDs.  
This was done for the 139 compounds, but unfortunately, during the course of this 
research the ZINC lead like library was updated from version 7 (2,710,002 
compounds) to version 8 (4,390,615 compounds).  Following this update, many of 
the compounds which had previously been reported as available in ZINC version 7, 
were no longer available.  Target synthesis of all the compounds was far too costly, 
thus a much smaller subset of the compounds was settled upon. 
The supplier ChemBridge
62
 was able to offer 19 of the compounds from our list of 
139 structures, each at quantities of 5 milligrams (mg) which was sufficient for 
biological analysis.  The structures and labels for these purchased compounds are 
shown in table 3.5. 
Table. 3.5  Compounds purchased from LBVS, together with their Final_Score (in brackets). 
 
 
 
VS01 (4.931) VS02 (4.5) VS03 (4.625) 
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VS04 (4.625) VS05 (4.625) VS06 (4.5) 
 
 
 
VS07 (4.625) VS08 (4.5) VS09 (4.5)  
  
 
VS10 (4.568) VS11 (4.739) VS12 (4.661) 
 
 
 
VS13 (4.625) VS14 (5.038) VS15 (4.980) 
 
  
VS16 (4.884) VS17 (4.5) VS18 (4.893) 
 
  
VS19 (4.625)   
With a high scoring and structurally diverse selection of compounds purchased, 
biological testing could be performed to evaluate the potential of these structures as 
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novel lead like chemotypes, active against Pfbc1.  Chapter IV will discuss the details 
of the biological testing that was performed, together with analysis of the resulting 
active chemotypes. 
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4. Ligand Based Virtual Screening Testing & Analysis 
This chapter is concerned with the third phase of the molecular design loop (fig. 4.1), 
biological testing.  If the synthesis of the nineteen compounds described in table 2.1 
and their testing against Pfbc1 is considered to be one complete iteration of the loop, 
then the use of their structures in Chapter II represents the beginnings of a new 
iteration of the loop through LBVS.  Phase two (chemical synthesis) of this iteration 
represents the purchasing of the compounds from the third party vendor (Chapter 
III), with the second iteration of the loop finally completed as follows. 
 
Fig. 4.1  Molecular design loop. 
4.1 Biological Testing 
Biological testing is crucial to all aspects of the drug discovery process,
1
 allowing 
compounds to be assigned quantitative and/or qualitative information with regard to 
their pharmacological activity.  Bioassays offer an excellent way to measure this in 
vitro, and are particularly useful in the early stages of drug development.  The use of 
bioassays in antimalarial drug design is well documented, with research continually 
ongoing to optimise, develop and refine the techniques,
2-5
 as their reliability and 
reproducibility are key.
6
  In vitro testing is usually fairly cheap and straight forward 
1 
Computational 
Chemistry 
2 
Chemical 
Synthesis 
3 
Biological 
Testing 
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to perform, and may often be automated such that large numbers of compounds can 
be tested, making them suited to high throughput screening.
7
  Promising drug 
candidates may ultimately undergo further in vitro testing, and eventual in vivo 
analysis. 
A number of bioassays were employed in order to test the antimalarial potential of 
the 19 compounds purchased as a result of LBVS.  Selectivity is crucial in drug 
discovery to avoid off target toxicity and other undesirable effects.  Once a 
compound which inhibits growth of the malaria parasite had been found, further 
testing could be performed to allow assessment of its selectivity.  Ideally though, an 
antimalarial compound would be selective for the malaria parasite, having little or no 
ill effect on the patient. 
It is common practice within antimalarial drug design to first identify compounds 
active against the malaria parasite using whole cell screening, and to then screen the 
actives with specific bioassays to determine possible modes of action.
8
  Therefore 
the 19 purchased compounds, as shown in table 4.1, were tested against several 
bioassays. 
Table. 4.1  Compounds purchased from LBVS, together with their Final_Score (in brackets). 
 
 
 
VS01 (4.931) VS02 (4.5) VS03 (4.625) 
   
VS04 (4.625) VS05 (4.625) VS06 (4.5) 
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VS07 (4.625) VS08 (4.5) VS09 (4.5)  
  
 
VS10 (4.568) VS11 (4.739) VS12 (4.661) 
 
 
 
VS13 (4.625) VS14 (5.038) VS15 (4.980) 
 
  
VS16 (4.884) VS17 (4.5) VS18 (4.893) 
 
  
VS19 (4.625)   
 
4.1.1 Whole Cell Growth Inhibition Bioassay 
The all important first step during biological testing was to determine whether any of 
the 19 compounds showed potential as antimalarials.  This required the use of a 
whole cell growth inhibition assay, which was performed according to the ‘Whole 
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Cell Growth Inhibition Assay (3D7) Protocol’ as described in the Experimental 
Chapter.
2, 9-11
  The assay was performed using the CQS strain of P. falciparum, 3D7.  
IC50 values were recorded for each of the compounds that inhibited the parasite, and 
though the assay did not consider compound selectivity, it provided an initial means 
for assessing a compounds antimalarial potential. 
Compounds were first tested to a maximum in vitro concentration of 1.0 µM.  
However, when this failed to produce any quantitative hits, the maximum 
concentration for testing was increased to 10 µM.  Of the 19 compounds, 5 were 
subsequently found to have IC50 values less than 10 µM, ranging between 4.53 and 
8.18 µM.  These results are shown in table 4.2.  These activity values were highly 
encouraging, with similar work involving the use of LBVS to discover novel 
plasmepsin inhibitors (a family of malarial parasitic aspartyl proteases), reporting 
whole cell growth inhibition values of as much as 40 µM.
9
  There are also several 
other instances where µM hits have led to nM lead structures.
10-12
 
Table. 4.2  In vitro IC50 values against 3D7 strain of P. falciparum for the LBVS hits. 
ID IC50 (µM) 3D7 
VS01 5.24 
VS09 4.53 ± 1.86 
VS10 6.41 ± 1.73 
VS16 5.39 
VS18 8.18 
All compounds were tested in triplicate.  Three reported activity values only once, 
whilst the other two (VS09 and VS10) were consistently reproducible (shown by the 
presence of SD values).  As the goal was to identify novel antimalarial chemotypes 
amenable to further optimisation, these initial activity values looked very 
encouraging.  Recent work involving the use of virtual screening to identify novel 
and selective pteridine reductase 1 (PTR1) inhibitors for the treatment of human 
African trypanosomiasis (HAT), or sleeping sickness, tested the selected compounds 
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at a concentration of 100 µM.
13
  Though high, it was rationalised that given the low 
MW of the screened hits, and that the intention was to optimise these structures 
further, inhibition at 100 µM was deemed encouraging.  In this instance, the two 
most potent hits which observed just over 50% inhibition at 100 µM, led to PTR1 
inhibitors with low nM potency, and favourable physicochemical properties.  The 
same approach may therefore be possible for the 5 active compounds described in 
table 4.2. 
Given that nineteen compounds were purchased and five reported some in vitro 
activity against 3D7, the hit/success rate for the LBVS work described in Chapter II 
was therefore over 26%.  This is a crude estimate, given that the compounds were 
partly selected owing to their availability, but this figure is certainly significant, and 
higher than what would have been achieved had the compounds simply been selected 
at random (~0.1% hit rate)
14-16
 from the 2.7 million in ZINC.
17
 
For the 5 active compounds, testing could begin with regard to assessing their 
selectivity and toxicity.  Unfortunately, owing to the difficulties and expense of 
isolating the Pfbc1 enzyme, testing was not performed against this bioassay.  
However, two other assays were employed that would each provide additional 
information about the 5 active compounds. 
4.1.2 Complex I (NDH2) Bioassay 
PfNDH2 is an alternative target for antimalarial drug design (Chapter I),
18
 thus the 
NDH2 assay was performed to see whether any of the compounds in table 4.2 were 
active against this enzyme.  This was useful in assessing the potential cross over 
between bc1 and NDH2 activity.
19, 20
  The NADH:ubiquinone oxidoreductase 
enzyme (complex I) catalyses the reaction shown in figure 4.2, and it is this reaction 
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which can be monitored in vitro to assess the effect of a particular compound against 
complex I.
5
 
NADH + Quinone → NAD
+
 + Quinol 
Fig. 4.2  Reaction taking place during the NDH2 bioassay.  Process catalysed by complex I. 
The NDH2 bioassay is used to monitor the enzyme inhibition of a query compound, 
using the ‘Complex I (NDH2) Bioassay Protocol’ as described in the Experimental 
Chapter.
5
  The in vitro reaction is monitored spectrophotometrically at 283 and 340 
nm, with these values monitoring the quinone reduction and NADH oxidation 
respectively.  For each compound tested two inhibition values were reported, one at 
283 nm and the other at 340 nm.  Though the two are generally similar in magnitude, 
previous work found that monitoring the reaction at 340 nm, (that is NADH 
oxidation and not quinone reduction) reduced the potential interference from 
inhibitors and generated more robust assay performance measures.
5
   
The results of the NDH2 bioassay for the 5 hits are reported in table 4.3.  The 
compounds were each tested at a concentration of 28 µM, which was the maximum 
drug concentration the assay could deal with before secondary effects were observed, 
leading to inaccurate results.  Percentage inhibition values at this concentration were 
recorded. 
Table. 4.3  In vitro percentage inhibition of NDH2 at 340 and 283 nm. 
 Inhibition of NDH2 at 28 µM (%) 
ID 340 nm 283 nm 
VS01 0.8 2.6 
VS09 5.9 5.0 
VS10 3.3 4.1 
VS16 4.6 7.6 
VS18 6.0 4.1 
As can be seen, all 5 of the compounds produced little or no inhibition of NADH 
activity, with VS18 giving the highest percentage inhibition of only 6% (at 340nm).  
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The NDH2 assay was performed to see whether the compounds were killing the 
parasite through complex I inhibition, but this is clearly not the case.  This offers 
indirect support for the selectivity of the compounds as Pfbc1 inhibitors.  However, 
had the compounds inhibited NDH2 this would still have been a positive result, as 
perhaps more than one target was being hit (dual inhibition), and so resistance would 
be more difficult to acquire owing to multiple sites of action.  From these results it 
was therefore possible to conclude that the 5 hits still looked to show much potential, 
particularly VS09 and VS10, thanks to the reproducibility of their in vitro activities. 
4.1.3 Bovine Complex III (bc1) Bioassay 
Owing to difficulties in obtaining enough material to perform the Pfbc1 bioassay 
(with estimates being at least nine months to grow enough parasite), additional 
information relating to the hits was collected in preparation.  The bovine bc1 
bioassay was performed according to the ‘Bovine Complex III (bc1) Bioassay 
Protocol’ detailed in the Experimental Chapter.  This assay is very similar to the one 
which will be performed when sufficient amounts of the Pfbc1 enzyme are available, 
only using the bovine bc1 complex as oppose to that of plasmodium.  The principal 
behind the assay is to measure the effect (if any) a compound has on cytochrome c 
reductase activity.  As was discussed extensively in the introduction, during the Q-
cycle, a proton gradient is generated across the mitochondrial membrane, leading to 
the release of four protons into the inter membrane space.
21, 22
  During this process, 
cytochrome c becomes reduced whilst ubiquinol (QH2) is oxidised to ubiquinone 
(Q).  The assay monitors this reduction of cytochrome c spectrophotometrically,
2
 
with compounds that halt reduction therefore acting as bc1 inhibitors. 
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Though this assay measures bovine bc1 inhibition, it has been found to also provide a 
means for identifying potentially toxic compounds.  It has been observed that 
compounds which show strong inhibition of bovine bc1, often produce cardiotoxicity 
in humans.
2, 3
  This may be attributed to the high degree of sequence identity 
between the human and bovine binding sites.
23
  An example of this is SMA, which 
though highly active towards Pfbc1 (IC50 of 12 ± 1 nM), shows similar potency 
towards bovine bc1 (IC50 of 2.4 nM), and thus strong inhibition of human liver bc1 
(IC50 of 15 ± 0.2 nM).  Conversely, the potent dihydroacridinedione compound 
WR249685 (fig. 4.3) was found to be highly selective for Pfbc1 (IC50 of 3 ± 2 nM), 
but showed poor inhibition of both bovine bc1 (IC50 of > 13,800 nM) and human 
liver bc1 (IC50 of > 13,800) nM).  Given this trend, it is preferable that compounds 
avoid inhibiting bovine bc1, and show improved selectivity for the parasite. 
 
Fig. 4.3  WR 249685. 
The 5 hits produced bovine bc1 inhibition values as shown in table 4.4.  Similar to 
the complex I bioassay, the assay had a maximum drug concentration it could deal 
with before secondary effects were observed, which in this case was 56 µM.  
Compounds were therefore tested up to this maximum concentration, and their 
percentage inhibitions recorded. 
Table. 4.4  In vitro percentage inhibition of bovine bc1. 
ID Inhibition of bovine bc1 at 56 µM (%) 
VS01 0 
VS09 1.1 
VS10 3.4 
VS16 9.6 
VS18 0 
Chapter IV 
 
207 
 
The highest inhibition of the 5 compounds was found to be just under 10% (VS16), 
whilst the others all had very little or no inhibition.  This is encouraging given the 
high concentration at which they were tested, and suggests that given previous 
observations,
2
 these compounds may avoid the associated cardiotoxicity concerns of 
other bc1 inhibitors.  If indeed (after future testing) these compounds prove to inhibit 
Pfbc1, then these results support their selectively and their avoidance of bovine bc1 
inhibition. 
4.2 Analysis of Active Compounds 
The results of biological testing are summarised in table 4.5, together with the 
chemical structures of the hits.  Analysis of the actives involved careful examination 
of any trends in the data, as well as looking more thoroughly at the promising lead 
like candidates. 
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Table. 4.5  Summary of in vitro testing results. 
   
NDH2 
(% inhibition) 
 
Structure ID 
3D7 IC50 
(µM) 
340 
nm 
283 
nm 
Bovine bc1 
(% 
inhibition) 
 
VS01 5.24 0.8 2.6 0 
 
VS09 4.53 ± 1.86 5.9 5.0 1.1 
 
VS10 6.41 ± 1.73 3.3 4.1 3.4 
 
VS16 5.39 4.6 7.6 9.6 
 
VS18 8.18 6.0 4.1 0 
To summarise, 5 of the 19 purchased compounds reported activity against the 3D7 
strain of the malaria parasite.  The reported IC50 values themselves are all 
encouraging, particularly with regard to recent precedent in the literature for novel 
hit to lead structures of antimalarials.
24-26
  There were slight concerns with regard to 
the reproducibility of the in vitro activities, but for VS09 and VS10 this was not a 
concern, as both compounds performed consistently, reporting low SD values.  
Unfortunately however, only single IC50 values were recorded for VS01, VS16 and 
VS18.  Therefore from 3D7 testing alone, VS09 and VS10 appeared to be the most 
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promising hits.  Additionally, NDH2 inhibition was consistently low across all 5 
compounds, as was bovine bc1 inhibition.  This is particularly significant as it 
reduces the number of possible sites of action for the compounds, and also indicates 
that they avoid hitting an enzyme known to be indicative of cardiotoxicity in 
humans. 
4.2.1 Ligand Efficiency 
Ligand efficiency (LE) is a measure of the binding energy between a ligand and its 
binding partner, such as a receptor or enzyme.
27
  It is essentially a measure of the per 
atom potency of a compound, and is commonly used in drug discovery efforts to 
assist in narrowing down lead compounds with favourable physicochemical and 
pharmacological properties.
28
  Ligand efficiency was initially defined numerically as 
the ratio of the Gibbs free energy (ΔG) to the number of non-hydrogen atoms (N) in 
a compound.
29
  However, given that non-hydrogen atoms can be of many different 
types, and that MW is a key property in a compound, the concept of LE has been 
extended.
30
  The binding efficiency index (BEI) offers a means to associate the 
potency of a compound to its MW, on a per kDa scale.
28
  BEI is calculated using to 
equation 4.1, where          is defined as           . 
    
       
       
 
Eq. 4.1  Binding efficiency index formula. 
The BEI values for the 5 active compounds and CQ are reported in table 4.6.  The 
inclusion of CQ enabled a comparison between the results, as it is a known, potent 
inhibitor of 3D7.  A recent publication has shown CQ to have an IC50 value of 
around 15 nM.
31
  A reference value for BEI of 27.0 is also reported in table 4.6 (note 
that this is a general value and not something specific to 3D7), based on idealised 
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values for MW and IC50.
30
  MW was taken to be 0.333 kDa, as this was found to be 
near the mean value of MW based on a large sample of marketed oral drugs,
32, 33
 
with the IC50 value simply defined as 1 nM. 
Table. 4.6  Calculation of BEI for the LBVS hits. 
Molecule IC50 3D7 (µM) IC50 3D7 (M)         MW (Da) MW (kDa) BEI 
CQ 0.015 0.000000015 7.82 319.9 0.3199 24.5 
VS01 5.24 0.00000524 5.28 345.1 0.3451 15.3 
VS09 4.53 0.00000453 5.34 232.0 0.2320 23.0 
VS10 6.41 0.00000641 5.19 334.1 0.3341 15.5 
VS16 5.39 0.00000539 5.27 305.2 0.3052 17.3 
VS18 8.18 0.00000818 5.09 320.2 0.3202 15.9 
Reference 0.001 0.000000001 9 333.0 0.3330 27.0 
The BEI for CQ was found to be 24.5, very similar to the reference value (27.0).  CQ 
could therefore be used as a reference point to which the other compounds can be 
compared for their 3D7 potency.  In CQ, each atom clearly contributes highly to its 
overall activity, making it highly ligand efficient.  Though the BEI values for the 
purchased hits are lower than that of CQ, they are still largely comparable.  In 
particular, VS09 was found to have a highly promising BEI value of 23.0.  
Considering how small the molecule is (MW of 232), it undoubtedly shows much 
potential for subsequent SAR investigation and chemical optimisation. 
4.2.2 Novelty of the Chemotypes 
Several datasets of compounds have recently been published which report the 
structures and activity values of many compounds known to inhibit the malaria 
parasite.  Two such datasets are the GSK and St Jude’s databases.34, 35  GSK 
screened over two million compounds and tested them against 3D7 P. falciparum at 
a concentration of 2 µM.  Around 13,000 (13,519) of the compounds had greater 
than 80% inhibition, and were thus reported in the GSK database.  Similarly, the St 
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Jude’s database reported the identity of around 1,300 (1,236) hits from an initial 
screen of 300,000 compounds which observed greater than 80% inhibition of 3D7, at 
a concentration of 7 µM.  These sets of compounds with known antimalarial 
behaviour were used to assess the novelty of the 5 active hits identified from LBVS. 
There were a few core motifs which represented the central chemotypes of the 5 
active hits (table 4.5).  These were: pyrrolopyrimidine-2,4-dione; benzothiazole; 
isoalloxazine ring; piperazine.  A substructure search of the four chemotypes in both 
the GSK and St Jude’s databases was performed using the ‘Substructure Searching 
Protocol’ as described in the Experimental Chapter.  Table 4.7 illustrates the number 
of times a particular chemotype appeared in the database. 
Table. 4.7  Frequency of chemotypes in the GSK and St Jude’s databases. 
 Frequency 
Chemotype 
GSK 
(13,519 compounds) 
St Jude’s 
(1,236 compounds) 
Pyrrolopyrimidine-2,4-dione 0 0 
Benzothiazole 79 62 
Isoalloxazine Ring 0 0 
Piperazine 1208 114 
As can be seen, the pyrrolopyrimidine-2,4-dione and isoalloxazine chemotypes were 
not observed in either of the databases, offering support that these are both novel 
chemotypes active against malaria.  Though the piperazine ring was fairly common 
in both datasets, this shouldn’t be of too much concern given that it is a small 
heterocycle, and quite often was only a small subunit of much larger compounds.  Of 
particular relevance is the presence of the benzothiazole chemotype in both datasets.  
As is discussed during the literature review to follow (section 4.4), the benzothiazole 
chemotype has been shown to have widespread applications, including in the field of 
antimalarial drug design, therefore its presence in these datasets was not surprising.  
Though this may call into question the novelty of the chemotype with regard to its 
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antimalarial potential, there has thus far been no mention of it acting as a selective 
bc1 inhibitor, therefore the chemotype is still highly promising.  Furthermore, the 
compounds which contained benzothiazole all had alternative side chains and 
substitution patterns to those present in VS09. 
A fingerprint similarity search of the five active compounds was performed against 
the GSK and St Jude’s databases, using the ‘Fingerprint Similarity Search Protocol’ 
as described in the Experimental Chapter.  The FCFP_4
36, 37
 molecular fingerprint 
method was used to perform the similarity search, with similarity assessed using the 
Tanimoto coefficient.
38
  Only compounds with a similarity value equal to or greater 
than 0.5 were reported.  This cut off was chosen as it offered a midpoint between 
similarity and dissimilarity.  Also, it was lower than the cut off of 0.7 which was 
used during LBVS, and given that this was used to represent sufficient similarity, 
anything lower might suggest the opposite.  The number of hits which had a 
Tanimoto coefficient value greater than 0.5 are reported in table 4.8. 
Table. 4.8  Frequency of chemotype hits in the GSK and St Jude’s databases. 
 Frequency 
Active Compound 
GSK 
(13,519 compounds) 
St Jude’s 
(1,236 compounds) 
VS01 0 0 
VS09 0 0 
VS10 0 0 
VS16 3 0 
VS18 3 1 
As can be seen, for VS01, VS09 and VS10, that is the pyrrolopyrimidine-2,4-dione, 
benzothiazole and isoalloxazine chemotypes there were no hits in either chemical 
library with a Tanimoto coefficient value greater than or equal to 0.5, greatly 
supporting the novelty of these active hits.  So, although the benzothiazole core was 
found to be fairly well reported in both libraries, the quantitative similarity of these 
compounds compared to VS09 appeared to be sufficiently low, making VS09 a 
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unique and promising compound.  There were a few hits for the piperazine 
containing compounds (VS16 and VS18), but considering their linear structures this 
is hardly surprising.  Also, these two compounds don’t have particularly distinct 
chemotypes like the other actives, making them the least attractive of the hits for 
future optimisation. 
Once the novelty of the 5 hits had been considered, the active compounds were each 
investigated in turn.  Their activity profiles will now be discussed together with any 
precedent they showed across the literature, as well as their possible modes of action.  
Their potential for future investigation will also be discussed. 
4.3 VS01 
VS01 (fig. 4.4) consists of a pyrrolopyrimidine-2,4-dione core with phenyl 
substituent’s.  It was shown to have promising 3D7 inhibition (IC50 of 5.24 µM) with 
little or no NDH2 and bovine bc1 activity, as well as a reasonable BEI value of 15.3.  
Though the synthesis of pyrrolopyrimidine-2,4-dione compounds has been of some 
interest,
39, 40
 their only reported pharmacological use has been as agonists and 
antagonists of adenosine receptors that belong to the superfamily of GPCRs, in 
particular the adenosine A2B receptor.
41
  It is thought that A2B antagonists may have 
potential clinical applications, as this receptor is implicated in both inflammation and 
asthma.
42, 43
 
 
Fig. 4.4  VS01. 
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A literature search showed there to be no previous reporting of pyrrolopyrimidine-
2,4-diones being used as antimalarials, suggesting that this is indeed a novel 
chemotype suitable for antimalarial investigation.  There was however a single 
publication which reported the use of pyrrolopyrimidines of the general formula 
shown in figure 4.5, as potentially useful for the treatment of highly drug resistant 
mutant strains of PfDHFR.
44
  To refresh, antifolate compounds such as the prodrug 
proguanil (fig. 1.12) have been used for the treatment and prophylaxis of malaria,
45-
47
 as they inhibit the crucial enzyme DHFR.  This is required by plasmodia for the 
synthesis of tetrahydrofolic acid, which forms a vital part of the folate biosynthetic 
pathway, essential for the production of certain nucleotides and amino acids.  
However, emerging resistance due to an accumulation of mutations in the dhfr gene 
has led to a need for new DHFR inhibitors.
48, 49
  If pyrrolopyrimidine containing 
compounds are capable of circumventing this resistance, then perhaps the 
pyrrolopyrimidine-2,4-dione template exemplified by VS01, may afford an 
alternative avenue of investigation, and perhaps go some way to explain the activity 
of this hit, should it later be found to be inactive towards Pfbc1. 
 
Fig. 4.5  General pyrrolopyrimidine antifolate structure.  (R. K. B. Brobey, M. Iwakura, F. Itoh, K. 
Aso and T. Horii, Parasitol. Int., 1998, 47, 69-78.) 
A possible area of interest for the pyrrolopyrimidine-2,4-dione chemotype would be 
to investigate how alterations in the side chain affect its in vitro activity.  From this a 
SAR study could be developed to potentially improve its potency.  Further biological 
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study of VS01 and other pyrrolopyrimidine-2,4-diones may also yield further insight 
into the potential mode of action for these compounds. 
4.4 VS09 
VS09 (fig. 4.6) contains a benzothiazole connected to an imidazole alcohol group via 
an amine linker.  VS09 reported the best activity of the five compounds, with an IC50 
value against 3D7 of 4.53 ± 1.86 µM.  Additionally, VS09 proved to be the most 
consistent in vitro, and displayed little activity towards NDH2, as well as bovine bc1, 
suggesting that Pfbc1 may well be its target site.  Its BEI value was also found to be 
the highest of the five actives, which at 23.0 made it highly comparable to that of CQ 
(24.5), and therefore a potent compound given its relatively small size. 
 
Fig. 4.6  VS09. 
The benzothiazole scaffold has been widely reported across the literature with many 
applications.  It can be found in the dye thioflavin which is used in the study of 
protein aggregation, particularly in Alzheimer’s disease patients.50  It is also found in 
riluzole,
51
 a drug for the treatment of motor neurone disease, as well as in nature in 
benzothiazole alkaloids.
52
  Earlier, the use of virtual screening to identify novel and 
selective PTR1 inhibitors for the treatment of HAT was discussed, in particular the 
use of 100 µM to define what constitutes a hit.
13
  Two novel chemical series were 
identified from this study, one of which contained the benzothiazole scaffold, the 
other a benzimidazole.  Further study of these series led to the proposition of their 
binding modes, as well as low nM PTR1 inhibitors. 
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The benzothiazole heterocyclic structure clearly has widespread applications, but it 
has also been previously noted for its potential use in antimalarial drug design.  
Though there are only a few instances of benzothiazole being used in antimalarials, 
the first paper reported its possible interest as far back as the late 1960’s.53, 54  In this 
paper, Plasmodium berghei (P. berghei),
55
 which is a plasmodium species that 
affects African murine rodents and is of no direct concern to man, was used as a 
surrogate to rapidly test compounds to identify new antimalarials.  This practice is of 
wide interest as it offers a model from which human malaria can be studied, together 
with analysis of malaria genes using genetic modification.
56
  A series of synthesised 
benzothiazole’s were tested for activity against P. berghei mice, with several amino 
alcohols showing weak antimalarial activity.  However, activity was only found to 
occur at toxic doses. 
Later work detailed the study of dioxobenzothiazoles as potential antimetabolites of 
coenzyme Q.
57
  Though one compound (fig. 4.7) was shown to have good 
prophylactic activity without toxicity against Plasmodium gallinaccum in chicks, a 
form of plasmodium that causes malaria in poultry, work moved away from the 
study of benzothiazole’s and towards the investigation of alterative 
bicycloheterocyclic quinones.
58
  This was in the hope of elucidating the nature of 
inhibition at the enzymatic site of CoQ. 
 
Fig. 4.7  5-n-undecyl-6-hydroxy-4,7-dioxobenzothiazole. 
More recently the benzothiazole moiety has been incorporated into much larger 
structures active against malaria in the single µM range (i.e. fig. 4.8).
59, 60
  De novo 
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design was used to develop a new class of non-peptidic inhibitors active against 
malarial aspartic protease plasmepsin II (PMII).  Plasmepsins are a class of enzyme 
produced by plasmodia, and given that their haemoglobin degradation activity is an 
important cause of symptoms in malaria suffers, plasmepsins therefore pose an 
interesting target for antimalarial drug design.
61
  The benzothiazole moiety was 
included in the compounds to residue within a hydrophobic pocket of the PMII 
active site, forming interactions thought to be crucial to its antimalarial activity. 
 
Fig. 4.8  Benzothiazole containing PMII inhibitor. 
Perhaps the most important occurrence of the benzothiazole chemotype in the 
literature was in a series of 2-substituted 6-nitro- and 6-amino-benzothiazoles which 
were synthesised and tested against P. falciparum.
62
  The most promising candidates 
from in vitro studies to assess activity and toxicity were carried forward into in vivo 
assays on P. berghei infected mice.  From this, two had specific antimalarial 
properties (fig. 4.9) and were active against all stages of the parasite.  They were also 
active on the mitochondrial membrane potential (MMP), causing a drop in MMP that 
could alter the respiratory chain and lead to parasite death, similar to ATOV.  There 
was however, no discussion about which specific enzymes they may have been 
inhibiting to produce this drop.  Also these compounds were active against multiple 
pathways (i.e. MMP; haem crystallisation), which may allow for increased efficacy 
and the reduced development of resistance.  Both compounds were deemed worthy 
of further chemical and biological investigation, though these results have yet to be 
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published.  This work is highly supportive of VS09, and shows the potential which 
lies within the benzothiazole heterocycle for antimalarial design.  Though these 
compounds do affect MMP, there is no mention as to a particular enzyme they might 
target, and they are clearly not selective.  Thus there are currently no known Pfbc1 
inhibitors containing the benzothiazole scaffold. 
  
Fig. 4.9  2-substituted 6-nitro- and 6-amino-benzothiazoles. 
The benzothiazole template has also appeared in a number of compounds active 
against the K1 CQR strain of P. falciparum, which were later found to inhibit P. 
berghei in mice.
63
  However, the most recent appearance of benzothiazole in the 
literature was concerned with the synthesis of a series of analogues that were 
designed based on a SBVS study to identify compounds that inhibited falcipain 
cysteine proteases.
64
  The cysteine proteases of P. falciparum are collectively known 
as falcipains,
65
 and are responsible for the host haemoglobin hydrolysis.  Their 
inhibition therefore results in parasite cell death, making this a viable antimalarial 
target.  Though the compounds (i.e. fig. 4.10) showed activity against CQR 
parasites, their IC50 values were all fairly poor, with many greater than 50 µM.  This 
would suggests that there is still much room to optimise and refine compounds that 
contain the benzothiazole chemotype. 
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Fig. 4.10  Falcipain inhibitor containing benzothiazole. 
Given that the benzothiazole heterocycle has already proven to be of much biological 
interest, both as an antimalarial structure and in other areas, it looks to be a highly 
promising lead chemotype to take from the LBVS work performed.  By combining 
the encouraging testing results collected so far, along with earlier discussions in the 
literature about the possibility that benzothiazole containing compounds may act as 
antimetabolites of CoQ, the chemotype certainly warrants further investigation to 
determine its potential as a Pfbc1 inhibitor.  It’s presence amongst the literature with 
regard to alternative malaria targets is also encouraging, as it may suggest a strong 
pharmacological profile for VS09.  Also, though the benzothiazole chemotype is 
present in the literature, the papers are all concerned with extensions/side chains 
unlike that of VS09, whose novelty lies not only in its inception, but also in the 
combination of the substituted imidazole group, as much as it does in the presence of 
benzothiazole itself.  There is clearly much scope with regard to chemical 
optimisation of the benzothiazole chemotype, and indeed VS09 itself. 
4.5 VS10 
VS10 (fig. 4.11) contains a rigid, aromatic tricyclic structure comprised of a 
pteridine-2,4-dione structure attached to a benzene ring, with a side chain branching 
out from one of the central amines.  This is commonly referred to as an isoalloxazine 
ring.  VS10 was consistently active against 3D7, with an IC50 value of 6.41 ± 1.73 
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µM.  It was also poorly active against both NDH2 and bovine bc1, making it a 
potentially promising compound, although its BEI was lower than that of CQ at 15.5. 
 
Fig. 4.11  VS10. 
The pteridine moiety observed in VS10 is crucial to the folate biosynthetic pathway, 
and is the core chemotype present in folic acid, which is needed to build and repair 
DNA.  Pteridine has therefore been of much interest with regard to developing potent 
and selective inhibitors of DHFR.
66, 67
  Given that pteridine derivatives compete in 
the active site of folate enzymes, pteridine containing compounds may also 
potentiate the activity of other DHFR inhibitors.
68
  The chemotype is also present in 
methotrexate (fig. 4.12), a well known antimetabolite and antifolate drug used in the 
treatment of cancer and autoimmune diseases.
69
  These observations would suggest 
that VS10 could potentially be a DHFR inhibitor, an avenue which certainly 
warrants future exploration. 
 
Fig. 4.12  Methotrexate. 
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The isoalloxazine ring highly resembles that of flavin mononucleotide (FMN, fig. 
4.13), which plays a critical role in the ETC.  It acts as a prosthetic group for various 
oxidoreductases, including NADH dehydrogenase, through its reversible inter-
conversion of its oxidised (FMN), semiquinone, and reduced (FMNH2) forms. 
 
Fig. 4.13  Flavin mononucleotide (FMN). 
The ETC is a complicated process and has been discussed in Chapter I.
21, 70-72
  It 
begins with the oxidation of ubiquinone (Q) to ubiquinol (QH2), which is catalysed 
by NADH:quinone oxidoreductase.  NADH binds to complex I, transferring two 
electrons to FMN, thereby reducing it to FMNH2.  The electron accepting 
isoalloxazine ring of FMN is identical to that of flavin adenine dinucleotide (FAD, 
fig. 4.14), thus making VS10 structurally related to both FMN, and FAD.  FAD is 
formed at complex II (SDH) through oxidation of FADH2, in a step vital to feed 
electrons along the mtETC to complex III.
73
  FMNH2 is then oxidised in two, one 
electron steps via a semiquinone intermediate.  Each electron transfers from FMNH2 
to an Fe-S cluster, and then from the Fe-S cluster to Q, ultimately reducing it to 
QH2.  As a result, four protons translocate across the membrane producing a proton 
gradient.  It has been noted that FMN is a stronger oxidising agent than NAD
+
, being 
particularly useful as it can take part in both one, and two electron transfers. 
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Fig. 4.14  Flavin adenine dinucleotide (FAD). 
Upon initial consideration you would expect that a compound containing the 
isoalloxazine chemotype, whose chemical structure is clearly essential to the ETC 
(i.e. FMN and FAD), would make for an undesirable template for lead optimisation.  
The presence of the isoalloxazine ring in VS10 could have even potentially promoted 
activity of the ETC.    However, testing results show this is not the case, being that it 
had good, reproducible active against 3D7, and observed little toxicity (according to 
its bovine bc1 activity).  The novelty of VS10 as an antimalarial compound must 
therefore lie in its side chain, which contains an alkyl chain terminating with a 
benzene group via an oxygen linker.  All things considered, though the aim was to 
identify chemotypes active against complex III, VS10 may actual elicit its response 
through competitive inhibition of either one or both of FMN and/or FAD, at 
complexes I and II respectively.  This would still however, block electron transfer, 
thus inhibiting the ETC.  Further biological testing is required to validate this 
hypothesis.  Alteration of the side chain may therefore make for an interesting future 
study of the isoalloxazine chemotype. 
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4.6 VS16 and VS18 
VS16 and VS18 (fig. 4.15) are perhaps the least interesting chemical structure of the 
five hits, given that they do not have traditional chemotypes amenable to chemical 
optimisation.  Both contain a piperazine ring with varying functionality branching 
from either amine.  The 3D7 IC50 values for these compounds were fairly good, 
being 5.39 µM and 8.18 µM respectively, yet the results were not reproducible, 
slightly hampering their potential.  Also, though not massive, VS16 observed the 
highest inhibition of the five active compounds against bovine bc1 (10%), perhaps 
further limiting its potential owing to off target toxicity.  Both compounds did 
however have reasonable BEI values of 17.3 and 15.9 respectively, though these 
were lower than that of CQ, and indeed some of the other hits. 
 
 
Fig. 4.15  VS16 and VS18. 
Piperazine containing antimalarials have been noted amongst the literature, with one 
paper describing a number of aryl piperazine derivatives active against both CQS 
and CQR strains of malaria in µM concentrations.
74
  More recently, this series was 
used to develop statistically significant QSARs models, which were later found to 
successfully predict the activity of unknown compounds.
75
  There are also several 
other mentions of aryl piperazine derivative being active against malaria.
76, 77
  
However, given the small nature of the piperazine chemotype, it often tends to form 
part of much larger compounds.  An example of this involved the hit to lead 
optimisation of an imidazolopiperazine containing compound (fig. 4.16) active 
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against sensitive and resistant parasite strains.
11
  The lead compounds from this study 
ultimately showed good potencies in vitro, as well as decent oral exposure levels in 
vivo. 
 
Fig. 4.16  Imidazolopiperazine compound. 
Despite their inconsistent performance in the 3D7 bioassay, the literature would 
suggest that there is still potential within the piperazine heterocycle for use in 
antimalarial drug design.  Perhaps further development and optimisation of the side 
chains of VS16 and VS18 may yield some improvements in their activity profiles. 
4.7 Summary of Testing/Analysis 
From the results presented in this chapter it can be concluded that five of the 
compounds identified by LBVS were active against the 3D7 strain of the malaria 
parasite, with each containing a novel structural chemotype.  Though the aim of 
LBVS was to identify novel Pfbc1 inhibitors suitable for chemical optimisation, 
further in vitro testing is required (when it becomes available) in order to validate 
this claim.  However, the results collected thus far look highly promising, with the 
benzothiazole chemotype being of particular interest.  It would therefore be possible 
to conclude that LBVS was successful in its aim of using existing chemical 
information to inform drug development with regard to antimalarial design.  
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Ultimately, these novel chemotypes will go on to form the basis of another iteration 
of the molecular design loop, to continually refine the discovery process. 
The 5 active hits have also been the subject of a molecular docking study, the results 
of which are discussed in the following chapter.  These results were used to further 
rationalise their potential as Pfbc1 inhibitors.  Chapter V also reports the findings 
from a number of other docking studies, which were performed to rationalise/explain 
the observed activity patterns of other compounds active against the bc1 complex. 
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5. Molecular Docking Studies 
Predicting the binding modes and affinities of compounds when they interact with a 
protein binding site lies at the heart of structure based drug design.
1
  Molecular 
docking and its uses have already been reviewed in Chapter I, but in essence, its aim 
is to predict the preferred binding orientation of one molecule with respect to a 
second.
2
  Protein-ligand docking is of massive importance in rational drug design, as 
it enables the prediction of the binding orientation of small molecules within a 
protein, which may be used to predict it’s binding affinity.3  A large number of 
methods are currently available for use in protein-ligand docking,
4-7
 including 
DOCK,
8
 FlexX,
9
 PRO_LEADS
10
 and GOLD,
11, 12
 with most approaches considering 
the protein to be (almost) rigid, and the ligand to be flexible.
6
 
The key characteristic of a good docking protocol however, is its ability to reproduce 
the experimental binding mode of a ligand.
1
  To test this, a ligand should be removed 
from the crystal structure of its protein-ligand complex, and then docked back into its 
binding site.  The docked binding mode is then compared with the experimental 
binding mode, with RMSD providing a means of measuring the similarity between 
the actual and predicted poses.  The prediction of a binding mode is considered 
successful if the RMSD is below a certain threshold, usually 2 Å.
1
 
The protein-ligand docking described in this thesis was all performed using the 
docking program GOLD 5.0.1
13
 (Genetic Optimisation for Ligand Docking), which 
searched for the best ligand interaction poses using a genetic algorithm (Chapter I).  
Work has previously been carried in order to establish the success rate of GOLD in 
predicting binding poses, using a large and carefully constructed set of protein-ligand 
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complexes.
14
  GOLD was shown to reproduce the native binding pose of a ligand 
with a 68% success rate, when using the CCDC/Astex validation set of 305 
complexes, all of which were taken from the PDB library.
15
 
Molecular docking essentially consists of two problems, the first being the necessity 
of a mechanism for exploring the extremely large “search space” of possible protein-
ligand geometries, and the second the need to score and/or rank poses in order to 
identify the most likely binding modes.  Both of these concepts have already been 
explored during Chapter I, so particular scoring methods will now be introduced. 
A docking protocol developed in GOLD
13
 consists of three main parts.
11, 12
  Firstly, a 
scoring function must be used in order to rank the different binding modes that are 
reported.  Next, a mechanism is required in order to place the ligand into the binding 
site.  GOLD uses a unique method to do this by adding fitting points to hydrogen 
bonding groups on the protein and ligand, mapping acceptor points on the ligand to 
donor points on the protein, and vice versa.  GOLD also generates hydrophobic 
fitting points in the protein cavity, onto which ligand CH groups are mapped.  
Finally, a search algorithm is employed to explore possible binding modes.  GOLD 
uses a GA in which several parameters are optimised, such as the dihedrals of the 
ligands rotatable bonds, the ligands ring geometries, dihedrals of protein OH and 
NH3
+
 groups, as well as the mapping of fitting points. 
5.1 Scoring Functions 
As it is not always clear which docking protocol will give the best result for a 
particular problem,
16, 17
 it is important to carefully consider each case individually.  
When several docking poses are generated it is crucial to score or rank these poses 
using some function related to the free energy of association of the intermolecular 
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complex.  There are a wide range of scoring functions available,
18
 and the ability to 
accurately predict the potency of ligand binding within a protein is of significant 
value, providing useful starting points for drug discovery.
19, 20
  Once the ligands are 
docked, the resulting interactions can be scored giving a quantitative measure of fit 
quality.  Scoring functions are approximate mathematical methods used to predict 
the strength of the non-covalent interactions between two molecules after they have 
been docked (also referred to as binding affinity), and it is common practice to use 
scoring functions in protein-ligand docking.
21
  Scoring functions can be grouped into 
three categories: force field based, empirical, and knowledge based.
22
 
Knowledge based methods rely on the idea that a sufficiently large data sample can 
serve to derive rules and general principles inherently stored in this knowledge 
database.
22-26
  It is based on statistical observations of intermolecular close contacts 
in large 3D datasets, such that the interaction potential between each ligand-protein 
atom pair is calculated as a potential of mean force.  The method is founded on the 
assumption that close intermolecular interactions between certain types of atoms or 
functional groups that occur more frequently than one would expect by a random 
distribution, are likely to be energetically favourable and therefore contribute 
favourably to binding affinity.
27
  Knowledge based methods were not employed in 
this research and will not be discussed further, as these methods could not be used to 
perform rescoring when a water molecule was present, which was essential for this 
research.  Examples of force field based and empirical methods will now be 
introduced more fully in the context of GOLD docking. 
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5.1.1 GOLDScore 
GOLDScore
11, 12
 is a force field based scoring function that provides a quantitative 
means of estimating the scoring affinity of a pose, by summing the strength of 
intermolecular van der Waals and electrostatic interactions between all atoms of the 
two molecules in the complex.  The intramolecular energies of the two binding 
partners is also frequently considered, and since binding normally takes place in the 
presence of water, the desolation energies of the ligand and the protein are 
sometimes taken into account using implicit solvation.  Force field based scoring 
functions are primarily derived from force fields such as AMBER,
28
 which are 
frequently used in molecular dynamics simulations. 
The GOLDScore of a pose can be calculated using equation 5.1.  The GOLDScore 
fitness function is comprised of four components: protein-ligand hydrogen bond 
energy (external H-bond;        ); protein-ligand van der Waals energy (external 
vdw;         ); intramolecular strain in the ligand vdw energy (internal vdw; 
        ); ligand torsional strain energy (internal torsion;         ).  A fifth 
component may also be added, which looks at the ligand intramolecular hydrogen 
bond energy (internal H-bond), but this is not included by default and its omission 
has been found to give better results.
1
 
                                             
Eq. 5.1  GOLDScore fitness function calculation. 
The fitness score is taken as the negative of the sum of the component energy terms 
so that a larger fitness score suggests a better binding complex.  The external vdw 
term is multiplied by a factor of 1.375 when the total fitness score is computed, and 
is an empirical correction to encourage protein-ligand hydrophobic contact.  The 
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GOLDScore fitness function has been optimised for the prediction of ligand binding 
positions rather than for the prediction of binding affinities. 
5.1.2 ChemScore 
ChemScore is an empirical based scoring method,
10, 29, 30
 derived to reproduce 
experimentally determined complex structures from physicochemical properties, 
based on counts of the number of various types of interactions between two binding 
partners.
31
  Counting may be based on the number of ligand and receptor atoms in 
contact with each other, or by calculating the change in solvent accessible surface 
area in the complex compared to the uncomplexed ligand and protein.  The 
coefficients of the scoring function are usually fitted using MLR methods, and may 
include contributions from hydrogen bonding, ionic interactions, lipophilic 
interactions and the loss of internal conformational freedom of the ligand.  
ChemScore was derived empirically from a set of 82 protein-ligand complexes for 
which measured binding affinities were available.  These were then trained by linear 
regression against the measured affinity data.  The ChemScore function estimates the 
total free energy of binding change (         ) that occurs on ligand binding, and is 
calculated using equation 5.2.  In equation 5.2,       ,        and       represent the 
scores for hydrogen-bonding, acceptor-metal and lipophilic interactions respectively, 
whilst      provides a measure for the loss of conformational entropy in the ligand 
upon binding to the protein.  The    terms in the equation are coefficients that were 
derived from the MLR analysis of the 82 protein-ligand complexes (table 5.1). 
                                                                
Eq. 5.2  ChemScore free energy of binding calculation. 
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Table. 5.1  ChemScore free energy of binding parameters. 
    -5.480 (kJ/mol) 
        -3.340 (kJ/mol) 
        -6.030 (kJ/mol) 
       -0.117 (kJ/mol) 
      2.560 (kJ/mol) 
The ChemScore function was adapted for docking by adding in a protein-ligand 
clash penalty term (      ) and an internal ligand energy torsion term (    ).  
Together these militate against close contacts in docking and poor internal 
conformations.  Additionally a covalent energy term (    ) was included, with 
ChemScore ultimately calculated using equation 5.3. 
                                     
Eq. 5.3  Calculation of ChemScore. 
As with GOLDScore, the higher the ChemScore value the better the predicted 
binding pose.  However, GOLDScore and ChemScore are unrelated and as such, are 
not comparable to one another.  Though GOLDScore has been found to perform 
marginally better at predicting native binding poses for certain complexes,
1
 it is 
difficult to generalise these observations, and thus it is necessary to evaluate the 
relative merits of different methods for individual examples. 
When protein-ligand docking is used to dock large libraries of compounds into a 
target binding site, the docking of each compound needs to be quick, otherwise 
fewer binding modes are sampled, potentially reducing the success rates.
1
  The 
ChemScore docking function is up to three times faster than that of GOLDScore, 
with minimal sacrifice of accuracy.
1
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5.2 Cytochrome bc1 Protein Target 
Pfbc1 has been validated as a target for novel antimalarial drug development through 
the study of drugs such as ATOV, which is a competitive inhibitor of CoQ.
32, 33
  The 
bc1 complex is a homodimeric transmembrane protein with a molecular mass of 240 
kDa.  It contains an electron-transferring core that is comprised of three catalytic 
subunits (cytochrome b, cytochrome c1, ISP) that catalyse the transfer of electrons 
from ubiquinol to cytochrome c, coupled with the translocation of protons across the 
inner mitochondrial membrane (fig. 5.1).
34, 35
  Loss of bc1 activity results in the loss 
of mitochondrial function, and the collapse of the transmembrane electrochemical 
potential.
36, 37
 
 
Fig. 1.16  (a) Homodimeric structure of the yeast cytochrome bc1 complex (PDB accession code 
3CX5).  (b) The structure and Q-cycle mechanism of the catalytic core of the bc1 complex.  (V. 
Barton, N. Fisher, G. A. Biagini, S. A. Ward and P. M. O'Neill, Curr. Opin. Chem. Biol., 2010, 14, 
440-446.) 
The generation of the membrane potential is achieved through a bifurcated redox 
pathway (Q-cycle) involving the endogenous compounds ubiquinol and ubiquinone, 
the net result of which is the release of two protons to the cytosolic side of the inner 
membrane per two electrons transferred from ubiquinol to cytochrome c.
32, 35, 38
  
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Fig. 1 - V. Barton, N. Fisher, G. A. Biagini, S. A. Ward and P. M. O'Neill, 
Curr. Opin. Chem. Biol., 2010, 14, 440-446.) 
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Ubiquinol is oxidised at the Qo site of the bc1 complex, which is located at the 
interface of two four-helical bundles in the cytochrome b subunit, residing in 
between the bL heme and the 2Fe-2S cluster of ISP.  The Qo site is on the other side 
of the membrane to Qi, linked via a transmembrane electron transfer pathway 
provided by the membrane spanning cytochrome b subunit and the bH heme.  The Qi 
site is responsible for the reduction of ubiquinone to ubiquinol. 
bc1 Inhibitors are traditionally divided into two classes based on their specific sites 
of action:  class I for Qo inhibitors and class II for Qi inhibitors.
39, 40
  Class I 
inhibitors such as SMA and myxothiazol (fig. 5.2) inhibit electron bifurcation at the 
Qo site, whilst class II inhibitors such as the natural fungicide antimycin A (fig. 5.3), 
block the electron transfer path from heme bH to quinone.  The use of these 
compounds is however limited as they are often highly toxic in mammals and other 
non-pathogenic organisms. 
 
 
SMA Myxothiazol 
Fig. 5.2  Known Qo inhibitors stigmatellin and myxothiazol. 
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Antimycin A 
Fig. 5.3  Known Qi inhibitor antimycin A. 
Molecular docking has been employed in an attempt to improve our understanding as 
to how certain compounds are thought to elicit their response against the cytochrome 
bc1 complex.  An atomic structure for Pfbc1 is not currently available, though work is 
ongoing to generate a protein structure using homology modelling.  In silico work 
was therefore performed largely using the crystal structure of the yeast cytochrome 
bc1 protein (PDB accession code 3CX5).
41
  Though not identical, the yeast protein 
shares 40% sequence homology with the parasite bc1 complex, and is highly 
conserved across the Qo region.
42
 
5.2.1 The Qo Site 
The Qo pocket of the bc1 complex is approximately 15 Å in length and has the shape 
of a saddle.
39
  It is highly hydrophobic and has a relatively wide opening at one end 
that becomes increasingly narrower moving inwards.  The pocket opens up again 
after the narrow, flat constriction but is sealed at the other end.  A number of 
aromatic and aliphatic residues line the inside of the Qo pocket and form several key 
interactions with inhibitors.  Qo inhibitors can be categorised as those which either 
promote movement, or fix the position of the water soluble domain of ISP.
43
  Several 
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compounds were docked into the Qo site, thus its structure will be discussed more 
fully. 
5.2.1.1  Stigmatellin 
SMA (fig. 5.2) is a natural antifungal agent produced by myxobacteria S. 
Aurantiaca.  It is a chromone derivative which fixes the position of the water soluble 
head group of ISP.  In fact, its binding to the Qo pocket is critically dependent on the 
presence of the ISP.
44
  The water soluble head group of ISP is a histidine amino acid 
(His181).  The protonated N atom of His181 forms hydrogen bonds with the 
methoxy oxygen and the carbonyl oxygen of the chromone head group of SMA, with 
distances of 3.5 Å and 3.4 Å respectively (heavy atom to heavy atom distances).
39
  
There is also a strong hydrogen bond (2.6 Å) between the hydroxyl group of SMA, 
and an oxygen atom of the glutamic acid (Glu272) amino acid in the Qo pocket, 
mediated by a water molecule to form a key hydrogen bonding network.  This water 
molecule is thought to bridge the gap between Glu272 and SMA, stabilising the 
chromone head group.  These two interactions are thought to be the most crucial in 
explaining the antimalarial activity of Qo inhibitors, and are illustrated in figure 5.4.  
Figure 5.5 illustrates the native binding pose of SMA in the yeast crystal structure of 
cytochrome bc1.  The interaction between SMA and His181 is particularly important 
as this prevents the oxidation of ubiquinol, and thus inhibits electron transfer.
45
 
Chapter V 
 
241 
 
 
Fig. 5.4  Diagram of the key interactions between SMA in the Qo pocket, and the His181 and Glu272 
amino acids in the cytochrome bc1 complex. 
 
Fig. 5.5  The native binding pose of SMA in the Qo pocket of the yeast cytochrome bc1 complex 
(3CX5).  Two key interactions are observed; one between His181 and the carbonyl and methoxy 
oxygen atoms of the chromone ring, the other a water mediated H-bonding network between Glu272 
and the hydroxyl group.  The yeast cytochrome b polypeptide backbone is represented in green, with 
the [2Fe2S] cluster of the Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-
bonds are indicated by black lines. 
Chapter V 
 
242 
 
There are however a number of additional van der Waals and hydrophobic 
interactions between the amino acids of the Qo pocket and SMA, which help to 
stabilise the compound in the active site.  The dimethoxyphenol moiety of the 
chromone ring of SMA intercalates between proline (Pro270) and isoleucine (Ile146) 
amino acids, whilst the largely hydrophobic tail interacts with phenylalanine 
(Phe274), methionine (Met124, Met129), alanine (Ala125) and leucine (Leu294) 
residues. 
As stated above there is good sequence homology between the parasite bc1 complex 
and the yeast protein, particularly in the Qo region.
42
  In fact, all of the residues 
involved in the binding of the head group in this region are fully conserved across all 
mitochondrial bc1 complexes.
45, 46
  For this reason the yeast protein was perfectly 
suited for the docking needs of the research undertaken. 
5.2.1.2  Qo Binding Mode 
Through structural analysis of the binding of hydroxyquinone inhibitor HHDBT (fig. 
5.6) and SMA at the Qo site, the electron and proton transfer procedures that occur at 
this site have been deduced.
45
 
 
Fig. 5.6  HHDBT Qo inhibitor. 
Figure 5.7 depicts this process.  The natural substrate ubiquinol is bound in the Qo 
pocket and stabilised with its functional groups pointing towards the primary 
acceptors of the low and high potential electron transfer chains, heme bL and the ISP 
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cluster respectively.  Glu272 rotates into the binding pocket and forms a hydrogen 
bond to the hydroxyl group facing the heme bL, as visible when SMA is bound at the 
Qo site.
47
  Since the extrinsic catalytic Rieske domain is mobile and His181 has a 
pKa of 7.5 when the cluster is oxidised,
48
 a considerable fraction of the latter is not 
protonated under physiological conditions.  Thus, the Rieske domain can be 
stabilised in the b-position by forming a hydrogen bond between deprotonated 
His181 and the hydroxyl group of ubiquinol.  This brings the ISP cluster into a 
suitable distance for electron transfer.  The initial enzyme-substrate complex is 
stabilised by hydrogen bonds to the primary ligands, His181 and Glu272, which 
additionally serve as primary proton acceptors.
47, 49
  Ubiquinol is oxidised in a 
bifurcated manner, transferring two electrons to the ISP cluster and heme bL.  The 
mechanism and order of events are heavily debated.  Some mechanisms assume a 
sequential reaction in which the first electron reduces the ISP cluster and a relatively 
unstable semiquinone intermediate reduces heme bL.
49
  A sequential mechanism has 
also been proposed in which a stable semiquinone is formed and is anti-
ferromagnetically coupled to the ISP centre until it is oxidised by heme bL.
50
  The 
concerted mechanism assumes that neither electron is transferred independently, but 
rather the semiquinone is so unstable that ubiquinol cannot reduce the ISP centre 
unless the semiquinone reduces heme bL.
51, 52
  In such a mechanism the 
concentration of ubisemiquinone is so low as to be almost nonexistent. 
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Fig. 5.7  Mechanism of ubiquinol oxidation as deduced from structural analysis of a hydroxyquinone 
anion (HHDBT) and SMA binding at the Qo site.  The oxidised ISP is indicated by black circles, with 
the reduced ISP shown in gray.  Hydrogen bonds which stabilise the enzyme-substrate complex as 
well as the b-position of the Rieske catalytic domain are indicated with dotted lines.  Panel 1:  Empty 
Qo site with Glu272 directed out of the binding pocket.  Panel 2:  Initial stabilisation of ubiquinol by 
cytochrome b residues.  Panel 3:  The electron donor complex (enzyme-substrate complex) with the 
Rieske protein docked in the b-position.  Panel 4:  Coupled electron-proton transfer to the Rieske 
protein as deduced from the binding of SMA.  Panel 5:  Stabilisation of the anti-ferromagnetically 
coupled ubisemiquinone anion and rotational displacement of protonated Glu272 as seen for HHDBT 
binding.  Panel 6:  Release of the reduced and protonated Rieske protein and of the oxidised 
ubiquinol, accompanied by displacement of Tyr279.  Steps 4 and 5 have to be interpreted as either 
intermediates of a sequential reaction or as transition state intermediates as proposed by the concerted 
mechanism hypothesis.  (H. Palsdottir, C. G. Lojero, B. L. Trumpower and C. Hunte, J. Biol. Chem., 
2003, 278, 31303-31311.) 
It has been suggested that SMA and alkyl-hydroxydioxobenzothiazoles mimic either 
intermediates during ubiquinol oxidation, or transition state intermediates.
45
  This 
allows for the possibility that a stable, anti-ferromagnetically coupled 
ubisemiquinone might be formed under some conditions.  SMA binding appears to 
mimic the binding of a protonated ubisemiquinone as shown through panel 4 of 
figure 5.7, whilst HHDBT binds in its deprotonated form as an anion, as shown in 
panel 5.  In both of these cases, however, the position of the reduced Rieske protein 
is stabilised by the hydrogen bond to His181.  This is in agreement with electron 
paramagnetic resonance (EPR) analysis which indicated that the reduced Rieske 
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Fig. 7 - H. Palsdottir, C. G. Lojero, B. L. Trumpower and C. Hunte, J. 
Biol. Chem., 2003, 278, 31303-31311.) 
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cluster is preferentially located in the b-position.
53
  Glu272 can accept a proton from 
ubiquinol or ubisemiquinone and consequently rotate towards heme bL, as seen for 
HHDBT where it is not interacting with the carbonyl group.  If a stable 
ubisemiquinone anion is formed it is stabilised by localisation of its negative charge 
on the oxygen atom interacting with protonated His181.  After transfer of the second 
electron, the product is no longer stabilised and will leave the binding pocket and 
give more mobility to Tyr279, thus breaking its hydrogen bond to the Rieske protein.  
The latter can then rotate into the binding pocket. 
The yeast cytochrome bc1 protein as described by 3CX5,
41
 was used throughout the 
docking and is cocrystallised with SMA.  The nature of SMA binding in the Qo 
pocket is such that it represents panel 4 in figure 5.7.  His181 is in its protonated 
form so that it hydrogen bonds to the carbonyl of SMA, as shown from figure 5.5, 
which illustrates the interactions between the protein and SMA.  The mechanistic 
study of the Qo binding
45
 does not discuss the importance of the water molecule in 
bridging the gap between SMA and Glu272 through forming the hydrogen bonding 
network.
41
  This interaction is however observed in the 3CX5 crystal structure.  The 
3CX5 crystal structure was selected given that it’s resolution was higher (1.90 Å) 
than that of comparable structures, such as that of the yeast cytochrome bc1 complex 
bound with cytochrome c (resolution 2.97 Å; PDB accession code 1KYO).
54
   SMA 
is a well documented binder at the Qo site and a known inhibitor of the bc1 complex, 
thus performing molecular docking using 3CX5 provided a means for docking 
compounds in their bioactive conformations, providing real and accurate 
representations as to how the compounds would bind. 
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5.2.2 Developing a Docking Protocol 
The first priority was to develop a suitable docking protocol which could reproduce 
the docking pose of the native ligand.  If the docking protocol could successfully 
reproduce the experimental binding mode of the native/cocrystallised ligand, then 
this could be applied to predict the binding pose of other ligands at the active site.
1
 
GOLD 5.0.1
13
 was used to develop a protocol which could reproduce the binding 
pose of SMA in the Qo active site, with one of the advantages of GOLD 5.0.1 being 
that it could incorporate water molecules into its docking calculations.
55
  This was 
particularly useful to model the key H-bonding network observed in the Qo active 
site.  The yeast cytochrome bc1 complex (3CX5)
41
 was first downloaded from the 
PDB
15
 library, and in order to reduce the computational time required to complete 
the docking calculations, redundant (with regard to the docking) areas of the protein 
were removed.  Using the molecular visualisation program PyMOL,
56
 the native 
ligand SMA was selected and only the amino acids within 20 Å around it selected.  
This reduced the protein to a smaller subunit which contained only the structural 
information required for docking at the Qo active site. 
The docking protocol was developed using the reduced protein, with the aim being to 
emulate the native binding pose of SMA in the active site.  A calculated docking 
pose was considered successful if it had an RMSD value of less than 2 Å
1
 when 
compared to the cocrystallised ligand, ultimately providing validation for the 
protocol.  The GOLD 5.0.1
13
 wizard was used to develop the Qo docking protocol, 
the full details for which can be found in the ‘Qo Docking Protocol’ as described in 
the Experimental Chapter.  In this protocol the SMA ligand was used to define the 
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Qo site ready for docking, with the cocrystallised water molecule routinely 
incorporated into docking to bridge the Glu272 interaction.  Additionally, the 
tautomeric state of the His181 amino acid had to be inverted such that the hydrogen 
atom of the imidazole was in line with the carbonyl group of SMA, so that the 
required H-bond could be formed, as per the literature.
39, 45
  (Any alterations to the 
standard protocol are discussed where appropriate.) 
5.2.2.1  Docking of Stigmatellin 
The native SMA ligand of the 3CX5 crystal structure was removed from Qo and then 
docked back into the active site using the GOLDScore
11, 12
 fitness function as 
described in the ‘Qo Docking Protocol’.  The resulting poses were then rescored 
using ChemScore.
10, 29, 30
  This scoring and rescoring approach has previously proven 
useful in not only identifying native binding poses, but also in virtual screening.
1
  
Ten GA runs were performed so that a range of poses could be collected.  Table 5.2 
illustrates the GOLDScore and ChemScore values across these ten poses, as well as 
the RMSD values when they were compared to the native ligand. 
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Table. 5.2  GOLDScore, ChemScore and RMSD values for the ten SMA docking poses at Qo. 
Pose ID GOLDScore ChemScore RMSD 
1 111.6 57.2 0.64 
2 107.3 57.4 0.64 
3 84.4 57.7 0.86 
4 77.5 52.4 4.41 
5 95.6 54.7 1.00 
6 106.5 56.3 0.51 
7 72.9 50.8 1.02 
8 95.4 50.9 1.29 
9 94.9 54.6 1.00 
10 76.7 47.8 1.35 
Highest 111.6 57.7 4.41 
Lowest 72.9 47.8 0.51 
Average 92.3 54.0 1.27 
SD 13.8 3.4 1.14 
Given that a docking run is considered successful if it can reproduce the binding 
pose of the native ligand with an RMSD value of less than 2 Å,
1
 table 5.2 shows that 
only one of the ten poses failed to meet this criterion.  With this in mind it should be 
remembered that by its very nature, the docking GA incorporates an element of 
randomness,
12, 57-59
 so the same solutions will not always be found.  The smallest 
RMSD value reported was only 0.51 Å, with the largest being 4.41 Å.  This gave an 
average RMSD value across the ten poses of only 1.27 Å, and an SD of 1.14.  The 
average result is very encouraging, and is perhaps a more fair way of assessing the 
performance of the docking, as oppose to considering any one result in isolation.  
Taking an average result allows for consideration of all the poses generated, not just 
the most suitable identified through visual inspection.  Removing the highest RMSD 
value for pose 4 which fell outside the cut off of 2 Å improved the average RMSD 
value further to 0.92 Å, with an SD of 0.29. 
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The GOLDScore and ChemScore values can be considered means of assessing how 
well a compound binds to a particular site, with higher values suggesting better 
binding.  The average GOLDScore value across the ten poses was 92.3 ± 13.8, with 
the highest individual value reported as 111.6.  It is interesting to note that the pose 
which had the lowest RMSD value (4.41 Å), also had one of the lowest 
GOLDScores (77.5).  It also had a low ChemScore value of 52.4, slightly lower than 
the average across all poses of 54.0 ± 3.4.  Therefore, given that the better poses (i.e. 
those with smaller RMSD values) also observed higher fitness function scores, this is 
highly encouraging and suggests that the docking protocol was suitable for 
molecular docking at the Qo binding site.  Figure 5.8 represents the binding pose of 
one of the solutions that was generated from the docking of SMA.  It had a high 
GOLDScore of 107.3, a ChemScore of 57.4, and an RMSD of 0.64 Å.  The results of 
SMA docking could be used for comparison between the scores of other docked 
compounds, in order to draw comment on their inhibition potential. 
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Fig. 5.8  Docking pose of SMA (shown in green) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The two key interactions, His181 and the water mediate Glu272 H-bond network 
are clearly illustrated.  The native binding pose of SMA is shown in yellow.  The yeast cytochrome b 
polypeptide backbone is represented in green, with the [2Fe2S] cluster of the Rieske protein 
represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
The docking of SMA was repeated using the ‘Qo Docking Protocol’, only this time 
the bridging water molecule was omitted to see what affect (if any) this would have 
on the results.  Ten docking poses were collected, the scores for which are shown in 
table 5.3. 
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Table. 5.3  GOLDScore, ChemScore and RMSD values for the ten SMA docking poses at Qo, when 
the crystallographic water molecule was removed. 
Pose ID GOLDScore ChemScore RMSD 
1 70.3 55.4 0.75 
2 100.8 55.9 0.69 
3 64.7 46.4 1.22 
4 63.6 51.2 0.81 
5 81.5 47.1 1.37 
6 50.7 42.7 3.21 
7 69.1 47.4 1.23 
8 79.9 54.0 0.33 
9 94.4 54.6 0.87 
10 103.5 57.4 0.56 
Highest 103.5 57.4 3.21 
Lowest 50.7 42.7 0.33 
Average 77.8 51.2 1.10 
SD 17.4 5.0 0.81 
The ten docking solutions all produced reasonable poses, with an average RMSD 
value compared to SMA of 1.1 Å.  An example of one solution is shown in figure 
5.9.  The average GOLDScore and ChemScore values were 77.8 ± 17.4 and 51.2 ± 
5.0 respectively, lower than the solutions from docking with the water present.  This 
reduction in the fitness functions is most likely due to the way in which the scores 
are calculated.  The absence of the water molecules resulted in the loss of additional 
H-bonds.  As these bonds contribute to the score, their omission resulted in smaller 
scores. 
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Fig. 5.9  Docking pose of SMA (shown in green) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5) when water is omitted from the docking.  The His181 interaction is observed along 
with a partial Glu272 H-bond network.  The native binding pose of SMA is shown in yellow.  The 
yeast cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the 
Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black 
lines. 
Not only do the fitness scores suffer when the water molecule is removed, but it 
must also be remembered that the water mediated interaction is supported by 
precedent in the literature.
39
  Inclusion of the water resulted in higher fitness scores 
and ultimately produces more meaningful solutions.  Given that GOLD 5.0.1
13
 
readily has the ability to include this water molecule in its docking runs, as well as 
the observed improvement to the fitness scores, there seems no reason to exclude it.  
Thus, all docking from here on was performed with the water molecule included. 
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5.2.2.2  Docking of Atovaquone 
ATOV is a class I inhibitor,
32
 competing with ubiquinol at the Qo site.
60
  It is 
currently the only drug in clinical use which targets Pfbc1,
33, 61, 62
 acting by 
collapsing the mitochondrial membrane potential.  However, it has yet to be 
cocrystallised with the bc1 complex, which made it an attractive compound for a 
molecular docking study.  High levels of resistance have been observed which are 
correlated to a number of point mutations in cytochrome b.  ATOV binds to the Qo 
site when the soluble domain of the Rieske protein is proximal to cytochrome b, and 
interacts directly with the ISP.  This prevents mobilisation to cytochrome c1, and 
consequently impairs the mitochondrial transmembrane potential.
61, 63-65
  The yeast 
crystal structure of the cytochrome bc1 complex was therefore suitable for docking, 
owing to its high sequence homology with the plasmodium.
42
 
Spartan ‘0866 was first used to construct ATOV in silico and then minimised using 
the ‘Energy Minimisation Protocol’ as described in the Experimental Chapter.  The 
equilibrium geometry calculation was performed using the molecular mechanics, 
MMFF level of theory,
67
 which was sufficient for the purpose of this application.  
The ‘Qo Docking Protocol’ was used to perform the molecular docking of ATOV 
into the Qo site, albeit with several modifications.  Given that it was not simply the 
native ligand being docked back into the active site, the number of GA runs was 
increased from 10 to 25.  To some degree the Qo site represents an SMA shaped 
pocket, so the increased number of GA runs allowed for a bigger range of solutions 
to be explored, capturing more diversity in the poses.  From these the most 
appropriate solutions were identified so that only those which were in line with 
literature precedent were considered.  The HOH7187 water molecule was again 
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incorporated into the docking calculation to mediate the interaction between the 
carbonyl of the quinone ring and Glu272, only this time it was allowed to translate 
from its original position within a radius of 2 Å, to better bridge the gap.  
Additionally, in order to ensure ATOV docked into the Qo site as appose to the 
hydrophobic pocket, a constraint was applied so that poses would be biased towards 
forming H-bond interactions with His181.  Though SMA docking showed the 
formation of a H-bond between the hydrogen of the His181 imidazole and the 
carbonyl group of SMA, for ATOV it has not been fully established which group 
contributes the hydrogen atom in the putative H-bond between His181 and the 
naphthoquinone hydroxyl of ATOV.
60
  Thus, the His181 residue was taken to be in 
its imidazolate ionisation state.  The resulting 25 solutions consisted of varying 
poses, with only four resembling the orientation suggested by the literature, shown in 
figure 5.10.
32, 64
 
 
Fig. 5.10  H-bond interactions of atovaquone within the Qo site.  (J. J. Kessl, B. B. Lange, T. Merbitz-
Zahradnik, K. Zwicker, P. Hill, B. Meunier, H. Palsdottir, C. Hunte, S. Meshnick and B. L. 
Trumpower, J. Biol. Chem., 2003, 278, 31312-31318.) 
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The other 21 poses had the naphthoquinone hydroxyl head group in the hydrophobic 
pocket, and given that ATOV is a known Qo inhibitor, we were only concerned with 
its docked orientation in the binding site, and not its resulting fitness scores.  
Therefore, only the GOLDScore fitness function was used as no comparison between 
ATOV and other molecules was necessary. 
The four poses in an orientation similar to that of figure 5.10 all observed the two 
crucial H-bond interactions, and had an average GOLDScore of 28.9 ± 4.1 (table 
5.4).  Though this is less than the average GOLDScore of SMA docking (92.3 ± 
13.8), it should be remembered that hydrophobic and van der Waals interactions 
contribute greatly to the overall GOLDScore, and thus, considering SMA has a long 
hydrophobic side chain, many more such interactions are formed, resulting in a 
higher score.  The aryl side chain of ATOV is much more rigid than that of SMA, 
and forms fewer such interactions. 
Table. 5.4  GOLDScore values for the four ATOV docking poses at Qo which resembled figure 5.10. 
Pose ID GOLDScore 
1 29.0 
2 32.5 
3 23.2 
4 31.0 
Highest 32.5 
Lowest 23.2 
Average 28.9 
SD 4.1 
This docking study was used to assist in our understanding as to how ATOV binds at 
the Qo site and elicits its response.  It also allowed for comment to be drawn as to 
how ATOV activity can be lost through mutation.  Resistance to ATOV is associated 
with a missense point mutation in cytochrome b of the Qo pocket.
32
  The mutation 
occurs at position 268, exchanging tyrosine for a serine (Y268S), or less frequently, 
Chapter V 
 
256 
 
asparagine (Y268N).
68-73
  Ordinarily, position Y268 in cytochrome b is highly 
conserved across all phyla, with the Pro260-Glu261-Trp262-Tyr263 (‘PEWY’) region 
located in the ef loop of the Qo site.  The side chain of the Y268 residue most likely 
forms a stabilising hydrophobic interaction with bound ubiquinol, and studies have 
suggested that ATOV is similarly stabilised.
60
  For the yeast cytochrome bc1 
complex, the introduction of the Y268S mutation (Y268S) resulted in an increased 
IC50 value, from 60 nM to >4000 nM.
74
  This result validates the significance of our 
docking at the Qo site of 3CX5, as ATOV clearly inhibits the yeast cytochrome bc1 
complex, making a mechanistic study attractive.  As no crystal structure of the 
parasite cytochrome bc1 complex currently exists, yeast is therefore a useful 
surrogate. 
The docking study was an updated version of previous work which had been 
performed,
75
 and the results were analysed to investigate the orientation of ATOV in 
the Qo active site.  ATOV was found to bind in a manner very similar to SMA, with 
the hydroxyl moiety of the hydroxynaphthoquinone ring forming a hydrogen bond to 
the nitrogen of the imidazolate group of His181 in the Rieske ISP (lowering the 
redox potential of the [2Fe2S]).  A second H-bond was formed between ATOV’s 
hydroxynaphthoquinone carbonyl group and the carboxylate of the cytochrome b ef 
loop residue Glu272, via the bridging water molecule.  These interactions are shown 
in figure 5.11.  This work has been published in The Journal of Biological Chemistry 
as part of the paper titled ‘Cytochrome b Mutation Y268S Conferring Atovaquone 
Resistance Phenotype in Malaria Parasite Results in Reduced Parasite bc1 Catalytic 
Turnover and Protein Expression’.76 
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Fig. 5.11  Docking pose of ATOV (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The two key interactions, His181 and the water mediate Glu272 H-bond network 
are clearly illustrated.  The yeast cytochrome b polypeptide backbone is represented in green, with the 
[2Fe2S] cluster of the Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-bonds 
are indicated by black lines. 
Additionally, the chlorophenyl ring of ATOV appears to sit in a hydrophobic pocket 
within cytochrome b, formed from the side chains of Phe121, Phe278, Ile125 and 
Ile299.  These can be seen in figure 5.12. 
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Fig. 5.12  Docking pose of ATOV (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The chlorophenyl ring of ATOV sits in a hydrophobic pocket formed by the side 
chains of Phe121, Phe278, Ile125 and Ile299.  The yeast cytochrome b polypeptide backbone is 
represented in green, with the [2Fe2S] cluster of the Rieske protein represented as spheres (sulphur: 
gold, iron: orange). 
Also, the amino acid Leu275 is predicted to form a stabilising hydrophobic contact 
with ATOV’s cyclohexyl moiety, as shown in figure 5.13.  All of these interactions 
are likely to occur in the corresponding residues of Pfbc1. 
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Fig. 5.13  Docking pose of ATOV (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The cyclohexyl moiety forms a stabilising hydrophobic contact with Leu275.  The 
yeast cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the 
Rieske protein represented as spheres (sulphur: gold, iron: orange). 
Y268 (Plasmodium numbering) is located near the PEWY region of the ef helix and 
is highly conserved.  In the yeast protein, the PEWY region corresponds to the 
amino acid residues Pro271-Glu272-Trp273-Tyr274.  Subsequently, the Tyr268 residue 
in the Plasmodium corresponds to Tyr279 in the yeast.  It has been suggested that the 
tyrosyl side chain of this residue participates in the positioning of Qo bound 
ubiquinol, and may also therefore contribute to stabilising hydrophobic interactions 
with the naphthoquinone group of ATOV.
45, 75
  Studies with mutant forms of bc1 
from the bacterium Rhodobacter sphaeroides, indicate that an aromatic or large 
hydrophobic side chain residue is required at this position within the ef loop for 
effective catalytic activity.
77
  Therefore, the point mutation of this amino acid to 
either a serine or asparagine may result in loss of activity.  Examination of the crystal 
structure of avian bc1 suggests that the hydroxyl group of this tyrosyl side chain may 
Chapter V 
 
260 
 
form a H-bond association with His181 of the Rieske protein (figure 5.14).
78
  In 
addition, mutations of the equivalent residue in man (Tyr279) have been linked to a 
variety of mitochondrial disorders.
79, 80
  As a whole, this docking study illustrates the 
importance of several amino acid residues in the binding of ATOV, and shows the 
drastic effect even a single point mutations can have on activity. 
 
Fig. 5.14  Docking pose of ATOV (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The hydroxyl group of Tyr279 forms a stabilising H-bond association with His181 
of the Rieske protein.  The yeast cytochrome b polypeptide backbone is represented in green, with the 
[2Fe2S] cluster of the Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-bonds 
are indicated by black lines. 
5.2.2.3  Docking of Quinolone Esters 
Based on the key interactions associated with activity at the Qo active site (His181 
and Glu272), it can be deduced that a polar head group is required in order to form 
the H-bond associations, together with an alkyl or aryl side chain with which to 
Chapter V 
 
261 
 
probe the cylindrical hydrophobic pocket.  This rationalisation has been supported by 
work which led to structures such as the quinolone ester in figure 5.15.
81
  However, 
whilst this core structure made for an interesting chemotype, the long flexible 
perfluorinated alkyl side chain was less than ideal in terms of its potential as a drug 
lead. 
 
Fig. 5.15  Quinolone ester. 
A potential advantage of the quinolone template is that when suitably substituted, it 
may yield compounds with the ability to chelate haem through π-stacking, in a 
similar manner to the 4-aminoquinolines.
82
  This could allow for a single drug 
capable of attacking the parasite by two separate mechanisms, a feature that may 
hinder the development of resistance.  From this, work within the antimalarial group 
at Liverpool aimed to identify suitable alternatives to the compound in figure 5.15 
which had the potential to drive forward the synthesis of quinolone esters.
42
  In all, 
twenty novel quinolones were developed as part of two parallel series based on the 
single core template shown in figure 5.16.
83
  The Gould-Jacobs methodology
84-86
 
was employed to synthesise a number of 6- and 7-substituted aryl quinolones.  These 
were then tested in vitro against cultured wild type 3D7 P. falciparum malarial 
parasites (see ‘Whole Cell Growth Inhibition Assay (3D7) Protocol’ in Experimental 
Chapter).  Activity values spanned a wide range of activities, from sub nM (0.46 
nM) to several µM (>10 µM) 
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Fig. 5.16  Core quinolone template. 
Whilst the synthesis, testing and analysis of the entire quinolone series does not form 
part of this thesis, molecular modelling was employed in an attempt to rationalise the 
key observation which emerged from the SAR study.  It was found that in almost all 
cases, the 7-aryl substituted compounds had superior activity to their 6-substituted 
counterparts, with one 7-substituted compound some 300 times more potent than the 
6-substituted analogue.  Given that this trend was true across most of the series, it 
was thought that by studying their binding modes in the Qo site, insight may be 
garnered as to why the activity of the 6- series was drastically reduced. 
Docking was therefore performed for two exemplary molecules from this data that 
observed this trend.  Compounds Xa and Xb are shown in table 5.5, with their 
respective IC50 values against 3D7 reported as 229.8 nM and 5.3 nM.  Compounds 
Xa and Xb were first drawn in Spartan ‘0866 and energy minimised according to the 
‘Energy Minimisation Protocol’. 
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Table. 5.5  Quinolone ester compounds Xa and Xb. 
Compound ID Structure 
IC50 3D7 
(nM) 
Xa 
 
229.8 
Xb 
 
5.3 
Docking was then performed using the ‘Qo Docking Protocol’ with the GOLDScore 
fitness function.  From the ten GA runs performed some interesting observations 
were found.  Eight out of the ten poses for Xb docked in a very similar manner to 
SMA, with an average GOLDScore value of 62.8 ± 1.4.  This may go some way to 
rationalising its potent in vivo activity.  One solution is shown in figure 5.17, and had 
a GOLDScore value of 62.8 (coincidentally the same as the average).  Of particular 
importance in this pose was the strong H-bond between His181 and the carbonyl 
group of the quinolone, as this prevents proton transfer between ISP and ubiquinol, 
and thus inhibition of subsequent electron transfer to ISP.  Additionally, the aryl side 
chain of Xb rests in a hydrophobic pocket within cytochrome b, comprised of 
Phe121, Phe278, Ile125 and Ile299.  This is very similar to ATOV binding.  Also, 
though it is more distant, the NH group of the quinolone could potentially form a H-
bond with Glu272 under the right circumstances. 
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Fig. 5.17  Docking pose of Xb (shown in blue) in the Qo pocket of the yeast cytochrome bc1 complex 
(3CX5).  His181 is shown forming a strong H-bond with the carbonyl oxygen of the quinolone.  The 
yeast cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the 
Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black 
lines. 
The ten docking solutions for Xa all produced similar poses, and had an average 
GOLDScore value of 65.1 ± 3.3.  However, the orientation of the quinolone head 
group was flipped in the active site when compared with Xb, such that the crucial 
His181 H-bond interaction could not be formed, as shown by figure 5.18.  Despite 
this, the water mediated Glu272 interaction was readily observed with the carbonyl 
group of the quinolone, but an unfavourable interaction existed between the NH of 
His181, and the NH of the quinolone.  Given the nature of activity at the Qo site, this 
observation may therefore account for the drastically reduced activity of the 6-aryl 
substituted series, as they do not bind strongly enough to prevent ubiquinol binding, 
and thus inhibit the ETC.  Whilst the GOLDScores may be comparable between Xa 
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and Xb, all they really tell us is that the sum of the in silico interactions suggest 
similar binding affinities, but this appears to be unrelated to their efficacies.  The 
orientation of the molecules in the active site therefore has a dramatic effect on in 
vitro activity. 
 
Fig. 5.18  Docking pose of Xa (shown in pink) in the Qo pocket of the yeast cytochrome bc1 complex 
(3CX5).  Unfavourable His181 and NH interaction observed, though water mediated H-bond network 
readily formed between the carbonyl group and Glu272.  The yeast cytochrome b polypeptide 
backbone is represented in green, with the [2Fe2S] cluster of the Rieske protein represented as 
spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
This binding behaviour may be explained by consideration of the steric bulk of the 
compounds.  Initial docking showed both Xa and Xb to fit nicely into the Qo pocket 
as shown, with the aryl side chains moving out into the hydrophobic pocket.  With 
this in mind, it was decided to bias the quinolone head group of the 6-substituted 
compound into an orientation which resembled that of the 7-substituted compound, 
to see how it would behave.  To do this the docking was repeated for both 
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compounds with constraints applied similar to those used in ATOV docking, so that 
poses would be biased towards forming H-bond interactions with His181 and 
Glu272. 
Compound Xb docked as before for all ten solutions, this time giving an average 
GOLDScore value of 42.2 ± 2.4 (value different to before owing to constraints affect 
on scoring).  The ten poses for Xa also observed the same orientation, with an 
average GOLDScore of 36.9 ± 2.4.  However, all were noticeably strained in their 
positioning, giving poses such as that in figure 5.19 (GOLDScore of 33.9).  As can 
be seen, the carbonyl group of the quinolone forms a H-bond with His181, and the 
water mediated Glu272 interaction also has the potential to be observed.  Despite 
this, when the pose was compared with that of Xb, concerns with regard to its 
validity were raised. 
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Fig. 5.19  Docking solution of Xa (shown in pink) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5) when constraints were applied.  The His181 and quinolone carbonyl H-bond is 
clearly observed, as is the potential for the Glu272 interaction.  The yeast cytochrome b polypeptide 
backbone is represented in green, with the [2Fe2S] cluster of the Rieske protein represented as 
spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
Figure 5.20 illustrates the strain of Xa in the Qo site when compared with one of the 
Xb solutions (GOLDScore of 45.4).  The figure shows the surface of the protein as a 
wire mesh, making it easier to spot the steric clashes.  Xb (shown in blue) rests 
nicely in the pocket with no clashes to neighbouring amino acids.  However, the 
methoxy linker of the aryl side chain of Xa (shown in pink) appears to sit very 
closely to the sulphur atom of Met295.  It is highly unfavourable for these two 
electronegative atoms to be so close to one another, owing to the repulsive nature of 
their respective lone pairs.  Additionally, the steric strain of their close proximity 
would also make the positioning of Xa in this orientation highly unlikely. 
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Fig. 5.20  Docking solutions of Xa (shown in pink) and Xb (shown in blue) in the Qo pocket of the 
yeast cytochrome bc1 complex (3CX5) when constraints were applied.  The methoxy linker of Xa is 
shown to have an unfavourable steric clash with Met295.  The protein surface is represented as a wire 
mesh, with the [2Fe2S] cluster of the Rieske protein shown as spheres (sulphur: gold, iron: orange). 
This study showed that the 7-substituted analogues of the quinolone series bound 
similar to SMA, with the quinolone head group mimicking the transition state 
semiquinone observed during the catalytic turnover of the bc1 complex, providing a 
H-bond donor and acceptor site.
87
  For the 6-substituted analogues however, these 
sites were not available, as the quinolone head group preferentially flipped during 
docking, owing to steric and repulsive interactions.  Given that the His181 
interaction was no longer observed, this may provide an explanation as to why the 6-
substituted quinolones had dramatically lower activity values compared to their 7-
substituted counterparts.  Quite simply, the molecules were unable to fit in the Qo 
site in a manner which promoted inhibition.  Observations from this docking study 
were reported as part of a publication in MedChemComm entitled ‘The development 
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of quinolone esters as novel antimalarial agents targeting the Plasmodium 
falciparum bc1 protein complex’.83 
5.2.2.4  Docking of Lead Quinolone Compound 
At Liverpool research is continually ongoing to identify new lead structures for drug 
development that are cost effective, and capable of inhibiting several targets in an 
attempt to circumvent developing resistance.  One such compound which is currently 
leading the way for a new generation of antimalarial quinolone compounds is SL-2-
25, shown in figure 5.21.  SL-2-25 has shown to be a promising candidate for the 
treatment and prophylaxis of uncomplicated malaria. 
 
Fig. 5.21  Compound SL-2-25. 
It is comprised of a novel, pyridine containing aryl side chain in the 2-position of the 
quinolone chemotype, and has been found to have a duel mechanism of action 
against two of the respiratory enzymes in the electron transport chain.  The activity 
values for this compound against several assays are reported in table 5.6.  Whole cell 
inhibition of SL-2-25 against the 3D7 parasite strain was 54 nM, with targeted 
activity against PfNDH2 and Pfbc1 of 14.6 nM and 15.1 nM respectively.  This gives 
a selectivity value between the two of 1.03, indicating the strong duel inhibition 
capabilities of the compound.  Additionally, bovine bc1 inhibition was reported as 
887 nM.  As has previously been discussed, strong inhibition of bovine bc1 is 
associated with cardiotoxicity in mammals,
88
 thus weak inhibition of bovine bc1 is 
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highly desirable.  This new generation of antimalarials therefore has the potential to 
overcome the limitations of existing treatment options such as ATOV, as it may 
circumvent developing resistance mechanisms. 
Table. 5.6  SL-2-25 activity values. 
Compound 3D7 IC50 PfNDH2 Pfbc1 Bovine bc1 
SL-2-25 54 ± 6 nM 14.6 nM 15.1 nM 887 nM 
Molecular docking was employed to rationalise the low nM activity of SL-2-25 
against Pfbc1, by docking it into the Qo site.  Once again, the yeast bc1 complex was 
used as a surrogate for the parasite, which though not identical, does share an overall 
40% sequence homology and is highly conserved across the Qo region.
42
  SL-2-25 
was constructed and energy minimised using the ‘Energy Minimisation Protocol’, 
with docking performed using the ‘Qo Docking Protocol’, only with 25 GA runs 
performed as oppose to 10.  The crystallographic water molecule present in the Qo 
site was incorporated into the docking run to mediate the Glu272 interaction, and 
allowed to translate from its original position within a radius of 2 Å.  Constraints 
were applied to only give solutions which formed H-bond interactions with His181 
and Glu272. 
All 25 solutions showed SL-2-25 in the same orientation, giving average 
GOLDScore and ChemScore values of 53.7 ± 2.2 and 30.7 ± 1.0 respectively.  One 
solution is shown in figure 5.22 (GOLDScore and ChemScore values of 46.9 and 
31.9 respectively).  SL-2-25 occupies a position within the Qo site of cytochrome b 
similar to SMA.  A strong H-bond is observed between the carbonyl of the quinolone 
head group and the imidazole ring of Rieske protein residue His181.  A water 
bridged H-bond is also observed between the quinolone NH group and Glu272 of the 
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PEWY motif.  Weaker hydrophobic and van der Waals interactions are also 
observed. 
 
Fig. 5.22  Docking solution of SL-2-25 (shown in green) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5) when constraints were applied.  The His181 and quinolone carbonyl H-bond is 
clearly observed, as is the Glu272 water mediate interaction with the NH group of SL-2-25.  The 
yeast cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the 
Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black 
lines. 
The observations from SL-2-25 docking formed part of a publication in the 
‘Proceedings of the National Academy of Sciences’ journal entitled ‘Generation of 
quinolone antimalarials targeting the Plasmodium falciparum mitochondrial 
respiratory chain for the treatment and prophylaxis of malaria’.89 
The docking of ATOV and the quinolone compounds showed that the His181 and 
Glu272 H-bonds are consistently observed in molecules which are highly active 
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towards the bc1 complex.  Though this had already been postulated in the literature 
based on previous work,
39
 the significance of this observation is that it may drive 
forward future drug discovery efforts, as compounds can be pre-screened to assess 
their potential as binders at the Qo site. 
5.2.3 The Qi Site 
Similar to the Qo site, the Qi site is also a promising target for antimalarial drug 
design.  Compounds which target this site are referred to as class II inhibitors, 
blocking the electron transfer path from heme bH to quinone.
39, 40
  However, the use 
of class II inhibitors has thus far been limited, as they are often highly toxic in 
mammals and other non-pathogenic organisms.  The Qi site is rigid and flat, but such 
is its size and shape that inhibitors can bind in a variety of ways based on the amino 
acid residues which line its pocket.
39
  A few residues lining the wall of the Qi pocket 
are thought to be involved in specific substrate binding, including His201, Ser205, 
Lys227 and Asp228 (bovine bc1 complex numbering).  However, it has been found 
that amino acid residues Trp31, Gly38, Met190, Met194, Leu197 and Ser35 provide 
specific interactions for the binding of Qi inhibitor antimycin A (fig. 5.3), whilst the 
Leu200, His201, Ser205, Phe220, Tyr224, Lys227 and Asp228 residues are more 
important for ubiquinone binding.  Structurally, these two groups of residues face 
each other on the opposite sides of the Qi pocket. 
5.2.3.1  Docking of Antimycin A 
Antimycin A is a natural fungicide (fig. 5.3) and a known class II inhibitor.
39, 40
  It 
binds to the Qi site to inhibit the oxidation of ubiquinol, disrupting the formation of 
the proton gradient across the inner membrane, and thus ATP generation.  Whereas 
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Qo inhibitors such as SMA are capable of stabilising the conformation of the ISP 
extrinsic domain, Qi inhibitors have no obvious effect on the mobility of ISP.
39
 
A molecular docking study of antimycin A was undertaken to develop and validate a 
docking protocol suitable for docking at the Qi site.  Given that the Qi bond 
interactions have already been reported for antimycin A,
39
 these could be used as a 
reference point to emulate the results, thus validating the protocol.  Antimycin A was 
first energy minimised using the ‘Energy Minimisation Protocol’, and then docked 
according to the ‘Qi Docking Protocol’, as described in the Experimental Chapter.  
This protocol was fairly similar to that used in Qo docking, but unlike Qo, there were 
no active water molecules present in the Qi binding site to mediate particular 
interactions.  Also, the Qi site of the yeast bc1 protein was empty, so it was first 
aligned with that of the bovine bc1 complex crystal structure (PDB accession code 
1SQX)
39
 using PyMOL,
56
 as the bovine protein had been cocrystallised with 
ubiquinone in the Qi site.  When the two proteins were aligned it was possible to 
incorporate the native ubiquinone ligand from bovine into the empty Qi site of yeast.  
Ubiquinone could then be used to define the Qi site for docking.  Prior to docking 
this modified yeast protein was first reduced in size as was done with the Qo docking 
protein, by considering only the amino acid residues within 20 Å of the ubiquinone 
ligand.  This reduced the computational time required to complete the docking runs 
by including only the essential structural information required.  The number of GA 
runs was also increased from 10 to 25 to incorporate any potential diversity amongst 
the solutions. 
The 25 poses had average GOLDScore and ChemScore values of 66.4 ± 8.1 and 22.8 
± 3.1 respectively.  What is particularly interesting is that all of the binding poses 
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had very similar orientations, despite the highly flexible side chains and the many 
degrees of freedom antimycin A possesses.  One such pose is illustrated in figure 
5.23 (GOLDScore and ChemScore values of 75.3 and 26.0 respectively).  The 
numbering of the amino acids in the protein differ to those which have been quoted 
previously, owing to the fact that this is the yeast protein and not the bovine.  Where 
appropriate, the corresponding bovine residue will be reported in brackets.  The 
expected interactions between Trp30 (Trp31), Gly37 (Gly38), Ser34 (Ser34) and 
Leu198 (Leu198) were all observed.  However, it has also been reported that 
antimycin A interacts with Met190 and Met194, and neither of these residues are 
present in yeast.  This suggests that perhaps the Qi site is not as highly conserved as 
that of Qo.  Additionally, interactions were observed with Phe225 (Phe220), Lys228 
(lys227) and Asp229 (Asp228), forming a nice pocket for the amide group on the 
benzene ring to sit in.  Most of the interactions appeared to be either hydrophobic in 
nature, or simple van der Waals contacts.  These observations support the validity of 
the ‘Qi Docking Protocol’. 
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Fig. 5.23  Docking solution of antimycin A (shown in blue) in the Qi pocket of the yeast cytochrome 
bc1 complex (3CX5).  Several hydrophobic and van der Waals interactions are observed.  The yeast 
cytochrome b polypeptide backbone is represented in green. 
Earlier it was discussed that two groups of residues have shown importance in Qi 
binding.  Figure 5.24 represents a mesh view of the protein bound with antimycin A.  
The Qi binding site opens up into a large hydrophobic pocket, into which the side 
chains of antimycin A can move.  Meanwhile, the amide substituted benzene ring 
can sit in a small pocket, opposite which resides another pocket, and it is believed 
that this alternative pocket preferentially binds alternative compounds. 
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Fig. 5.24  Docking solution antimycin A (shown in blue) in the Qi pocket of the yeast cytochrome bc1 
complex (3CX5).  Protein represented as a mesh surface. 
5.2.3.2  Docking of NQNO 
Given that resistance can quickly hamper the clinical applications of a drug 
candidate, it is becoming increasingly more desirable to develop compounds that 
observe dual inhibition, that is, compounds which act at more than one site.  Whilst 
SL-2-25 was found to inhibit two different enzymes in the ETC (PfNDH2 and 
Pfbc1), it is possible that a compound may act at two different sites in the same 
enzyme, such as the Qo and the Qi sites of the bc1 complex.  One such compound that 
has been found to observe this dual inhibition is 2-n-nonyl-4-hydroxyquinoline N-
oxide (NQNO, fig. 5.25).  NQNO contains a quinolone ring and is structurally 
similar to the natural substrate ubiquinone.  Studies have shown that it is capable of 
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binding to both the Qo and Qi sites, signifying an important discovery in inhibitor 
binding studies of bc1.
39, 40
 
 
Fig. 5.25  NQNO. 
To rationalise this dual binding a docking study was undertaken.  NQNO was first 
energy minimised using the ‘Energy Minimisation Protocol’, and then docked into 
the Qo and Qi sites using the ‘Qo Docking Protocol’ and ‘Qi Docking Protocol’ 
respectively.  Given the long alkyl side chain, the number of GA runs was increased 
from 10 to 25 to incorporate additional diversity in the solutions.  Also, constraints 
were applied to bias the docking solutions at Qo to form the His181 and Glu272 
interactions. 
The 25 docking poses at the Qo site were all in strong agreement with one another, 
showing the quinolone ring residing tightly in the Qo region, and the alkyl side chain 
moving into the hydrophobic pocket.  The solutions had an average GOLDScore of 
60.6 ± 2.4, and ChemScore of 35.1 ± 1.8.  One solution is shown in figure 5.26 
(GOLDScore and ChemScore values of 62.6 and 37.0 respectively).  NQNO binds 
similar to SMA, with the quinolone head group inserted between residues Ile147 and 
Pro271.  A strong H-bond is observed between the NH group of the His181 
imidazole, and the carbonyl of the quinolone.  The water mediated H-bond network 
is also observed between the OH group of NQNO and Glu272.  The alky side chain 
also moves out into the hydrophobic pocket and forms a number of van der Waals 
contacts. 
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Fig. 5.26  Docking solution of NQNO (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The His181 and quinolone carbonyl H-bond are clearly observed, as is the water 
mediated Glu272 interaction with the OH group of NQNO.  The yeast cytochrome b polypeptide 
backbone is represented in green, with the [2Fe2S] cluster of the Rieske protein represented as 
spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
The 25 docking solutions at the Qi site were also all in strong agreement with one 
another, and were found to bind similar to antimycin A.  The solutions had an 
average GOLDScore of 50.4 ± 1.7, and ChemScore of 27.6 ± 1.2.  One solution is 
shown in figure 5.27 (GOLDScore and ChemScore values of 53.2 and 27.5 
respectively).  As with antimycin A, the hydroxyquinoline head group rests in a 
pocket comprised of residues Trp30, Phe225, Lys228 and Asp229.  Interactions are 
also observed between Ser34 and Leu198, though the interaction with Gly37 is no 
longer seen as NQNO is too far away.  Additionally, the alkyl chain appears to forms 
contacts with Tyr16, Ile195 and Met199, none of which were observed in antimycin 
A binding.  This therefore supports the understanding that owing to the size and 
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shape of the Qi pocket, inhibitors can bind in different ways, utilising the different 
subsets of residues.
39
 
 
Fig. 5.27  Docking solution of NQNO (shown in blue) in the Qi pocket of the yeast cytochrome bc1 
complex (3CX5).  Several hydrophobic and van der Waals interactions are observed.  The yeast 
cytochrome b polypeptide backbone is represented in green. 
The docking study showed that NQNO could indeed bind to both the Qo and Qi sites, 
with visual inspection suggesting favourable orientations of the solutions, to provide 
the necessary H-bond, hydrophobic and van der Waals interactions to support 
activity.  However, it would be highly beneficial if there were a quantitative means 
for assessing a compounds inhibition potential.  The fitness scores may therefore 
provide additional support, as well as useful insight into the affinity of a compound 
at a particular target.  The docking results from the NQNO study provided an ideal 
opportunity for such an analysis, with table 5.7 showing the average GOLDScore 
and ChemScore values. 
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Table. 5.7  Average GOLDScore and ChemScore values from the docking study of NQNO at the Qo 
and Qi sites of yeast bc1. 
Docking Site Average GOLDScore Value Average ChemScore Value 
Qo 60.6 ± 2.4 35.1 ± 1.8 
Qi 50.4 ± 1.7 27.6 ± 1.2 
Though GOLDScore and ChemScore are unrelated to each other, independently they 
may be used to compare the docking scores of either different molecules at the same 
site, or the same molecule at different sites.  This will allow for comment to be 
drawn as to the relative strength of binding of a particular molecule at a particular 
site.  The average GOLDScore values for NQNO at the Qo and Qi sites were fairly 
similar to one another (60.6 and 50.4 respectively), suggesting that NQNO has 
broadly similar binding strengths at both sites.  GOLDScore alone therefore suggests 
it has dual inhibition, which it does.
39, 40
  The average GOLDScore at the Qo site is 
slightly higher than that at Qi however, but this is most likely due to the contribution 
of the strong H-bonds at Qo, which strengthen the scores more so than weaker 
hydrophobic and van der Waals interactions.  The same trend is also observed across 
the average ChemScore values. 
Here molecular docking was used to support the understanding that NQNO is both a 
Qo and Qi binder, and through consideration of the fitness scores it was possible to 
quantify this observation.  This line of investigation was subsequently expanded to 
see whether scoring functions could be used to predict whether a known bc1 inhibitor 
was either class I or class II, without the need for extensive in vitro study.  Inspection 
of the poses and their interactions could also potentially allow for conclusions to be 
drawn as to their binding modes. 
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5.2.3.3  Docking of HDQ 
To test this hypothesis a docking study was performed on HDQ (fig. 5.28).  HDQ is 
identical to NQNO, albeit with the alkyl side chain extended by two carbons.  It is 
shown to inhibit P. falciparum replication in nM concentrations,
90
 and given its 
structural similarity with ubiquinol, seems likely to target ubiquinol binding sites of 
respiratory enzymes.  This is indeed the case as it is a highly potent PfNDH2 
inhibitor,
91
 though its antimalarial use is limited owing to its poor drug like 
properties.
90, 92
  Previous work has also suggested that HDQ may inhibit other 
ubiquinone dependent pathways in addition to PfNDH2.
92
 
 
Fig. 5.28  HDQ. 
The HDQ related compound 2-heptyl-4-hydroxyquinoline N-oxide (HQNO, fig. 
5.29) is a known inhibitor of the mammalian and S. cerevisiae bc1 complex.  Several 
mutations causing resistance to HQNO have been reported in yeast, all of which are 
located in the Qi region of the bc1 complex.
93
  From this observation questions were 
raised as to whether the antimalarial activity of HDQ was due to inhibition of the bc1 
complex, more specifically the Qi site.  Single point mutations of the Qo site have 
been responsible for ATOV resistance.  However, it has been shown that for the 
parasite bc1 complex, both control and ATOV resistant strains are inhibited in sub 
µM concentrations by HDQ.  This suggests that ATOV and HDQ have different 
targets within the bc1 complex.  Further to this, the introduction of point mutations in 
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the Qi site in yeast (G33A, H204Y, M221Q and K228M) led to a marked decrease in 
HDQ inhibition. 
 
Fig. 5.29  HQNO. 
With these biological observations in hand, molecular docking was employed in an 
attempt to rationalise and offer support for these results.  HDQ was drawn and 
energy minimised using the ‘Energy Minimisation Protocol’, and then docked into 
both the Qo and Qi binding sites using the ‘Qo Docking Protocol’ and ‘Qi Docking 
Protocol’ respectively.  To complement the study, the same docking was 
simultaneously performed for SMA, allowing for a comparison of the fitness scores.  
The average GOLDScore and ChemScore values for SMA and HDQ across the 10 
GA solutions at both the Qo and Qi sites are shown in table 5.8. 
Table. 5.8  HDQ and SMA docking results at both the Qo and Qi sites. 
 Qo Qi 
 SMA HDQ SMA HDQ 
Average GOLDScore 92.3 ± 13.9 63.5 ± 1.3 45.4 ± 13.0 54.1 ± 3.5 
Average ChemScore 54.0 ± 3.4 37.7 ± 1.2 28.0 ± 4.7 28.6 ± 2.1 
Inspection of table 5.8 shows some interesting observations with regard to the fitness 
scores.  First off, the GOLDScore and ChemScore values were both significantly 
higher for SMA at the Qo site, as oppose to Qi.  Based on the scores alone this would 
suggest that SMA binds preferentially to the Qo site, which is indeed known to be the 
case.
39
  Though this is encouraging, the additional H-bonds at the Qo site contribute 
greatly to the fitness scores, therefore the higher values were expected.  Also, the Qo 
site is perfectly shaped for SMA as it is the native ligand.  It therefore may be more 
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meaningful to comment on the docking scores of different molecules at the same 
sites.  To this ends, it can be seen from table 5.8 that both the average GOLDScore 
and ChemScore values at the Qo site are considerable lower for HDQ, than SMA.  
From this it would be reasonable to say that SMA binds more strongly at Qo than 
HDQ.  Converse to this, the average GOLDScore and ChemScore values at Qi would 
suggest that HDQ is a stronger binder at Qi than SMA.  This is particularly evident 
with GOLDScore.  Using this docking study in combination with the knowledge that 
SMA is a known, potent Qo inhibitor would suggest that HDQ does indeed exert a 
large proportion of its bc1 inhibition effect through binding at Qi. 
Further validation of this could be garnered by consideration of the binding modes 
for HDQ.  Figure 5.30 represents one solution of HDQ docked into the Qo site.  As 
was expected, the quinolone head group resides nicely in the Qo site, with the alkyl 
side chain moving out into the hydrophobic pocket.  A strong H-bond between the 
carbonyl of the quinolone and the NH of the His181 imidazole is observed, as is the 
potential for a water mediated Glu272 interaction with the OH of HDQ.  Yet in 
comparison to SMA, the interactions are clearly not as strong and significant. 
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Fig. 5.30  Docking solution of HDQ (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The His181 H-bond with the quinolone carbonyl is clearly observed, as is the 
potential for a water mediated interaction with Glu272.  The yeast cytochrome b polypeptide 
backbone is represented in green, with the [2Fe2S] cluster of the Rieske protein represented as 
spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
Of more importance is the binding mode of HDQ in the Qi site.  Figure 5.31 
represents one such docking solution, though all of the poses bound similarly.  The 
hydroxyl moiety of Ser34 was shown to potentially form a H-bond to the carbonyl 
group of HDQ, along with another H-bond between the HDQ N-oxide, and the 
hydroxyl moiety of residue Ser206.  Additionally, a H-bond was also predicted to 
form between Asp229 and bound HDQ.  Several weaker van der Waals and 
hydrophobic interactions were also observed, such as Tyr16 and Met221. 
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Fig. 5.31  Docking solution of HDQ (shown in blue) in the Qi pocket of the yeast cytochrome bc1 
complex (3CX5).  Several potential H-bond, hydrophobic and van der Waals interactions are shown.  
The yeast cytochrome b polypeptide backbone is represented in green. 
Analysis of the fitness scores and docking solutions seem to suggest that HDQ is 
indeed a Qi binder.  To offer further support, the native Qi ligand ubiquinone (fig. 
5.32) was similarly docked into the Qi site using the ‘Qi Docking Protocol’. 
 
Fig. 5.32  Ubiquinone. 
The results of this docking are shown in table 5.9, along with the fitness scores of 
SMA and HDQ for comparison.  Given that ubiquinone is the native ligand of the Qi 
site, its fitness scores were used as a point of reference from which comparisons 
could be made.  Ubiquinone had an average GOLDScore of 48.3 ± 1.4 across the 10 
GA runs, and was therefore comparable to that of SMA (45.4 ± 13.0).  HDQ on the 
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other hand clearly bound more strongly than both SMA and ubiquinone, with an 
average GOLDScore of 54.1 ± 3.5.  This tight binding could potentially explain the 
observed cardiotoxicity of HDQ in mammals.  Unfortunately however, ChemScore 
failed to replicate this trend, though this is not too discouraging as it should be 
routine to investigate multiple scoring functions for different applications.
16, 17
 
Table. 5.9  Ubiquinone, HDQ and SMA docking results at the Qi site. 
 Qi 
 SMA HDQ Ubiquinone 
Average GOLDScore 45.4 ± 13.0 54.1 ± 3.5 48.3 ± 1.4 
Average ChemScore 28.0 ± 4.7 28.6 ± 2.1 22.3 ± 3.8 
By combining insight garnered from the study of yeast with specific cytochrome b 
mutations, and by using molecular docking, it has been shown that HDQ inhibition 
at the cytochrome bc1 complex is most significantly mediated via Qi binding.  
Therefore, HDQ displays a novel inhibitory mode of action and offers further 
support that the Qi site of Pfbc1 is a viable target for antimalarial drug development.  
This docking study formed part of a publication in the journal of ‘Antimicrobial 
Agents and Chemotherapy’ entitled ‘HDQ, a potent inhibitor of Plasmodium 
falciparum proliferation, binds to the quinone reduction site of the cytochrome bc1 
complex’.94 
5.2.4 Docking of LBVS Hits 
To supplement the detailed analysis of the LBVS hits at the end of Chapter IV, the 
five compounds (VS01, VS09, VS10, VS16, VS18) which were found to be active 
against the malaria parasite (table 4.5) were docked into the Qo and Qi sites of the 
yeast bc1 complex.  This was done to gather further information in support of the 
hypothesis that they are Pfbc1 inhibitors, given that the biological testing which 
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would definitively prove this was unavailable.  The five compounds were 
constructed and energy minimised using the ‘Energy Minimisation Protocol’, and 
then docked into the Qo and Qi sites using the ‘Qo Docking Protocol’ and ‘Qi 
Docking Protocol’ respectively.  The average docking scores for each of the 
compounds at Qo and Qi are shown in tables 5.10 and 5.11 respectively. 
Table. 5.10  Fitness function scores for the docking results of the LBVS hits at the Qo site. 
 VS01 VS09 VS10 VS16 VS18 
Average GOLDScore 47.1 ± 6.2 53.3 ± 0.8 52.6 ± 3.5 64.9 ± 2.2 57.9 ± 4.4 
Average ChemScore 30.0 ± 2.2 20.2 ± 0.5 19.8 ± 6.0 29.1 ± 1.7 30.7 ± 1.8 
Table. 5.11  Fitness function scores for the docking results of the LBVS hits at the Qi site. 
 
VS01 VS09 VS10 VS16 VS18 
Average GOLDScore 49.7 ± 3.6 48.6 ± 0.5 55.2 ± 1.5 48.1 ± 2.6 47.3 ± 0.6 
Average ChemScore 26.6 ± 4.1 17.2 ± 1.3 27.5 ± 0.7 20.8 ± 1.7 23.9 ± 1.2 
The scores were quite similar across the five compounds; therefore the solutions 
were visually inspected in order to draw comment as to the nature of their binding.  
At Qo, VS01 (fig. 4.4) was found to bind according to figure 5.33.  A weak H-bond 
was observed between the NH group of His181 and a carbonyl group on the 
pyrrolopyrimidine-2,4-dione core.  However, owing to the bulk of the phenyl groups 
and the narrow entrance of the Qo site, the compound could not orientate itself 
tightly in the pocket, thus the water mediate interaction with Glu272 was not seen.  
The presence of the His181 interaction clearly supports the assumption that this 
compound is a Pfbc1 inhibitor, but its otherwise poor binding may explain its lack of 
reproducibility in vitro.  Though Qi docking was less informative, there was the 
potential for H-bonding between a carbonyl group in VS01, and the hydroxyl moiety 
of Ser206 and the amine group of Gln22, similar to the observed binding of HDQ 
(fig. 5.31). 
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Fig. 5.33  Docking solution of VS01 (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The His181 H-bond with one of the pyrrolopyrimidine-2,4-dione carbonyl groups 
is clearly shown.  The yeast cytochrome b polypeptide backbone is represented in green, with the 
[2Fe2S] cluster of the Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-bonds 
are indicated by black lines. 
Of the five compounds, VS09 (fig. 4.6) appeared to be the most promising from 
docking analysis.  A representative pose for VS09 is shown in figure 5.34.  There 
was a strong H-bond between His181 and the nitrogen of the benzothiazole ring, as 
well as a water mediated H-bonding network between the imidazole side chain and 
Glu272.  The strength of these bonds may go some way to rationalising the relatively 
potent 3D7 inhibition of this compound (IC50 = 4.53 ± 1.86 µM), as well as its good 
in vitro reproducibility.  Given the size of this compound and its positioning in the 
Qo active site, there is clearly much scope for chemical optimisation with regard to 
this chemotype, and all things considered it looks to be the most promising lead like 
structure from the virtual screening study. 
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Fig. 5.34  Docking solution of VS09 (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The His181 H-bond with the benzothiazole nitrogen is clearly shown, as well as 
the potential for a water mediated interaction with Glu272 and the side chain of VS09.  The yeast 
cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the Rieske 
protein represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
VS09 also docked very well into the Qi site, suggesting that it may have dual 
inhibition at both sites, similar to NQNO.  A strong H-bond was observed between 
the hydroxyl group of its side chain and the Asp229 amino acid, as well as a number 
of potential H-bonds between the Ser206 and Gln22 protein residues and the 
nitrogen of the benzothiazole chemotype and nitrogen linker, as observed in figure 
5.35. 
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Fig. 5.35  Docking solution of VS09 (shown in blue) in the Qi pocket of the yeast cytochrome bc1 
complex (3CX5).  Several hydrophobic and van der Waals interactions are observed, as well as 
potential H-bond contacts.  The yeast cytochrome b polypeptide backbone is represented in green.  H-
bonds are indicated by black lines. 
The rigid isoalloxazine ring of VS10 (fig. 4.11) docked into the Qo site, forming a H-
bond between one of its carbonyl groups and His181, as shown in figure 5.36.  The 
strength of this interaction helped to rationalise its observed activity (IC50 = 6.41 ± 
1.73 µM), and the potential of the isoalloxazine chemotype as a lead like structure.  
Similar to VS01 and VS09 (fig. 5.35), the carbonyl group of VS10 was able to H-
bond to Ser206 and Gln22 at the Qi site. 
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Fig. 5.36  Docking solution of VS10 (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The His181 H-bond with the isoalloxazine ring is clearly shown.  The yeast 
cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the Rieske 
protein represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
Neither VS16 nor VS18 (fig. 4.15) contain traditional chemotypes (i.e. heterocyclic 
structures with unique functionality), thus their docking at the Qo site was fairly 
unremarkable.  However, both were found to observe strong H-bond interactions 
between a carbonyl group and His181, as shown in figures 5.37 and 5.38 
respectively.  These observations may go some way to explaining their in vitro 
activities.  Unfortunately, when docked at the Qi site, though their docking scores 
were comparable to the other hits, no significant interactions were observed. 
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Fig. 5.37  Docking solution of VS16 (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The His181 H-bond with a carbonyl group is clearly shown.  The yeast cytochrome 
b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the Rieske protein 
represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
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Fig. 5.38  Docking solution of VS18 (shown in blue) in the Qo pocket of the yeast cytochrome bc1 
complex (3CX5).  The His181 H-bond with a carbonyl group is clearly shown.  The yeast cytochrome 
b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the Rieske protein 
represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
By combining this docking analysis with the earlier interpretation of the chemotypes 
and biological results (Chapter IV), it is indeed most likely that these compounds are 
inhibiting the Pfbc1 complex.  The docking therefore offers further support of the 
strength of the LBVS work which was performed, and by extension, that a number 
of exciting lead like chemotypes have been identified. 
5.3 Summary of Docking Studies 
Combined, these studies show that molecular docking has many applications in 
modern drug discovery.  Not only can it be used to explain a compounds activity 
profile through consideration of observed interactions, but it has also proven useful 
in confirming the identity of novel antimalarial targets, and in rationalising 
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observations with regard to emerging resistance.  Clearly there is much potential and 
scope to utilise molecular docking tools to aid in the systematic design of new 
antimalarial compounds, active against the cytochrome bc1 complex.  With work 
ongoing to design and validate a homology model of Pfbc1, docking will help to 
drive forward ongoing efforts to further refine the molecular design loop. 
Chapter VI will discuss the application of QSAR methods to tackle two problems.  
Firstly, to develop QSARs that could be used to predict the activity of 4-
aminoquinoline compounds against CQ sensitive and CQ resistant strains of malaria.  
And secondly, to develop models for the assessment of drug safety for a series of 
thiazolide compounds active against hepatitis C.  QSAR methods will be fully 
introduced and discussed, together with appropriate validation techniques. 
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6. Quantitative Structure Activity Relationships 
Quantitative structure activity relationships (QSAR) involve correlating the 
structural and/or physicochemical features of a molecule with a measured property, 
such as biological activity,
1
 with most QSARs taking the general form of equation 
6.1 (Chapter I). 
                                    
Eq. 6.1  General QSAR equation. 
The most popular and widely used machine learning technique for QSAR is that of 
MLR (eq. 6.2), which is an extension of simple linear regression.
1
  The dependent 
variable ( ) corresponds to the property of interest (i.e. biological activity), whilst 
the independent variables ( ) are the molecular descriptors used.  Statistical methods 
such as the squared correlation coefficient (  ) can then be used to assess the 
performance of a model.  However, there are many additional criteria which need to 
be satisfied in order to be confident of a models performance, as well as several other 
machine learning methods which can be considered to develop these QSARs. 
                    
Eq. 6.2  Multiple linear regression equation. 
In this thesis, QSAR methods have been successfully applied to two distinct datasets, 
the results of which will now be discussed.  The first dataset was that of a number of 
4-aminoquinoline analogues with reported antimalarial activities, whilst the other 
was a number of thiazolide compounds which had been tested against hepatitis C.  
QSAR methods and analysis procedures will be fully introduced as and when they 
are used. 
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6.1 Antimalarial 4-Aminoquinoline QSARs 
4-aminoquinoline compounds (i.e. CQ) continue to attract interest because their 
mechanisms of action and resistance appear to be unrelated.
2
  It is commonly 
accepted that CQ exerts its antimalarial activity by inhibiting haemozoin formation 
in the digestive vacuole of the parasite,
3-5
 with the cause of resistance thought to be 
an increased efflux of the drug from the vacuole.
6, 7
  However, several analogues and 
derivatives of CQ retain significant activity against CQR P.falciparum strains,
8-11
 
leading to suggestions that resistance could be compound specific, and not related to 
changes in the structure of the drug target.
2
  Owing to this, there is still much 
potential within the 4-aminoquinoline class of compounds in attempting to combat or 
circumvent this resistance.  QSAR is one computational approach which can be used 
to enhance our understanding of how certain chemical agents elicit their biological 
response.  The results from QSAR can assist in optimising existing compounds in 
order to increase potency, with insight garnered later fed directly back into synthetic 
work. 
The US patent ‘Method of treating chloroquine-resistant malaria with 
aminoquinoline derivatives’,12 describes aminoquinoline derivatives of the general 
formula shown in figure 6.1.  The R groups ranged from simple chlorine or hydrogen 
atoms, to carbon chains and trifluoromethyl groups (the appendices for this chapter 
are all on the disk in the stated folders; Quantitative Structure Activity 
Relationships\Appendix 01).   
Chapter VI 
 
304 
 
 
Fig. 6.1  Aminoquinoline template described in US patent 5596002.  (W. Hofheinz, C. Jaquet and S. 
Jolidon, United States Patent, 1997, 5596002.) 
The compounds were all tested against a CQS (NF54) and CQR (K1) strain of the 
P.falciparum parasite, with values shown in table 6.1.  The observed resistance 
between these two strains is most likely attributed to molecular differences in the 
parasites, as a result of point mutations.  The activity of CQ was also recorded for 
reference. 
Table. 6.1  IC50 values for the 4-aminoquinoline compounds from Patent 5596002 tested against CQS 
(NF54) and CQR (K1) strains of malaria. 
ID 
CQS Strain (NF54) CQR Strain (K1) 
IC50 (ng/ml) IC50 (ng/ml) 
1 4 9 
2 7 14 
3 7 12 
4 7 15 
5 4 7 
6 5 9 
7 4 8 
8 5 11 
9 11 32 
10 7 17 
11 5 18 
11a 7 15 
12 6 10 
12a 7 9 
13 30 47 
14 9 21 
15 2 6 
16 3 9 
17 3 15 
18 4 14 
19 7 9 
19a 6 9 
Chapter VI 
 
305 
 
20 3 10 
21 21 34 
22 14 22 
23 6 15 
24 7 15 
25 8 22 
26 7 15 
27 8 18 
28 7 16 
29 6 16 
30 7 14 
31 5 11 
32 7 16 
33 8 14 
33a 7 8 
33b 8 17 
33c 8 24 
33d 8 23 
33e 12 53 
33f 12 41 
33g 5 17 
33h 7 18 
CQ 8 114 
The dataset was a suitable candidate for QSAR analysis as models could be 
developed for the biological data of both strains, enabling a comparison between the 
models, and conclusions to be drawn with regard to potential resistance mechanisms.  
Individual QSAR models could also be interpreted. 
QSARs were developed for both strains through a three stage process:
13
 
i. Data preparation 
ii. Data analysis 
iii. Model validation 
6.1.1 Data Preparation 
The 45 compounds reported in the dataset were first constructed and energy 
minimised using the ‘Energy Minimisation Protocol’ as described in the 
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Experimental Chapter.  Next, the IC50 values for the NF54 and K1 strains were 
converted into activity values using negative log transformations to normalise the 
data,
14
 and are reported in table 6.2 (Quantitative Structure Activity 
Relationships\Appendix 02).  Two files were then created, one for each strain, with 
both containing the 45 structures together with their respective activity values (as per 
table 6.2).  For both strains the activity values covered a sufficient range, with 
guidelines suggesting the spread of values across the dependent variable from the 
least active to the most active should be greater than two orders of magnitude for 
successful QSAR models.
15
 
Table. 6.2  IC50 values and negative log transformations for the 45 compounds tested against CQS 
(NF54) and CQR (K1) strains of malaria. 
ID 
CQS Strain (NF54) CQR Strain (K1) 
IC50 (ng/ml) Activity Value IC50 (ng/ml) Activity Value 
1 4 7.82 9 7.47 
2 7 7.62 14 7.32 
3 7 7.62 12 7.38 
4 7 7.64 15 7.31 
5 4 7.80 7 7.55 
6 5 7.74 9 7.49 
7 4 7.84 8 7.54 
8 5 7.76 11 7.42 
9 11 7.48 32 7.02 
10 7 7.67 17 7.29 
11 5 7.80 18 7.25 
11a 7 7.65 15 7.32 
12 6 7.68 10 7.46 
12a 7 7.60 9 7.49 
13 30 7.01 47 6.81 
14 9 7.55 21 7.18 
15 2 8.12 6 7.64 
16 3 7.99 9 7.51 
17 3 7.98 15 7.29 
18 4 7.88 14 7.34 
19 7 7.70 9 7.59 
19a 6 7.66 9 7.49 
20 3 8.03 10 7.50 
21 21 7.17 34 6.96 
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22 14 7.31 22 7.11 
23 6 7.70 15 7.31 
24 7 7.64 15 7.31 
25 8 7.60 22 7.16 
26 7 7.64 15 7.31 
27 8 7.60 18 7.25 
28 7 7.66 16 7.30 
29 6 7.72 16 7.30 
30 7 7.64 14 7.34 
31 5 7.82 11 7.48 
32 7 7.67 16 7.31 
33 8 7.54 14 7.29 
33a 7 7.57 8 7.51 
33b 8 7.54 17 7.21 
33c 8 7.52 24 7.04 
33d 8 7.52 23 7.06 
33e 12 7.39 53 6.74 
33f 12 7.39 41 6.85 
33g 5 7.72 17 7.19 
33h 7 7.58 18 7.17 
CQ 8 7.60 114 6.45 
6.1.2 Molecular Descriptors 
Molecular descriptors (Chapter I) are calculated based on a molecular structure, and 
encode chemical and/or physicochemical information in numerical form.
16
  They are 
generated using specific programs which perform various feature recognition and 
transformation steps, to generate a series of values for each compound.
17, 18
  One 
such program is DRAGON 3.0
19
 which encodes almost 1500 descriptors (1497), 
encompassing 0, 1, 2 and 3D molecular properties.  Another program is 
ADMEWORKS Modelbuilder,
18
 which can describe just over 500 descriptors (523). 
Through combining 0, 1, 2 and 3D molecular descriptors, it is hoped that the bulk of 
a molecules properties will be fairly well represented.  However, the generation of 
3D descriptors may be problematic, requiring the prediction of a compounds active 
conformation, which can be difficult for highly flexible molecules.
20
  With this in 
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mind, QSAR analysis can still prove useful using just 0, 1 and 2D descriptors,
21
 
providing reliable and interpretable results that are easily automated and adapted to 
the task of database searching, or virtual screening. 
Given the large number of molecular descriptors available, selection procedures can 
be readily used to identify those descriptors which best represent the data.  It is only 
natural that given the large amount of information there is likely to be some 
redundancy, therefore descriptor selection is an integral part of QSAR development, 
helping to reduce the often vast number of descriptors, to increase the chance of 
finding a significant QSAR model.
22
 
6.1.2.1  Objective Descriptor Selection Methods 
Descriptor selection methods are divided into two categories; objective or subjective.  
Objective selection methods involve removing descriptors based on their relationship 
to the other descriptors, as it is ultimately important to consider only those 
descriptors which describe unique information about the chemical structures, 
removing those which are highly correlated to others. 
6.1.2.1.1  Descriptor Correlation 
Descriptor correlations should be checked as a matter of routine to avoid over 
representing a dataset.  Many correlations can be identified from simple scatterplots 
between pairs of descriptors, with the ideal situation being no discernible 
relationship between the two.  However, when many descriptors need to be 
considered it is much more convenient to compute a pair wise correlation matrix, one 
that quantifies the degree of correlation between all pairs of descriptors.  Each entry 
( , ) in the correlation matrix represents the correlation coefficient between the 
Chapter VI 
 
309 
 
descriptors    versus   .  The correlation coefficient   is then found using equation 
6.3, where   is the number of molecules,   is set to 1, and  
    is the mean of the independent variables.1 
  
                         
 
   
             
  
               
  
   
 
Eq. 6.3  Correlation coefficient equation. 
The value of the correlation coefficient ranges from -1.0 to +1.0.  A value of +1.0 
indicates a perfect positive correlation, with a plot of    versus    giving a straight 
line with a positive gradient.  Conversely, a value of -1.0 indicates a perfect negative 
relationship.  A gradient of zero would suggest that no relationship exists between 
the variables, and it is these descriptors which best produce the more meaningful 
QSAR models. 
When a pair of descriptors are found to be highly correlated, a decision needs to be 
made as to which to keep and which to discard.  One approach is to remove the 
descriptor which has the most correlations to other descriptors, yet one may also 
choose to keep this descriptor, in order to reduce the size of the dataset. 
6.1.2.1.2  CORCHOP 
CORCHOP provides a means for making such decisions.  With the growing number 
of descriptors used to characterise molecules, the amount of information available 
can be overwhelming, so it is important to extract the information which best 
represents the data, and avoid “chance” correlations.  Although techniques to analyse 
correlations have been well implemented, there are issues when deciding which 
highly correlated parameters to discard.  The computer routine CORCHOP was 
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devised to aid in the systematic reduction of large amounts of data, by reducing the 
number of descriptors whilst retaining the intrinsic information they describe.
23
  
When two descriptors each correlate with the same descriptors, it is essential that one 
be removed.  CORCHOP acts by removing those descriptors whose distribution 
deviates most from normal. 
6.1.2.2  Subjective Descriptor Selection Methods 
With highly correlated descriptors removed, subjective selection methods can be 
used to select the most appropriate descriptors, based on their relationships to the 
dependent variable.  When the number of descriptors in a dataset is very large 
compared to the number of compounds it contains, a learning algorithm is faced with 
the problem of selecting a relevant subset of these descriptors, from which to 
develop the QSAR models.
24
  A general rule of thumb is that there should be at least 
five compounds per descriptor in an MLR regression.
1
  Several subjective selection 
methods will now be introduced. 
6.1.2.2.1  Forward Selection 
Forward selection is a searching method that begins with an empty set of features,
24
 
and generates an equation containing just one descriptor from a dataset, typically 
chosen to be the variable which would contribute most to a model, as assessed by the 
 -statistic (see later).1    models are learnt containing just one descriptor each, with 
the best model chosen based on its statistics, effectively selecting the best descriptor 
to model the given property.  Subsequent descriptors are then added using the same 
criteria.      feature subsets are made by pairing the chosen descriptor with all the 
remaining     descriptors, one by one.      models are learnt and their 
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statistics compared to select the best performing model, in effect, selecting the next 
best descriptor to explain the dependent variable.  The process is repeated and 
terminates when either a predetermined number of variables have been reached, or 
when the last variable has an insignificant contribution to the regression equation.
25
 
6.1.2.2.2  Backward Elimination 
Backward elimination refers to a search involving the full set of descriptors,
26
 and 
starts with an equation using all   descriptors, each of which is then periodically 
removed in turn, usually starting with the descriptor that has the smallest 
contribution to the reduction of predictive sum of squares (see later),
25
 or which has 
the smallest  -statistic.1  Each descriptor is then dropped one by one, and   models 
are learnt containing     descriptors.  Based on the statistics of these   models, 
the best model is selected to identify the best feature set, effectively eliminating the 
worst descriptor for modelling the given dependant variable.      feature subsets 
containing     descriptors are then developed by dropping all of the descriptors 
one by one.      models are learnt and their statistics compared to select the best 
performing model.  The best is then selected, eliminating the next least important 
descriptor.  These iterations are repeated until a predefined target size is reached, or 
until all variables are considered significant.  A comparison between forwards and 
backwards selection found that forward selection generally performs better.
24
 
6.1.2.2.3  Stepwise Regression 
In a stepwise regression a variable that enters a model may in the earlier stages of 
selection be deleted.
25
  It is essentially a forward selection routine, but at each stage 
the possibility of deleting a variable (as with backward elimination) is considered.  
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The number of variables retained in a model is based on the levels of significance 
assumed for inclusion and exclusion of variables from the model.  The model 
building terminates when no variable in the new model can be removed, and all the 
next best candidates cannot be retained. 
6.1.2.2.4  Genetic Algorithm 
Genetic algorithms (GAs) are based on various computational models of Darwinian 
evolution,
27
 and have found use in data analysis to reduce the number of features in a 
regression model.  They can be used to generate a population of linear regression 
QSAR equations, each with different combinations of descriptors.
28
  Over a number 
of generations, these equations undergo mutation, with some being removed (death 
rate), some new ones generated (birth rate), and the best ones being carried on from 
one generation to another (elitism).  The output from this is a family of models from 
which one can select the highest scoring model, or analyse the data further to 
determine the most commonly occurring descriptors.
1, 22
 
GAs do not search for just one solution, but instead a population, attempting to 
increase the fitness of the population at each generation.
22
  Each solution is evaluated 
based on some domain-specific function, then kept or discarded based on that 
evaluation.  If discarded, that member of the population is replaced by a new 
solution, which is created by combining parts of good solutions.  This process is 
repeated over and over, combining different aspects of good solutions, searching for 
an optimal combination of features. 
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6.1.3 QSAR Development Excluding 3D Descriptors 
An array of descriptor selection methods have now been discussed, but in order for 
them to be applied, descriptor subsets had to be calculated for the compounds 
contained within the aminoquinoline datasets.  To begin with, QSARs were 
developed using only the 0, 1 and 2D descriptors.  This was done to remove the 
initial need for conformational analysis and alignment of the compounds to a 
common pharmacophore, required for the calculation of 3D descriptors.  For the 45 
structures a total of 957 descriptors were calculated using both ADMEWORKS 
Modelbuilder
18
 and DRAGON 3.0.
19
  QSARs were built using the program 
PHAKISO
29
 (Pharmacokinetics In Silico) which contains a host of functions and 
machine learning methods highly amenable to model development.  These 
algorithms allow computers to learn and recognise complex patterns, making 
intelligent decisions based on inputted data.
 30, 31
 
6.1.3.1  Multiple Linear Regression 
MLR has proven to be a very useful tool for the generation of QSAR models.
1
  
However, before relationships such as those in equation 6.2 could be developed, it 
was crucial that the descriptors be normalised.  Molecular descriptors were therefore 
autoscaled (Chapter I), meaning that the variables each had a mean of zero and a 
standard deviation of one.
1
  MLR attempts to find the smallest possible sum of 
squared differences between the actual dependent observations, and those predicted 
from the regression equation.  The most common method of assessing a regression 
equation is the squared correlation coefficient (  ) (Chapter I).  It is calculated using 
equation 6.4, and allows comment to be drawn as to the estimated proportion of the 
variation in the dependent variable that is explained by the regression equation.
30
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When      then there is no linear relationship observed, whilst values greater than 
zero suggest a stronger relationship between the two, up to a maximum value of one, 
indicating a perfect fit. 
   
   
   
 
       
   
   
   
   
 
Eq. 6.4  Calculation of the    relationship. 
The literature suggests that a good model has an    value greater than 0.7, but less 
than one, as a value of one is usually indicative of over training.
31, 32
  However, 
whilst    is useful in highlighting promising models, several other statistical 
parameters should also be considered in order to be certain of its validity, and thus 
predictive potential. 
6.1.3.2  Internal Validation 
   is part of a family of statistical methods that fall under the umbrella of internal 
validation.  Internal validation techniques are used to assess the performance of a 
model to see how well it predicts the dependant variable for the set of molecules 
which were used to develop the equation.
33, 34
  These techniques can be used to 
overcome some of the limitations of the    statistic alone, mainly in cases where the 
data has been over fitted (i.e.     ).  Generally however, the    value for a model 
can be increased with the addition of more independent variables, even if the added 
variable does not reduce the unexplained variance of the dependent variable. 
6.1.3.2.1  Standard Error of Prediction 
The standard error of prediction ( ) indicates how well the regression function 
predicts the observed data, and is calculated by equation 6.5.
1
      (eq. 1.12) 
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represents the residual sum of squares,   the number of data points, and   the 
number of independent variables in the equation. 
   
   
     
 
Eq. 6.5  Calculation of standard error of prediction. 
6.1.3.2.2   -Statistic 
The Fisher statistic ( ), or the variance ratio, is another commonly used measure to 
assess a linear regression, calculated by dividing ESS (eq. 1.11) by RSS (eq. 1.12), 
as shown in equation 6.6. 
1, 22
  The form of this equation reflects the number of 
degrees of freedom associated with each parameter. 
  
   
 
     
   
 
Eq. 6.6  Calculation of the Fisher statistic. 
The  -statistic is used to test the statistical significance of the observed differences 
amongst the means of two or more random samples.  The experimental value of   
can be compared with values from statistical tables, or those calculated manually at 
different confidence levels.  If the experimental value is greater than the tabulated 
value, then the equation is said to be significant at that particular confidence level.  
Higher values of   therefore suggest a higher level of significance, increasing the 
confidence in the models ability.  At a given confidence level the threshold value of 
  falls as the number of independent variables decreases, and/or the number of data 
points increases, consistent with the desire to describe as large a number of data 
points, with as few independent variables as possible. 
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6.1.3.2.3   -Statistic 
The  -statistic comments on the significance of each independent variable in the 
linear regression equation.
1
  If    represents the coefficient in the regression equation 
associated with a particular variable   , then the  -statistic is given by equation 6.7, 
where       is the standard error of the coefficient. 
   
  
     
         
   
     
 
 
            
  
   
 
Eq. 6.7  Calculation of the  -statistic. 
Similar to the  -statistic, values of   can be compared to those listed in statistical 
tables at various confidence levels.  If the calculated value is greater than that in the 
table, then the coefficient is considered significant at that confidence level. 
6.1.3.2.4  Cross-Validation 
Cross-validation is one of the most common validation techniques.  It involves the 
removal of one or more compounds form a dataset, in such a way that each object is 
removed only once.  A QSAR model is then derived given the remaining data, which 
is then used to predict the dependent variable of the molecule/s removed.  The 
squared differences between the true response (  ) and the predicted response 
(       ) for each compound left out are added to give the predictive residual sum of 
squares (PRESS), as calculated by equation 6.8.  PRESS is analogous to RSS, but 
rather than using the calculated values (       ) from the model, PRESS uses the 
predicted values (       ) for data not used to derive the model. 
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Eq. 6.8  Calculation of the predictive residual sum of squares. 
The simplest cross-validation procedure is the leave-one-out (LOO) approach, where 
each compound is removed one at a time.  The process is repeated for every entry, 
leading to the cross-validated    statistic (  ), calculated by equation 6.9.     is 
always lower than   , and whilst    measures the goodness-of-fit,    attempts to 
measure the goodness-of-prediction. 
     
     
   
 
Eq. 6.9  Calculation of   . 
The leave-many-out (LMO) cross-validation approach can also be used, and may 
provide a more realistic estimate as to the predictive ability of a model, particularly 
for larger datasets.  The dataset can be divided into several groups, each of which is 
left out in turn to generate the    statistic.  By repeating this procedure a large 
number of times, selecting different groupings at random each time, a mean    can 
be derived.  For a well-behaved system there should not be much variation in the 
equations obtained during such a procedure, nor should the    value calculated using 
the entire dataset be significantly larger than the mean    value.  If there is a large 
discrepancy, then it is likely that the data has been over-fitted, and the model may 
not be robust. 
Often a high value of    (greater than 0.5) is considered proof of a models predictive 
ability, but this assumption can be misleading.
35
  A high    does not automatically 
mean that the model has a high predictive ability, as the only way to estimate its true 
predictive power is to externally validate it on a test set.  A test set represents a 
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subset of compounds that were not used during model development, and to which a 
model can be applied.  A high    value is therefore a necessity for model validation, 
but is not sufficient in itself.
35
 
6.1.3.2.5  Bootstrapping 
Bootstrapping is a widely popular technique that can provide answers when other 
validation procedures fail.
22
  It is based on building a distribution sample for a 
statistic by re-sampling the initial data.
36
  The idea is to simulate what would happen 
if the samples were randomly selected from a dataset which was representative of the 
entire population. 
Typically,   groups of size   are generated by a repeated random selection of   
objects from the original dataset.
37
  Some of these objects can be included in the 
same random sample several times, whilst others will never be selected.  The model 
obtained on the   randomly selected objects is used to predict the target properties 
for the excluded sample.  The difference between the parameters calculated from the 
original dataset and the average of the parameters calculated from the bootstrap 
samplings is a measure of the bias of the original calculation.  The calculated 
variance of the parameter estimates the accuracy with which any of the parameters 
can be estimated from the input data, and as with the cross-validation technique, a 
high average    in bootstrap validation is indicative of a robust model.37 
6.1.3.2.6  Y-Scrambling 
Y-scrambling can also prove to be another useful internal validation method.
38
  It is 
widely used to validate the robustness of a QSAR model, identifying models based 
on chance correlation.
22
  When selecting descriptors that are of relevance to a 
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particular property, it is possible to find some descriptors purely by chance.  Using 
correlation-based selection methods it is possible to select descriptors that are of no 
real significance, but seem to fit the property of interest well.  Y-scrambling attempts 
to identify these chance correlations. 
Y-scrambling is performed by calculating the quality of models, via    and   , when 
the dependent variable has been randomly modified.  It is modified by randomly 
assigning each compound a different dependent variable from the true set of 
responses.
39
  If the original model is genuine, then there is a significant difference in 
the quality of the original model and that found using Y-scrambling.  This procedure 
is repeated several hundred times, and it is expected that the resulting QSAR models 
should generally have low    and    values.37 
6.1.3.2.7  Criteria for Internal Validation 
Table 6.3 illustrates a list of internal validation parameters which were compiled to 
determine the success of a QSAR model.  These guidelines were based on a 
consensus across the literature, and were used to assess the developed models.
1, 13, 22, 
35, 40, 41
 
Table. 6.3  Internal validation criteria. 
Parameter Threshold Value 
General Parameters 
Number of data points ≥ 10 
Dependent variable data range ≥ Two orders of magnitude 
Molecules/Descriptor Ratio ≥ 5 
Internal Validation Statistics 
   > 0.7 
   > 0.5 
 -statistic Higher than table value 
Bootstrapping No more than 0.3 lower than    
Dependent Variable Statistics 
 -statistic ≥ 2 
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Though internal validation is essential, it has been recommended that the only true 
test of a model lays in its predictive ability,
13
 which can be assessed using external 
validation.  For this there exists an additional set of criteria. 
6.1.3.3  External Validation 
External validation greatly influences the success of a model, as it is highly desirable 
to be able to accurately predict the activity of compounds which were not used 
during model development.  Though internal validation allows for comment to be 
drawn as to the robustness of a particular model, it gives no rational measure as to its 
predictive ability.  Therefore, external validation is the only true predictive test for a 
model, and provides supplementary information in support of internal validation.
37
 
It has been demonstrated that the widely accepted    statistic is an inadequate 
characteristic with which to assess the predictive capacity of a model.
35
  There is also 
evidence to support that there exists no correlation between the values of    for the 
training set, and the accuracy of prediction (  ) for the test set.13  The only way to 
estimate the true predictive power of a model is to test it on a sufficiently large 
collection of compounds from an external test set.  There is typically insufficient 
data available to test newly synthesised compounds, so the best approach is to use a 
rationally selected training and test set, chosen from the original data.
13
  It has been 
argued that training and test sets must satisfy the following criteria:
42, 43
 
i. Representative points of the test set must be close to those of the training set 
ii. Representative points of the training set must be close to representative 
points of the test set 
iii. Training set must be diverse 
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It has been demonstrated that models found using a rational division of an 
experimental dataset, generally lead to better predictive models.
42
  There are several 
approaches available to split datasets. 
6.1.3.3.1  Sphere Exclusion Algorithm 
The sphere-exclusion algorithm is one such approach, and is widely used for the 
comparison of chemical databases or libraries.
44-46
  It attempts to specify which 
compounds most effectively cover the available property space, with the basic 
sphere-exclusion algorithm taking the following form:
1
 
1. Define a threshold dissimilarity,   
2. Select a compound and place it in the subset 
3. Remove all molecules from the dataset that have a dissimilarity to the 
selected molecule of less than   
4. Return to step 2 if there are molecules remaining in the dataset 
The first compound is selected for inclusion in the subset, after which all compounds 
in the dataset that are within the similarity threshold to the selected compound are 
removed from consideration.  This is analogous to enclosing the compound within a 
hypersphere and removing all compounds from the dataset that fall within the 
sphere.  This sphere can be constructed using equation 6.10, where   is the total 
volume occupied by the representative points in the normalised descriptor space,   
the number of descriptors,   the number of molecules, and   the dissimilarity level, 
which can be varied to construct different training and test sets.
45, 46
  Several variants 
of the algorithm exist, differing in the way in which the first compound is selected, 
the threshold value used, and the way that the next compound is selected at each 
iteration. 
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Eq. 6.10  Sphere exclusion algorithm. 
6.1.3.3.2  Assessing Predictive Power 
Once a suitable training and test set split is identified models can be developed and 
validated.  It is the ability of the QSAR model to accurately predict the dependent 
variable of the test set which really assesses its predictive capabilities, and is 
quantitatively estimated by the external    statistic, calculated using equation 6.11. 
37
     represents the observed response for the  
   object,    the predicted response 
for the     object, and     the average response value for the entire training set. 
     
    
        
     
   
          
    
   
 
Eq. 6.11  Calculation of external   . 
Further statistical parameters referred to as the Tropsha parameters, act to assess the 
predictive capabilities of a model, and are calculated based on graphical plots of the 
predictions.
35, 38
  For an ideal model, the slope of the gradient when the observed and 
predicted dependent variables are plotted against one another should be equal to one, 
with an intercept of zero, and a correlation coefficient ( ) of one.    can be 
calculated using equation 6.12, where   and    are the average values of the observed 
and predicted activities respectively. 
  
              
                
 
 
Eq. 6.12  Calculation of correlation coefficient. 
A real QSAR model could be considered to have a high predictive ability if it is 
close to the ideal situation.  This implies that the correlation coefficient between the 
actual ( ) and predicted ( ) activities must be close to one.  Regressions of   against 
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  or   against   through the origin, i.e.        and        , respectively, should 
therefore be characterised by at least either   or    being close to one, with the slopes 
  and    calculated using equation 6.13. 
  
     
   
                  
     
   
  
Eq. 6.13  Calculation of the slope gradients for regression equations passing through the origin. 
Plotting both   against   and   against   may appear redundant, however, these two 
plots can be distinguished by different statistics.
47
  Figure 6.2 illustrates a case where 
the correlation between the actual activities and those predicted by a QSAR model 
for an external test set, gave an    of 0.95, and   and    values both close to 1, but 
yet despite this the predictions were found to be inaccurate.  This was shown via 
regression lines through the origin, as defined by        and         (intercepts 
set to zero). 
  
(a) (b) 
Fig. 6.2  Examples of regression between observed vs. predicted (a) and predicted vs. observed (b) 
activities for compounds from an external test set.  Despite high    and   and    close to 1, the model 
is not highly predictive due to the regression lines through the origin not being close to the optimal 
regressions, and   
  and   
   being considerably different to one another. 
Both correlation coefficients for these lines (  
  and   
  ), as calculated by equations 
6.14, had very different values, and were also significantly different from that of   . 
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Eq. 6.14  Calculation of   
  and   
  . 
This example demonstrates the need to impose additional conditions to validate the 
predictive ability of a QSAR model.  Another consideration is that the    value 
should be sufficiently similar to that of   
  and   
  , with the difference between the 
two not being too high. 
6.1.3.3.3  Criteria for External Validation 
The external validation criteria have been compiled in table 6.4, based on 
observations across the literature.
35, 37, 41
 
Table. 6.4  External validation criteria. 
Parameter Threshold Value 
        
        
      
  
  
      
Slope of line through origin ( )             
   
    
         
If a QSAR equation is found to satisfy both the internal and external validation 
criteria, then it is likely that a significant and valid model has been developed. 
6.1.3.4  NF54 Dataset 
QSAR models were first built for the NF54 dataset of compounds.  ‘QSAR Protocol 
1’ as described in the Experimental Chapter, was employed to develop a number of 
models (Quantitative Structure Activity Relationships\Appendix 03) using all 45 
compounds and excluding the 3D descriptors (957 descriptors used in total).  
Following objective descriptor selection, subjective methods were used to find the 
best subset of these descriptors in order to model the dependent variable.  Backward 
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elimination and stepwise regression failed to produce any descriptor subsets that 
gave valid models, with forward selection also performing poorly, with the best 
model having an internal    value of only 0.50.  GA produced the best model for the 
data, which had an    of 0.80, as shown in table 6.5. 
Table. 6.5  Statistics for model 1. 
Model 1 
Subjective selection method Genetic algorithm 
 
Training set size 45 
 
Number of descriptors 9 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 5 
 
Internal Validation 
Parameter Value Valid? 
   0.80 Yes 
   0.66 Yes 
 -statistic 15.07 Yes (Table value 2.16) 
Bootstrapping 0.42 Almost (Ideally > 0.50) 
Despite a slightly low bootstrapping value the model suggested that the data could be 
modelled successfully, giving good internal statistics.  However, the true test for the 
model would be its predictive ability.
13
  The dataset was split using the sphere 
exclusion algorithm, with 37 molecules in the training set, and 8 in the test set.  A 
general rule of thumb is that there should be between 15 to 40% of the total number 
of molecules in the test set.
48
  ‘QSAR Protocol 2’ as described in the Experimental 
Chapter was employed to build a model using GA subjective descriptor selection 
(Quantitative Structure Activity Relationships\Appendix 03), the statistics for which 
are illustrated in table 6.6. 
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Table. 6.6  Statistics for model 2. 
Model 2 
Subjective selection method Genetic algorithm 
 
Training set size 37 
 
Test set size 8 
 
Number of descriptors 7 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 5.286 
 
Internal Validation 
Parameter Value Valid? 
   0.80 Yes 
   0.69 Yes 
 -statistic 16.04 Yes (Table value 2.35) 
Bootstrapping 0.61 Yes (Ideally > 0.50) 
External Validation 
Parameter Value Valid? 
   -0.51 No 
   0.17 No 
      
      0.34 No 
  0.99 Yes 
   
    
    1.21 No 
The model was internally significant (      ) but failed externally (       ).  
Figure 6.3 illustrates the predicted versus actual activity values for the training and 
test sets, with a clear linear relationship observed for the training set, but not the test 
set, as an outlier appeared to skew the data.  So whilst internally the model appeared 
to be robust and have good predictive capabilities (i.e.        ), this was clearly 
not the case, emphasising the importance of external validation. 
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Fig. 6.3  Graph representing the predicted vs. actual activity values for model 2. 
The reason for the poor predictive capabilities of the model were thought to lie with 
the descriptors used to describe the spread of molecular properties.  There were 
several pairs of enantiomers in the dataset, with both compounds in each pair 
reporting different activities to one another.  Therefore, the 0, 1 and 2D molecular 
descriptors were not sufficient to make this distinction, as they did not encode for 
stereocentres.  Take for example molecules 33g and 33h (fig. 6.4).  Both had the 
same structure but were enantiomers of each other, with 33g (S isomer) being more 
potent than 33h (R isomer) by a few ng/ml depending on the strain.  The 
stereochemistry of these molecules plays a critical role in their activity, and 
represents their only distinguishing feature.  3D molecular descriptors are therefore 
essential to make this distinction. 
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33g 
NF54  IC50 = 5 ng/ml (pIC50) 
K1  IC50 = 17 ng/ml (pIC50) 
 
33h 
NF54  IC50 = 7 ng/ml (pIC50) 
K1  IC50 = 18 ng/ml (pIC50) 
Fig. 6.4  Molecules 33g and 33h. 
6.1.3.5  K1 Dataset 
Prior to the calculation of 3D descriptors, QSAR models were first developed for the 
K1 dataset using the same 0, 1 and 2D descriptors (957 descriptors in total), mainly 
to support the hypothesis that 3D descriptors were essential to accurately model 
activity.  ‘QSAR Protocol 1’ was used to develop regression models (Quantitative 
Structure Activity Relationships\Appendix 04), with GA subjective descriptor 
selection once again providing the best model (       ), as shown by table 6.7. 
Table. 6.7  Statistics for model 3. 
Model 3 
  
Subjective selection method Genetic algorithm 
 
Training set size 45 
 
Number of descriptors 9 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 5 
 
Internal Validation 
Parameter Value Valid? 
   0.73 Yes 
   0.43 No 
 -statistic 10.39 Yes (Table value 2.16) 
Bootstrapping -9.57 No (Ideally > 0.43) 
Using only 0, 1 and 2D descriptors no models were found that passed all of the 
internal validation criteria, with model 3 having a    value of only 0.43.  Again, this 
is most likely due to insufficient molecular descriptors to model activity and 
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distinguish between closely related compounds.  For completeness, models were 
developed and tested externally using the K1 data via ‘QSAR Protocol 2’ 
(Quantitative Structure Activity Relationships\Appendix 04), with the statistics for 
the best model shown in table 6.8. 
Table. 6.8  Statistics for model 4. 
Model 4 
Subjective selection method Genetic algorithm 
 
Training set size 37 
 
Test set size 8 
 
Number of descriptors 7 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 5.286 
 
Internal Validation 
Parameter Value Valid? 
   0.80 Yes 
   0.70 Yes 
 -statistic 16.95 Yes (Table value 2.35) 
Bootstrapping -3.05 No (Ideally > 0.50) 
External Validation 
Parameter Value Valid? 
   -0.2.44 No 
   0.246 No 
      
      0.09 Yes 
  0.99 Yes 
   
    
    5.65 No 
Though internally this model saw an improvement over model 3, externally it was 
poorly predictive.  The improvement internally may have been due to the smaller 
training set, or perhaps the sphere exclusion algorithm simply split the data in a 
manner better suited for regression modelling,
13
 removing the most dissimilar 
compounds.  Regardless, the model still failed externally.  Figure 6.5 illustrates more 
clearly this failure, with the data of the test set at odds with the strong linear 
relationship observed by the training set. 
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Fig. 6.5  Graph representing the predicted vs. actual activity values for model 4. 
Though the 0, 1 and 2D molecular descriptors could produce internally significant 
models for both datasets, externally they showed little potential as predictive entities.  
3D molecular descriptors were therefore investigated in attempts to overcome the 
limitations of these models. 
6.1.4 QSAR Development Including 3D Descriptors 
To calculate the 3D descriptors it was first necessary to map each of the compounds 
to a known pharmacophore or bioactive conformation from across the series.  This 
was done using conformation search and similarity analysis methods. 
6.1.4.1  Conformation Search & Similarity Analysis 
The pharmacophore/bioactive conformation of the 45 compounds was taken to be 
the lowest energy conformation of the most active compound in the series.  Usually 
the lowest energy confirmation fits the pharmacophore,
49
 due to low energy 
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conformers being more highly popular than others according to Boltzmann 
distribution.
50
  Compound 15 (fig. 6.6) was found to have the most potent activity 
against both parasite strains, therefore a conformer distribution calculation of its 
structure was performed using the ‘Conformer Distribution Protocol’ detailed in the 
Experimental Chapter.  100 conformations were calculated, with the energy (kJ/mol) 
and Boltzmann distribution values for several of the most promising conformations 
reported in table 6.9.  The bioactive conformation was identified as that which had 
the lowest energy/highest Boltzmann distribution values (conformer 001). 
 
15 
Fig. 6.6  Molecule 15. 
Table. 6.9  Energy and Boltzmann distribution values for several conformers of molecule 15. 
Conformer Boltzmann Distribution Energy (kJ/mol) 
001 0.774661687 139.319048 
013 0.067193963 145.38013 
024 0.062738299 145.550227 
035 0.010870281 149.89599 
046 0.009892085 150.129766 
057 0.007285027 150.888166 
068 0.007183015 150.923127 
079 0.005686303 151.502397 
The chemical function descriptors (CFDs) available within Spartan ’0851 were used 
to define the pharmacophore, and are described in table 6.10.  Figure 6.7 illustrates 
the lowest energy conformation of compound 15 (hydrogen atoms not shown), 
together with labels indicating the corresponding CFDs.  It is important to note that 
Spartan ‘0851 does not consider the directionality of the pharmacophore, such as the 
direction of H-bond donors or acceptors, simply the presence of absence of particular 
features. 
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Table. 6.10  Chemical functional descriptors. 
Label CFD Chemical Meaning 
1 Hydrophobe Sterically-crowded region 
2 Aromatic Aromatic π system 
3 Hydrogen-bond donor Acidic hydrogen 
4 Hydrogen-bond acceptor Lone pair 
5 Positive ionisable site Basic site 
6 Negative ionisable site Acidic site 
 
 
Fig. 6.7  CFDs of the lowest energy conformation of compound 15 (pharmacophore). 
A conformer library was generated for the other 44 molecules in the dataset, using 
the ‘Conformer Library Protocol’ as described in the Experimental Chapter.  The 
conformer of each compound that most closely matched the pharmacophore was 
assumed to be that compounds bioactive conformation.  The CFD pharmacophore of 
compound 15 was first defined and then each conformer in the library for all 
molecules compared to it.  This was done using the ‘Similarity Analysis Protocol’ as 
described in the Experimental Chapter.  Each conformer was scored between zero 
and one, with a score of one indicating perfect similarity between the conformer and 
the pharmacophore (according to CFDs), and a score of zero indicating no 
similarity.
52
  The highest scoring conformer for each molecule (all of which had a 
similarity score above 0.6) was taken to be the bioactive conformer for that 
compound. 
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673 3D descriptors were calculated with DRAGON 3.0
19
 using the bioactive 
conformation of the 45 compounds, making for a total of 1630 descriptors, 
describing the 0, 1, 2 and 3D chemical properties of the molecules.  QSAR models 
could then be developed to see how the inclusion of 3D descriptors affected the 
results. 
6.1.4.2  NF54 Dataset 
With this increased number of descriptors, a different approach was taken to reduce 
these to only those which best described the activity.  To begin, models were 
developed for the NF54 dataset using all descriptors via ‘QSAR Protocol 2’ 
(Quantitative Structure Activity Relationships\Appendix 05), with table 6.11 
describing the most successful model. 
Table. 6.11  Statistics for model 5. 
Model 5 
Subjective selection method Genetic algorithm 
 
Training set size 40 
 
Test set size 5 
 
Number of descriptors 8 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 5 
 
Internal Validation 
Parameter Value Valid? 
   0.84 Yes 
   0.75 Yes 
 -statistic 20.47 Yes (Table value 2.26) 
Bootstrapping 0.66 Yes (Ideally > 0.54) 
External Validation 
Parameter Value Valid? 
   0.56 Yes 
   0.72 Yes 
      
      0.002 Yes 
  1.004 Yes 
   
    
    0.14 Yes 
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This model (model 5) had excellent internal and external statistics, but the sphere 
exclusion algorithm only allowed a split with a maximum of five compounds in the 
test set, despite alterations to the dissimilarity parameters.  This is most likely due to 
the large number of descriptors and difficulties in dividing the data.  To combat this 
it was necessary to reduce the number of descriptors prior to splitting.  The 1630 
descriptors were calculated using ADMEWORKS Modelbuilder
18
 (523 descriptors) 
and DRAGON 3.0
19
 (1107 descriptors), so models were built for each of these 
descriptor sets independently, using ‘QSAR Protocol 1’ (Quantitative Structure 
Activity Relationships\Appendix 06).  The descriptors from each of the valid models 
were inspected, and those with a  -statistic greater than 2 were considered to be the 
best in describing the activity of the NF54 strain.  In total, 38 descriptors across the 
two descriptor sets obeyed this criterion.  This subset of descriptors were used to 
develop further models according to ‘QSAR Protocol 2’ (Quantitative Structure 
Activity Relationships\Appendix 07), with three internally and externally valid 
models found using the GALib
53
 subjective selection method, as detailed in table 
6.12.  The test sets for each of these models contained ten molecules, making them 
excellent sample sets with which to test the predictive capabilities of the models.
41
 
Table. 6.12  Statistics for the three internally and externally significant NF54 models. 
Model Data Method 
Training set statistics Test set statistics 
r
2
 q
2 
F rBS
2
 q
2
 r
2
 (r
2
-r0
2
)/r
2
 k |r
2
 – r0
2
| 
6 NF54 GALib-MLR 0.90 0.69 20.70 0.59 0.75 0.88 0.03 1.00 0.11 
7 NF54 GALib-MLR 0.83 0.53 18.23 0.70 0.68 0.80 0.01 1.01 0.12 
8 NF54 GALib-MLR 0.85 0.59 18.54 0.61 0.64 0.86 0.05 1.01 0.17 
Table 6.13 gives the full statistics for one of the models in the series. 
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Table. 6.13  Statistics for model 7. 
Model 7 
Subjective selection method GALib 
 
Training set size 35 
 
Test set size 10 
 
Number of descriptors 7 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 5 
 
Internal Validation 
Parameter Value Valid? 
   0.83 Yes 
   0.72 Yes 
 -statistic 18.23 Yes (Table value 2.37) 
Bootstrapping 0.70 Yes (Ideally > 0.53) 
External Validation 
Parameter Value Valid? 
   0.68 Yes 
   0.80 Yes 
      
      0.01 Yes 
  1.01 Yes 
   
    
    0.12 Yes 
Though the models looked encouraging, the LMO cross-validation approach was 
used for additional validation.  The LMO cross-validation method involves dividing 
the dataset into several groups, and then building models for each of these subsets 
and calculating the    statistic.  Through repetition, a mean    can be found, which 
ideally should not be much lower than the    value calculated for the entire dataset.  
Usually a high value of    (greater than 0.5) is considered proof of a models 
predictive ability,
35
 and is a useful addition to evaluate a models performance.  It is 
also a more rigorous validation procedure than LOO cross-validation.
22
  Y-
scrambling was performed for both the    and LMO-   statistics.  Y-scrambling is 
useful to validate the robustness of a QSAR model, identifying those models based 
on chance correlation.
22
  Models are developed and assessed when the dependent 
variable is randomly modified by assigning each compound a different dependent 
variable from the true set of responses.
39
  If the original model is significant then 
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there should be a significant difference in the quality of the original model, and the 
average of those found using Y-scrambling.
37
 
These additional statistical parameters for models 6 to 8 are shown in table 6.14.  
They were calculated using R 2.9.0,
54
 which is a command line program used for 
statistical computing.  The LMO cross-validation statistic was found by dividing the 
training set into five groups and then calculating the    value for the data not used to 
develop the model.  This was performed 1000 times and an average LMO value 
taken.  Y scrambling was performed for both the    and LMO-   parameters using 
1000 iterations. 
Table. 6.14  Additional statistics for the three internally and externally significant NF54 models. 
Model Data Method 
Training set statistics 
r
2
 
Average r
2
 
(Y scrambling) 
LMO q
2
 
Average LMO q
2
 
(Y scrambling) 
6 NF54 GALib-MLR 0.90 0.30 0.59 0.036 
7 NF54 GALib-MLR 0.83 0.21 0.59 0.034 
8 NF54 GALib-MLR 0.85 0.23 0.52 0.032 
All three models had acceptable statistics, with    values above 0.7, and LMO-   
values above 0.5.  When Y scrambling was performed, these statistics were 
significantly lower as the data had been jumbled and therefore predictive models 
could not be found.  This suggests that these models were not down to chance, and 
are more easily explained in graphical form.  The first two graphs in figure 6.8 
represent the histograms of the    and LMO-   values from Y scrambling for model 
7.  The vertical line represents the actual value for that statistic for the model, with 
the histogram showing the distribution of that statistic across the 1000 scrambled 
models.  In both cases, the bars of the histogram are much lower than the actual 
value, indicating that scrambling the data does indeed affect the models, and thus it 
is unlikely that model 7 is down to chance.  The third graph shows the relationship 
between    and LMO-   across all 1000 models, with the green spot representing 
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model 7.  This offers further support for the quality of model 7.  These graphs were 
similar for models 6 and 8 also, further supporting their quality. 
 
Fig. 6.8  Graphs illustrating the effect of Y scrambling on the    and LMO-   statistics for model 7. 
The overall performance of the QSARs when only the 38 pre-selected descriptors 
were used produced much better models.  Figure 6.9 illustrates the predicted versus 
actual activity values for both the training and test sets of models 7.  As can be seen, 
unlike the previous models for the NF54 dataset, there is a clear linear relationship 
for both the training and test sets, indicative of the good predictive ability of the 
model.  Importantly, it can also be seen that the data points are well distributed 
across the range of activities in both the training and test sets. 
 
Fig. 6.9  Graph representing the predicted vs. actual activity values for model 7. 
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The most commonly occurring descriptors across the three significant models were 
identified as those which best described the NF54 activity.  Only those descriptors 
which had a  -statistic greater than 2 were considered meaningful, with figure 6.10 
illustrating the frequency of the descriptors across the models. 
 
Fig. 6.10  Frequency of descriptors across the three significant NF54 models with a  -statistic greater 
than 2. 
Six descriptors were found to be present in all three models (G3u; Hy; JGI5; 
Mor31m; PCHGMH; RDF055m) and were deemed to be of most interest.  However, 
models were first developed for the K1 dataset to enable a comparison of the most 
important descriptors in modelling the activity of both strains.  From this, 
conclusions could be drawn as to the chemical properties that effect the prediction of 
activity. 
6.1.4.3  K1 Dataset 
The same approach was therefore used to develop models for the K1 dataset when 
the 3D descriptors were included.  As with the NF54 dataset, when all 1630 
descriptors were first used to develop models for K1 via ‘QSAR Protocol 2’, this 
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yielded no externally valid models (Quantitative Structure Activity 
Relationships\Appendix 08).  The descriptors were therefore split into two subsets 
(ADMEWORKS Modelbuilder
18
 and DRAGON 3.0
19
 descriptors) and ‘QSAR 
Protocol 1’ was used to build models for each.  Several internally significant models 
were identified (Quantitative Structure Activity Relationships\Appendix 09), with the 
descriptors from models that had a  -statistic greater than 2 considered to be those 
which best described the activity of the K1 strain.  This gave 33 descriptors which 
were used to develop further models via ‘QSAR Protocol 2’ (Quantitative Structure 
Activity Relationships\Appendix 10).  Four internally and externally valid models 
were found using the GA and stepwise regression subjective selection methods, as 
shown by table 6.15. 
Table. 6.15  Statistics for the four internally and externally significant K1 models. 
Model Data Method 
Training set statistics Test set statistics 
r
2
 q
2 
F rBS
2
 q
2
 r
2
 (r
2
-r0
2
)/r
2
 k |r
2
 – r0
2
| 
9 K1 GA-MLR 0.91 0.83 35.09 0.78 0.72 0.75 0.019 1.00 0.011 
10 K1 GA-MLR 0.91 0.83 33.48 0.72 0.57 0.68 0.0027 1.00 0.11 
11 K1 Stepwise 0.68 0.56 22.45 0.53 0.88 0.89 0.038 1.00 0.031 
12 K1 Stepwise 0.74 0.62 25.06 0.56 0.59 0.68 0.018 1.00 0.051 
The test sets for models 9 to 12 contained a varying number of molecules, with one 
of the best performing models built using only 31 compounds, and externally 
validated on the other 14.  The statistics for this model (model 12) are shown in table 
6.16. 
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Table. 6.16  Statistics for model 12. 
Model 12 
Subjective selection method Stepwise regression 
 
Training set size 31 
 
Test set size 14 
 
Number of descriptors 3 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 10.333 
 
Internal Validation 
Parameter Value Valid? 
   0.74 Yes 
   0.62 Yes 
 -statistic 25.06 Yes (Table value 2.96) 
Bootstrapping 0.56 Yes (Ideally > 0.44) 
External Validation 
Parameter Value Valid? 
   0.59 Yes 
   0.68 Yes 
      
      0.018 Yes 
  1.00 Yes 
   
    
    0.051 Yes 
As with the NF54 models, additional validation of models 9 to 12 was sought using 
LMO cross-validation, and Y scrambling of the    and LMO-   statistics (1000 
iterations).  The results of this analysis can be seen in table 6.17. 
Table. 6.17  Additional statistics for the four internally and externally significant K1 models. 
Model Data Method 
Training set statistics 
r
2
 
Average r
2
 
(Y scrambling) 
LMO q
2
 
Average LMO q
2
 
(Y scrambling) 
9 K1 GA-MLR 0.91 0.28 0.82 0.042 
10 K1 GA-MLR 0.91 0.23 0.82 0.053 
11 K1 Stepwise 0.68 0.085 0.56 0.046 
12 K1 Stepwise 0.74 0.10 0.62 0.057 
These statistics offered further validation of the predictive nature of the four models, 
suggesting that the QSARs were meaningful and not just down to chance.  Figure 
6.11 illustrates the results of Y scrambling for the best model (model 12), with the 
bars of the histograms being much lower than the actual model values for both    
and LMO-  .  Models 9, 10 and 11 reported similar graphs. 
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Fig. 6.11  Graphs illustrating the effect of Y scrambling on the    and LMO-   statistics for model 
12. 
With the models sufficiently validated it could be concluded that successful QSARs 
had been developed to model the K1 data, with figure 6.12 clearly illustrating the 
linear relationship observed between the training and test sets for model 12. 
 
Fig. 6.12  Graph representing the predicted vs. actual activity values for model 12. 
The commonly occurring descriptors across the four valid K1 models which had a  -
statistic greater than 2 were identified, as was done with the NF54 models.  The 
frequency of these descriptors is shown in figure 6.13.  Only the Mor31e descriptor 
appeared in all four of the models, but several others did appear in half of them (i.e. 
DIPY, HARD, Rings count). 
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Fig. 6.13  Frequency of descriptors across the four significant K1 models with a  -statistic greater 
than 2. 
Figure 6.14 shows the frequency of the molecular descriptors for both of the strains.  
DIPY and HARD were found to be the only descriptors common to models from 
both strains, whilst many others were unique to a particular strain.  These descriptors 
were hoped to provide useful insight with regard to the nature of resistance between 
the two strains. 
 
Fig. 6.14  Comparison of descriptor frequencies for the NF54 and K1 models. 
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Table 6.18 gives a brief definition of each of the descriptors in figure 6.14. 
Table. 6.18  Descriptor abbreviations. 
Abbreviation Description 
DIPY Dipole Moment Y 
FDI folding degree index 
G3u 3st component symmetry directional WHIM index / unweighted 
GATS7p Geary autocorrelation - lag 7 / weighted by atomic polarizabilities 
H5m H autocorrelation of lag 5 / weighted by atomic masses 
H5p H autocorrelation of lag 5 / weighted by atomic polarizabilities 
HARD Hardness 
HATS7p leverage-weighted autocorrelation of lag 7 / weighted by atomic polarizabilities 
Hy hydrophilic factor 
J3D 3D-Balaban index 
JGI5 mean topological charge index of order5 
Mor04e 3D-MoRSE - signal 04 / weighted by atomic Sanderson electronegativities 
Mor11e 3D-MoRSE - signal 11 / weighted by atomic Sanderson electronegativities 
Mor31e 3D-MoRSE - signal 31 / weighted by atomic Sanderson electronegativities 
Mor31m 3D-MoRSE - signal 31 / weighted by atomic masses 
PCHGMH Mean partial charge on H atoms 
R8u+ R maximal autocorrelation of lag 8 / unweighted 
RDF055m Radical Distribution Function - 5.5 / weighted by atomic masses 
Rings count Number of rings 
X2Av average valence connectivity index chi-2 
6.1.5 Combinatorial MLR Calculations 
To gather further support of the descriptors detailed in figure 6.14, work was 
performed using UNIX codes to run MLR calculations that could account for any 
possible combination of descriptors, up to a maximum of 23.
55
  A set of criteria were 
set such that only the most useful information would be recorded, with separate 
models built for both strains using the same 20 molecular descriptors for each.  
These 20 descriptors were those described in figure 6.14, as these had previously 
proven to be significant across both datasets.  Only models with an    value greater 
than 0.7, and between 1 and 9 descriptors were reported 
For the NF54 dataset there were 41 models which fit these criteria, the results of 
which are shown in table 6.19.  The frequency of the descriptors within these 41 
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models is expressed numerically and as a percentage, as well as the percentage 
population of the descriptor across all models. 
Table. 6.19  Descriptor frequencies across the 41 models generated via combinatorial MLR 
calculations for the NF54 dataset. 
Descriptor 
Frequency 
(Number) 
Frequency 
(Percentage) 
Population of descriptor 
(Percentage) 
Hy 41 100.00% 13.44% 
JGI5 40 97.56% 13.11% 
RDF055m 39 95.12% 12.79% 
Mor31m 37 90.24% 12.13% 
H5m 34 82.93% 11.15% 
PCHGMH 28 68.29% 9.18% 
HARD 25 60.98% 8.20% 
DIPY 17 41.46% 5.57% 
H5p 9 21.95% 2.95% 
FDI 7 17.07% 2.30% 
GATS7p 7 17.07% 2.30% 
Mor31e 6 14.63% 1.97% 
HATS7p 4 9.76% 1.31% 
Mor04e 3 7.32% 0.98% 
J3D 2 4.88% 0.66% 
Rings count 2 4.88% 0.66% 
G3u 2 4.88% 0.66% 
R8u+ 1 2.44% 0.33% 
Mor11e 1 2.44% 0.33% 
The descriptor Hy was present in all 41 models, whilst JGI5 was found in all but 
one.  This is in strong accordance with the results in figure 6.14.  Additionally, the 
work showed that the descriptor HARD was of moderate importance within many of 
the models. 
The same combinatorial MLR analysis was performed for the K1 dataset, with 61 
models found to have fewer than 23 descriptors and an    value greater than 0.7.  
These results are shown in table 6.20. 
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Table. 6.20  Descriptor frequencies across the 61 models generated via combinatorial MLR 
calculations for the K1 dataset. 
Descriptor 
Frequency 
(Number) 
Frequency 
(Percentage) 
Population of descriptor 
(Percentage) 
Mor31e 61 100.00% 15.48% 
J3D 53 86.89% 13.45% 
HARD 53 86.89% 13.45% 
DIPY 50 81.97% 12.69% 
HATS7p 29 47.54% 7.36% 
JGI5 25 40.98% 6.35% 
Mor04e 23 37.70% 5.84% 
H5p 21 34.43% 5.33% 
PCHGMH 17 27.87% 4.31% 
X2Av 16 26.23% 4.06% 
Rings count 15 24.59% 3.81% 
FDI 11 18.03% 2.79% 
H5m 9 14.75% 2.28% 
Hy 6 9.84% 1.52% 
Mor31m 3 4.92% 0.76% 
R8u+ 1 1.64% 0.25% 
G3u 1 1.64% 0.25% 
The Mor31e descriptor was present in all models, with HARD also found to be 
particularly prevalent.  Once again, this is in line with GA-MLR analysis (fig. 6.14).  
Given that HARD was present in models for both the NF54 and K1 datasets; this 
suggests that the hardness of the molecules plays a key role in their antimalarial 
activity against both strains.  Thus far only QSAR models developed using MLR 
have been discussed.  However, it can be useful to use a consensus of different 
approaches,
56, 57
 to identify commonality between the results which will hopefully 
offer further support for conclusions drawn from descriptor analysis.  
6.1.6 Partial Least Squares 
Partial least squares (PLS) regression is a useful technique when the number of 
independent variables is comparable to, or much greater than, the number of 
compounds.  It can lead to stable and highly predictive models, even when there is a 
large degree of correlation between the descriptors.
58
  It is a statistical method which 
is a combination of MLR and principle components regression (PCR),
59
 and is used 
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to explain the variance across the descriptors, whilst attempting to obtain a good 
correlation between the dependent and independent variables.  In PCR, the principle 
components are used as variables in an MLR type equation.  This often leads to a 
concise QSAR equation as shown by equation 6.15, with the principle components 
selected based on their ability to explain the variance of the independent variables. 
                      
Eq. 6.15  Linear equation using principle components. 
PLS differs from PCR in that the components are calculated to explain the variation 
in both the independent and dependent variable, with the purpose being to find a 
small number of relevant factors that are predictive of the dependent variable, 
utilising the independent variables most efficiently.
60
  PLS expresses the dependent 
variable in terms of quantities termed latent variables (  ), as oppose to principle 
components seen in PCR.  This gives an MLR equation of the form shown in 
equation 6.16.
1
 
                        
Eq. 6.16  PLS regression equation. 
The latent variables (  ) are themselves linear combinations of the independent 
variables (  ) as shown by equations 6.17.
1
 
                       
                       
                       
Eq. 6.17  Latent variable equations. 
The number of latent variables that can be generated is the smaller of the number of 
descriptors, or the number of observations.  The latent variables are orthogonal to 
each other, and when calculated, PLS takes into account not only the variance in the 
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  variables, but also how this corresponds to the values of the dependent variable.  
The first latent variable (  ) is a linear combination of the   values which give a 
good explanation of the variance in the  -space.  However, it is also defined so that 
when multiplied by its corresponding coefficient (  ), it provides a good 
approximation of the variation in the dependent variable.  The second latent variable 
can then be determined and is orthogonal to the first, enabling more of the variation 
in the   dimension to be described, and for the prediction of the dependent variable 
to be further improved. 
Analysis of PLS models can provide information about how the variables in a dataset 
can be combined to form a quantitative relationship between   and  .  The weights 
of the various components provide understanding of which   variables are important, 
and which are uninformative,
22
 with PLS models subject to the same level of 
scrutiny as those from MLR (i.e. internal and external validation).  A major 
advantage of PLS is that unlike MLR, having a small number of descriptors is not a 
prerequisite for a meaningful model, in fact, sometimes a larger number of 
descriptors can create a better predictive model.
58, 61
 
6.1.6.1  PLS Models 
A series of QSAR models were developed for both the NF54 and K1 datasets 
(Quantitative Structure Activity Relationships\Appendix 11 and 12 respectively) 
using ‘QSAR Protocol 3’ as described in the Experimental Chapter, based on the 
previously selected descriptor subsets for each strain which had shown to be most 
promising (38 for NF54, 33 for K1). 
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6.1.6.1.1  NF54 Dataset 
Table 6.21 gives the statistics for the best performing NF54 model, in which all but 
the internal bootstrapping statistic indicated a good model. 
Table. 6.21  Statistics for model 13. 
Model 13 
Training set size 37 
 
Test set size 8 
 
Number of components 7 
 
Machine learning method PLS 
 
Internal Validation 
Parameter Value Valid? 
   0.97 Yes 
   0.60 Yes 
 -statistic 4.04x109 Yes (Table value 2.35) 
Bootstrapping 0.45
 
No (Ideally > 0.67) 
External Validation 
Parameter Value Valid? 
   0.72 Yes 
   0.84 Yes 
      
      0.007 Yes 
  1.01 Yes 
     
    0.07 Yes 
Figure 6.15 illustrates the predicted versus actual activity values for this model, for 
both the training and test sets.  As can be seen, strong linear relationships were 
observed for both. 
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Fig. 6.15  Graph representing the predicted vs. actual activity values for model 13. 
6.1.6.1.2  K1 Dataset 
Table 6.22 gives the statistics for the best performing K1 model which passed all 
internal and external validation testing. 
Table. 6.22  Statistics for model 14. 
Model 14 
Training set size 31 
 
Test set size 14 
 
Number of components 4 
 
Machine learning method PLS 
 
Internal Validation 
Parameter Value Valid? 
   0.98 Yes 
   0.75 Yes 
 -statistic 5.72x109 Yes (Table value 2.74) 
Bootstrapping 0.77
 
Yes (Ideally > 0.68) 
External Validation 
Parameter Value Valid? 
   0.80 Yes 
   0.85 Yes 
      
      0.01 Yes 
  1.01 Yes 
   
    
    0.01 Yes 
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Figure 6.16 illustrates the predicted versus actual values for this model, for both the 
training and test sets.  As with the model for the NF54 dataset, strong linear 
relationships were observed. 
 
Fig. 6.16  Graph representing the predicted vs. actual activity values for model 14. 
Generally, models developed using PLS produced excellent results, with the K1 
models performing slightly better than those from NF54 analysis.  The K1 models 
also required fewer components and explained a larger amount of data.  As PLS uses 
components not descriptors, it was necessary to look at the weights of the descriptors 
within these components to assess their respective contributions.  The descriptors 
with the largest weights added more to a particular component, and were therefore 
considered most useful in describing activity (Quantitative Structure Activity 
Relationships\Appendix 13). 
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6.1.7 Descriptor Frequencies 
By comparing the results of the MLR and PLS models a set of potentially useful 
descriptors were identified.  Some of these were common to both strains whilst 
others were unique to each.  Descriptors present in both strains were thought to be 
important in order to explain why these compounds were initially active, whilst those 
present in only one strain could highlight possible differences between the two.  It 
was thought that this information may be useful in understanding the resistance 
mechanism observed towards these 4-aminoquinoline compounds. 
The two most important descriptors to model the NF54 dataset were Hy and JGI5, as 
they were the most frequently occurring descriptors for both the MLR and PLS 
models.  Mor31e was found to be the most important/frequently occurring descriptor 
for modelling the K1 data, with the HARD descriptor fairly common across models 
from both strains of the parasite. 
6.1.8 Descriptor Interpretations 
Whilst it is not always essential to extract some sort of chemical meaning from a 
model, as it is its predictive ability which is most important, it can be useful to 
interpret the molecular descriptors and is a recommended practice.
22
  Some 
descriptors such as log P or molecular weight are easy to interpret, whilst others can 
be more difficult.  For several of the descriptors highlighted to be of interest from the 
study, it was difficult to infer some sort of easily understandable chemical meaning, 
however, what follows is an attempt to do so. 
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6.1.8.1  Hy 
The Hy descriptor represents the hydrophilic factor, or hydrophilicity index.  It was 
introduced by Todeschini and Gramatica
62
 as a measure for the hydrophilic 
properties of a compound, and thus is (negatively) related to its hydrophobic 
properties.
63
  Hy is a simple empirical index related to the hydrophilicity of a 
compound based on its substituent’s, and can be calculated using equation 6.18.62  In 
the equation,     represents the number of hydrophilic groups (-OH, -SH, -NH),    
the number of carbon atoms and   the number of atoms (excluding hydrogen). 
   
                        
 
      
 
   
 
   
  
         
 
Eq. 6.18  Hydrophilic factor equation. 
Statistically Hy was identified as the most important molecular descriptor across the 
NF54 models, with the observed positive coefficient value of Hy suggesting that 
increasingly hydrophilic compounds have improved activity.
64
  None of the K1 
models contain the Hy descriptor, so this may have some reflection towards the 
mechanism of resistance in the K1 parasite.  It would therefore be plausible to 
suggest, that given the hydrophilic factor of a molecule offers no indication as to 
how it will behave in the resistant strain, perhaps there has been some sort of 
hydrophobic change within the parasite, resulting in the acquisition of resistance.  
Either way, there has been some sort of change which has effected how hydrophilic 
molecules behave at the active site, because whilst the Hy descriptor was extremely 
important in exploring NF54 activity, it has no bearing on the models for K1. 
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6.1.8.2  JGI5 
The JGI5 descriptor represents the mean Galvez topological charge index of order 
5.
65
  Topological charge indices were proposed to evaluate the charge transfer 
between pairs of atoms, and therefore the global charge transfers in a given 
molecule.
66-68
  Since many important physical, chemical, and biological properties 
are related to the charge distribution, the introduction of a topological index which 
could characterise this essential property was necessary. 
Given the negative coefficient value of JGI5 across the NF54 models, it is possible 
that molecules which have a lower global charge transfer have better activity against 
the NF54 strain of the parasite, with only a moderate influence in the K1 strain (table 
6.20). 
6.1.8.3  Mor31e 
Mor31e is a 3D-MoRSE descriptor which encodes for signal 31 weighted by atomic 
Sanderson electronegativities.
65
  3D-MoRSE descriptors are 3D-molecular 
representations of structures based on electron diffraction.  They are based on the 
idea of obtaining information from the 3D atomic coordinates by the transformation 
used in electron diffraction studies for preparing theoretical scattering curves.
69
 
Very little information is available with regard to the chemical applications of the 
Mor31e descriptor, but it was found to be the most essential descriptor to explain and 
predict the activity of molecules against the K1 strain of the parasite.  The negative 
coefficient values of Mor31e across the models indicates that it has a negative effect 
on the activity of compounds against K1, and thus compounds with a smaller 
Mor31e value may give improved activity against K1.  A potential avenue of 
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exploration would be to consider calculating the Mor31e descriptor for a series of 
compounds and select those which report the lowest values, or to simply apply the 
full QSAR equation described in table 6.16 (model 12). 
6.1.8.4  HARD 
The HARD descriptor describes the hardness of a compound, and is calculated using 
MOPAC
70
 (Molecular Orbital PACkage).  MOPAC is a widely used semi-empirical 
quantum mechanical software package with a wide range of functionality.
71
  HARD 
measures the resistance to change of electron distribution in a collection of nuclei 
and electrons.
72
  It comes from the HSAB concept, which is an acronym for ‘hard 
and soft acids and bases’, also known as the Pearson acid base concept.73  This 
concept is widely used in chemistry for explaining the stability of compounds, 
reaction mechanisms and pathways, as well as to assign the terms ‘hard’ or ‘soft’, 
and ‘acid’ or ‘base’ to chemical species.  ‘Hard’ applies to species which are small, 
have high charge states and are weakly polarisable.  ‘Soft’ applies to species which 
are big, have low charge density and are strongly polarisable. 
The negative coefficient values of the HARD descriptor across the NF54 and K1 
models suggests that ‘hard’ molecules have a negative impact on activity against the 
parasite, with ‘soft’ molecules i.e. those which are big and have low charge density, 
having much higher activity. 
6.1.9 Descriptors and Chloroquine Resistance 
As the Hy descriptor was the most important descriptor in describing the NF54 
activity, and was absent from all the K1 models (bar 9.84% of the models calculated 
through combinatorial MLR analysis), it was therefore of little use in explaining the 
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activity of molecules toward the CQR strain of the parasite.  However, through 
closer inspection of the descriptor it was possible to comment on the relationship 
between Hy and the biological activity of the 4-aminoquinoline compounds.  As 
hydrophilic compounds are typically polar and capable of forming hydrogen bonds, 
they are more likely to become charged under the right conditions.  This lends itself 
well to the theory as to how CQ and other aminoquinoline compounds become 
trapped in the DV.  These hydrophilic compounds can become doubly protonated 
and membrane impermeable, thus leading to their accumulation in the acidic food 
vacuole.  The fact that none of the K1 models make use of the Hy descriptor 
suggests that whether the compounds are easily protonated or not, has no bearing on 
their activity against the CQR strain, suggesting other factors must be at play.  The 
molecules can easily be removed from the DV because of the mutation replacing the 
positive lysine with the neutral threonine.  These results may therefore act to support 
the findings of others with regard to explaining CQ drug resistance.
74
 
6.1.10  k-Nearest Neighbour 
Though MLR and PLS were proven to give comprehensive results, additional work 
was carried out to develop models using the k-Nearest Neighbour (kNN) machine 
learning method, which is conceptually one of the simplest machine learning 
algorithms.  Unlike regression methods which make the assumption that 
relationships are linearly related, kNN provides a non-linear method for deriving 
QSAR models.  The kNN technique is a simple approach to pattern recognition 
problems,
75
 with an unknown pattern being classified according to the majority of 
the class memberships of its k-nearest neighbours in the training set.  The nearness is 
measured by an appropriate distance metric (i.e. a molecular similarity measure as 
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applied to the classification of molecular structures).  The standard kNN method is 
implemented simply as follows:
76
 
1. Calculate distances between an unknown object (u) and all the objects in the 
training set 
2. Select k objects from the training set most similar to object u, according to 
the calculated distances (k is usually an odd number) 
3. Classify object u with the group to which a majority of the k objects belong 
An optimal k value is selected by the optimisation through the classification of a test 
set of samples, or via leave-N-out cross-validation.  An object is classified by a 
majority vote of its neighbours, with the object being assigned to the class most 
common amongst its k-nearest neighbours.  k is a positive integer, typically small.  If 
   , then the object is simply assigned to the class of its nearest neighbour.  In 
binary (two class) classification problems, it is helpful to choose k to be an odd 
number, as this avoids tied votes. 
The same method can be used for regression, by simply assigning the property value 
for the object to be the average of the values of its k nearest neighbours. It can be 
useful to weight the contributions of the neighbours, so that the nearer neighbours 
contribute more to the average than the distant ones. 
The neighbours are taken from a set of objects for which the correct classification 
(or, in the case of regression, the value of the property) is known. This can be 
thought of as the training set for the algorithm, though no explicit training step is 
required. In order to identify neighbours, the objects are represented by position 
vectors in a multidimensional feature space.  It is usual to use Euclidean distance, 
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though other distance measures, such as the Manhattan distance could in principle be 
used instead. The k-nearest neighbour algorithm is however sensitive to the local 
structure of the data. 
The kNN-QSAR method combines the kNN classification principle with the variable 
selection procedure.  For each predefined number of variables (nvar) it seeks to 
optimize the following using stochastic sampling and simulated annealing as an 
optimisation tool. 
1. The number of nearest neighbours (k) used to estimate the activity of each 
compound 
2. Selection of variables from the original pool of all molecular descriptors that 
are used to calculate similarities between compounds 
The upper limit of k is the total number of compounds in the data set, however, the 
best value has been found empirically to lie between 1 and 5.
75
  The philosophy of 
kNN is straightforward.  Since structurally similar compounds should have similar 
biological activities,
77
 then the activity of a compound can be predicted (or 
estimated) simply as the average of the activities of similar compounds. 
6.1.10.1  kNN Models 
‘QSAR Protocol 4’ as described in the Experimental Chapter outlines the method 
which was used in order to develop a series of models for the NF54 and K1 datasets, 
using the preselected descriptor subsets (38 and 33 respectively).  The main goal of 
kNN-QSAR was to see whether a non-linear method could identify any meaningful 
models.  The procedure involved using codes which generate large numbers of 
models for varying training and test set splits, optimising   for each one.  Those 
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which pass the required statistical parameters are recorded, and the subsequent 
models undergo randomization, with successful models grouped according to their 
significance. 
The randomization step produced a number of models for each of the strains.  The 
majority of the models for K1 were significant to 0.005%, whereas most of the 
models for NF54 were significant to only 1%.  The lower the percentage with which 
the models are significant, then the stronger the performance of the models, and the 
less likely it is that the relationships are down to chance.  The models for K1 were 
therefore statistically better than those for NF54.  This may be due to the 
characteristics of the datasets.  NF54 represents the sensitive strain, so a much 
broader set of chemical diversity is accommodated at the site of action, exhibited by 
the fact that CQ is active.  However, the activities of the molecules against the K1 
strain are dependent on a much more stringent set of criteria, so perhaps it is easier 
for this machine learning method to build models for this dataset.  This observation 
also holds true for the other machine learning methods employed, as generally the 
models for the K1 strain performed better than their NF54 counterparts. 
Figure 6.17 represents the average of the predicted values across all models, versus 
the actual values for the NF54 strain at 1% significance, including their SD values 
(Quantitative Structure Activity Relationships\Appendix 14). 
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Fig. 6.17  Average of the predicted values across all models vs. the actual values for the four NF54 
models significant to 1%. 
Only four models were found at the 1% significance level, with some of the 
molecules only being represented once.  This is why there appears to be very small 
error bars for some of the molecules, or none at all.  The data had an    value of 
0.63, which though encouraging, is not as promising as the results from MLR and 
PLS analysis. 
Figure 6.18 represents the average of the predicted values across all models, versus 
the actual values for the K1 strain at 0.005% significance, including their SD values 
(Quantitative Structure Activity Relationships\Appendix 14). 
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Fig. 6.18  Average of the predicted values across all models vs. the actual values for the eight K1 
models significant to 0.005%. 
The results are better than those for NF54, as there were eight models found to be 
significant at 0.005%, with the data having a    value of 0.68.  There is very little 
correlation/overlap between the descriptors used in the models for each strain, 
therefore the results are very limiting when it comes to extracting some sort of 
chemical meaning, as none stand out as more important than others.  The frequency 
of the descriptors across the four NF54 models is represented by table 6.23.  What is 
interesting to note is that none of the previously identified descriptors of interest (Hy 
and JGI5) were present in these models, nor was the HARD descriptor which was 
common to models for both strains.  This observation does not raise too much 
concern however, as the descriptors in kNN analysis are used in a non-linear fashion, 
and as such are less easy to interpret, compared to those from linear methods (i.e. the 
descriptor coefficient values). 
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Table. 6.23  Frequency of descriptors across the four NF54 models. 
Descriptors 
Frequency of Descriptor 
Across the Models 
DIP 4 
DIPX 4 
H5m 4 
Mor20e 4 
PCHGMH 4 
R1e 4 
RDF035e 4 
X2Av 4 
C-008 3 
GATS4e 3 
Mor24e 3 
R3u+ 3 
RDF055m 3 
G3u 2 
H-046 2 
H5p 2 
GGI1 1 
Mor31m 1 
The frequency of the descriptors across the eight K1 models was calculated and is 
represented by table 6.24.  The Mor31e descriptor which was common to most of the 
linear models was present in only three of the eight kNN models, whilst the HARD 
descriptor appeared in all of them.  These models are therefore much more 
supportive of the earlier conclusions. 
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Table. 6.24  Frequency of descriptors across the eight K1 models. 
Descriptors 
Frequency of Descriptor 
Across the Models 
FDI 8 
HARD 8 
HATS7p 8 
Mor20e 8 
DIPX 7 
RDF065m 6 
Mor04e 5 
RDF030m 5 
Mor31m 4 
PCHGMHT 4 
PW2 4 
BELp3 3 
ENEG 3 
Mor31e 3 
nCt 3 
R2u 3 
R8u+ 3 
SCOUNT(C-atom) 3 
DIPY 2 
G2v 2 
GGI1 2 
J3D 2 
LOGP 2 
RDF065m 2 
RTu+ 2 
Mor11e 1 
The main objective had however been achieved, which was to develop validated 
QSAR models for both strains using the kNN non-linear method.  The 
interpretability of these models is limited however when compared to the linear 
methods, as the descriptors cannot be easily weighted within the models, and are 
therefore unrelated to the mode of action of the molecules. 
This method created many training and test set splits to generate QSAR models, 
therefore in several of the statistically valid models, a number of the molecules were 
missing from the test set.  The reason for this may be due to the domain of 
applicability of the molecules within that model.  The kNN-QSARs were developed 
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by interpolating the activities of the k nearest neighbours for each compound to 
predict its activity.
75
  This procedure derives a special applicability domain specific 
to each particular model, to avoid making predictions for compounds that differ 
substantially from the training set molecules.
37
  The threshold    can be calculated 
from the training set models using equation 6.19.    is the average Euclidean 
distance between each compound and its k nearest neighbours (where k is the 
parameter optimized in the course of QSAR modelling),   is the standard deviation 
of these Euclidean distances, and   is an arbitrary parameter to control the 
significance level.  The default value of this parameter is set at 0.5, which formally 
places the allowed distance threshold at one-half of the standard deviation (assuming 
a Boltzmann distribution of distances between k-nearest neighbour compounds in the 
training set).  Thus, if the distance of the external compound from at least one of its 
nearest neighbours in the training set exceeds this threshold, the prediction is 
considered unreliable, and the result is omitted. 
        
Eq. 6.19  Threshold    calculation. 
6.1.11  Selective/Resistance Index 
Two distinct activity datasets for the same molecules can be compared through 
consideration of their selective or resistance index.  Calculating the ratio of activities 
between the NF54 and K1 strains (Quantitative Structure Activity 
Relationships\Appendix 16) for each compound gave an indication as to the 
resistance of the molecules between the two strains.  A higher value indicated a 
greater resistance for that particular molecule towards the K1 strain, with CQ 
therefore having the highest selective index value described in Patent 5596002.
12
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MLR models were first developed using ‘QSAR Protocol 1’ in order to identify a 
suitable descriptor subset using all 45 compound in the training set and all 1630 0 to 
3D molecular descriptors available.  From the statistically significant models which 
were generated, 33 descriptors were selected as these each had  -statistics greater 
than 2.  Further models were generated using this subset of descriptors according to 
‘QSAR Protocol 2’.  Whilst all of the models developed were internally valid 
(Quantitative Structure Activity Relationships\Appendix 17), externally they failed to 
meet all of the required parameters.  Table 6.25 and figure 6.19 illustrate the results 
from one such model. 
Table. 6.25  Statistics for model 15. 
Model 15 
Subjective selection method Genetic algorithm 
 
Training set size 38 
 
Test set size 7 
 
Number of descriptors 8 
 
Machine learning method MLR 
 
Molecule/Descriptor Ratio 4.750 
 
Internal Validation 
Parameter Value Valid? 
   0.85 Yes 
   0.70 Yes 
 -statistic 20.59 Yes (Table value 2.28) 
Bootstrapping 0.63 Yes (Ideally > 0.55) 
External Validation 
Parameter Value Valid? 
   0.43 No 
   0.76 Yes 
      
      0.01 Yes 
  1.01 Yes 
   
    
    0.15 Yes 
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Fig. 6.19  Graph representing the predicted vs. actual selective index values for model 15. 
In an ideal situation, the linear relationships between the training and test set would 
be as close to each other as possible.  Here however they have different gradients, 
indicating the poor predictive ability of the model.  This can also be seen by looking 
at the external    statistic for model 15.  The reason for this is most likely due to 
there being very little spread within the data.  All of the selective index values are 
within a range of 0.18, with CQ appearing as an outlier in the data.  This skews the 
results giving a cluster and a point, which becomes very difficult to accurately 
model.  Additional calculations were performed with CQ removed, but this still 
failed to produce any externally valid models, supporting the conclusion that the 
range of the dataset was too narrow to model in this manner. 
6.1.12  Summary of 4-Aminoquinoline QSAR Analysis 
A series of statistically significant QSAR models were generated for the 45 4-
aminoquinoline compounds described in Patent 5590002,
12
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against both the NF54 and K1 strains of the malaria parasite.  A host of machine 
learning methods were investigated, and the molecular descriptors contained within 
these valid models were interpreted with reference to the mechanistic mode of action 
of the 4-aminoquinolines.  Considerations were also been put forward with regard to 
combating the observed resistance in the parasite towards this class of compound.  
Several significant models were identified which were shown to have strong 
predictive abilities for both strains of the parasite.  These models can now be used to 
predict the antimalarial potential for new 4-aminoquinoline compounds, even before 
they have been synthesised.  This will help to refine the molecular design loop, and 
may help to reduce the number of redundant compounds which are made, thus 
creating a more efficient development process, as well as saving both time and 
money. 
6.2 Hepatitis C Thiazolides QSARs 
An additional QSAR study was performed in order to develop QSAR models for a 
series of thiazolide compounds which were active as antiviral agents against the 
hepatitis C virus (HCV).  This small study is now discussed. 
6.2.1 Hepatitis C Virus 
HCV is a single-stranded RNA virus of the Flaviviridae family that is responsible 
for hepatitis C in humans.
78
  Hepatitis C is an infectious disease primarily affecting 
the liver.  The infection is often asymptomatic, but chronic infection can lead to 
scarring of the liver and ultimately liver fibrosis, cirrhosis and cancer, which may 
appear up to 30 years later.
79-81
  About 170 million people worldwide are chronically 
infected with HCV, which is transmitted principally through blood infection, and for 
which there is currently no vaccine available.
82
  Many genotypes of HCV have been 
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recognised; with genotypes IA/IB accounting for about 70% of all cases, and 
genotypes IA/IB and IIA/IIB combined accounting for over 90%.
83
  Evaluation of 
anti HCV agents therefore usually begins with genotypes IA/IB. 
A number of therapeutic approaches to HCV treatment are possible.
78, 84
  However, 
the combination of (pegylated) interferon α (IFN-α) and ribavirin (fig. 6.20) is still 
regarded as standard of care (SOC), even though a sustained virological response is 
only observed in 50-60% of patients, with genotype I infections being more difficult 
to treat.
85, 86
  The mode of action of IFN-α-ribavirin is not wholly clear, but some 
kind of immunomodulatory effect does seem to be involved, and indeed a number of 
candidate anti-HCV therapies involve either new formulations of IFNs or other 
immune stimulants.
87
 
 
Fig. 6.20  Ribavirin. 
Nitazoxanide (NTZ, fig. 6.21) is a broad spectrum thiazolide anti-infective which has 
been licensed in the US for the treatment of diarrhoea.  It has also been shown to be 
effective against both DNA and RNA viruses, in particularly the hepatitis B virus 
(HBV) which causes hepatitis B, another infectious inflammatory disease of the 
liver.
88-90
  It is currently thought that NTZ acts via modulation of host cell 
processes,
91, 92
 and is an effective anti-HCV agent either alone or in combination 
with SOC treatment.
93-95
  Several thiazolide analogues have also shown promising 
anti-viral activity, with in vitro activity values comparable to those of NTZ with 
good cell safety indexes.
96
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Fig. 6.21  Nitazoxanide. 
It was hoped that by implementing QSAR methods using a number of thiazolide 
derivatives, good predictive models with which to model activity could be generated.  
A series of 27 compounds were considered, each of which had been tested against 
several assays for various HCV genotypes.
96
  Though manual interpretation of the 
SAR led to some interesting observations, such as methylation of the benzene ring 
leads to a decrease in activity, QSAR analysis allows for more informative 
conclusions to be drawn, as well as models which could be used for future 
prediction.  The 27 thiazolide derivatives could be split into two subsets according to 
their general structures.  The first subset contained 15 5’-nitro- and 5’-halothiazolide 
derivatives of the general structure shown in table 6.26, which also reports the 
activity values for each compound.  The primary assay was used to test against 
genotype IB, with CC50 and EC50 values reported for each compound in µM.  The 
former represents the concentration at which 50% cell cytotoxicity was observed, 
and the later the half maximal effective concentration of the compound.  Combined, 
these measure the cell safety and the in vitro activity of a molecule respectively.  
Compounds showing good efficacy in the primary assay were then subjected to a 
secondary assay of the same genotype, as well as a primary assay against genotype 
1A. 
 
 
 
 
Chapter VI 
 
369 
 
Table. 2.26  Activities of 5’-nitro and 5’-halothizolides against HCV replication. 
 
      
Primary assay 
Genotype 1B 
Secondary 
assay 
Genotype 1B 
Secondary 
assay 
Genotype 1A 
Compound R1 R2 R3 R4 R5 
CC50
 
(µM) 
EC50
 
(µM) 
CC50 
(µM) 
EC50 
(µM) 
CC50 
(µM) 
EC50 
(µM) 
1 Ac H H H NO2 38 0.21 35 0.25 49 0.33 
2 H H H H NO2 15 0.15 18 0.15 14 0.25 
3 H H H H Cl 15 10 
    
4 Ac H H H Cl 4.3 0.23 4.9 0.31 5.7 0.4 
5 H Me H H NO2 5 0.36 11 0.35 12 0.39 
6 H H H Cl NO2 >100.0 2     
7 Ac H H H Br 15 3.8 12 4.3 21 3.3 
8 H H H H Br 20 10 98 4.9 88 2.8 
9 H Me H H Br 21 1.9 15 >10.0 25 >10.0 
10 Ac H H Me Br 12 4.2 10 3 11 3 
11 H Cl H H Br 14 5.2 10 >10.0 11 >10.0 
12 Ac Me H H Cl 12 0.59 16 1.5 14 1 
13 H H Me H Cl 30 >10.0 
    
14 H H H Me Cl 2.3 >20.0 20 10 16 10 
15 H H H H F 24 >10.0 
  
2.9 >10.0 
Table 6.27 represents the second subset which consists of 12 4’- and 5’substituted 
thiazolides with the general structure shown, together with their activity. 
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Table. 6.27  Activities of 4’- and 5’-substituted thiazolides against HCV replication. 
 
    
Primary assay Secondary assay Secondary assay 
Genotype 1B Genotype 1B Genotype 1A 
Compound R1 R2 R3 
CC50 EC50 CC50 EC50 CC50 EC50 
(µM) (µM) (µM) (µM) (µM) (µM) 
16 Ac CF3 H 3.7 4.3 1.7 >10.0 1.4 >10.0 
17 Ac H CF3 2.8 >10.0     
18 H Me H 45 4.2 
    
19 H NHAc H 11 >10.0 
    
20 H CO2Et H 14 >10.0     
21 H H Ph 26 3.5 14 >10.0 29 >10.0 
22 H H SOMe 63 2 
    
23 H H SO2Me 85 0.5     
24 H SO2Me H 43 1.5     
25 H Br Me 15 >10.0 
    
26 H Br Ph 16 2.2 100 >10.0 62 >10.0 
27 H CN H 15 3.7 15 >10.0 11 >10.0 
Between the two subsets there were a total of 27 thiazolide derivatives.  Similar to 
the analysis of the 4-aminoquinoline dataset, QSARs were developed using the 
following three steps:
13
 
i. Data preparation 
ii. Data analysis 
iii. Model validation 
6.2.2 Data Preparation 
The 27 thiazolide derivatives were first constructed and energy minimised using the 
‘Energy Minimisation Protocol’.  946 (0, 1 and 2D) molecular descriptors were then 
calculated for each of the molecules using DRAGON 6.0.
97
  QSARs were developed 
for several of the assay datasets present in tables 6.26 and 6.27, however, in order to 
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assess the predictive ability of a model several considerations had to be put in place.  
A training set was required to contain a minimum of ten compounds,
40
 whilst the 
external test set should have a minimum of five compounds.
98
  As such, sufficient 
quantitative data existed for only four of the assays: primary assay genotype IB CC50 
(26 data points); primary assay genotype IB EC50 (20 data points); secondary assay 
genotype IB CC50 (15 data points); secondary assay genotype IA CC50 (16 data 
points).  These datasets allowed for sufficient splitting (large training and test sets), 
and also contained evenly distributed values with low µM or sub µM activities.  The 
CC50 and EC50 values were converted into pCC50 and pEC50 values using negative 
log transformations in order to normalise the data and hopefully create better fits 
(Quantitative Structure Activity Relationships\Appendix 18).
14
 
6.2.3 Model Development 
Initially, models were constructed for the dataset using GA-MLR according to 
‘QSAR Protocol 1’ (Quantitative Structure Activity Relationships\Appendix 19), with 
models validated using the previously discussed criteria for internal validation (table 
6.3).  Table 6.28 gives the statistics for the best performing model for each of the 
four assays when using all molecules in the training set.  As can be seen, a robust 
selection of models were found, each satisfying the specified internal validation 
criteria, and showing good correlations between measured and predicted activity 
values. 
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Table. 6.28  GA-MLR QSAR models and their performance statistics for the primary assay genotype 
IB CC50, primary assay genotype IB EC50,  secondary assay genotype IB CC50, secondary assay 
genotype IA CC50. 
 Primary assay genotype IB Secondary assay 
 CC50 EC50 
Genotype IB 
CC50 
Genotype IA 
CC50 
   0.81 0.77 0.81 0.77 
   0.68 0.60 0.63 0.62 
   
  0.60 0.50 0.51 0.48 
  21.73 12.29 15.37 13.38 
Significant descriptors BLI 
GATS8m 
P_VSA_MR_2 
RDF030p 
ATSC2p 
P_VSA_i_3 
G2u 
R5s+ 
nX 
JGI9 
RDF090m 
SpMax_B(s) 
RDF040v 
G1v 
One correlation is illustrated by figure 6.22, which shows the calculated against 
experimental activity values for the primary assay genotype 1B CC50. 
 
Fig. 6.22  GA-MLR regression model for the primary assay genotype IB CC50. 
The molecular descriptors used within each model were all significant as they 
observed  -statistic values greater than 2.  However, with only one exception, the 
descriptors were challenging to interpret with respect to aiding further manual 
molecular design.  The one interpretable descriptor was within the secondary assay 
IB CC50, model and encoded the number of halogens in a compound (nX).  For the 
other descriptors in the models a correlation with physically interpretable descriptors 
R² = 0.805 
3.5 
4 
4.5 
5 
5.5 
6 
3.5 4 4.5 5 5.5 6 
C
a
lc
u
la
te
d
 p
C
C
5
0
 
Experimental pCC50 
Chapter VI 
 
373 
 
was sought, with descriptors which had greater than or equal to 0.75 correlation 
identified.  For the primary assay genotype IB EC50, a high correlation was 
discovered between ATSC2p (negative correlation with respect to activity) and nH 
(number of hydrogen atoms) and N% (percentage of N atoms).  Additionally R5s+ 
(negative correlation with respect to activity) was negatively correlated with nH.  
This presents apposing opinions with regard to the nH descriptor, and thus is of little 
use.  Finally the SpMax_B(s) descriptor in the secondary assay genotype IA CC50 
model observed negative correlation with activity, and was negatively correlated 
with nF (number of F atoms).  Despite strong correlations, these descriptors are still 
of little use with reference to manual molecular design, and thus the mode of action 
for these compounds. 
The models all perform very well internally, but as has been stated throughout this 
chapter, the only true evaluation of a models predictive ability comes through 
external validation.
38
  When an internally significant model was developed it was to 
be applied to a test set and assessed using the external validation criteria specified in 
table 6.4.  The four assay datasets which contained sufficient data points needed to 
be split in order for their predictive ability to be studied.  To do this a number of 
splitting methods were considered.  Initially the sphere-exclusion algorithm was 
used,
44
 however, owing to the narrow range of activity values which spanned less 
than two orders of magnitude, this method had difficulties creating a suitable test set 
that represented the spread of the points suitably.  For this reason the CADEX 
(Computer Adjunct Data Evaluator X) algorithm
99
 was employed, with the test sets 
for each assay contained five molecules, satisfying the minimum number of 
molecules for the test set, yet leaving a suitably large training sets.  Models were 
then developed using GA-MLR via ‘QSAR Protocol 2’ (Quantitative Structure 
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Activity Relationships\Appendix 19).  Despite all the models having good internal 
statistics, when they were applied to their test sets they fell apart, failing to pass the 
external validation criteria.  Figure 6.23 represents the training and test set for one 
such failed model, in this case for the primary assay genotype 1B CC50 dataset.  
Though the    value for the test set had an acceptable value (       ), all the 
other statistics were poor.  The reason for this may once again be due to the limited 
spread of the data points in the test set. 
 
Fig. 6.23  Training and test set for the failed GA-MLR regression model of the primary assay 
genotype IB CC50. 
The final splitting method involved using activity binning.  Each molecule within the 
various assays was assigned to a specific bin, with the central molecule from each 
bin selected for the test set.  In cases where the bin contained an even number of 
molecules the highest median was selected, with this trend performed across all other 
even numbered bins.  This was then repeated only with the lower median compounds 
selected, and QSARs developed for both test splitting patterns.  However, even this 
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method of splitting failed to produce any meaningful models when developed using 
‘QSAR Protocol 2’. 
With linear QSAR methodology failing to produce any externally significant models 
despite a number of splitting methods being used, it was decided to explore the 
possibilities of a nonlinear method.  SVM has been discussed briefly in Chapter I, 
and has proven to be a useful technique for addressing a wide range of classification 
and regression problems.
100, 101
  SVM models were developed using a grid search 
approach through the workflow program KNIME,
102
 as outlined by ‘QSAR Protocol 
5’ described in the Experimental Chapter.  This grid search approach allowed for the 
parameters to be optimised in order to converge towards the best solutions.  Splitting 
of the dataset was performed prior to model development, with the CADEX 
algorithm failing to produce any splits which went on to yield meaningful models 
(Quantitative Structure Activity Relationships\Appendix 20).  Thus, activity binning 
was used and showed some success. 
It was performed by creating eqully sized bins which represented a particular 
proportion of the spread in activity values.  If five molecules were required in the test 
set, then the molecules were assigned to one of five unique bins.  The central 
molecule from each bin was then chosen to represent the test set.  As before, if an 
even number of molecules were in the bin then the highest median was selected, and 
QSARs built for this dataset, with the process repeated using the lowest median.  
Table 6.29 illustrates the external validation statistics for the best SVM QSAR 
models found using activity binning for each of the four assays (Quantitative 
Structure Activity Relationships\Appendix 21).  A statistically signicant model, both 
internally and externally, was found for only the primary assay genotype 1B CC50 
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dataset.  This assay had the largest number of data points (26 compounds), and the 
subsequent model passed all internal and external criteria. 
Table. 6.29  SVM QSAR models and their external validation performance statistics for the primary 
assay genotype IB CC50, primary assay genotype IB EC50,  secondary assay genotype IB CC50, 
secondary assay genotype IA CC50. 
 Primary assay genotype IB Secondary assay 
 CC50 EC50 
Genotype IB 
CC50 
Genotype IA 
CC50 
   0.8052 0.420 0.0109 0.5218 
   0.561 0.396 -0.0329 0.1051 
   
    
    0.0001 0.0001 0 0 
      
      0.000103 0.000104 0 0 
  1.0073 0.987 1.0096 1.0176 
Figure 6.24 represents the plot of the training and test set for the primary assay 
genotype IB CC50 model.  It can be seen that in this case activity binning selected a 
diverse set of compounds for the test set, which accurately represented the spread of 
activity points.  Of the three assay datasets for which no externally valid models 
could be found, it is interesting to note that in all of these models, the training set had 
perfect correlation, with internal    values of 1.  This suggests that the data had been 
overtrained, and was therefore unsuitable for use in a predictive capacity.  Also, the 
failed datasets had the smallest number of data points, with narrow activity windows, 
potentially explaining why poor models were found. 
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Fig. 6.24  Training and test set for the failed GA-MLR regression model of the primary assay 
genotype IB CC50 
6.2.4 Summary of Thiazolide QSAR Analysis 
A significant model was developed for the primary assay genotype 1B CC50 dataset.  
It is hoped that this model will be useful for future compound selection and design, 
as it can successfully predict the cell safety indices of thiazolide derivatives.  Though 
no meaningful models were found for the other assays, this is most likely due to the 
fewer number of data points available, so once additional data has been collected it is 
hoped that similarly predictive models will be developed. 
Combined, the 4-aminoquinoline and thiazolide studies illustrate the power and 
potential of QSAR methods, as both have led to validated/predictive models which 
can be used to aid in drug design and safety respectively.  In certain cases, QSAR 
may also be used to aid in biological interpretation, in order to gain insight into 
potential modes of activity and resistance. 
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Chapter VII is the final results chapter of this thesis and reports the design and 
synthesis of a novel series of pyrroloquinolone containing compounds, which were 
later shown to be active against malaria. 
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7. Synthesis of Quinolone Antimalarials 
Chemical synthesis is a vital part of the molecular design loop (fig. 4.1), and indeed 
all aspects of modern drug discovery.  Medicinal chemists play a key role in 
optimising biological activity through SAR exploration and understanding, as well as 
contributing to the discovery of new chemotypes.
1
  The importance of organic 
synthesis for the development of antimalarial treatments has already been discussed 
in Chapter I, with reference to lead candidates such as CQ.
2
  As there are many 
potential pharmaceutical targets for the malaria parasite, synthetic work is vital in 
probing chemical space to find suitably active compounds.  Several chemotypes have 
already been explored which target Pfbc1, yet the hydroxynaphthoquinone compound 
ATOV
3-5
 (fig. 1.17) is currently the only one in clinical use.  Other promising 
candidates active against Pfbc1 include pyridone compounds such as GW844520
6-8
 
(fig. 1.26),  but due to the recent termination of development of this drug owing to 
unexpected cardiotoxicity, 
9
 it is clear that continued research efforts into new 
chemotypes is essential.  One such chemotype which is currently undergoing much 
study is that of the basic quinolone core shown in figure 7.1.
10
 
 
Quinolone 
Fig. 7.1  Basic quinolone template. 
Quinolone containing compounds have long been of interest as antimalarial agents 
against Pfbc1,
11
 with floxacrine and WR249685 (fig. 7.2) being just two examples.
9
  
These compounds both show haem binding as well as Pfbc1 inhibitory properties.  
However, whilst floxacrine kills parasites via a haem mediated process similar to 
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that of CQ, WR249685 is a much weaker haem binder, and inhibits Pfbc1 by binding 
selectively with the parasite Qo site.  In fact, WR249685 is around 5,000 fold more 
selective for the parasite bc1 complex than that of human bc1, and roughly 200 times 
more selective than ATOV.  This is important as it reduces the potential for toxicity.  
This class of compound therefore has much potential for Pfbc1 inhibition. 
  
Floxacrine WR249685 (S enantiomer) 
Fig. 7.2  Floxacrine and WR249685 quinolones. 
The importance of quinolone compounds has already been discussed in Chapter V, 
in which several were docked into the Pfbc1 active site in order to propose possible 
binding modes with relation to their biological activity.
12
  The rationale behind the 
quinolone template lies in the understanding of its role in the Qo active site.  It 
appears to fix the position of the Rieske iron-sulphur protein, with the polar 
quinolone template forming key H-bond associations within the binding pocket,
10
 
and the long alkyl or aryl side chain residing in the hydrophobic pocket (i.e. fig. 
5.22). 
7.1 Pyrroloquinolone Motif 
A SAR study around a particular chemotype or template is performed by making 
generally conservative alterations to a structure, based upon existing information or 
understandings.  By combining the known antimalarial potential of the quinolone 
template (fig. 7.1) with new insight garnered from rigid tricyclic inhibitors such as 
floxacrine and WR249685, it was decided to expand upon the quinolone chemotype 
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and investigate, through periodic modifications, the pyrroloquinolone scaffold 
shown in figure 7.3. 
 
Pyrroloquinolone 
Fig. 7.3  Basic pyrroloquinolone scaffold. 
Compounds containing the pyrroloquinolone scaffold, such as that in figure 7.4, 
have previously shown to be potent and selective PDE5 inhibitors.  Compounds 
which inhibit PDE5 have found use as potential treatments for erectile dysfunction, 
and have been the subject of several SAR studies.
13, 14
 
 
Fig. 7.4  Pyrroloquinolone lead structures known to inhibit PDE5.  Ar denotes various aromatic side 
chains. 
7.2 Docking of the Pyrroloquinolone Motif 
Though the use of pyrroloquinolone containing compounds for the treatment of 
malaria has yet to be reported in the literature, the addition of a pyrrole ring to the 
quinolone template seemed like a natural progression of the quinolone SAR, 
particularly when considering the nature of the binding site.  To offer additional 
support for the pyrroloquinolone template, a molecular docking study was 
undertaken.  The Qo active site is a compact and flat hole, opening into a large 
hydrophobic pocket.  Rigid structures such as ATOV appear to fit nicely into this 
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active site,
15
 so pyrroloquinolone compounds would be expected to replicate this 
mode of binding, and observe the H-bond interactions which are thought to be 
crucial for antimalarial activity.
16, 17
 
The basic pyrroloquinolone template shown in figure 7.3 was first constructed and 
energy minimised using the ‘Energy Minimisation Protocol’ as described in the 
Experimental Chapter, and then docked into the Qo site using the ‘Qo Docking 
Protocol’, also described in the Experimental Chapter.  Constraints were applied 
such that poses were biased towards forming H-bonds with His181 and Glu272, and 
the crystallographic water molecule was allowed to translate and rotate within a 
radius of 2 Å.  A total of 25 GA runs were performed, with the average GOLDScore 
and ChemScore values across the poses found to be 45.8 ± 1.8 and 28.9 ± 0.5 
respectively.  All the solutions were positioned in the centre of the Qo pocket 
between residues Pro271 and Ile147.  A strong H-bond was observed in all cases 
between the imidazole NH group of His181, and the carbonyl group of 
pyrroloquinolone.  Most poses also showed potential to form the water mediated 
Glu272 interaction.  Generally the solutions fell into one of two orientations, either 
the NH group of the pyrrole was directed towards the hydrophobic pocket, as in 
figure 7.5, or it was positioned facing the opposite direction.  Either way, the 
template showed exciting potential as a bc1 inhibitor, and by adding a side chain to 
the pyrrole nitrogen, it was hoped this would allow for additional hydrophobic or 
van der Waals contacts in the hydrophobic pocket of Qo, ultimately strengthening the 
binding, and hopefully activity.  This study represents how docking can be used to 
either support synthetic efforts, or drive them forward. 
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Fig. 7.5  Docking solution of pyrroloquinolone template (shown in blue) in the Qo pocket of the yeast 
cytochrome bc1 complex (3CX5).  The His181 H-bond with the pyrroloquinolone carbonyl group is 
clearly shown, as well as the potential for a water mediated interaction with Glu272.  The yeast 
cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] cluster of the Rieske 
protein represented as spheres (sulphur: gold, iron: orange).  H-bonds are indicated by black lines. 
7.3 Introduction of Synthetic Techniques 
The following sections discuss the synthesis and testing of a series of 
pyrroloquinolone compounds, with several side chains being substituted onto the 
nitrogen of the pyrrole ring, in order to allow for a small SAR analysis around the 
chemotype.  A review of the literature for several of the synthetic procedures used 
will be followed by a detailed analysis of the results, together with interpretation of 
the data. 
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7.3.1 Camps Cyclisation 
In 1899, a convenient route for the synthesis of quinolones was reported via Camps 
cyclisation, from simple acetyl-ortho-amidoacetophenone (fig. 7.6), where 
depending on the substituent’s at the carbonyl groups, 2- or 4-quinolones were 
formed selectively.
18-22
  Though reaction products can be depicted as quinolines, it is 
believed that the keto form (quinolone) predominates over its enol counterpart, both 
in solid state and in solution.
23
 
 
Fig. 7.6  Synthesis of 2- and 4-quinolone compounds via Camps cyclisation. 
7.3.2 Witkop Oxidation 
The Camps cyclisation received increased interest when it was found that the starting 
materials required for the reaction could be easily prepared through oxidative 
cleavage of the 2,3-double bond of substituted indoles, in a reaction termed Witkop 
oxidation.
24
  The rational for the Witkop oxidation came from the understanding of 
an important intermediate in the biosynthetic oxidation of tryptophan in the liver, in 
which a dicarbonyl is formed from an indole (fig. 7.7).
25
  Enzymes play a key role in 
this process in order to first oxidise the indole, and to then hydrolyse the amide to 
form kynurenine, an essential step in the biosynthesis of coenzyme NAD.
26, 27
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Fig. 7.7  Metabolism of tryptophan. 
Through the study of ozonolysis for a series of indoles and indole containing natural 
products, it was possible to oxidise the indole double bond (fig. 7.8), and to even 
replicate the degradation of tryptophan to kynurenine.
28
  The reaction was found to 
proceed via the formation of an ozonide, with subsequent rearrangement to the 
amide product.
29, 30
 
 
Fig. 7.8  Witkop oxidation with ozone. 
Of particular importance was the combination of the ozonolysis reaction described 
by Witkop with a basic workup.  This allowing for the conversion of several 
tetrahydroharman alkaloids into linear pyrroloquinolones, as depicted in figure 7.9. 
 
Fig. 7.9  Oxidation of tetrahydroharman alkaloids.  R groups include hydrogen atoms, alcohol, 
carbonyl and ester functionality. 
Alternative methods have been investigated for the oxidation of 2,3-disubstituted 
indole derivates, including the use of chromium trioxide (CrO3).  Though good 
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yields were reported for phenyl and methyl substituted indoles, the yields were poor 
for other alkyl substituent’s (fig. 7.10).31, 32 
 
Fig. 7.10  Oxidation of indoles using chromium trioxide. 
Witkop also investigated the use of oxygen in the presence of a platinum catalyst in 
order to oxidise the indole double bond, as illustrated by figure 7.11.  The 
hydroperoxide intermediate rearranged to the dicarbonyl compound, with acidic 
conditions found to accelerate this rearrangement process.
33, 34
  The mechanism of 
the hydroperoxide induced rearrangement was comparable to that of the ozonolysis 
reaction. 
 
Fig. 7.11  Oxidation of indoles using Pt/O2. 
Through the study of a series of cycloalkylindoles it was found that the tendency to 
form the Camps cyclisation quinolone product was dependent on the ring size (fig. 
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7.12).
24, 35
  Interestingly, the oxidation of the 8-membered ring led to the formation 
of a carbonyl compound instead of the dicarbonyl product.
36
 
 
Fig. 7.12  Autoxidation/oxidation of cycloalkylindoles homologs. 
During this study it was found that several of the investigated 2,3-disubstituted 
indoles formed their respective dicarbonyl product by autoxidation whilst standing 
on the shelf.
24, 37-39
  A mechanism was subsequently proposed for oxidation which 
was consistent with that suggested for the Witkop oxidation (fig. 7.13).
40, 41
  This 
mechanism shows the decomposition of the hydroperoxide bridge to form the 
dicarbonyl product. 
 
Fig. 7.13  Oxidation mechanism. 
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Additionally, sodium periodate (NaIO4) has also provided a convenient oxidation 
reagent for the cleavage of the indole double bond, demonstrating excellent yields 
(fig 7.14). 
 
Fig. 7.14  Oxidation of indoles with NaIO4. 
7.3.3 Winterfeldt Oxidation 
The sequential combination of Witkop oxidation and Camps cyclisation is 
commonly referred to as the Winterfeldt oxidation (fig. 7.15).
42
  The Winterfeldt 
oxidation introduced NaH/O2 and t-BuOK/O2 as oxidation reagents, which owing to 
their basic nature, directly convert the dicarbonyl intermediates from the Witkop 
oxidation to their Camps cyclisation products. 
 
Fig. 7.15  Winterfeldt oxidation reaction. 
Following suggestions that the natural product camptothecin, an anti leukaemia drug, 
is biosynthetically formed by oxidation of a corresponding carboline derivative and 
subsequent Camps cyclisation,
43
 Winterfeldt exploited this strategy for the total 
synthesis of (±)-camptothecin (fig. 7.16).
44
  What was of particular interest was that 
the selection of an inorganic base allowed the reaction to proceed directly from the 
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indole to the quinolone, without isolation of the dicarbonyl intermediate.  In figure 
7.16 the indole was oxidised using sodium hydride and oxygen in 
dimethylformamide (DMF), giving a yield of 75% for the pyrroloquinolone product. 
 
Fig. 7.16  Winterfeldt’s synthesis of (±)-camptothecin. 
Winterfeldt further investigated the direct conversion of a number of indoles to their 
quinolone counterpart.
42, 44, 45
  One particular example is the oxidation of the natural 
product ajmalicine, which occurred with an excellent yield of 92% (fig. 7.17). 
 
Fig. 7.17  Winterfeldt oxidation of indole alkaloids. 
Additional studies using Winterfeldt’s method have also been successfully applied 
for the preparation of pyrroloquinolones, as illustrated in figure 7.18.
46
  Yields 
ranged between 40-92%, depending upon the side chains of the starting material. 
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Fig 7.18  Synthesis of substituted pyrroloquinolones. 
As was discussed earlier, pyrroloquinolone containing compounds have found use as 
PDE5 inhibitors for the treatment of male erectile dysfunction, many with activity in 
the picomolar (pM) range.
13, 14, 47
  These series’ of pyrroloquinolones were 
synthesised utilising the Winterfeldt oxidation procedure.  It was also found that no 
racemisation occurred when stereoisomer’s underwent Winterfeldt oxidation (fig. 
7.19).
48
 
 
Fig 7.19  Synthesis of PDE5 inhibitors via Winterfeldt oxidation. 
7.4 Synthesis of Novel Pyrroloquinolone Analogues 
Given the previous successes of the Winterfeldt oxidation procedure it was used to 
synthesise the novel pyrroloquinolone analogues.  In order to explore the SAR 
around this chemotype, a number of simple aromatic side chains were attached to the 
nitrogen of the pyrrole ring via a methyl linker (fig. 7.20). 
 
Fig. 7.20  Pyrroloquinolone template.  Ar denotes aromatic substituents. 
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Figure 7.21 illustrates the two step procedure which was followed in order to 
synthesise the pyrroloquinolone compounds.  The first step was to attach the 
required aromatic side chain to the tetrahydropyridoindole compound, which then 
underwent subsequent Winterfeldt oxidation, converting the indole to the 
pyrroloquinolone compound. 
 
Fig. 7.21  Overall reaction scheme for the synthesis of novel pyrroloquinolone compounds. 
The tetrahydropyridoindole compound was chosen as the starting material as it was 
commercially available.  However, had this not been the case, it could have been 
synthesised via the Pictet Spengler reaction, which involves the condensation and 
ring closure of β-arylethylamines such as tryptamine, using an aldehyde or ketone in 
the presence of an acidic catalyst, usually whilst heating (fig. 7.22).
49, 50
 
 
Fig. 7.22  Pictet Spengler reaction. 
Figure 7.23 illustrates the mechanism of the Pictet Spengler reaction that begins with 
a Mannich reaction.
51
  Under acidic conditions the amine attacks the 
aldehyde/ketone, after which the loss of water forms the iminium ion.  It is the 
electrophilicity of this imine double bond which drives the electrophilic substitution 
at the 2-position,
52
 after which the loss of a proton forms the final product. 
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Fig. 7.23  Mechanism of the Pictet Spengler reaction. 
7.4.1 Alkylation Reaction 
Aromatic bromides were substituted onto the 1,2,3,4-tetrahydro-9H-pyrido[3,4-
b]indole (THPI) starting material via a fairly simple procedure, outlined by figure 
7.24.  One equivalent of THPI was dissolved in dry tetrahydrofuran (THF), together 
with two equivalents of triethylamine and 1.2 equivalents of the aromatic bromide in 
question.  When the reaction was complete, the products were purified via flash 
column chromatography. 
 
Fig. 7.24  General procedure for the alkylation reaction. 
In total, seven aromatic bromides (1-7) underwent alkylation to THPI.  The 
structures of these aromatics bromides, together with the products they formed and 
their respective yields are shown in table 7.1.  The alkylation products have been 
labelled 8-14 and will be referred to as such from here on.  The yields of these 
reactions were generally good and ranged from 46-86%.  However, purification via 
flash column chromatography gave varying yields for the more polar compounds. 
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Table. 7.1  The substituted tetrahydropyridoindole products and their yields for the alkylation 
reactions. 
Aromatic 
Bromide 
ID 
Tetrahydropyridoindole 
Product 
ID Appearance Yield 
 
1 
 
8 Pale yellow solid 66% 
 
2 
 
9 Yellow solid 75% 
 
3 
 
10 Pale orange solid 79% 
 
4 
 
11 Pale yellow solid 86% 
 
5 
 
12 Orange solid 86% 
 
6 
 
13 Orange/yellow solid 53% 
 
7 
 
14 Pale yellow solid 46% 
The general mechanism for the alkylation reaction can be found in figure 7.25.  An 
SN2 type reaction occurs in which the lone pair of electrons on the amine nitrogen of 
THPI act as a nucleophile and attack the aromatic bromide at the electrophilic 
carbon.  The proton of the resulting cation is then removed by triethylamine. 
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Fig. 7.25  Proposed mechanism for the alkylation reaction. 
7.4.2 Wohl-Ziegler Bromination 
Aromatic bromides 1-6 were all commercially available.  However, to investigate 
how a simple extension of the side chain altered the in vitro behaviour of the 
compounds, aromatic bromide 7 had to be synthesised.  This was done via the Wohl-
Ziegler bromination of 4-phenyl toluene,
53
 as it is a particularly useful reaction for 
the selective bromination of benzylic hydrogen’s under neutral conditions.54  The 
method which was used is outlined in figure 7.26, and involved dissolving 4-
phenyltoluene in acetonitrile, together with 1.8 equivalents of N-bromosuccinimide 
(NBS), and 0.2 equivalents of 2,2’-azobisisobutyronitrile (AIBN) to act as a radical 
initiator.  The reaction then proceeded under reflux until the 4-phenyltoluene had 
been consumed, with the product purified via flash column chromatography.  The 
brominated product was isolated in an excellent yield of 89%.   
 
Fig. 7.26  Wohl-Ziegler bromination of 4-phenyltoluene. 
The mechanism for this reaction, as depicted in figure 7.27, consists of initiation and 
propagation steps.  Under heat and in the presence of the AIBN initiator, homolytic 
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cleavage of the NBS nitrogen-bromine bond occurs, allowing for the abstraction of a 
methyl hydrogen from 4-phenyltoluene to form a stabilised radical intermediate.  
This radical then reacts with NBS to form the bromo-substituted product 7.  7 then 
underwent alkylation to THPI to form 14. 
 
Fig. 7.27  Proposed mechanism for the Wohl-Ziegler bromination. 
7.4.3 Winterfeldt Oxidation 
The substituted tetrahydropyridoindoles were all converted to their pyrroloquinolone 
counterparts via the Winterfeldt oxidation procedure, outlined in figure 7.28.  These 
conditions were shown to give good yields for a variety of substituent’s.20  This one 
pot synthesis allowed for the direct conversion of the tetrahydropyridoindoles 8-14 
to their respective pyrroloquinolones.  The general procedure involved dissolving a 
1:1 mixture of the substituted tetrahydropyridoindole and potassium tertiary butoxide 
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in DMF.  A constant stream of oxygen was bubbled through the solution until all of 
the tetrahydropyridoindole had been consumed.  The mixture was then neutralised 
and an organic extraction and wash performed to isolate the product. 
 
Fig. 7.28  General procedure for Winterfeldt oxidation reaction. 
The tetrahydropyridoindoles 8-14 each underwent Winterfeldt oxidation to form the 
substituted pyrroloquinolone products 15-21, shown in table 7.2.  The yields of these 
reactions were variable and ranged between 24-79%.  The poorer yields may be 
attributed to difficulties in extracting the product from the reaction mixture, owing to 
the limited solubility of the pyrroloquinolone compounds. 
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Table. 7.2  The substituted pyrroloquinolone products and their yields for the Winterfeldt oxidation 
reactions.  
Pyrroloquinolone 
Product 
ID Appearance Yield 
 
15 Yellow solid 33% 
 
16 Yellow solid 79% 
 
17 Yellow solid 48% 
 
18 Pale yellow solid 25% 
 
19 Yellow solid 32% 
 
20 Pale yellow solid 24% 
 
21 Yellow solid 41% 
The proposed mechanism for the Winterfeldt oxidation can be found in figure 7.29, 
and begins with oxygen breaking the 2,3-indole double bond and forming a peroxide 
bridge.
42
  Degradation of this peroxide bridge leads to the dicarbonyl/Witkop 
intermediate.  The instability of this intermediate and the presence of base (
t
BuOK) 
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drive forward the intramolecular aldol type reaction to form the stable six membered 
ring/Camps cyclisation product.
55
 
 
Fig. 7.29  Proposed mechanism for the Winterfeldt oxidation reaction. 
7.5 Biological Analysis 
±The substituted pyrroloquinolone compounds 15-21 were each tested in vitro using 
the ‘Whole Cell Growth Inhibition Assay (3D7) Protocol’ as described in the 
Experimental Chapter.  This assay was chosen as it would provide a quantitative 
measure of the activity of each of the analogues against malaria, allowing for 
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comment to be drawn as to the potential SAR of the series.  The 3D7 whole cell IC50 
values are reported in table 7.3.  At the time of reporting the testing had only been 
performed once. 
Table. 7.3  3D7 whole cell inhibition IC50 values for compounds 15-21.  
Pyrroloquinolone 
Product 
ID 
3D7 Whole Cell IC50 
(nM) 
 
15 136 
 
16 552 
 
17 75 
 
18 352 
 
19 179 
 
20 1020 
 
21 774 
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As can be seen the biological testing results span a wide range of activities, from as 
few as 75 nM to 1.02 µM.  This allowed for some interesting observations to be 
made. 
7.6 Topliss Scheme 
The Topliss scheme provides a means for navigating through the SAR of a 
chemotype, in order to maximise the chances of synthesising the most potent 
compounds in a series as early as possible.
1, 56
  The procedure is particularly useful 
when compounds are fairly simple to synthesise, yet there is a considerable time lag 
in acquiring activity data.  A Topliss scheme takes the form of a decision tree flow 
diagram and provides a route for selecting the most promising substituent to make.  
The Topliss schemes have been designed by considering how the hydrophobicity and 
electronic factors of various substituent’s affect a compounds behaviour, and are 
designed such that optimum substituent’s can be found as efficiently as possible. 
The hydrophobicity of a drug is crucial to how easily it crosses the cell membrane, 
and may also be important in receptor interactions.
1
  Changing the substituent’s on a 
drug may well have significant effects on its hydrophobic character, and therefore its 
biological activity.  The partition coefficient of a compound can be calculated 
theoretically by knowing the contribution that the various substituent’s make.  This 
overall contribution is known as the substituent hydrophobicity constant (π), and is a 
measure of how hydrophobic a substituent is relative to hydrogen.  If π has a positive 
value then the substituent is more hydrophobic than hydrogen, if it is negative then it 
is less hydrophobic.  The π values are characteristic for the substituent and can be 
used to calculate how the partition coefficient (log P) of a drug would be affected if 
these substituent’s were present. 
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The electronic effects of various substituent’s will have an impact on a drugs 
ionisation or polarity, which may in turn have an effect on how easily a drug can 
pass through cell membranes, or how strongly it can interact with a binding site.
1
  It 
is therefore useful to measure the electronic effect of a substituent.  The Hammett 
substitution constant (σ) provides a measure of the electron withdrawing or donating 
ability of a particular substituent.  A positive value indicates an electron withdrawing 
group such as nitro, which has a stabilising influence on the ionised form of a 
compound.  A negative Hammett constant value however indicates an electron 
donating group such as an alkyl substituent, which shifts the equilibrium the other 
way (fig. 7.30). 
 
Fig. 7.30  Position of equilibrium depending on substituent group X. 
The Topliss scheme in figure 7.31 can be used when substitutions are being made to 
an aromatic side chain.  It assumes that the lead compound has a unsubstituted 
aromatic ring, whose biological activity is already known.  The next analogue in the 
scheme is the 4-chloro derivative.  The chloro substituent is more hydrophobic and 
electron withdrawing than hydrogen, and so has positive π and σ values.  When the 
analogue has been synthesised it can be tested, after which there are three 
possibilities as to which branch of the Topliss scheme to follow.  The analogue will 
be one of the following in comparison to the unsubstituted parent compound: less 
active (L); equally active (E); more active (M).  Generally, if the activity increases 
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for the analogue then the M branch is followed, if it remains the same the E branch is 
followed, and if it decreases the L branch is followed.  Then the next analogue along 
this branch is synthesised and the process repeated. 
 
Fig. 7.31  Topliss scheme for aromatic substituent’s (J. G. Topliss, Journal of Medicinal Chemistry, 
1972, 15, 1006-1011.) 
If the activity increases with the 4-chloro derivative, then as the chloro group has 
positive π and σ values, this implies that these properties are important for biological 
activity.  Thus, if π and σ are both important, an additional chloro group should 
increase the biological activity further.  If it does, then the substituent’s can be varied 
further to increase these values.  If however it doesn’t, then an unfavourable steric 
interaction or excessive hydrophobicity is indicated. 
If the opposite to the above is true for the 4-chloro derivative, and the activity 
decreases, this suggests that negative π and σ values are important for biological 
activity, or that para substituent’s are sterically unfavourable.  It is first assumed that 
an unfavourable σ effect is the most likely reason for the reduced activity, and so the 
next substituent is one with a negative σ effect (i.e. OMe).  If activity improves then 
further changes are suggested to test the relative importance of the σ and π factors.  
This text box is where the unabridged thesis included the following third 
party copyrighted material: 
(Scheme I - J. G. Topliss, Journal of Medicinal Chemistry, 1972, 15, 1006-
1011.) 
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However, if OMe fails to improve activity, then it is assumed unfavourable steric 
factors are at work and the next substitution occurs in the meta position. 
7.7 Analysis of Results 
The biological results of compounds 15-21 will now be interpreted with reference to 
the Topliss scheme (fig. 7.31).  The parent compounds 15, that is the 
pyrroloquinolone structure with an unsubstituted benzene ring attached to the pyrrole 
nitrogen via a methyl linker, reported an activity of 136 nM.  Despite being the first 
analogue in the series, this proved to be a very promising start, demonstrating good 
nM activity.  The initial modification (based on Topliss) was to substitute the 
hydrogen in the para position of the benzene ring with a chloro group (16).  This 
was actually shown to decrease the biological activity to 552 nM, so in line with the 
Topliss scheme the next substitution to be made was to consider an OMe group (20).  
However, this greatly reduced the activity further, to only 1.02µM (least active 
analogue in the series).  This may suggest that para substituent’s are sterically 
unfavourable, and that substituent’s with a negative σ value (electron donating 
groups) have a detrimental effect on activity.  However, before investigating this 
branch further, it was decided to first investigating the effect of substituent’s with 
increased π and σ values.  Despite the 4-chloro analogue decreasing activity in 
comparison to the unsubstituted compound, the inclusion of an addition chloro group 
in the meta position (17) gave the most potent derivative, with an excellent activity 
of 75 nM.  This did indeed suggest that electron withdrawing groups were preferable 
for this chemotype, as were more hydrophobic substitution patterns.  The availability 
of reagents did limit the exploration of the Topliss scheme slightly, however, 
additional derivatives were synthesised and led to some interesting observations.  As 
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predicted by Topliss, the substitution of a CF3 group in the para position (18) did 
decrease the activity compared to the dichloro (17) derivative, with an activity of 352 
nM.  Yet the inclusion of a methoxy linker (OCF3, 19) led to a compound with an 
activity of 179 nM, similar to that of the parent molecule (15), but interestingly this 
had a more favourable solubility profile.  An extension of the Topliss scheme was to 
lengthen the side chain by substituting into the para position an additional phenyl 
group (21).  This was however shown to decrease the activity (774 nM).  This again 
may be to due to unfavourable steric interactions at this position. 
The dichloro compound (17) was the most potent compound in the series, and thus 
represents the lead candidate.  Future testing and validation of its activity will allow 
for a more in depth analysis of its potential as an antimalarial drug.  There is still 
however much scope for consideration with regard to the pyrroloquinolone template.  
The Topliss scheme suggests that 3-CF3-4-Cl and 3-CF3-4-NO2 substitutions may 
lead to more active derivatives, but it may also be prudent to investigate 
modifications and substitutions in the meta position, as would similar exploration 
around the SAR of the biphenyl derivative (21).  One potential limitation of these 
pyrroloquinolone compounds may be their poor solubility in most solvents, so 
chemical modification to improve this may be a rewarding avenue of investigation. 
7.8 Docking of the Synthesised Pyrroloquinolones 
To further validate the potential of the synthesised pyrroloquinolone compounds as 
Pfbc1 inhibitors, structures 15-21 were each docked into the Qo site of the yeast bc1 
complex (PDB accession code 3CX5)
57
 using the ‘Qo Docking Protocol’, following 
the energy minimisation of their structures using the ‘Energy Minimisation 
Protocol’.  The average GOLDScore and ChemScore values across the 10 GA runs 
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are shown in table 7.4.  It was hoped that from these results, comment could be 
drawn with regard to their binding orientation in the active site, as well as any 
potential trends between docking scores and in vitro activity. 
Table. 7.4  Docking results for the synthesised pyrroloquinolone compounds at the Qo site. 
 15 16 17 18 19 20 21 
Average 
GOLDScore 
58.5 ± 
1.6 
62.3 ± 
0.5 
61.2 ± 
0.8 
58.9 ± 
0.5 
62.1 ± 
1.2 
61.6 ± 
1.1 
56.1 ± 
3.0 
Average 
ChemScore 
38.0 ± 
2.2 
39.5 ± 
0.2 
40.4 ± 
2.3 
36.9 ± 
1.6 
36.0 ± 
0.9 
36.8 ± 
2.5 
41.9 ± 
1.0 
As can be seen the docking scores were all fairly similar across the seven 
compounds, and given the ranging activity values for these compounds (table 7.3), 
there appears to be no linear relationship between fitness scoring and activity.  This 
is not surprising however, given that they all share the central pyrroloquinolone 
chemotype and vary only in their side chains.  Furthermore, the similar fitness scores 
across the series can be further explained through consideration of their docking 
poses.  The compounds all docked similar to one another, with only slight 
movements in the location of the pyrroloquinolone core in the Qo pocket, and their 
respective side chains in the hydrophobic pocket.  These binding poses were very 
similar to that of the native binding ligand SMA (see fig. 5.5). 
The docking pose of 17, the most active compound in the pyrroloquinolone series, is 
shown in figure 7.32.  This docking pose is representative of the entire series, with 
the carbonyl oxygen of the pyrroloquinolone core forming a strong H-bond with 
His181, as well as a water mediated H-bonding network between Glu272, and the 
amine group.  The presence of these interactions offers a strong argument to account 
for their antimalarial activity, rationalising the observed activity for this series of 
compounds. 
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Fig. 7.32  Docking pose of 17 (shown in blue) in the Qo pocket of the yeast cytochrome bc1 complex 
(3CX5).  The two key interactions, His181 and the water mediate Glu272 H-bond network are clearly 
illustrated.  The yeast cytochrome b polypeptide backbone is represented in green, with the [2Fe2S] 
cluster of the Rieske protein represented as spheres (sulphur: gold, iron: orange).  H-bonds are 
indicated by black lines. 
The inclusion of the aromatic side chain also appears to have strengthened the 
docking when compared to the previous study of just the pyrroloquinolone core 
alone (fig. 7.5; respective GOLDScore and ChemScore values of 45.8 ± 1.8 and 28.9 
± 0.5).  This may be due to an increased number of van der Waals and/or 
hydrophobic interaction in the hydrophobic pocket, or perhaps additional stability of 
the compounds in the Qo pocket. 
Clearly the docking protocol is unable to distinguish quantitatively between good 
and poorly active compounds.  However, it can nicely predict possible binding 
orientations for known active compounds, each of which observe interactions known 
to be crucial for activity.
58
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7.9 Summary of Synthetic Study 
Synthetic work has led to the rational design of a novel chemotype active against the 
malaria parasite.  A SAR investigation of the pyrroloquinolone template has shown it 
to have much potential and scope, with molecular docking offering further support 
for possible Qo binding and therefore Pfbc1 inhibition.  Subsequent modifications of 
the pyrroloquinolone side chain around the Topliss scheme may yield more potent 
hits, but it will be crucial to remain mindful of solubility issues with regard to these 
compounds, and work should therefore be performed to improve upon this. 
  
Chapter VII 
 
414 
 
7.10 References 
1. G. L. Patrick, An Introduction to Medicinal Chemistry, Oxford University Press, 2005. 
2. M. Schlitzer, ChemMedChem, 2007, 2, 944-986. 
3. M. Fry and M. Pudney, Biochem. Pharmacol., 1992, 43, 1545-1553. 
4. M. W. Mather, E. Darrouzet, M. Valkova-Valchanova, J. W. Cooley, M. T. McIntosh, F. 
Daldal and A. B. Vaidya, J. Biol. Chem., 2005, 280, 27458-27465. 
5. J. Krungkrai, S. R. Krungkrai, N. Suraveratum and P. Prapunwattana, Biochem. Mol. Biol. 
Int., 1997, 42, 1007-1014. 
6. H. Xiang, J. McSurdy-Freed, G. S. Moorthy, E. Hugger, R. Bambal, C. Han, S. Ferrer, D. 
Gargallo and C. B. Davis, J. Pharm. Sci., 2006, 95, 2657-2672. 
7. C. L. Yeates, J. F. Batchelor, E. C. Capon, N. J. Cheesman, M. Fry, A. T. Hudson, M. 
Pudney, H. Trimming, J. Woolven, J. M. Bueno, J. Chicharro, E. Fernandez, J. M. Fiandor, 
D. Gargallo-Viola, F. G. de las Heras, E. Herreros and M. L. Leon, Journal of Medicinal 
Chemistry, 2008, 51, 2845-2852. 
8. A. R. Crofts, B. Barquera, R. B. Gennis, R. Kuras, M. Guergova-Kuras and E. A. Berry, 
Biochemistry, 1999, 38, 15807-15826. 
9. G. A. Biagini, N. Fisher, N. Berry, P. A. Stocks, B. Meunier, D. P. Williams, R. Bonar-Law, 
P. G. Bray, A. Owen, P. M. O'Neill and S. A. Ward, Mol. Pharmacol., 2008, 73, 1347-1355. 
10. R. W. Winter, J. X. Kelly, M. J. Smilkstein, R. Dodean, D. Hinrichs and M. K. Riscoe, Exp. 
Parasitol., 2008, 118, 487-497. 
11. R. W. Winter, J. X. Kelly, M. J. Smilkstein, R. Dodean, G. C. Bagby, R. K. Rathbun, J. I. 
Levin, D. Hinrichs and M. K. Riscoe, Exp. Parasitol., 2006, 114, 47-56. 
12. R. Cowley, S. Leung, N. Fisher, M. Al-Helal, N. G. Berry, A. S. Lawrenson, R. Sharma, A. 
E. Shone, S. A. Ward, G. A. Biagini and P. M. Oneill, MedChemComm, 2012. 
13. Z. H. Sui, J. H. Guan, M. J. Macielag, W. Q. Jiang, S. Y. Zhang, Y. H. Qiu, P. Kraft, S. 
Bhattacharjee, T. M. John, D. Haynes-Johnson and J. Clancy, Journal of Medicinal 
Chemistry, 2002, 45, 4094-4096. 
14. J. C. Lanter, Z. H. Sui, M. J. Macielag, J. J. Fiordeliso, W. Q. Jiang, Y. H. Qiu, S. 
Bhattacharjee, P. Kraft, T. M. John, D. Haynes-Johnson, E. Craig and J. Clancy, Journal of 
Medicinal Chemistry, 2004, 47, 656-662. 
15. V. Barton, N. Fisher, G. A. Biagini, S. A. Ward and P. M. O'Neill, Curr. Opin. Chem. Biol., 
2010, 14, 440-446. 
16. B. L. Trumpower, Biochim. Biophys. Acta-Bioenerg., 2002, 1555, 166-173. 
17. H. Palsdottir, C. G. Lojero, B. L. Trumpower and C. Hunte, J. Biol. Chem., 2003, 278, 
31303-31311. 
18. R. Camps, Arch. Pharm., 1899, 237, 659-691. 
19. R. Camps, Ber. Deutsch. Chem. Ges., 1899, 3228-3234. 
20. M. Mentel and R. Breinbauer, Curr. Org. Chem., 2007, 11, 159-176. 
21. M. A. Prezent and V. A. Dorokhov, Russ. Chem. Bull., 2003, 52, 2454-2456. 
22. R. H. Manske, Chemical Reviews, 1942, 30, 113-144. 
23. C. P. Jones, K. W. Anderson and S. L. Buchwald, The Journal of Organic Chemistry, 2007, 
72, 7968-7973. 
24. B. Witkop, J. B. Patrick and M. Rosenblum, Journal of the American Chemical Society, 
1951, 73, 2641-2647. 
25. A. Ek, H. Kissman, J. B. Patrick and B. Witkop, Experientia, 1952, 8, 36-40. 
26. W. E. Knox and A. H. Mehler, J. Biol. Chem., 1950, 187, 419-430. 
27. A. H. Mehler and W. E. Knox, J. Biol. Chem., 1950, 187, 431-438. 
28. B. Witkop, Justus Liebigs Ann. Chem., 1944, 556, 103-114. 
29. B. Witkop and J. B. Patrick, Journal of the American Chemical Society, 1952, 74, 3855-
3860. 
30. B. Witkop and J. B. Patrick, Journal of the American Chemical Society, 1952, 74, 3861-
3866. 
31. K. Schofield and R. S. Theobald, Journal of the Chemical Society (Resumed), 1949, 796-
799. 
32. K. Schofield and R. S. Theobald, Journal of the Chemical Society (Resumed), 1950, 1505-
1509. 
33. B. Witkop and J. B. Patrick, Journal of the American Chemical Society, 1951, 73, 2188-
2195. 
Chapter VII 
 
415 
 
34. B. Witkop and J. B. Patrick, Journal of the American Chemical Society, 1951, 73, 2196-
2200. 
35. B. Witkop and S. Goodwin, Journal of the American Chemical Society, 1953, 75, 3371-
3376. 
36. E. Leete, Journal of the American Chemical Society, 1961, 83, 3645-3647. 
37. R. J. S. Beer, T. Donavanik and A. Robertson, Journal of the Chemical Society (Resumed), 
1954, 4139-4142. 
38. R. J. S. Beer, L. McGrath and A. Robertson, Journal of the Chemical Society (Resumed), 
1950, 2118-2126. 
39. R. J. S. Beer, L. McGrath and A. Robertson, Journal of the Chemical Society (Resumed), 
1950, 3283-3286. 
40. F. McCapra and Y. C. Chang, Chemical Communications (London), 1966, 522-523. 
41. F. McCapra, D. G. Richardson and Y. C. Chang, Photochemistry and Photobiology, 1965, 4, 
1111-1121. 
42. E. Winterfeldt, Annalen Der Chemie-Justus Liebig, 1971, 745, 23-30. 
43. E. Wenkert, K. G. Dave, R. G. Lewis and P. W. Sprague, Journal of the American Chemical 
Society, 1967, 89, 6741-6745. 
44. M. Boch, Winterfe.E, J. M. Nelke, H. Radunz, D. Pike and T. Korth, Chem. Ber.-Recl., 1972, 
105, 2126-&. 
45. J. Warneke and Winterfe.E, Chem. Ber.-Recl., 1972, 105, 2120-&. 
46. J. F. Carniaux, C. KanFan, J. Royer and H. P. Husson, Tetrahedron Lett., 1997, 38, 2997-
3000. 
47. W. Q. Jiang, Z. H. Sui, M. J. Macielag, S. P. Walsh, J. J. Fiordeliso, J. C. Lanter, J. H. Guan, 
Y. H. Qiu, P. Kraft, S. Bhattacharjee, E. Craig, D. Haynes-Johnson, T. M. John and J. 
Clancy, Journal of Medicinal Chemistry, 2003, 46, 441-444. 
48. W. Q. Jiang, Z. H. Sui and X. Chen, Tetrahedron Lett., 2002, 43, 8941-8945. 
49. A. Pictet and T. Spengler, Berichte der deutschen chemischen Gesellschaft, 1911, 44, 2030-
2036. 
50. W. M. Whaley and T. R. Govindachari, Organic Reactions, 1951, 6, 151-190. 
51. J. Clayden, N. Greeves, S. Warren and P. Wothers, Organic Chemistry, Oxford University 
Press, 2001. 
52. E. D. Cox and J. M. Cook, Chemical Reviews, 1995, 95, 1797-1842. 
53. C. Djerassi, Chemical Reviews, 1948, 43, 271-317. 
54. H. Togo and T. Hirai, Synlett, 2003, 702-704. 
55. M. Mentel, M. Peters, J. Albering and R. Breinbauer, Tetrahedron, 2011, 67, 965-970. 
56. J. G. Topliss, Journal of Medicinal Chemistry, 1972, 15, 1006-1011. 
57. S. R. N. Solmaz and C. Hunte, J. Biol. Chem., 2008, 283, 17542-17549. 
58. L. Esser, B. Quinn, Y. F. Li, M. Q. Zhang, M. Elberry, L. Yu, C. A. Yu and D. Xia, Journal 
of Molecular Biology, 2004, 341, 281-302. 
 
Conclusions & Future Work  
Conclusions & Future Work 
 
417 
 
Malaria is a devastating disease, and continued efforts are required to develop new 
therapeutic options to both treat and prevent the disease.  The work described within 
this thesis explores possible solutions for the discovery of novel antimalarial 
compounds using a host of methods spanning multiple specialities.  Drug discovery 
in itself is multidisciplinary, requiring collaboration and expertise in many areas.  
Chemoinformatics and chemical synthesis have both been used here to discover new 
chemotypes active against malaria, with these results validated through biological 
screening. 
Following an extensive introduction of malaria and modern drug discovery methods 
in Chapter I, Chapter II discussed a host of LBVS methods and their application.  
Using the chemical structures of 19 compounds with known Pfbc1 activities, six 
methods were applied to the ZINC lead like library of compounds, generating a 
diverse range of hits.  In Chapter III these hits were merged, and each molecule 
scored based on its frequency across the methods, and also their physicochemical 
properties.  Consensus analysis was used to place emphasis onto compounds 
identified across several methods, as these had received the most support from 
virtual screening.  Compounds were filtered to remove those with unfavourable 
chemical properties, or whose structure contained known toxicophores as reported 
across the literature.  A final selection of 19 compounds was made, and these 
purchased and tested as described in Chapter IV, using several different bioassays.  5 
of the compounds reported single digit µM IC50 values, with each containing novel 
structural chemotypes, such as an isoalloxazine ring, or a pyrrolopyrimidine-2,4-
dione motif.  The lead candidate contained a benzothiazole core, and reported an 
IC50 value of 4.53 ± 1.86 µM.  Additional testing showed the compounds to have 
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little or no inhibition of bovine bc1, which is highly promising as bovine bc1 
inhibition has been shown to be indicative of cardiotoxicity in humans. 
Future work with regard to these 5 active hits will include validation of their site of 
action, as these compounds were selected based on their potential as Pfbc1 inhibitors.  
This will require testing against the Pfbc1 bioassay.  This will be performed as and 
when the parasite can be cultured in the sufficient amount required for testing.  
Further to this, the most promising candidates will form the basis of the next 
iteration of the molecular design loop.  In particular, the benzothiazole chemotype 
will become the focus of a SAR study to investigate how the optimisation of its side 
chain affects its in vitro activity, initially beginning with exploration of the Topliss 
scheme.  The chemotypes of the other hits may also form the basis of similar 
investigation, and they may all form the basis of another round of virtual screening. 
Chapter V described the use of molecular docking to rationalise the activity of 
compounds which inhibit malaria through inhibition of the bc1 complex.  Following 
the successful development of a suitable docking protocol, this was applied to 
rationalise the observed activity of a number of known Pfbc1 inhibitors, including 
stigmatellin, atovaquone, antimycin A, HDQ, as well as several other quinolone 
containing compounds which had been previously been synthesised and tested at 
Liverpool.  Inhibition of bc1 has been attributed to binding at both the Qo and Qi sites 
of the complex, with Chapter V providing detailed discussion of the crucial 
interactions at either site, required for antimalarial activity.  Methods were also 
developed to be able to distinguish between Qo and Qi inhibitors, as well as further 
validation sought for the 5 active hits from virtual screening and their potential as 
Pfbc1 inhibitors.  Combined, these studies show that molecular docking has many 
applications in modern drug discovery, and not only can it be used to explain a 
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compounds activity profile through consideration of observed interactions, but it has 
also proven useful in confirming the identity of novel antimalarial targets, and in 
rationalising observations with regard to emerging resistance.  With work ongoing to 
design and validate a homology model of Pfbc1, docking will help to drive forward 
ongoing efforts to further refine the molecules. 
In Chapter VI a series of QSAR models were discussed that were generated for two 
datasets.  The first dataset was that of a set of 45 4-aminoquinoline compounds that 
had been tested against both the NF54 and K1 strains of malaria.  MLR, PLS and 
kNN machine learning methods were investigated, with the molecular descriptors 
contained within valid models interpreted with reference to the mechanistic mode of 
action of the 4-aminoquinoline compounds.  Significant models were identified and 
shown to have strong predictive abilities for both strains of the parasite, and may 
ultimately prove useful in the future for the prediction of activity for similar 4-
aminoquinoline compounds.  The second dataset was that of a series of thiazolide 
containing compounds which had shown activity against HCV.  After investigating 
several machine learning methods, SVM was found to give a significant model for 
the primary assay genotype 1B CC50 dataset, with this model able to predict the cell 
safety indices of the thiazolide derivatives.  Combined, the 4-aminoquinoline and 
thiazolide studies illustrate the power and potential of QSAR methods, as both have 
led to predictive models which can be used to aid in drug design and safety 
respectively. 
Finally, Chapter VII detailed the rational design of the novel pyrroloquinolone 
chemotype for antimalarial investigation.  A total of 7 synthetic analogues were 
made using alkylation and Winterfeldt oxidation reactions, with compounds 
reporting activity values between 75 nM and 1.02 µM against the 3D7 malaria 
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parasite.  A SAR investigation showed the chemotypes to have much potential, with 
molecular docking offering further support for possible Qo binding and therefore 
Pfbc1 inhibition for these compounds.  Future work with regard to the 
pyrroloquinolone chemotype will involve improving the solubility of the motif, as 
well as investigating additional substitutions on the aromatic side chain to improve 
potency. 
Experimental Chapter 
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Ligand Based Virtual Screening Methods 
Fingerprint Similarity Searching Protocol 
Fingerprint similarity searching protocol built and utilised within Pipeline Pilot 
Student Edition v6.1.
1
  Structures manipulated using the SMILES chemical 
language.
2, 3
  Twelve compounds active against Pfbc1 tagged as reference structures.  
References used to screen the Zinc lead like library
4, 5
 of compounds.  Several 
molecular fingerprint methods used: ECFP_2; ECFP_4; ECFP_6; FCFP_2; FCFP_4; 
FCFP_6; MDLPublicKeys.
6, 7
  Similarity between reference structures and those in 
the chemical library assessed using the Tanimoto coefficient.
8
  Compounds reported 
as hits provided they fell within minimum and maximum similarity cut-off values of 
0.70 and 0.99 respectively.  All other settings left as standard.  Reference structures 
and duplicate molecules removed.  Hits reported in SMILES format with highest 
Tanimoto coefficient values recorded. 
Turbo Similarity Searching Protocol 
Turbo similarity searching protocol built and utilised within Pipeline Pilot Student 
Edition v6.1.
1
  Structures manipulated using the SMILES chemical language.
2, 3
  
Twelve compounds active against Pfbc1 tagged as reference structures.  References 
used to screen the Zinc lead like library
4, 5
 of compounds.  Several molecular 
fingerprint methods used: ECFP_2; FCFP_2; MDLPublicKeys.
6, 7
  Similarity 
between reference structures and those in the chemical library assessed using the 
Tanimoto coefficient.
8
  Compounds reported as hits provided they fell within 
minimum and maximum similarity cut-off values of 0.80 and 0.99 respectively.  All 
other settings left as standard.  The hits from ZINC with the highest Tanimoto 
coefficient values capped at a maximum of 250 molecules.  These 250 molecules are 
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used in a second iteration of similarity searching, using the same fingerprint method.  
Results from the two searches are merged, with reference structures and duplicate 
molecules removed.  Hits reported in SMILES format with highest Tanimoto 
coefficient values recorded. 
Bioisostere Substructure Searching Protocol 
Quinolone core used as bioisostere query
9, 10
 and reported using SMILES chemical 
language.
2, 3
  BROOD version 1.1.2
11
 used to identify bioisosteres of the query in the 
f5 and f50 fragment libraries.  Searches performed four times using different 
searching methods: color; elect; struc; queryAnalog.  Fragments ranked according to 
shape and chemistry.  Hitlists merged in Pipeline Pilot Student Edition v6.1
1
 and 
novel fragments identified according to their ring assemblies using the ‘Find Novel 
Fragments’ component.  Dataset filtered to include only neutral fragments with a 
ring count greater than one.  Resulting bioisosteres used to perform a substructure 
search of the Zinc lead like library.
4, 5
  When the number of hits for a particular 
bioisostere exceeds 200, a representative sample of 200 compounds is taken using 
the ‘Diverse Molecules’ component with FCFP_4 fingerprints.6, 7  Results merged.  
Hits reported in SMILES format.  All other settings left at default. 
Principal Component Analysis Protocol 
PCA model for the twelve active compounds (tagged as reference structures) built 
using Pipeline Pilot Student Edition v6.1.
1
  Structures manipulated using the 
SMILES chemical language.
2, 3
  Physicochemical descriptors calculated for each 
compound: AlogP; Molecular_Weight; Num_H_Donors; Num_H_Acceptors; 
Num_RotatableBonds; Num_Atoms; Num_Rings; Num_AromaticRings.  
Descriptors used to calculate PCs, with PCA model developed to ensure greater than 
Experimental Chapter 
 
 
424 
 
75% of the variance in the data is explained.  Model applied to the Zinc lead like 
library
4, 5
 of compounds and mapped onto PC space.  Molecules assessed according 
to their Euclidean distance
8
 from one of the reference structures, with the 5,000 
closest molecules selected and reported in SMILES format.  All other settings left at 
default. 
Naïve Bayesian Classification Protocol 
Naïve Bayesian classification performed based on the structures of the twelve active 
and seven inactive compounds, qualitatively labelled ‘yes’ or ‘no’ respectively.  
Structures manipulated using the SDF file format.  Physicochemical descriptors 
calculated using Pipeline Pilot Student Edition v6.1
1
: AlogP; Molecular_Weight; 
Num_H_Donors; Num_H_Acceptors; Num_RotatableBonds; Num_Atoms; 
Num_Rings; Num_AromaticRings; Num_Fragments.  Bayesian model built within 
KNIME 2.3.3.
12
  Data filtered to remove descriptors with low variance or which 
were highly correlated (correlation threshold 0.9).  Descriptors normalised (Min-
Max) and data partitioned as required.  Additionally, SMOTE
13
 could be performed 
at this stage.  Classification model built using ‘Naïve Bayes Learner’ component 
then applied to predict the class membership of external compounds with ‘Naïve 
Bayes Predictor’.  Classification predictions reported in a confusion matrix.  Further 
validation sought using 100 iterations of LOO cross validation.  Validated Bayesian 
model applied to Zinc lead like library,
4, 5
 with compounds defined as either active or 
inactive.  Potentially active compounds filtered off and reported in an SDF file.  All 
settings left at default unless otherwise stated. 
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Decision Tree Analysis Protocol 
Decision tree analysis performed based on the structures of the twelve active and 
seven inactive compounds, qualitatively labelled ‘yes’ or ‘no’ respectively.  
Structures manipulated using the SDF file format.  Physicochemical descriptors 
calculated using Pipeline Pilot Student Edition v6.1
1
: AlogP; Molecular_Weight; 
Num_H_Donors; Num_H_Acceptors; Num_RotatableBonds; Num_Atoms; 
Num_Rings; Num_AromaticRings; Num_Fragments.  Decision tree built within 
KNIME 2.3.3.
12
  Data filtered to remove descriptors with low variance or which 
were highly correlated (correlation threshold 0.9).  Descriptors normalised (Min-
Max) and data partitioned as required.  Additionally, SMOTE
13
 could be performed 
at this stage.  Decision tree built using ‘J48 Weka’14 node, then applied to predict the 
class membership of external compounds with ‘Decision Tree Predictor’ 
component.  Classification predictions reported in a confusion matrix.  Further 
validation sought using 100 iterations of LOO cross validation.  Validated decision 
tree model applied to Zinc lead like library,
4, 5
 with compounds defined as either 
active or inactive.  Potential actives filtered off and reported in an SDF file.  All 
settings left at default unless otherwise stated. 
Ligand Based Virtual Screening Scoring & Selection Methods 
Consensus Scoring Protocol 
Consensus scoring implemented in Pipeline Pilot Student Edition v6.1
1
 using custom 
scripts and suitable components.  See Chapter III for more details. 
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Compound Filtering Protocol 
Compound filtering implemented in Pipeline Pilot Student Edition v6.1
1
 using 
custom scripts and substructure filters.  See Chapter III for more details. 
Diverse Compound Selection Protocol 
Diverse compound selection implemented in Pipeline Pilot Student Edition v6.1
1
 
using ‘Diverse Molecules’ component and FCFP_4 fingerprints.6, 7  All other settings 
left at default. 
AGNES Clustering Protocol 
AGNES
15
 clustering performed in Pipeline Pilot Student Edition v6.1
1
 utilising the R 
programming language.
16
  Compounds clustered into required number of clusters 
using the ‘R Cluster Agnes’ component according to their FCFP_4 fingerprints,6, 7 
with a sample molecule selected from each cluster using the ‘Diverse Molecules’ 
component and FCFP_4 fingerprints.  All other settings left at default. 
CLARA Clustering Protocol 
CLARA
15
 clustering performed in Pipeline Pilot Student Edition v6.1
1
 utilising the R 
programming language.
16
  Compounds clustered into required number of clusters 
using the ‘R Cluster Clara’ component according to their FCFP_4 fingerprints,6, 7 
and the central molecule from each selected.  All other settings left at default. 
 
 
 
Experimental Chapter 
 
 
427 
 
Biological Assay Methods 
Whole Cell Growth Inhibition Assay (3D7) Protocol 
Compounds tested for 3D7 inhibition according to the standard procedure detailed 
below:
17-23
 
P. falciparum (3D7 strain) cultures consisted of a 2% (v/v) suspension of O+ 
erythrocytes in RPMI-1640 medium (R 8758, glutamine and NaHCO3) 
supplemented with 10% pooled human AB+ serum, 25 mM HEPES (pH 7.4), and 20 
µM gentamicin sulphate.  Cultures were grown under a gaseous headspace of 4% O2, 
3% CO2 in N2 at 37ºC.  Parasite growth was synchronized by treatment with sorbitol.  
Drug susceptibilities were assessed by the measurement of fluorescence after the 
addition of SYBR Green I.  Drug IC50 values were calculated from the log of the 
dose/response relationship, as fitted with Grafit software (Erithacus Software, Kent, 
UK).  The results are given as the means of at least three separate experiments. 
Complex I (NDH2) Bioassay Protocol 
Compounds tested for NADH:decylubiquinone oxidoreductase inhibition according 
to the standard procedure detailed below:
23-25
 
Recombinant PfNDH2 activities were assayed in a reaction medium consisting of 50 
nM potassium phosphate (pH 7.5), 2 mM EDTA, 200 µM NADH and 10 mM KCN.  
NADH:decylubiquinone oxidoreductase activity was initiated by the addition of 50 
µM decylubiquinone.  Decylubiquinone reduction was monitored at 283 nm (ε283 = 
8.1 mM
-1
 cm
1) and 340 nm (ε340 = 6.22 mM
-1
 cm
1
) in a Cary 4000 
spectrophotometer.  Percentage inhibition of NADH:decylubiquinone 
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oxidoreductase activity for drugs at a concentration of 28 µM determined using 
Excel.
26
 
Bovine Complex III (bc1) Bioassay Protocol 
Compounds tested for cytochrome c reductase inhibition according to the standard 
procedure detailed below:
17, 23, 25
 
Cytochrome c reductase activity measurements were assayed in 50 mM potassium 
phosphate (pH 7.5), 2 mM EDTA, 10 mM KCN, and 30 µM equine cytochrome c 
(Sigma) at room temperature.  Cytochrome c reductase activity was initiated by the 
addition of decylubiquinol (50 µM).  Reduction of cytochrome c was monitored in a 
Cary 4000 spectrophotometer at 550 versus 542 nm.  Initial rates (computer-fitted as 
zero-order kinetics) were measured as a function of decylubiquinol concentration.  
Turnover rates of cytochrome c reduction were determined using ε550-542 = 18.1 mM
-1
 
cm
-1
.  Inhibitors of bc1 activity were added without prior incubation.  DMSO in the 
assays did not exceed 0.3 % (v/v).  Percentage inhibition of cytochrome c reductase 
activity for drugs at a concentration of 56 µM determined using Excel.
26
 
Molecular Docking Methods 
Qo Docking Protocol 
 Protein-ligand molecular docking at the Qo binding site performed using 
GOLD 5.0.1.
27
 
 Wizard utilised to setup and performing docking calculations. 
 Load appropriate file of reduced 3CX5 protein which includes SMA bound in 
the Qo active site (pdb format).
28
 
 Hydrogen atoms added to the protein. 
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 HOH7187 water molecule extracted for inclusion in docking calculation.28-30  
All other crystallographic water molecules removed. 
 Tautomeric state of His181 altered such that the hydrogen atom forms a H-
bond with the carbonyl group of SMA, and the lone pair of electrons on the 
nitrogen of His181 are directed towards ISP, in line with literature 
precedent.
30, 31
 
 SMA ligand removed and used to define the Qo binding site, together with all 
atoms around the ligand within 6Å. 
 Ligand file/s loaded containing the compound/s to be docked (sdf format).  
As standard, for each ligand 10 GA runs are performed. 
 If re-docking the native ligand, then load said ligand to enable RMSD 
comparison. 
 Select the required fitness scoring function i.e. GOLDScore.32, 33  If rescoring 
is required then select an additional scoring method i.e. ChemScore.
34-36
 
 Option for early termination turned off. 
 Default search efficiency used. 
 All parameters left as standard, unless otherwise stated. 
 Submit calculation and review results. 
Qi Docking Protocol 
 Protein-ligand molecular docking at the Qi binding site performed using 
GOLD 5.0.1.
27
 
 Wizard utilised to setup and performing docking calculations. 
 Load appropriate file of reduced 3CX5 protein which includes ubiquinone 
bound in the Qi active site (pdb format).
28
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 Hydrogen atoms added to the protein. 
 All crystallographic water molecules removed. 
 Ubiquinone ligand removed and used to define the Qi binding site, together 
with all atoms around the ligand within 6Å. 
 Ligand file/s loaded containing the compound/s to be docked (sdf format).  
As standard, for each ligand 10 GA runs are performed. 
 Select the required fitness scoring function i.e. GOLDScore.32, 33  If rescoring 
is required then select an additional scoring method i.e. ChemScore.
34-36
 
 Option for early termination turned off. 
 Default search efficiency used. 
 All parameters left as standard, unless otherwise stated. 
 Submit calculation and review results. 
Additional Computational Methods 
Energy Minimisation Protocol 
Spartan ‘08 was used to perform energy minimisation calculations.37  The required 
molecule for calculation was built using the construction tools within Spartan.  An 
equilibrium geometry calculation was then performed at ground state, using the 
molecular mechanics, MMFF level of theory.
38
  The total charge was adjusted 
accordingly and all other settings left at default. 
Conformer Distribution Protocol 
Spartan ’08 was used to perform conformer distribution calculations.37  The required 
molecule for calculation was built using the construction tools within Spartan. A 
conformer distribution calculation was then performed at ground state, using the 
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molecular mechanics, MMFF level of theory.
38
  All other settings left at default.  
One hundred conformations were calculated, with a spreadsheet used to record the 
energy and Boltzmann distribution values for each conformer. 
Conformer Library Protocol 
Spartan ’08 was used to perform conformer library calculations.37  The required 
molecule for calculation was built using the construction tools within Spartan. A 
conformer library calculation was then performed, in which the lowest energy 
conformer of a molecule is replaced with a set of conformers spanning all shapes 
accessible to the molecule, with no regard for its energy.
39
  All settings left at 
default. 
Similarity Analysis Protocol 
Spartan ’08 was used to perform similarity analysis calculations.37  The 
pharmacophore with which to map additional molecules against is loaded.  A 
similarity analysis calculation can then be performed, mapping each compound in a 
specified conformer library to the pharmacophore.  Similarity can be assessed using 
the CFDs of the pharmacophore, with each compound assigned a score between 0 
and 1.
39
  All other settings left at default. 
Substructure Searching Protocol 
Substructure search protocol built and utilised within Pipeline Pilot Student Edition 
v6.1.
1
  Structures manipulated in their SDF format.  Library of compounds searched 
for a query structure using the ‘Substructure Filter from File’ component.  Results 
written in SDF format, all other settings left at default. 
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Fingerprint Similarity Search Protocol 
Fingerprint similarity search protocol built and utilised within Pipeline Pilot Student 
Edition v6.1.
1
  Structures manipulated in their SDF format.  Query structure used to 
screen a library of compounds using FCFP_4 molecular fingerprints.
6, 7
  Similarity 
between query and library compounds assessed using the Tanimoto coefficient.
8
  
Compounds filtered according to required level of similarity.  Results written in SDF 
format, all other settings left at default. 
QSAR Experimental Procedures 
QSAR Protocol 1 MLR; Training set 
The following procedure was used to develop QSAR models using MLR when all of 
the molecules formed part of a training set.  Calculation of internal validation 
statistics are also discussed: 
 Load the data into PHAKISO40 as a training set. 
 Use Autoscale to normalise the descriptors. 
 Perform objective descriptor selection: 
o General descriptor selection.  (Removes descriptors with the same 
value for 80% of the training set and those with missing values.) 
o CORCHOP41 descriptor selection.  (Removes descriptors with very 
highly correlated R values (0.99), with a maximum allowed 
correlation of 0.75, and a maximum allowed kurtosis of 100.) 
 Perform subjective descriptor selection using the required selection method: 
Forward selection; Backward elimination; Stepwise Regression; Genetic 
algorithm; GALib.  Adjusted coefficient of determination used as the error 
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measurement.  Max/min number of variables altered accordingly to produce 
favourable molecule/descriptor ratios. 
 Train the data using MLR machine learning.8 
 Predict the internal statistics.  Process automated through PHAKISO to 
calculate statistical parameters such as the correlation coefficient, coefficient 
of determination,  -statistic etc.  Additionally the cross validation parameter 
   can be calculated, as can the N fold cross validation40 and Bootstrapping42 
statistics. 
 Calculate the  -statistics for the descriptors using the data analysis, regression 
tools in Excel.
26, 43
 
 Tabulate the results in a summary file. 
QSAR Protocol 2 MLR; Training and test set 
The following procedure was used to divide a dataset into a training and test set.  
QSAR models were then developed using MLR.  Calculation of internal and external 
validation statistics are also discussed: 
 Load the data into PHAKISO40 as a dataset. 
 Divide the data into a training and test set using the most appropriate method: 
o Sphere exclusion algorithm.  (All settings left at default unless 
stated.) 
o CADEX.  (All settings left at default unless stated.) 
o Activity binning.  (Performed in Excel.)26 
 Use Autoscale to normalise the descriptors. 
 Perform objective descriptor selection: 
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o General descriptor selection.  (Removes descriptors with the same 
value for 80% of the training set and those with missing values.) 
o CORCHOP41 descriptor selection.  (Removes descriptors with very 
highly correlated R values (0.99), with a maximum allowed 
correlation of 0.75, and a maximum allowed kurtosis of 100.) 
 Perform subjective descriptor selection using the required selection method: 
Forward selection; Backward elimination; Stepwise Regression; Genetic 
algorithm; GALib.  Adjusted coefficient of determination used as the error 
measurement.  Max/min number of variables altered accordingly to produce 
favourable molecule/descriptor ratios. 
 Train the data using MLR machine learning.8 
 Predict the internal statistics.  Process automated through PHAKISO to 
calculate statistical parameters such as the correlation coefficient, coefficient 
of determination,  -statistic etc.  Additionally the cross validation parameter 
   can be calculated, as can the N fold cross validation40 and Bootstrapping42 
statistics. 
 Calculate the  -statistics for the descriptors using the data analysis, regression 
tools in Excel.
26, 43
 
 Apply internally validated model to the test set. 
 Predict the external statistics.  Process automated through PHAKISO to 
calculate statistical parameters such as the correlation coefficient, coefficient 
of determination,  -statistic etc. 
 In Excel plot the predicted vs. actual and actual vs. predicted activity values 
for the training and test sets. 
 Calculate the Tropsha parameters using the graphs.44, 45 
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 Tabulate the results in a summary file. 
QSAR Protocol 3 PLS; Training and test set 
The following procedure was used to divide a dataset into a training and test set.  
QSAR models were then developed using PLS.  Calculation of internal and external 
validation statistics are also discussed: 
 Load the data into PHAKISO40 as a dataset. 
 Divide the data into a training and test set using the most appropriate method: 
o Sphere exclusion algorithm.  (All settings left at default unless 
stated.) 
o CADEX.  (All settings left at default unless stated.) 
o Activity binning.  (Performed in Excel.)26 
 Use Autoscale to normalise the descriptors. 
 Find the optimum number of components to explain the data.  Usually when 
the combined components have a    > 0.5, with the last component 
increasing the explained variance by more than 5%.  (Use the single 
parameter trainer with PLS and adjusted coefficient of determination.) 
 Set the number of components and train the data using the PLS machine 
learning method.
46
 
 Predict the internal statistics.  Process automated through PHAKISO to 
calculate statistical parameters such as the correlation coefficient, coefficient 
of determination,  -statistic etc.  Additionally the cross validation parameter 
   can be calculated, as can the N fold cross validation40 and Bootstrapping42 
statistics. 
 Apply internally validated model to the test set. 
Experimental Chapter 
 
 
436 
 
 Predict the external statistics.  Process automated through PHAKISO to 
calculate statistical parameters such as the correlation coefficient, coefficient 
of determination,  -statistic etc. 
 In Excel plot the predicted vs. actual and actual vs. predicted activity values 
for the training and test sets. 
 Calculate the Tropsha parameters using the graphs.44, 45 
 Tabulate the results in a summary file. 
QSAR Protocol 4 kNN 
The following procedure was used to develop models with the kNN machine 
learning method: 
 Construct two text files, one which contains the molecule names and 
associated descriptors, the other the molecule names with their activities. 
 Use unsupervised forward selection (UFS) to reduce the number of 
descriptors.  UFS was designed for use in the development of QSARs as a 
data reduction algorithm that selects from a data matrix, a maximal linearly 
independent set of columns with a minimal amount of multiple correlation 
i.e. it removes highly correlated descriptors.
47
 
 Normalize the data. 
 Run the kNN calculation through Cygwin using codes which were developed 
by Dr N. Berry at Liverpool University from executable codes provided by 
Prof. A. Tropsha at UNC.  Cygwin is a unix-like environment and command-
line interface for Microsoft Windows.
48
  Conditions can be specified as to the 
splitting of the data into training and test sets, as well as the number of 
models per split, and the maximum and minimum descriptor range. 
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 The codes construct all possible models within the specified conditions, and 
randomise the data such that all statistically good models are reported at 
varying significance levels, and grouped accordingly. 
QSAR Protocol 5 SVM; Training and test set 
The following procedure was used to divide a dataset into a training and test set.  
QSAR models were then developed using SVM.  Calculation of internal and external 
validation statistics are also discussed: 
 In PHAKISO40 use Autoscale to normalise the descriptors. 
 Perform objective descriptor selection: 
o General descriptor selection.  (Removes descriptors with the same 
value for 80% of the training set and those with missing values.) 
o CORCHOP41 descriptor selection.  (Removes descriptors with very 
highly correlated R values (0.99), with a maximum allowed 
correlation of 0.75, and a maximum allowed kurtosis of 100.) 
 Divide the data into a training and test set using the most appropriate method: 
o CADEX.  (All settings left at default unless stated.) 
o Activity binning.  (Performed in Excel.)26 
 SVM protocol built using KNIME.12 
 Training set read in. 
 Low variance and linear correlation filters performed, both at default settings. 
 SVM regression models built using the radial basis function (RBF) kernel via 
the GridSearch node.  The grid search algorithm found the SVM model with 
RBF kernel parameters ε and γ that gave the highest correlation coefficient in 
10-fold cross-validation.  The ε parameter was initially altered in a range of 
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2
-10
 to 2
1, and the γ parameter was from 2-15 to 23, in line with 
recommendations in the literature.
49
  Both parameters were altered as powers 
of 2, and the grid search was allowed to extend three times.  The C parameter 
for the RBF was manually scanned from 1 to 1000 in factors of 10 initially, 
and then in half order of magnitude once a coarse optimum region of 
parameter space was identified. 
 Internal and external validation statistics calculated using Excel by plotting 
the predicted vs. actual and actual vs. predicted activity values for the 
training and test sets. 
 Calculate the Tropsha parameters using the graphs.44, 45 
 Tabulate the results in a summary file. 
Chemical Synthesis 
All reactions were carried out in dry conditions under a nitrogen atmosphere unless 
otherwise stated.  Melting points were determined with a Gallenkamp apparatus and 
are uncorrected.  Elemental analysis was performed by the microanalysis service at 
the University of Liverpool.  Mass spectra were collected using a Fisons TRIO 1000 
by the mass spec lab at the University of Liverpool.  Infrared spectra were recorded 
on a Perkin Elmer 4100-typeA FTIR spectrometer.  
1
H-NMR spectra were recorded 
on a Bruker AMX 400 (400MHz) spectrometer, as were 
13
C-NMR spectra in 
solutions of CDCl3 and MeOD.  The chemical shifts are in parts per million (ppm), 
with tetramethylsilane as the internal reference and the coupling constants in hertz 
(Hz).  TLC was performed on silica plates, and columns were run on silica gel 
specifically for flash chromatography.  Reagents were purchased from Sigma-
Aldrich. 
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Wohl-Ziegler Bromination Reaction 
 
4-(bromomethyl)-1,1'-biphenyl (7).   
4-methyl-1,1'-biphenyl (0.3146 g, 1.870 mmol) was dissolved in acetonitrile (40 mL) 
and the system flushed with nitrogen.  AIBN (0.0976 g, 0.5944 mmol) and NBS 
(0.9521 g, 5.350 mmol) were then added to the solution and left to stir at reflux until 
all of the biphenyl was consumed.  The reaction was then cooled to room 
temperature and the solid brown residue filtered off.  The orange filtrate was then 
concentrated to give the crude product as an orange solid.  The product was then 
purified via flash column chromatography (silica gel, 3:97 EtOAc/Hexane) to give 
the pure product as an orange solid (0.4095 g, 88.61%).;  mp 81
o
C;  
1H NMR δ ppm 
(CDCl3, 400 MHz):  4.51 (s, 2H), 7.31-7.61 (m, 8H);  
13C NMR δ ppm (CDCl3, 100 
MHz):  33.9, 127.9, 128.4, 129.1, 129.4, 130.0, 137.2, 140.9, 141.8;  IR (neat cm
-1
) 
2978, 2357, 1485;  MS (m/z) 246 [M-H], 182 [M-C6H5], 168 [M-Br];  Anal. Calcd 
for C13H11Br:  C, 63.18%; H, 4.49%.  Found:  C, 56.26%; H, 3.86%. 
Experimental data in agreement with literature precedent.
50
 
Alkylation Reactions 
 
2-benzyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (8).  1,2,3,4-tetrahydro-9H-
pyrido[3,4-b]indole (0.5092 g, 2.957 mmol) was dissolved in anhydrous THF (40 
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mL) at 0
o
C under inert conditions.  Triethylamine (0.82 mL, 5.883 mmol) was added 
dropwise to the solution and left to warm to room temperature for 1 hour.  
(Bromomethyl)benzene (1) (0.42 mL, 3.531 mmol) was then added and left to stir 
until all of the 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole was consumed.  Once the 
solvents were removed, the crude product was purified via flash column 
chromatography (silica gel, 40:60 EtOAc/Hexane) to give the pure product as a pale 
yellow solid (0.5096 g, 65.73%).;  mp 138
o
C;  
1H NMR δ ppm (CDCl3, 400MHZ):  
2.71 (t, J=5.3 Hz, 2H), 2.79 (t, J=5.3 Hz, 2H), 3.42 (s, 2H), 3.63 (s, 2H), 6.96-7.38 
(m, 8H);  
13C NMR δ ppm (CDCl3, 100MHz):  21.6, 50.5, 51.3, 62.4, 108.7, 111.2, 
118.4, 119.7, 121.7, 127.7, 127.7, 128.9, 129.6, 132.3, 136.4, 138.8;  IR (neat cm
-1
) 
2978, 2360,1454;  MS (m/z) 263 [M+H]
+
;  HRMS (CI) calcd for C18H19N2 (MH
+
) 
requires 263.1544, found 263.1548.  Anal. Calcd for C18H18N2:  C, 82.41%; H, 
6.92%; N, 10.68%.  Found:  C, 82.36%; H, 6.96%; N, 10.60%. 
Experimental data in agreement with literature precedent.
51, 52
 
 
2-(4-chlorobenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (9).  1,2,3,4-
tetrahydro-9H-pyrido[3,4-b]indole (1.0 g, 5.806 mmol) was dissolved in anhydrous 
THF (80 mL) at 0
o
C under inert conditions.  Triethylamine (1.62 mL, 11.612 mmol) 
was added dropwise to the solution and left to warm to room temperature for 1 hour.  
4-chlorobenzyl bromide (2) (1.45 g, 7.127 mmol) was then added and left to stir until 
all of the 1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole was consumed.  Once the 
solvents were removed, the crude product was purified via flash column 
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chromatography (silica gel, 40:60 EtOAc/Hexane) to give the pure product as a 
yellow solid (1.2969 g, 75.33%).;  mp 186
o
C;  
1H NMR δ ppm (CDCl3, 400 MHz):  
2.83 (t, J=5.3 Hz, 2H), 2.90 (t, J=5.3 Hz), 3.66 (s, 2H), 3.74 (s, 2H), 7.06-7.48 (m, 
8H);  
13C NMR δ ppm (CDCl3, 100MHz):  22.5, 41.8, 55.8, 61.5, 108.6, 111.1, 
118.3, 119.6, 121.7, 127.8, 128.9, 130.9, 133.4, 133.5, 137.4, 137.6;  IR (neat cm
-1
) 
3132, 3059, 2924, 2839;  MS (m/z) 297 [M+H]
+
;  HRMS (CI) calcd for C18H18N2Cl 
(MH
+
) requires 297.11585, found 297.11559.  Anal. Calcd for C18H17N2Cl:  C, 
72.83%; H, 5.77%; N, 9.44%.  Found:  C, 72.63%; H, 5.82%; N, 9.39%. 
Experimental data in agreement with literature precedent.
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2-(3,4-dichlorobenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (10).  1,2,3,4-
tetrahydro-9H-pyrido[3,4-b]indole (1.0 g, 5.806 mmol) was dissolved in anhydrous 
THF (80 mL) at 0
o
C under inert conditions.  Triethylamine (1.62 mL, 11.612 mmol) 
was added dropwise to the solution and left to warm to room temperature for 1 hour.  
3,4-dichlorobenzyl bromide (3) (1.1 mL, 7.565 mmol) was then added and left to stir 
until all the 1,2,3,4-tetrahydro-9H-pyrido[3,4-b] was consumed.  Once the solvents 
were removed, the crude product was purified via flash column chromatography 
(silica gel, 40:60 EtOAc/Hexane) to give the pure product as a pale orange solid 
(1.5258 g, 79.39%).;  mp 158
o
C;  
1H NMR δ ppm (CDCl3, 400 MHz):  2.83 (t, 
J=5.2Hz, 2H), 2.91 (t, J=5.2Hz, 2H), 3.67 (s, 2H), 3.72 (s, 2H), 7.07-7.53 (m, 7H);  
13C NMR δ ppm (CDCl3, 100MHz):  21.5, 50.6, 51.3, 61.1, 108.9, 111.1, 118.4, 
119.9, 121.9, 128.6, 130.7, 131.1, 131.9, 133.2, 133.8, 135.9, 136.4, 139.5;  IR (neat 
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cm
-1
) 3059, 2958, 2916, 2839;  MS (m/z) 331 [M+H]
+
;  HRMS (CI) calcd for 
C18H17N2Cl2 (MH
+
) requires 331.07688, found 331.07736.  Anal. Calcd for 
C18H16N2Cl2:  C, 65.25%; H, 4.87%; N, 8.46%.  Found:  C, 65.07%; H, 4.84%; N, 
8.34%. 
 
2-(4-(trifluoromethyl)benzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (11).  
1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole (1.0 g, 5.806 mmol) was dissolved in 
anhydrous THF (80 mL) at 0
o
C under inert conditions.  Triethylamine (1.62 mL, 
11.612 mmol) was added dropwise to the solution and left to warm to room 
temperature for 1 hour.  4-(trifluoromethyl)benzyl bromide (4) (1.67 g, 6.986 mmol) 
was then added and left to stir until all of the 1,2,3,4-tetrahydro-9H-pyrido[3,4-
b]indole was consumed.  Once the solvents were removed, the crude product was 
purified via flash column chromatography (silica gel, 40:60 EtOAc/Hexane) to give 
the pure product as a pale yellow solid (1.6377 g, 85.50%).;  mp 167
o
C;  
1H NMR δ 
ppm (CDCl3, 400MHZ):  2.82 (t, J=5.3 Hz, 2H), 2.89 (t, J=5.3 Hz, 2H), 3.61 (s, 2H), 
3.79 (s, 2H), 7.06-7.60 (m, 8H);  
13C NMR δ ppm (CDCl3, 100MHz):  21.6, 50.6, 
51.3, 61.7, 108.6, 111.1, 118.3, 119.8, 121.8, 123.3, 125.6, 126.0, 127.6, 129.6, 
132.0, 136.5, 143.2;  IR (neat cm
-1
) 3143, 3062, 2941, 2833;  MS (m/z) 331 [M+H]
+
;  
HRMS (CI) calcd for C19H18N2F3 (MH
+
) requires 331.14221, found 331.14199.  
Anal. Calcd for C19H17N2F3:  C, 69.08%; H, 5.19%; N, 8.48%.  Found:  C, 69.00%; 
H, 5.22%; N, 8.45%. 
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2-(4-(trifluoromethoxy)benzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (12).  
1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole (1.0 g, 5.806 mmol) was dissolved in 
anhydrous THF (80 mL) at 0
o
C under inert conditions.  Triethylamine (1.62 mL, 
11.62 mmol) was added dropwise to the solution and left to warm to room 
temperature for 1 hour.  4-(trifluoromethoxy)benzyl bromide (5) (1.0 mL, 6.250 
mmol) was then added and left to stir until all the 1,2,3,4-tetrahydro-9H-pyrido[3,4-
b] was consumed.  Once the solvents were removed the crude product was purified 
via flash column chromatography (silica gel, 40:60 EtOAc/Hexane) to give the pure 
product as an orange solid (1.7342 g, 86.24%).;  mp 116
o
C;  
1H NMR δ ppm 
(CDCl3, 400 MHz):  2.83 (t, J=5.3Hz, 2H), 2.91 (t, J=5.3Hz, 2H), 3.66 (s, 2H), 3.77 
(s, 2H), 7.07-7.49 (m, 8H);  
13C NMR δ ppm (CDCl3, 100MHz):  21.6, 50.6, 51.3, 
61.4, 100.0, 108.8, 111.1, 118.4, 119.3, 121.3, 121.8, 127.6, 130.7, 132.0, 136.4, 
137.7, 148.8;  IR (neat cm
-1
) 3180, 3100, 2825, 1508, 1269;  MS (m/z) 347 [M+H]
+
;  
HRMS (CI) calcd for C19H18N2OF3 (MH
+
) requires 347.13712, found 347.13701.  
Anal. Calcd for C19H17N2OF3:  C, 65.89%; H, 4.95%; N, 8.09%.  Found:  C, 65.25%; 
H, 4.89%; N, 7.94%. 
 
2-(4-methoxybenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (13).  1,2,3,4-
tetrahydro-9H-pyrido[3,4-b]indole (0.5270 g, 3.060 mmol) was dissolved in 
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anhydrous THF (40 mL) at 0
o
C under inert conditions.  Triethylamine (0.85 mL, 
6.098 mmol) was added dropwise to the solution and left to warm to room 
temperature for 1 hour.  1-(bromomethyl)-4-methoxybenzene (6) (0.51 mL, 3.643 
mmol) was then added and left to stir until all the 1,2,3,4-tetrahydro-9H-pyrido[3,4-
b] was consumed.  Once the solvents were removed the crude product was purified 
via flash column chromatography (silica gel, 40:60 EtOAc/Hexane) to give the pure 
product as an orange solid (0.4719 g, 52.75%).;  mp 131
o
C;  
1H NMR δ ppm 
(CDCl3, 400 MHz):  2.71 (t, J=5.4Hz, 2H), 2.78 (t, J=5.4Hz, 2H), 3.41 (s, 2H), 3.67 
(s, 2H), 6.73-7.37 (m, 8H);  
13C NMR δ ppm (CDCl3, 100MHz):  21.6, 50.5, 51.3, 
55.7, 62.3, 108.6, 111.2, 114.8, 118.4, 119.7, 122.0, 127.7, 129.8, 132.3, 136.5, 
140.5, 160.2;  IR (neat cm
-1
) 2939, 1971, 1597, 1462;  MS (m/z) 293 [M+H]
+
;  
HRMS (CI) calcd for C19H21N2O (MH
+
) requires 293.1647, found 293.1654.  Anal. 
Calcd for C19H20N2O:  C, 78.05%; H, 6.89%; N, 9.58%.  Found:  C, 77.21%; H, 
6.77%; N, 9.35%. 
 
2-([1,1'-biphenyl]-4-ylmethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (14).  
1,2,3,4-tetrahydro-9H-pyrido[3,4-b]indole (0.2904 g, 1.686 mmol) was dissolved in 
anhydrous THF (30 mL) at 0
o
C under inert conditions.  Triethylamine (0.47 mL, 
3.372 mmol) was added dropwise to the solution and left to warm to room 
temperature for 1 hour.  4-(bromomethyl)-1,1'-biphenyl (7) (0.5 g, 3.643 mmol) was 
then added and left to stir until all the 1,2,3,4-tetrahydro-9H-pyrido[3,4-b] was 
consumed.  Once the solvents were removed the crude product was purified via flash 
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column chromatography (silica gel, 40:60 EtOAc/Hexane) to give the pure product 
as a pale yellow solid (0.2970 g, 45.80%).;  mp 160
o
C;  
1H NMR δ ppm (CDCl3, 400 
MHz):  2.84 (t, J=5.4Hz, 2H), 2.94 (t, J=5.4Hz, 2H), 3.66 (s, 2H), 3.80 (s, 2H), 7.06-
7.62 (m, 13H);  
13C NMR δ ppm (CDCl3, 100MHz):  21.6, 50.6, 51.4, 62.1, 108.8, 
111.1, 118.4, 119.8, 121.7, 127.5, 127.5, 127.7, 127.7, 129.2, 130.0, 132.3, 136.4, 
137.9, 140.6, 141.3;  IR (neat cm
-1
) 3394, 2978, 1450;  MS (m/z) 339 [M+H]
+
;  
HRMS (CI) calcd for C24H23N2 (MH
+
) requires 339.1848, found 339.1861.  Anal. 
Calcd for C24H22N2:  C, 85.17%; H, 6.55%; N, 8.28%.  Found:  C, 84.68%; H, 
6.56%; N, 8.12%. 
Winterfeldt Oxidation Reactions 
 
2-benzyl-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9(4H)-one (15).  2-benzyl-
2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (8) (0.2972 g, 1.133 mmol) and potassium 
tert-butoxide (0.1290 g, 1.150 mmol) were dissolved in DMF (10 mL).  A steady 
stream of oxygen was bubbled through the solution and the reaction was monitored 
via the consumption of the indole.  Water (75 mL) was added and the solution was 
neutralised using 1M HCl.  The precipitate was filtered off and an extraction was 
carried out on the filtrate using ethyl acetate.  The solvents were removed and the 
two crops of solid combined.  DCM was added to the collected solid and following 
vigorous shaking, the mixture was filtered to give the product as a yellow solid 
(0.1016 g, 32.46%).;  mp 222
o
C;  
1H NMR δ ppm (MeOD + trifluoroacetic acid, 400 
MHz):  4.65 (s, 2H), 4.71 (s, 2H), 4.86 (s, 2H), 7.46-8.29 (m, 9H);  
13C NMR δ ppm 
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(MeOD + trifluoroacetic acid, 100MHz):  57.8, 57.9, 60.4, 113.0, 120.2, 126.4, 
126.6, 126.9, 131.1, 131.8, 132.0, 134.5, 138.0, 142.3, 147.5, 175.5;  IR (neat cm
-1
) 
2804, 2357, 1570, 1504;  MS (m/z) 277 [M+H]
+
;  HRMS (CI) calcd for C18H17N2O 
(MH
+
) requires 277.1341, found 277.1341.  Anal. Calcd for C18H16N2O:  C, 78.24%; 
H, 5.84%; N, 10.14%.  Found:  C, 74.83%; H, 5.61%; N, 9.59%. 
Experimental data in agreement with literature precedent.
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2-(4-chlorobenzyl)-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9(4H)-one (16).  2-(4-
chlorobenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (9) (0.5991 g, 2.019 mmol) 
and potassium tert-butoxide (0.2235 g, 1.992 mmol) were dissolved in DMF (15 
mL).  A steady stream of oxygen was bubbled through the solution and the reaction 
was monitored via the consumption of the indole.  Water (150 mL) was added and 
the solution was neutralised using 1M HCl.  The precipitate was filtered off and an 
extraction was carried out on the filtrate using ethyl acetate.  The solvents were 
removed and the two crops of solid combined.  DCM was added to the collected 
solid and following vigorous shaking, the mixture was filtered to give the product as 
a yellow solid (0.4961 g, 79.08%).;  mp 251
o
C;  
1H NMR δ ppm (MeOD + 
trifluoroacetic acid, 400 MHz):  4.64 (s, 2H), 4.70 (s, 2H), 4.87 (s, 2H), 7.45-8.28 
(m, 8H);  
13C NMR δ ppm (MeOD + trifluoroacetic acid, 100MHz):  57.8, 57.9, 
59.5, 113.0, 120.3, 126.4, 126.5, 126.9, 130.6, 131.2, 133.7, 134.5, 138.1, 142.2, 
147.5, 175.4;  IR (neat cm
-1
) 3064, 2926, 2783, 2364, 1898;  MS (m/z) 311 [M+H]
+
, 
185 [M-C7H6Cl]
+
;  HRMS (CI) calcd for C18H16ClN2O (MH
+
) requires 311.09512, 
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found 311.09378.  Anal. Calcd for C18H15ClN2O:  C, 69.57%; H, 4.86%; N, 9.01%.  
Found:  C, 69.16%; H, 4.92%; N, 8.84%. 
 
2-(3,4-dichlorobenzyl)-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9(4H)-one (17).  
2-(3,4-dichlorobenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (10) (0.5610 g, 
1.694 mmol) and potassium tert-butoxide (213.60 mg, 1.903 mmol) were dissolved 
in DMF (15 mL).  A steady stream of oxygen was bubbled through the solution and 
the reaction was monitored via the consumption of the indole.  Water (150 mL) was 
added and the solution was neutralised using 1M HCl.  The precipitate was filtered 
off and an extraction was carried out on the filtrate using ethyl acetate.  The solvents 
were removed and the two crops of solid combined.  DCM was added to the 
collected solid and following vigorous shaking, the mixture was filtered to give the 
product as a yellow solid (0.2785 g, 47.63 %).;  mp 244
o
C;  
1H NMR δ ppm (MeOD 
+ trifluoroacetic acid, 400 MHz):  4.66 (s, 2H), 4.70 (s, 2H), 4.89 (s, 2H), 7.46-8.29 
(m, 7H);  
13C NMR δ ppm (MeOD + trifluoroacetic acid, 100MHz):  57.9, 58.0, 
58.9, 122.9, 120.3, 126.4, 126.5, 126.8, 132.0, 132.4, 133.2, 134.1, 134.5, 134.9, 
135.7, 142.2, 147.5, 175.8;  IR (neat cm
-1
) 3080, 2929, 2810, 2349, 1845;  MS (m/z) 
345 [M+H]
+
, 185 [M-C7H5Cl2]
+
;  HRMS (CI) calcd for C18H15Cl2N2O (MH
+
) 
requires 345.05614, found 345.05507.  Anal. Calcd for C18H14Cl2N2O:  C, 62.63%; 
H, 4.09%; N, 8.11%.  Found:  C, 61.98%; H, 3.99%; N, 7.98%. 
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2-(4-(trifluoromethyl)benzyl)-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9(4H)-one 
(18).  2-(4-(trifluoromethyl)benzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (11) 
(0.5128 g, 1.552 mmol) and potassium tert-butoxide (0.1754 g, 1.563 mmol)  were 
dissolved in DMF (12 mL).  A steady stream of oxygen was bubbled through the 
solution and the reaction was monitored via the consumption of the indole.  Water 
(150 mL) was added and the solution was neutralised using 1M HCl.  The precipitate 
was filtered off and an extraction was carried out on the filtrate using ethyl acetate.  
The solvents were removed and the two crops of solid combined.  DCM was added 
to the collected solid and following vigorous shaking, the mixture was filtered to 
give the product as a pale yellow solid (0.1321 g, 24.72%).;  mp 265
o
C;  
1H NMR δ 
ppm (MeOD + trifluoroacetic acid, 400 MHz):  4.67 (s, 2H), 4.81 (s, 2H), 4.90 (s, 
2H), 7.46-8.29 (m, 8H);  
13C NMR δ ppm (MeOD + trifluoroacetic acid, 100MHz):  
58.0, 58.2, 59.5, 113.0, 117.9, 120.3, 126.4, 126.5, 126.9, 127.8, 127.9, 132.8, 134.5, 
136.2, 142.2, 147.5, 175.4;  IR (neat cm
-1
) 3066, 2931, 2814, 2334, 1895;  MS (m/z) 
345 [M+H]
+
, 185 [M-C8H6F3]
+
;  HRMS (CI) calcd for C19H16N2OF3 (MH
+
) requires 
345.12147, found 345.12096.  Anal. Calcd for C19H15N2OF3:  C, 66.23%; H, 4.39%; 
N, 8.14%.  Found:  C, 63.70%; H, 4.38%; N, 6.81%. 
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2-(4-(trifluoromethoxy)benzyl)-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9(4H)-
one (19).  2-(4-(trifluoromethoxy)benzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole 
(12) (0.6146 g, 1.775 mmol) and potassium tert-butoxide (0.2200 g, 1.960 mmol) 
were dissolved in DMF (16 mL).  A steady stream of oxygen was bubbled through 
the solution and the reaction was monitored via the consumption of the indole.  
Water (150 mL) was added and the solution was neutralised using 1M HCl.  The 
precipitate was filtered off and an extraction was carried out on the filtrate using 
ethyl acetate.  The solvents were removed and the two crops of solid combined.  
DCM was added to the collected solid and following vigorous shaking, the mixture 
was filtered to give the product as a yellow solid (0.2015 g, 31.51%).;  mp 257
o
C;  
1H NMR δ ppm (MeOD + trifluoroacetic acid, 400 MHz):  4.68 (s, 2H), 4.76 (s, 2H), 
4.90 (s, 2H), 7.46-8.28 (m, 8H);  
13C NMR δ ppm (MeOD + trifluoroacetic acid, 
100MHz):  57.9, 58.0, 59.4, 113.0, 120.3, 123.4, 126.4, 126.5, 126.9, 130.9, 134.1, 
134.5, 142.3, 147.5, 160.5, 160.9, 175.4;  IR (neat cm
-1
) 2812, 2337, 1570, 1512;  
MS (m/z) 361 [M+H]
+
;  HRMS (CI) calcd for C19H16N2O2F3 (MH
+
) requires 
361.1147, found 361.1147.  Anal. Calcd for C19H15N2O2F3:  C, 63.33%; H, 4.20%; 
N, 7.77%.  Found:  C, 63.23%; H, 4.24%; N, 7.72%. 
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2-(4-methoxybenzyl)-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9(4H)-one (20).  2-
(4-methoxybenzyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (13) (0.3007 g, 1.029 
mmol) and potassium tert-butoxide (0.1170 g, 1.043 mmol) were dissolved in DMF 
(10 mL).  A steady stream of oxygen was bubbled through the solution and the 
reaction was monitored via the consumption of the indole.  Water (75 mL) was 
added and the solution was neutralised using 1M HCl.  The precipitate was filtered 
off and an extraction was carried out on the filtrate using ethyl acetate.  The solvents 
were removed and the two crops of solid combined.  DCM was added to the 
collected solid and following vigorous shaking, the mixture was filtered to give the 
product as a pale yellow solid (0.0749 g, 23.77%).;  mp 216
o
C;  
1H NMR δ ppm 
(MeOD + trifluoroacetic acid, 400 MHz):  4.65 (s, 2H), 4.67 (s, 2H), 4.85 (s, 2H), 
7.11-8.29 (m, 8H);  
13C NMR δ ppm (MeOD + trifluoroacetic acid, 100MHz):  56.4, 
57.9, 60.4, 113.0, 115.7, 117.3, 117.4, 120.2, 123.8, 126.4, 126.6, 132.3, 133.1, 
134.5, 142.3, 147.4, 175.4;  IR (neat cm
-1
) 3070, 2850, 2890, 1570, 1516;  MS (m/z) 
307 [M+H]
+
;  HRMS (CI) calcd for C19H19N2O2 (MH
+
) requires 307.1444, found 
307.1447.  Anal. Calcd for C19H18N2O2:  C, 74.49%; H, 5.92%; N, 9.14%.  Found:  
C, 74.41%; H, 6.01%; N, 9.12%. 
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2-([1,1'-biphenyl]-4-ylmethyl)-2,3-dihydro-1H-pyrrolo[3,4-b]quinolin-9(4H)-one 
(21).  2-([1,1'-biphenyl]-4-ylmethyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole (14) 
(0.2560 g, 0.7564 mmol) and potassium tert-butoxide (0.0908 g, 0.8091 mmol) were 
dissolved in DMF (10 mL).  A steady stream of oxygen was bubbled through the 
solution and the reaction was monitored via the consumption of the indole.  Water 
(75 mL) was added and the solution was neutralised using 1M HCl.  The precipitate 
was filtered off and an extraction was carried out on the filtrate using ethyl acetate.  
The solvents were removed and the two crops of solid combined.  DCM was added 
to the collected solid and following vigorous shaking, the mixture was filtered to 
give the product as a yellow solid (0.1088 g, 40.81%).;  mp 245
o
C;  
1H NMR δ ppm 
(MeOD + trifluoroacetic acid, 400 MHz):  4.68 (s, 2H), 4.75 (s, 2H), 4.89 (s, 2H), 
7.39-8.28 (m, 13H);  
13C NMR δ ppm (MeOD + trifluoroacetic acid, 100MHz):  
57.4, 57.5, 59.7, 112.6, 119.8, 126.0, 126.2, 126.6, 128.1, 129.1, 130.1, 130.2, 132.1, 
134.1, 141.1, 141.9, 144.6, 147.0, 175.1;  IR (neat cm
-1
) 2981, 1747, 1570, 1508;  
MS (m/z) 353 [M+H]
+
;  HRMS (CI) calcd for C24H21N2O (MH
+
) requires 353.1646, 
found 353.1654.  Anal. Calcd for C24H20N2O:  C, 81.79%; H, 5.72%; N, 7.95%.  
Found:  C, 77.85%; H, 5.70%; N, 7.25%.  
Experimental Chapter 
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166 Bioisostere Structures used during Bioisostere 
Substructure Searching 
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274 Toxicophores taken from the Literature and used 
during Compound Filtering 
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Final Selection of 139 Compounds 
 










